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Abstract 
Peroxisome proliferator-activated receptors (PPARs), the nuclear hormone 
and ligand-dependent transcription factor, encoded by distinct genes consist of three 
isoforms: PPARa, (3 and y. Among the isoforms, PPARa is the one that has been 
well characterized and appears to play a critical role in adaptive responses to energy 
deprivation such as fasting and diabetes through transcriptional regulation of genes 
involved in energy homeostasis, in particular fatty acid oxidation. The indispensable 
role of PPARa in regulating energy homeostasis is stressed by severe hepatomegaly, 
hepatic steatosis, hypoketonemia, elevated fatty acid levels and hypothermia in 
PPARa-null mice fasted for 24, 48 or 72 hr compared with their corresponding wild-
type controls. These results indicate that PPARa is pivotal in maintaining lipid 
homeostasis during energy deprivation. However, the complex network of PPARa-
dependent signaling pathways in regulating hepatic fatty acid oxidation during energy 
deprivation is still not clear. Identification of PPARa-dependent genes might provide 
insight into how PPARa regulates and coordinates fatty acid metabolism during 
energy deprivation. 
The aim of the present study was to study the complex network of PPARa-
dependent signaling pathways in regulating hepatic fatty acid oxidation by identifying 
the spectrum of PPARa-dependent genes involved in regulation of hepatic lipid 
homeostasis during fasting using fluorescent differential display. Both wild-type and 
PPARa-null mice were divided into two groups. One group was deprived of food for 
72 hr, while the other group had free access to rodent chow diet. PPARa-dependent 
and fasting-responsive genes that were either up- or down-regulated in wild-type or 
i 
PPARa-null starved group when comparing to their corresponding fed controls were 
identified by means of fluorescent differential display. 
I 
Using the method of fluorescent differential display, thirteen PPARa-
dependent and fasting-responsive genes were identified in the present study. PPARa-
dependent genes that were up-regulated during fasting including the mouse EST 
(clone D3#3), medium-chain acyl-CoA dehydrogenase (MCAD), L-specific 
multifunctional beta-oxidation protein (L-PBE), phytanoyl-CoA hydroxylase (Phyh), 
2-hydroxyphytanoyl-CoA lyase (Hpcl), cytochrome P450 4A10 (CYP4A10), 
cytochrome P450 4A14 (CYP4A14), 3-hydroxy-3-methylglutaryl-CoA synthase 
(HMG-CoAS), betaine-homocysteine methyltransferase (Bhmt), and 
argininosuccinate lyase (ASL). Serine protease inhibitor 1-3 (Spil-3) and major 
urinary protein II (MUP II) were PPARa-dependent and down-regulated during 
starvation. Interestingly, up-regulation of mouse cathepsin L (Ctsl) during fasting 
was dramatically down-regulated by PPARa. Collectively, in response to fasting, 
PPARa stimulates hepatic fatty acid oxidation by transcriptional up-regulation of 
genes involved in mitochondrial P-oxidation, peroxisomal a - and P-oxidation, 
microsomal co-oxidation and ketogenesis. In addition, PPARa also play a role in 
regulating protein metabolism during energy deprivation. However, the functional 
consequence of transcriptional alteration of a certain gene by PPARa during fasting 
is still uncertain, especially the novel cDNA subclone. Characterization of mouse 
EST and further identification of PPARa-dependent and fasting-responsive genes in 
future are necessary for studying the complex network of PPARa-dependent 
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Chapter 1 Introduction 
Peroxisome proliferator-activated receptors (PPARs), the nuclear hormone 
and ligand-dependent transcription factor, encoded by distinct genes consist of three 
isoforms: PPARa, P and y. Among the isoforms, PPARa is the one that has been 
well characterized and appears to play a critical role in adaptive responses to energy 
deprivation such as fasting and diabetes through transcriptional regulation of genes 
involved in energy homeostasis, in particular fatty acid oxidation. The indispensable 
role of PPARa in adaptive response to fasting is manifested by the occurrence of 
severe hepatic steatosis, hypoglycemia, hypoketonemia, hypothermia and elevated 
free fatty acid levels in fasted PPARa-null mice as compared with fasted wild-type 
mice in recent studies (Kersten et al., 1999; Leone et al., 1999; Hashimoto et al,, 
2000). 
To date, the complex mechanism of PPARa-mediated regulatory response to 
energy deprivation induced by fasting is yet to be fully explored. Identification of 
novel PPARa target genes in response to fasting might provide insight into the 
molecular mechanism of PPARa regulation in lipid homeostasis during fasting, a 
condition in which high demand of fatty acid is required (Lee et al., 2002). 
Various methods such as microarray (Cherkaoui-Malki et al., 2001; Kersten et 
al., 2001; Yamazaki et al., 2002), subtractive hybridization (Kersten et al., 2000; 
Kersten et al., 2001) and fluorescent differential display (Lee et al., 2002) are 
available for identifying novel PPARa target genes in response to PPARa agonists or 
fasting. Fluorescent differential display was chosen for the present study because it is 
a rapid, sensitive and reproducible technique that allows easy comparison of 
differentially expressed transcripts between more than two treatment groups 
1 
simultaneously. Using fluorescent differential display technique, it enables 
comparisons of differentially expressed transcripts between four treatment groups 
f 
(WT/Fed, WT/Starved, KO/Fed and KO/Starved) simultaneously in my present study 
(Lee et aL, 2002). Thus, the aim of the present study was to identify the spectrum of 
fasting-responsive and PPARa-dependent genes by fluorescent differential display 
and PPARa-null mouse in vivo animal model. 
2 
Chapter 2 Literature review 
2.1 Peroxisome proliferator-activated receptors (PPARs) 
The discovery of the remarkable phenomenon of structurally diverse 
peroxisome proliferators-induced peroxisome proliferation and predictable pleiotropic 
responses in rodent liver such as induction of genes involved in lipid metabolism and 
tumor formation have focus the significant role of PPARs as the mediator in the above 
mechanism (Corton et al., 2000). PPARs, the nuclear hormone receptor and ligand-
dependent transcription factor, consist of three distinct isoforms, PPARa, PPARp and 
PPARy, encoded by different genes. To date, three subtypes of PPARs have been 
described in various species such as xenopus (Krey et al., 1993), rodents (Braissant et 
al., 1996) and humans (Palmer et al., 1998). PPARs can be activated by both 
endogenous and exogenous ligands and form a heterodimer with the common partner 
retinoid X receptor (RXR), with 9-cis retinoic acid as the ligand (Michalik and Wahli, 
1999). Binding of the PPAR/RXR heterodimer to specific peroxisome proliferator 
response elements (PPREs) in enhancer regions of target genes and interaction with 
cofactors result in alteration of transcription of PPAR responsive genes (IJpenberg et 
al., 1997). In addition, transcriptional activity of PPARs is also modulated by 
signaling cross-talk between PPARs and other nuclear hormone receptors (Miyamoto 
et al, 1997). 
Both differential tissue distribution and spectrum of activators of various 
PPAR isoforms implicate distinct physiological functions between them (Escher and 
Wahli, 2000). Among the three isoforms, PPARa is the one that has been well 
characterized. PPARa has been linked to play a role in lipid (Gervois et al, 2000), 
amino acid (Kersten et al,, 2001) and lipoprotein metabolism (Gervois et al,, 2000), 
3 
inflammation (Lee et aL, 2000), atherosclerosis (Staels et al., 1998b; Marx et al., 
1999), epidermal differentiation (Rivier et al., 1998), fasting (Kersten et al., 1999; 
f 
Leone et al., 1999; Hashimoto et al., 2000), and carcinogenesis (Peters et al,, 1997a). 
PPARy has been associated with adipocyte differentiation (Gerhold et aL, 2002) and 
inflammation (Harris and Phipps, 2001). PPARp has been shown to affect embryo 
implantation (Lim et al., 1999) and myelination, neuronal signaling, and lipid 
metabolism in the central nervous system (Berger and Moller, 2002). 
2.1.1 Structure of PPAR 
PPARs exhibit a common primary organization as other nuclear receptors and 
are composed of four functional domains including A/B, C, D, and E/F (Figure 2.1) 
(Mangelsdorf et al, 1995). The A/B domain located in the N-terminal contains a 
ligand-independent transcriptional activation domain (AF-1) that modulation of this 
domain by phosphorylation may alter the transcriptional activity of PPARs (Passilly 
et al., 1999). Insulin-induced phosphorylation of human PPARa enhances the 
transcriptional activity of the receptor (Shalev et al., 1996). AF-1 domain of PPARa 
is an acidic activation domain and the helix-forming property is implicated in the 
transactivation function (Hi et al,, 1999). The C region encodes the highly conserved 
DNA-binding domain (DBD), possessing two zinc finger DNA binding motifs that 
are responsible for targeting the receptor to specific PPREs in responsive genes. The 
E/F domain or ligand-binding domain (LBD) is responsible for ligand binding 
resulting in conversion of PPARs from an inactive form to a form that can bind DNA 
and alter transcription of genes. Binding of ligands to PPARa stabilizes the receptor 
from degradation (Hirotani et al., 2001) and induces conformational change in the 

























































































the LBD of PPARa are essential for heterodimerization between PPARa and RXR 
(Gorla-Bajszczak et al., 1999). Mutation of a conserved amino acid residue lowers 
the ligand binding properties of mouse PPARa (Causevic et al,, 1999). Besides, 
amino acid residues in both the DBD and LBD of human PPARa affect 
transcriptional activity of the receptor (Myers et al., 1997). The ligand-dependent 
transactivation domain (AF-2) near the C-terminus of the E/F domain is important in 
dimerization, nuclear localization and association with modulators of transcription 
such as coactivators and corepressors. AF-2 domain of mouse PPARa has been 
found to be indispensable for protein kinase A-mediated activation of the receptor 
(Lazennec et al., 2000). The D region encodes a flexible hinge region that allows 
independent movement between the DBD and LBD. 
2.1.2 Ligands of PPAR 
To get better understanding of the physiological functions of PPARs, it is 
important to investigate the mechanism of activation of the PPAR isoforms. Ligand 
binding activates PPARs, like their counterparts the classical steroid receptors. 
Transactivation assays are a common way to identify and characterize PPAR ligands. 
Cultured cells are transfected with a PPAR expression vector and a reporter construct 
containing a PPRE-driven reporter gene. Activation of the reporter system occurs 
when a measurable response is induced by the application of ligands (Forman et al, 
1997). Alternatively, a fibrate，GW2331, has been used as a radioligand in 
competitive PPAR ligand binding assays (Kliewer et al,, 1997). Recently, a 
fluorescent-based method has been implemented to investigate the interactions of 
PPARs with ligands (Lin et al, 1999). 
6 
To date, a variety of naturally occurring and synthetic ligands has been 
identified. Peroxisome proliferators are one of the major groups of exogenous ligands 
f 
of PPARs and are composed of structurally diverse compounds. However, most of 
the peroxisome proliferators have some structural similarity to fatty acids, and two 
chemical features are considered to be important in peroxisome proliferators including 
an anionic group and a lipophilic backbone (Gorton et al., 2000). Peroxisome 
proliferators include numerous clinical drugs (e.g., antidiabetic agents such as 
thiazaolidinediones and hypolipidemic agents such as fibrate derivates) and industrial 
compounds (e.g., plasticizers such as phthalates and pesticides such as phenoxyacetic 
acids) (Roberts, 1999). Metabolites of environmental chemicals such as 
trichloroethylene, perchloroethylene and di(2-ethylhexyl)phthalate activate PPARa, 
but not by the parent chemicals (Maloney and Waxman, 1999). Fatty acids, 
eicosanoids and hypolipidemic agents have been identified as ligands of PPARs (Krey 
et al” 1997). Fatty acids and eicosanoids activate PPARa and PPARy through direct 
binding to them (Kliewer et al., 1997; Wolf, 1998). A potent chemotactic agent 
leukotriene B4 that initiates, coordinates, sustains and amplifies the inflammatory 
response has been shown to be an activator of PPARa (Devchand et al., 1996). 
PPARa interacts with unsaturated C:18 fatty acids, arachidonic acid and leukotriene 
B4 with affinity in nanomolar range (Lin et al,, 1999). Conjugated linoleic acid, a 
mixture of dietary conjugated derivatives of linoleic acid, is a naturally occurring 
ligand and activators of PPARa (Moya-Camarena et al., 1999). Both pristanic acid 
and phytanic acid are naturally occurring PPARa ligands (Zomer et al., 2000). 
Substituted analogs of 2-(4-chlorophenoxy)-acetic acid are PPARa activators, and 
both structural and steric characteristic of 2-(4-chlorophenoxy)-acetic acid analogs 
play an important role in the activation of PPARa (Rangwala et al., 1997). 
7 
2.1.3 Peroxisome proliferator responsive elements (PPREs) 
As a member of the nuclear hormone receptor superfamily, dimerization is 
essential for the activity of PPARs in order to modulate the transcription of their 
target genes (IJpenberg et al., 1997). PPARs activated by their ligands 
heterodimerize with the common partner RXR with 9-cis retinoic acid as the ligand, 
forming a complex that is able to bind to the specific PPRE located in the promoter 
region of PPAR target genes. PPREs are direct repeat-1-like elements consisting of 
two hexanucleotides with the consensus sequence AGGTCA (or variants) separated 
by a single nucleotide spacer with a high preference for adenine. These elements bind 
PPAR/RXR heterodimers with PPAR occupying the 5, and RXR the 3’ position of 
this direct repeat. Interaction of the activated heterodimer with the promoter alters the 
transcription of PPAR target genes (IJpenberg et al,, 1997). The trans activation 
potential of PPAR subtypes can be differentially regulated by distinct PPREs (Kassam 
et al., 1998). Up to now, numerous PPAR target genes containing functional PPREs 
have been identified and most of them encode for enzymes involved in lipid and 
lipoprotein metabolism, and fatty acid transport (Table 2.1). 
2.1.4 Coactivators and corepressors of PPAR 
The transcriptional activation of nuclear receptors is modulated by the 
recruitment of cofactors. Several cofactor proteins, coactivators and corepressors, 
that mediate the ability of nuclear receptors to initiate or suppress the transcription 
process have been identified recently (Xu et al., 1999). For instance, PPAR gamma 
CO activator 1 is a coactivator of PPARa in the transcriptional control of mitochondrial 
fatty acid p-oxidation enzymes. Mammalian cell cotransfection experiments have 





































































































































































































































































































































































































































































































































































































































































































































































































































































































activation of reporter plasmids containing PPARa target elements (Vega et a/., 2000). 
In addition to PPAR gamma coactivator 1, the integrator protein, p300, also functions f 
as a coactivators for PPARa. PPARa interacts with the major intestinal coactivators 
p300 in the presence of its specific ligands (Mochizuki et al., 2002). Ligand-
dependent interaction of PPARa with p300 requires amino acids within the carboxyl 
terminus of PPARa and residues within the hinge region (Dowell et al., 1997a). 
However, conflicting results for steroid receptor coactivator-1 as a coactivator 
essential for PPARa-mediated transcriptional activation in vivo has been reported 
recently. The typical pleiotropic responses induced by PPARa ligands occur 
indistinguishably from steroid receptor coactivator-1 -deficient mice and wild-type 
mice, demonstrating the redundancy of the nuclear receptor coactivator (Qi et al., 
1999). The short heterodimer partner receptor modulates PPARa/RXRa-mediated 
transcription in a response element-specific manner that it serves as a negative 
regulator and inhibits transcription by PPARa/RXRa heterodimers from the acyl-
CoA oxidase-PPRE but acts positively from the peroxisomal enoyl-CoA hydratase/3-
hydroxyacyl-CoA dehydrogenase-PPRE (Kassam et al., 2001). Nuclear receptor 
corepressor is a corepressor of PPARa that suppresses PPARa-dependent 
transcriptional activation in PPARa/RXRa heterodimer bound to a PPRE in human 
embryonic kidney 293 cells. In contrast to the interaction of PPARa with the 
coactivator protein, p300, interaction between PPARa and nuclear receptor 
corepressor does not require any part of PPARa ligand binding domain. However, 
interaction between nuclear receptor corepressor and PPARa is suppressed by 
PPARa ligands (Dowell et aL, 1999). Thus, coactivators and corepressors play a 
crucial role in modulation the transcriptional properties of PPARa. 
10 
2.1.5 Signaling cross-talk between PPAR and other nuclear 
hormone receptors 
Transcriptional regulation ofPPRE resulting in alteration of gene transcription 
is a net aggregate response generated by several factors, including the availability of 
PPARs, the nature of the response element, cofactors that include corepressors and 
coactivators, the presence and absence of ligands as well as signaling cross-talk 
between PPARs and other nuclear hormone receptors (Kassam et al., 2001). 
Convergence of nuclear hormone receptor signaling pathways can occur at multiple 
levels, including competition for a common heterodimerization partner and/or binding 
to the same DNA response element between PPARs and other nuclear receptors. 
PPARa is stabilized through heterodimerization with RXR (Hirotani et al., 2001). 
The human orphan nuclear hormone receptor liver X receptor (LXRa) can bind 
directly to PPARa and the common heterodimerization partner RXRa. LXRa can 
competitively inhibit the binding of PPARa/RXRa heterodimers to PPREs through 
the formation of both LXRa/PPARa and LXRa/RXRa heterodimers. The 
heterodimer complex formed by LXRa and PPARa is incapable of binding to PPREs 
or LXRa response elements. Thus, PPARa-signaling pathways is negatively 
controlled by LXRa which antagonizes peroxisome proliferator signaling mediated 
by PPARa/RXRa through inhibition of binding of PPARa/RXRa heterodimers to 
PPREs and competition for the common heterodimer RXRa (Miyata et al, 1996). 
PPAR-mediated gene expression is suppressed by thyroid hormone receptor (TR). 
TR/RXR heterodimers inhibit PPAR/RXR heterodimers to bind to PPREs by serving 
as potential competitors with PPAR/RXR for binding to PPREs. Since TR bound to 
PPREs cannot initiate transcriptional activation, TR inhibits PPAR-mediated 
11 
transcriptional activation at the level of PPAR binding to PPREs (Miyamoto et al., 
1997). The monomeric orphan nuclear hormone receptor, retinoid Z receptor (RZRa), 
modulates PPARa/RXRa-dependent transactivation in a response-element dependent 
manner. RZRa stimulates ligand-mediated transactivation by PPARa from 
peroxisomal enoyl-CoA hydratase/3-hydroxyacy 1-CoA dehydrogenase-PPRE, but 
does not affect that of an acyl-CoA oxidase-PPRE reporter gene. These results 
demonstrate that there is cross-talk between the RZRa and PPARa signaling 
pathways in the regulation of the enoyl-CoA hy dratase/3 -hydroxyacyl-Co A 
dehydrogenase gene at the level of the enoyl-CoA hy dratase/3 -hydroxyacyl-Co A 
dehydrogenase-PPRE (Winrow et al., 1998). In addition, there is also signaling 
cross-talk between PPAR/RXR and estrogen receptor though a response element other 
than PPREs. PPAR/RXR inhibits transactivation by the estrogen receptor through 
competition for the vitellogenin A2 estrogen response element binding but without 
transcriptional activation (Keller et al, 1995). 
2.1.6 Tissue distribution of PPAR 
Expression of the three PPAR isoforms has been assessed in Xenopus, mice, 
rats, humans and chickens. The localization of the receptors in various tissues may 
help to clarify the physiological roles of PPARs. The expression patterns of the 
PPAR genes in adult rat and during embryonic development have been investigated 
by in situ hybridization using specific probes for PPARa, PPARp and PPARy and 
immunohistochemisty using a polyclonal antibody that recognized the three rat PPAR 
subtypes (Braissant et al., 1996; Braissant and Wahli, 1998). In adult rats, PPARa is 
highly expressed in liver, heart, intestine, and the proximal tubule cells of kidney. 
PPARp shows a ubiquitous expression, with higher expression than PPARa and 
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PPARy. High PPARy expression is found in the adipose tissue and immune system 
(Braissant et al., 1996). During embryonic development, PPARa expresses late with 
f 
increasing levels in organs such as liver, kidney, intestine and pancreases; PPARy is 
highly expressed in brown adipose tissue while PPARp is ubiquitously expressed. 
Moreover, PPARa shows transient expression in the central nervous system and 
embryonic epidermis and PPARy in the central nervous system (Braissant and Wahli, 
1998). In chicken, PPARa shows similar tissue distribution as other species reported 
(Diot and Douaire, 1999). Recently, the expression of PPARa is also reported in 
human skeletal muscle (Su et al., 1998; Loviscach et al., 2000), adipose tissue 
(Loviscach et aL, 2000), dermal and epithelial hair follicle cells (Billoni et al, 2000), 
aortic smooth-muscle cells (Staels et al., 1998b), carotid artery endothelial cells 
(Marx et al., 1999), monocyte-derived macrophages (Chinetti et al,, 1998), both 
human and rat testis (Schultz et al., 1999), rat granular cells of the cerebellar cortex 
(Kainu et al,, 1994), some neurones of cerebral cortex (Kainu et al., 1994), cartilage 
(Bordji et aL, 2000) and mouse keratinocytes (Thuillier et al., 2000). In rat, PPARa 
expression is restricted to hepatic parenchyma cells but not Kupffer cells (Peters et aL, 
2000). 
2.2 PPARa and lipid metabolism 
In mammals, the main source of fat is through direct absorption from the diet, 
although fat can be synthesized endogenously, using lipids, carbohydrates, or amino 
acids. Lipid ingested is emulsified by bile salt and eventually reabsorbed in the gut 
lumen after hydrolysis. Upon reabsorption, lipids are reformed by reesterification and 
delivered to the circulation via the lymph in form of chylomicrons that are mainly 
13 
composed of triglycerides, cholesterols and lipoproteins. Fatty acids are then released 
from the triglyceride component of the chylomicrons and delivered to target cells by 
the activity of extracellular lipoprotein lipase located at the surface of vascular 
endothelial cells. Other nonesterified fatty acids circulating in the bloodstream are 
mainly carried by serum albumin (Desvergne and Wahli, 1999). 
The energy status of the organism is the main determinant for the fate of fatty 
acids. When the energy fuels such as carbohydrates and fatty acids are abundant, 
fatty acids in the liver are preferably reesterified into triglycerides and released to the 
systemic circulation as very low density lipoproteins. The fatty acid content of very 
low density lipoproteins is mainly taken up by adipose tissue and muscle cell for 
storage. In contrast, when plasma fatty acid levels are high and carbohydrates levels 
are low during starvation, exercise or energy metabolism related diseases such as 
diabetes, there are dramatic hormonal and metabolic changes in mammals in order to 
maintain energy homeostasis. Generally, fasting results in decrease in serum insulin, 
leptin, triglycerides, glucose, liver glycogen and body weight, and an increase in 
plasma norepinephrine, glucocorticoid, corticosterone, non-esterified fatty acid and 3-
hydroxybutyrate (Vila et al., 1999; Zauner et al., 2000; Escher et al., 2001). Fatty 
acids are mobilized from storage tissues and directed for oxidative pathway leading to 
the production and secretion of ketone bodies as the energy fuel for brain, muscle, 
kidney and other peripheral tissues. Therefore, liver plays a critical role in regulating 
the levels of circulating fat in form of nonesterified fatty acid, triglycerides and ketone 
bodies by regulating the relative rates of fatty acid uptake, esterification into 
triglycerides and oxidation (Desvergne and Wahli, 1999). 
PPARa plays an indispensable role in mediating the adaptive response to 
maintain energy homeostasis during fasting. PPARa-null mice show severe hepatic 
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steatosis, hypoglycemia, hypoketonemia, hypothermia and elevated free fatty acid 
levels after fasting compared with fasted wild-type mice indicating a marked 
impairment of fatty acid uptake and oxidation in the absence of PPARa (Kersten et 
al., 1999; Leone et al., 1999; Hashimoto et al., 2000). Moreover, plasma free fatty 
acid levels increase at 48 hr of starvation and then return to near normal levels at 72 
hr in wild-type mice, whereas the increase in plasma free fatty acid levels in fasted 
PPARa-null mice are maintained at 72 hr of starvation. Besides, previous studies 
have shown that there is a dramatic increase in 3 -hydroxybutyrate in fasted wild-type 
mice but the increase in PPARa-null mice are not as mark (Kersten et al., 1999; 
Hashimoto et al., 2000). In addition, expression of PPARa is markedly induced upon 
fasting in liver (Van der Lee et al., 2001)，despite the fact that its expression is 
stimulated by stress, glucocorticoids and follows a diurnal rhythm under normal 
conditions (Lemberger et al., 1994; Lemberger et al., 1996; Djouadi and Bastin， 
2001). 
It is now recognized that fasting leads to transcriptional activation of genes 
encoding for peroxisomal, microsomal, and certain mitochondrial fatty acid oxidation 
enzymes in liver via PPARa (Kroetz et al., 1998; Leone et al., 1999; Hashimoto et al, 
2000; Le May et al., 2000). PPARa mediates fasting-induced up-regulation of gene 
expression of medium-chain acyl-CoA dehydrogenase involved in mitochondrial |3-
oxidation (Leone et al., 1999), 3-hydroxy-3-methylglutaryl-CoA synthase involved in 
ketogenesis (Le May et al., 2000), acyl-CoA oxidase (Leone et al,, 1999), 
bifunctional protein (Kroetz et al., 1998) and 3-ketoacyl-CoA thiolase involved in 
peroxisomal P-oxidation (Kroetz et al., 1998), cytochrome P450 4A1, cytochrome 
P450 4A2, cytochrome P450 4A3 (Kroetz et al., 1998; Leone et al., 1999) and 
cytochrome P450 4A14 involved in microsomal co-oxidation (Lee et al,, 2002). By 
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immunoblotting analyses, liver proteins of very long-chain acyl-CoA synthase 
involved in fatty acid activation, 3-hydroxy-3-methyIglutary 1-CoA synthase involved 
in ketogenesis, carnitine octanoyltransferase involved in fatty acid transport, straight-
chain acyl-CoA oxidase, bifunctional protein and sterol carrier protein x involved in 
peroxisomal P-oxidation are increased by fasting in a PPARa-dependent manner 
although the amounts of several enzymes under fed state are lower in PPARa-null 
mice (Hashimoto et al., 2000). 
In addition to transcriptional activation during starvation, constitutive 
expression of genes encoding several mitochondrial fatty acid catabolizing enzymes 
are also regulated by PPARa. Mitochondrial fatty acid metabolizing enzymes 
including very long-chain acyl-CoA dehydrogenase, long-chain acyl-CoA 
dehydrogenase, short chain-specific 3-ketoacyl-CoA thiolase and long-chain acyl-
CoA synthase are expressed at lower levels in untreated PPARa-deficient mice 
compared with wild-type mice (Aoyama et al., 1998; Watanabe et al., 2000). This 
also demonstrated that PPARa might positively regulate mitochondrial p-oxidation. 
Studies have shown that various genes involved in cellular uptake, activation 
and entry of fatty acids into mitochondria are also PPARa target genes. Transport of 
fatty acids across the cell membrane and activation of fatty acids into their acyl-CoA 
derivatives are the steps being encountered by fatty acids before they can be directed 
for reesterification to triglycerides or oxidation. It is noteworthy that the two 
independent transport proteins including fatty acid translocase and fatty acid transport 
protein are induced via PPARa by PPARa activators (Motojima et al., 1998). In 
mouse, PPARa activators induce both fatty acid transport protein and fatty acid 
translocase in liver and intestine, but fatty acid translocase shows a lesser induction in 
intestine (Motojima et al., 1998). Also, mouse fatty acid transport protein has been 
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verified to contain a functional PPRE (Frohnert et al., 1999). Acyl-CoA synthase, 
which is responsible for converting fatty acids into their acyl-CoA derivatives, is 
f 
induced in rat liver and kidney by PPARa activators (Martin et al., 1997), and a 
PPRE has been identified in the promoter region of acyl-CoA synthase (Schoonjans et 
al, 1995). The first limiting step in mitochondrial P-oxidation is the entry flux of 
fatty acids into mitochondria, which is controlled by a camitine-dependent facilitated 
transport system. PPARa plays an important role in mitochondrial fatty acid 
metabolism by regulating the muscle-type carnitine palmitoyl-CoA transferase I 
which catalyzes the formation of fatty acylcamitine at the outer mitochondrial 
membrane for translocation of fatty acids across the inner mitochondrial membrane 
(Brandt et al., 1998; Minnich et al., 2001), and a PPRE has been identified in the 
promoter region of muscle-type carnitine palmitoyl-CoA transferase I (Mascaro et al， 
1999). Moreover, fasting increases hepatic carnitine content via PPARa (Hashimoto 
et al., 2000), and this may be important for facilitating fatty acid uptake of 
mitochondria for (3-0x1 dation. 
Taken together, most of the PPARa target genes identified are involved in 
lipid metabolism and fatty acid transport. Transcriptional regulation of genes via 
PPARa and its ligands may provide implications for the mechanism, significance and 
consequence of such regulations by PPARa. However, the regulatory role of PPARa 
in maintaining lipid or energy homeostasis during energy deprivation such as fasting 
is yet to be fully elucidated, as the underlying molecular mechanism of fasting-
induced PPARa-dependent novel genes such as fasting induced adipose factor 
(Kersten et al., 2000) and a novel gene B3 (Lee et al, 2002) is still uncertain. 
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2.3 PPARa, cholesterol and lipoprotein metabolism 
PPARa has been found to be involved in regulation of bile acid biosynthesis, 
which is an important pathway for cholesterol elimination (Hunt et al., 2000). 
Cholesterol is an essential component of cell membranes and serves as precursor for 
steroids and bile acid synthesis. Fasting for 24 hr induces the transcription of sterol 
12a-hydroxylase, a branch-point enzyme in the bile acid biosynthetic pathway 
determining the ratio of cholic acid to chenodeoxycholic acid, in mouse liver in a 
PPARa-dependent manner (Hunt et al., 2000). Besides, PPARa expression is 
required for the activation of sterol 12a-hydroxylase-PPRE in a reporter plasmid 
(Hunt et al., 2000). PPARa-dependent regulation of sterol 12a-hydroxylase is further 
supported by the expected increase in the relative amount of cholic acid in wild-type 
mice treated with PPARa activators but not in PPARa-deficient mice (Hunt et al., 
2000). In addition, fatty acid-activated PPARa stimulates both mouse and human 7a-
hydroxylase gene promoters in transfected McArdle RH-7777 rat hepatoma cells, 
whereas mouse 7a-hydroxylase gene promoter shows greater sensitivity to activated 
PPARa (Cheema and Agellon, 2000). It appears that the differential response of the 
mouse and human 7a-hydroxylase gene promoters to activated PPARa is attributed 
to the additional PPARa/RXRa binding site in the mouse 7a-hydroxylase gene 
promoter (Cheema and Agellon, 2000). 
In addition to intracellular cholesterol metabolism, PPARa also plays a 
critical role in modulating lipoprotein metabolism (Staels et al., 1998a). PPARa 
mediates activator-induced down-regulation of hepatic apolipoprotein C-III in mice 
(Peters et al., 1997b), an atherogenic component of apolipoprotein B-containing 
lipoproteins, which inhibits lipoprotein lipase activity and impairs the apolipoprotein 
18 
E-dependent uptake of triglyceride-rich lipoproteins and remnants by the liver 
(Fredenrich, 1998). Besides, lipoprotein lipase expression in rat liver is induced by 
PPARa activators in a PPARa-dependent manner (Schoonjans et al, 1996). 
Consequently, suppression of hepatic apolipoprotein C-III production and induction 
of lipoprotein lipase by PPARa appears to be beneficial as lipolysis of very light 
density lipoprotein is increased and the resulting light density lipoprotein is efficiently 
removed from the plasma (Desvergne and Wahli, 1999). However, PPARa agonists 
inhibit lipoprotein lipase activity in cultured cardiomyocytes by a posttranscriptional 
and posttranslational mechanism (Carroll and Severson, 2001). Thus, it seems that 
PPARa regulation of lipoprotein lipase activity involves complex tissue-specific 
actions. 
Hypolipidemic drugs such as fibrates enhance plasma high density lipoprotein 
level in human, whereas reduction of high density lipoprotein level occurs in rodents 
(Berthou et al., 1996; Staels and Auwerx, 1998). In human, plasma level of high 
density lipoprotein is increased by fibrates via transcriptional activation of 
apolipoprotein A-I and apolipoprotein A-II，which are major high density lipoprotein 
apolipoprotein, through PPARa activation (Gervois et al, 2000). Consistently, 
functional PPREs have been identified in the regulatory region of the human 
apolipoprotein A-I and apolipoprotein A-II but not in rat promoter for apolipoprotein 
A-I (Vu-Dac et al., 1995; Staels and Auwerx, 1998). In rodents, decreased high 
density lipoprotein level in fibrate treatment is attributed to reduced transcription of 
apolipoprotein A-I gene. The lack of induction of rodent apolipoprotein A-I gene 
expression by fibrates is due to three nucleotide differences in apolipoprotein A-I 
promoter A site between rats and humans, eliminating binding of PPAR and 
activation by fibrates. Moreover, suppression of apolipoprotein A-I transcription in 
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rat by fibrates is due to fibrate-induced nuclear receptor Rev-erbalpha, which binds to 
a negative response element adjacent to the TATA box of the rat apolipoprotein A-I 
( 
promoter (Vu-Dac et al., 1998). 
2.4 PPARa and glucose metabolism 
Gluconeogenesis is impaired in PPARa-null mice as they suffer from 
hypoglycemia after prolong fasting (Kersten et al., 1999). After prolong fasting, 
blood glucose is exclusively maintained by gluconeogenesis. Fasting hypoglycemia 
in PPARa-null mice cannot be attributed to inappropriate induction of the two rate-
limiting enzymes of gluconeogenesis, glucose-6-phosphatase and 
phosphoenoylpymvate carboxylase, as they are normally induced in the liver of both 
wild-type and PPARa-null mice upon fasting (Le May et al., 2000). Inactivation of 
pyruvate dehydrogenase complex by increased pyruvate dehydrogenase kinase 
activity promotes gluconeogenesis by conserving three-carbon substrates. This helps 
to maintain glucose levels during starvation. Pyruvate dehydrogenase kinase 4 is 
induced in liver, heart, kidney, skeletal muscle and lactating mammary gland but not 
in brain, brown and white adipose tissues during fasting (Wu et al., 1999; Wu et al., 
2000; Holness et al., 2002). In addition to pyruvate dehydrogenase kinase 4, pyruvate 
dehydrogenase kinase 2 also increases in liver, kidney and lactating mammary gland 
in response to starvation (Wu et al., 2000). However, recent results indicate that 
pyruvate dehydrogenase kinase 4 induction during fasting is mediated by PPARa-
independent mechanism as this also occurs in PPARa-deficient mice (Holness et al., 
2002). Upregulation of pyruvate dehydrogenase kinase 4 gene expression in 
starvation may be promoted by decreased level of insulin and increased level of fatty 
acids and glucocorticoids (Huang et al, 2002). 
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2.5 PPARa and amino acid metabolism 
PPARa has prominent effects in the regulation of lipid metabolism. However, 
relatively little is known about the regulatory role of PPARa in the expression of 
genes encoding for amino acid metabolism. Recently, studies have shown that 
PPARa mediates activator-induced down-regulation of hepatic genes involved in 
amino acid metabolism (Kersten et al., 2001). PPARa activators inhibit the 
expression of genes involved in urea cycle including carbamoyl-phosphate synthase I, 
ornithine trans-carbamylase, arginino-succinate synthase and arginino-succinate lyase, 
but not arginase (Kersten et al., 2001). In addition, PPARa also influences 
expression of genes involved in transamination. Cytosolic aspartate aminotransferase 
and alanine glyoxylate aminotransferase are suppressed by PPARa activators in 
PP ARa-dependent manner while mitochondrial aspartate aminotransferase is induced 
instead (Kersten et al., 2001). 
2.6 PPARa，atherosclerosis and inflammation 
It has been suggested that PPARa ligand fibrates inhibit atherosclerosis 
development by improving the plasma lipid profile as well as by reducing 
inflammation in the vascular wall (Fruchart et al., 1999). Fibrates seems to exert their 
beneficial effects in lowering plasma triglyceride and increasing plasma high density 
lipoprotein levels by altering lipoprotein metabolism through PPARa-mediated 
down-regulation of apolipoprotein C-III and up-regulation of apolipoprotein A-I, 
apolipoprotein A-II and lipoprotein lipase (Schoonjans et al., 1996; Peters et aL, 
1997b; Gervois et a/., 2000). 
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The presence of PPARa expression and activity in vascular cell types 
including monocyte-derived macrophages (Chinetti et al., 1998), endothelial cells 
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(Marx et al., 1999) and vascular smooth muscle cells (Staels et al., 1998b) suggest 
that PPARa plays a role in anti-atherosclerosis. The potential of PPARa activators in 
inhibiting inflammatory response of aortic smooth-muscle cells and decreasing the 
concentration of plasma acute-phase proteins implicates that PPARa in the vascular 
wall may influence the process of atherosclerosis (Staels et al., 1998b). PPARa 
activators inhibit tumor necrosis factor a-induced vascular cell adhesion molecule-1 
expression, which plays a critical role in leukocyte recruitment to atherosclerotic 
lesion, in human endothelial cells (Marx et al., 1999). Moreover, PPARa ligands 
induce apoptosis of tumor necrosis factor a-activated macrophages (Chinetti et al., 
1998). In aortic smooth-muscle cells, PPARa ligands exert inhibitory effect on 
interleukin-1 -induced production of interleukin-6 and prostaglandin and expression of 
cyclooxygenase-2 (Staels et al., 1998b). Transcriptional inhibition of 
cyclooxygenase-2 induction is a result of PPARa repression of NF-kappaB signaling. 
Recent studies show that PPARa may have regulatory role in the initial step of 
reverse-cholesterol-transport pathway via the activation of ABC A-1 -mediated 
cholesterol efflux in human macrophages (Chinetti et al., 2001). 
In addition, PPARa has been proposed to play a crucial role in the negative 
feedback regulation of leukotriene B4 metabolism in the liver (Devchand et al,, 1996). 
However, recent studies do not support the feedback metabolism of leukotriene B4 as 
activation of PPARa by leukotriene B4 or other PPARa activators do not correlate 
with an increase in leukotriene B4 metabolism (Fiedler et al, 2001). PPARa has a 
proinflammatory role in mediating the activation of endothelial cells to produce 
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monocyte chemotactic activity in response to oxidized phospholipids and lipoproteins. 
Minimally oxidized/modified LDL and oxidation product of l-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphocholine activate endothelial cells to produce 
monocyte chemotactic protein-1 and interleukin-8 via PPARa (Lee et al‘, 2000). 
However, activated PPARa blocks monocyte chemotactic protein-1-induced 
monocyte migration (Kintscher et al., 2000). 
2.7 PPARa and epidermal differentiation 
PPARa is tightly linked to the epidermal differentiation process and is 
involved in the control of the epidermal lipid barrier in a skin equivalent model 
(Rivier et al., 1998; Rivier et al., 2000). Keratinocytes express functional PPARa 
and its activators exert moderate protective role against skin tumor promotion 
(Thuillier et al., 2000). Activated PPARa promotes keratinocyte/epidermal 
differentiation and decreases proliferation. Topical treatment with PPARa activators 
increases apoptosis, decreases cell proliferation and accelerates recovery of barrier 
function following acute barrier abrogation. Expression of structural proteins of the 
upper apinous/granular layer including involucrin, profilaggrin-filaggrin and loricrin 
are induced by ligand-activated PPARa. Besides, the expression of the structural 
proteins is lower in PPARa-null mice compared to wild-type mice (Komuves et al., 
2000b). In addition, PPARa activator treatment can normalize epidermal cell 
proliferation. PPARa activators decrease epidermal hyperplasia in both the subacute 
and chronic models of hyperproliferation. Moreover, topical treatment with PPARa 
activators restores the decreased involucrin, profilaggrin-filaggrin and loricrin in 
hyperproliferative epidermis towards normal (Komuves et al., 2000a). 
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2.8 PPARa and peroxisome proliferator-induced liver 
injury 
PPARa is the mediator involved in both short-term and long-term pleiotropic 
responses induced by peroxisome proliferators in mouse liver. Exposure to 
peroxisome proliferators such as Wy-14,643 for a short period of time (2 weeks) 
results in hepatomegaly, peroxisome proliferation, and transcriptional-activation of 
target genes in wild-type mice but these effects are not observed in PPARa-null mice 
(Lee et al., 1995). Besides, PPARa is necessary for nongenotoxic peroxisome 
proliferators to induce hepatocarcinogenesis in rodents. This is supported by the 
results that there is a 100% incidence of hepatic neoplasma in wild-type mice fed with 
the peroxisome proliferator WY 14,643 for 11 month, whereas none of the PPARa-
null mice develop liver cancer (Peters et al., 1997a). However, the mechanism of 
PPARa-mediated carcinogenic effects is yet to be fully elucidated. Different 
hypotheses have been proposed to account for peroxisome proliferator-induced 
hepatocarcinogenesis in rodents. Hepatomegaly and hepatocarcinogenesis induced by 
peroxisome proliferators are associated with peroxisome proliferation, induction of 
hepatic DNA synthesis and suppression of apoptosis (Roberts et al., 2000). PPARa 
have been found to mediate the suppression of hepatocyte apoptosis in response to 
peroxisome proliferators (Hasmall et al, 2000). Besides, hepatocarcinogenesis may 
also be contributed by PPARa-dependent alterations in cell cycle regulatory proteins 
in response to peroxisome proliferators (Peters et al., 1998). 
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Chapter 3 Objectives 
Recent studies indicate that PPARa is critical in maintaining lipid homeostasis 
during energy deprivation through transcriptional regulation of genes involved in 
energy homeostasis, in particular fatty acid oxidation. However, the complex 
network of PPARa-dependent signaling pathways in regulating hepatic fatty acid 
oxidation during energy deprivation is still not clear. The aim of the present study is 
to identify the spectrum fasting-responsive and PPARa-dependent genes involved in 
hepatic lipid metabolism, in which fasting mimic a condition with high demand for 
fatty acid metabolism. Objectives of this study are summarized as following: 
1. To identify the spectrum of fasting-responsive and PPARa-dependent genes in 
livers of four groups of mice (WT/Fed, WT/Starved, KO/Fed and KO/Starved) by 
fluorescent differential display and PPARa-null mice. 
2. To study the physiological role of PPARa in adaptation to fasting. 
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Chapter 4 Materials and Methods 
/ / 
4.1 Animal tail-genotyping 
The genotypes of PPARa (+/+) and PPARa (-/-) mice were confirmed by 
PCR tail-genotyping before the experiment, as there was no external phenotypic 
difference between them (Figure 4.1). A pair of primers, forward primer (Fl, 5'-
GCCTGGCCTTCTAAACAT-3') located before the Pstl site (1330-1347) and reverse 
primer (R3, 5'-ACTCGGTCTTCTTGATGA-3') located after the Sphl site (1503-
1520) of exon 8 of PPARa gene, were designed for PCR tail-genotyping (Figure 4.2). 
The expected sizes of PCR products amplified from genomic tail DNA of PPARa 
(+/+) and PPAR (-/-) mice were 191 and 1248 bp, respectively (Lee et al., 2002). The 
difference in size was due to the replacement of a 83 bp genomic fragment between 
the Pstl and Sphl sites in exon 8 by a 1.14 kb neo gene. 
4.1.1 Materials 
Ethidium bromide and SDS were purchased from Sigma (USA). Proteinase K 
was purchased from Boehringer Mannheim (Germany). EDTA was purchased from 
Riedel-de Haen (Germany). Isopropanol was purchased from BDH (England). 
Trizma base, boric acid, sodium chloride and agarose were purchased from USB 
(USA). Tag polymerase and PCR buffer were purchased from Duncan (UK). 
Forward and reverse primers were synthesized and purchased from Gibco (USA). 
dNTP mix was purchased from Roche (Germany). DNA markers were purchased 
from Life Technologies (USA). 
4.1.2 Methods 
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Figure 4.1. External morphology of three months old male PPARa (+/+) and PPARa 
(-/-) mice. There is no obvious phenotypic difference between them. 
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Figure 4.2. A schematic diagram showing the genomic organization of PPARa (+/+) 
and PPARa (-/-) mice, and the designation of primers for PCR tail-genotyping. F1 
and R3 represent the forward and reverse primers, respectively (Lee et al,, 2002). 
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About 1 cm of mouse tail tip was cut and incubated in 0.5 ml of lysis buffer 
[100 mM Tris-HCl (pH 8.5), 5 mM EDTA (pH 8.0), 0.2% SDS, 200 mM NaCl and 
f 
100 |Lig/ml proteinase K] in a 15-ml tube in a 55�C shaker for overnight digestion. 
Next morning, tail DNA samples were vortexed and digested for an additional 2 hr. 
Samples were centrifuged at 3,000 rpm for 10 min and supernatant was transferred to 
new 1.5 ml eppendorfs. Supernatant was centrifuged at 14,000 rpm for 10 min and 
then transferred to new eppendorf containing 0.5 ml isopropanoL Tail DNA was 
precipitated out by shaking the tubes horizontally with hands and transferred to new 
eppendorfs by pipette tips. DNA pellet was air-dried and resuspended in 150 jul TE 
buffer [10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA (pH 7.5)]. Samples were 
incubated at 55°C for overnight. DNA was mixed by finger tapping, pipetting up and 
down, and stored at 4°C. 
One microliter of a 10-fold diluted tail DNA sample was used for PCR tail-
genotyping. The PCR reaction was performed in a final concentration of Ix PCR 
buffer, 0.05 mM dNTP mix, 0.35 |iM forward primer (Fl), 0.35 jiM reverse primer 
(R3) and 0.1 U/jixl Taq polymerase (Appendix A, Table Al) in a thermal cycler 
(GeneAmp® PCR system 9700). The PCR profile was as follows: 95�C for 2 min, 
followed by 34 cycles of 92°C for 15 sec, 60�C for 30 sec and 72�C for 2 min, and 
followed by 72°C for 7 min and hold at 4°C. PCR products of PPARa (+/+) mice 
were resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining, while 
that of PPARa (-/-) mice were resolved on 1% gels. 
4.2 Animal treatment 
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In order to study the physiological role of PPARa in lipid metabolism, fasting 
was used as a mean to manifest the effect of PPARa involved in lipid metabolism 
during energy deprivation. In addition, the effect of fasting was compared between 
the PPARa (+/+) and PPARa (-/-) mice. 
4.2.1 Animals 
Three months old male PPARa (+/+) and PPARa (-/-) mice on Sv/129 
background were used for all the experiments. They were the offspring of breeder 
mice obtained from the National Cancer Institute (National Institutes of Health, USA). 
4.2.2 Treatment 
Male PPARa (+/+) and PPARa (-/-) mice were kept on a 12 hr light/dark 
cycle. One to three mice were housed per cage and provided with ozonated water ad 
libitum. Both PPARa (+/+) and PPARa (-/-) mice were either fed with rodent chow 
diet or deprived of food for 72 hr. Mice were then killed by cutting the neck with a 
pair of scissors and blood was allowed to drip from their necks into eppendorfs. Liver 
was removed, weighed, wrapped in aluminium foil and kept in liquid nitrogen until 
use. 
4.3 Serum P-hydroxybutyrate, triglyceride and cholesterol 
analyses 
To study PPARa-mediated regulation of lipid metabolism in adaptive 
response to energy deprivation induced by fasting, serum P-hydroxybutyrate, 
triglyceride and cholesterol levels were determined. 
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The method of enzymatic measurement of p-hydroxybutyrate was based upon 
the methodology initially described by Williamson et al., 1962. Oxidation of p-
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hydroxybutyrate to acetoacetate is catalyzed by p-hydroxybutyrate dehydrogenase. 
During this oxidation, an equimolar amount of nicotinamide adenine dinucleotide is 
reduced to NADH that absorbs light at 340 nm. The increase in absorbance at 340 nm 
is directly proportional to the P-hydroxybutyrate in the sample. 
Triglyceride levels were determined by enzymatic hydrolysis of triglycerides 
to glycerol and free fatty acids followed by coupled enzymatic measurement of 
glycerol produced. The procedure described herein is a modification of the method of 
McGowan et al., 1983. Firstly, triglycerides are hydrolyzed by lipoprotein lipase to 
glycerol and free fatty acids. Then, glycerol is phosphorylated by adenosine 
triphosphate (ATP) catalyzed by glycerol kinase forming glycerol-1 -phosphate (G-l-P) 
and adenosine-5'-diphosphate (ADP). G-l-P is oxidized by glycerol phosphate 
oxidase to dihydroxyacetone phosphate and hydrogen peroxide. A quinoneimine dye 
is generated by peroxidase catalyzed coupling of 4-aminoantipyrine and sodium N-
ethyl-N-(3-sulfopropyl)m-anisidine with hydrogen peroxide which shows an 
absorbance maximum at 540 nm. The increase in absorbance at 540 nm is directly 
proportional to triglyceride concentration of samples. 
Serum cholesterol levels were determined by enzymatic hydrolysis of 
cholesterol esterase to cholesterol and free fatty acids. Free cholesterol is then 
oxidized by cholesterol oxidase to cholest-4-en-3-one and hydrogen peroxide. Then, 
the hydrogen peroxide combines with hydroxy-benzoic acid and 4-aminoantipyrine in 
the presence of peroxidase to form a quinoneimine dye that is quantitated at 500 nm. 




Triglyceride (GPO-Trinder), infinity™ cholesterol reagent and p-
hydroxybutyrate (p-HBA) were obtained from Sigma (USA). Curvet was purchased 
from Ntimbrecht (Germany). 
4.3.2 Methods 
4.3.2.1 Serum preparation 
Blood samples were allowed to clot at room temperature for 30 min and 
centrifliged at 2,400 rpm for 15 min. Serum was transferred to new eppendorfs, 
centrifuged again at 2,400 rpm for 10 min, transferred to new eppendorfs, and stored 
at -20�C. 
4.3.2.2 p-hydroxybutyrate determination 
Twenty-five microliters of water or serum samples were added to cuvets 
containing 1.5 ml of freshly reconstituted P-HBA reagent. Samples were mixed by 
wrapping the opening of cuvets with parafilm and inverting for several times. After 
mixing, initial absorbance of water blank and samples was recorded at 340 nm using 
water to set zero. After recoding the initial absorbance, 25 |ul P-HBDH solution was 
added to each of the cuvets and mixed by inverting for several times. Final 
absorbance was recorded after 20 min incubation at room temperature. Serum (3-
HBA was calculated as following: 
Serum P-HBA (mg/dL) = (change of Asampie - change of Abiank) x 104 
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where factor 104 = 1.55 x 104.1 x 100 
f 
6.22 X 0.025 X 1000 
1.55 = total reaction volume (mL) 
104.1 = molecular weight of P-HBA 
100 = conversion of mg/mL to mg/dL 
6.22 = millimolar absorptivity ofNADH at 340 nm 
0.025 = sample volume (mL) 
1000 = conversion of |ug to mg 
4.3.2.3 Triglyceride determination 
Triglyceride working reagent was prepared by combining 4 ml of freshly 
reconstituted reagent A with 1 ml of freshly reconstituted reagent B. Ten microliters 
of deionized water, standard or sample were added to cuvets containing 1 ml of 
triglyceride working reagent. Samples were mixed by wrapping the opening of cuvets 
with parafilm and inverting for several times. Absorbance was recorded at 540 nm 
using water to set zero and after 15 min incubation at room temperature. Serum 
triglyceride was calculated as following: 
Serum triglyceride (mg/dL) = (Asampie — Abiank / Astandard - Abiank) X concentration of 
standard 
4.3.2.4 Cholesterol determination 
Ten microliters of cholesterol calibrator or serum samples were added to 
cuvets containing 1 ml of freshly reconstituted infinity cholesterol reagent. Samples 
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were mixed by wrapping the opening of cuvets with parafilm and inverting for several 
times. Absorbance was recorded at 500 nm using water to set zero and after 20 min 
f 
incubation at room temperature. Serum cholesterol was calculated as following: 
Serum cholesterol (mg/dL) = (Asampie / Acaiibrator) x calibrator value 
4.4 Total RNA isolation 
The quality of total RNA is critical in obtaining good results from reverse 
transcription (RT), RT-PCR, reverse dot blot and Northern blot analyses. 
4.4.1 Materials 
Trizol reagent was purchased from Invitrogen (USA). Isopropanol was 
purchased from BDH (England). Ethanol was purchased from Riedel-de Haen 
(Germany). Chloroform was purchased from Merck (USA). Nuclease-free water was 
purchased from Promega (USA). Formamide was purchased from Boehringer 
Mannheim (Germany). 
4.4.2 Methods 
Livers were mixed with Trizol reagent (1 ml/g) and homogenized by a tissue 
tearor (Dremel®, USA). Homogenate was allowed to stand at room temperature for 5 
min. One milliliter of homogenate was mixed with 0.2 ml chloroform by vortexing 
and allowed to stand at room temperature for 2 min. Afterwards, homogenate was 
centrifUged at 14,000 rpm at 4°C for 15 min. After centrifugation, 0.4 ml of aqueous 
phase containing RNA was transferred to new eppendorfs containing 0.5 ml 
isopropanol and mixed by vortexing. The mixture was incubated at room temperature 
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for 10 min, and centrifiiged at 14,000 rpm at 4 � C for 10 min. Supernatant was 
discarded and RNA pellet was washed by 1 ml of 75% ethanol. After centrifligation 
at 14,000 rpm at 4 � C for 1 min, supernatant was discarded, and washing steps were 
repeated twice. After washing, RNA pellet was either stored in 1 ml of 100% ethanol 
at -80°C or air-dried and resuspended in nuclease-free water for cDNA synthesis or in 
formamide for Northern blot analysis. 
4.5 DNase I treatment 
Total RNA isolated was treated by DNase I in order to remove any possible 
genomic DNA contamination. Otherwise, genomic DNA will also be amplified in 
RT-PCR and lead to false-positive results during RT-PCR. 
4.5.1 Materials 
Trizma base was purchased from USB (USA). Magnesium chloride and 
sodium acetate were purchased from Sigma (USA). RNase-free DNase I, HPLC pure 
grade was purchased from Amersham Biosciences (England). Phenol: chloroform: 
isoamyl alcohol (25:24:1) was purchased from Gibco (USA). 
4.5.2 Methods 
Fifty micrograms of total RNA were treated with DNase I in the final 
concentration of 50 mM Tris-HCl (pH 7.5)，10 mM MgCh and 0.3 U/jul RNase-free 
DNase I (Appendix A, Table A2). The sample was mixed gently by finger tapping 
and incubated at 3TC for 30 min. After 30 min, the mixture was diluted to 500 |il 
with nuclease-free water, mixed with equal volume of phenol: chloroform: isoamyl 
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alcohol (25:24:1) by vortexing, and centrifliged at 14,000 rpm at 4°C for 30 min. 
Four hundred microliters of supernatant were transferred to new eppendorfs and 
mixed with 40 |li1 of 3 M sodium acetate (pH 5.2) and 800 jul of 100% ethanol for 
overnight precipitation of RNA. After precipitation, the mixture was centrifliged at 
14,000 rpm at 4°C for 30 min and the supernatant was discarded. The RNA pellet 
was washed by 75% ethanol and centrifliged at 14,000 rpm at 4°C for 10 min. The 
washing steps were repeated twice. RNA pellet was air-dried, resuspended in 30 jul of 
nuclease-free water, and stored at -80°C. 
4.6 Reverse transcription (RT) and non-fluorescent PCR 
(non-fluoroDD PCR) 
According to the fluoroDD manual obtained from Beckman (USA), total 
mRNA pools can be divided into twelve subsets by using 12 different 3，-oligo(dT) 
anchored primers (APs) (Figure 4.3) during first-strand cDNA synthesis. For each 
subset of first-strand cDNA, twenty different fluoroDD PCR can be performed to 
synthesize double-stranded cDNA by using a 3 '-tetramethylrhodamine-labeled 
oligo(dT) anchored primer (TMR-AP) (Figure 4.4), which has identical sequence as 
the corresponding AP used for the first-strand cDNA synthesis, and twenty different 
5'-arbitrary primers (ARPs) (Figure 4.5). Using 12 different APs and 20 different 
ARPs, 240 different RT-PCR combinations can be performed. However, not all of 
the primer combinations could give our desired differential gene expression patterns 
(A-H) as summarized in Table 4.1. Therefore, as a first step to screen out for the 
primer combinations which will give our desired differential gene expression patterns, 
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APl 5' ACGACTCACTATAGGGCTTTT~I 'TTTTTTTGA 3' 
AP2 5' ACGACTCACTATAGGGCTTTTTTTTTTTTGC 3' 
AP3 5' ACGACTCACTATAGGGCTTTTTTTTTTTTGG 3' 
AP4 5' ACGACTCACTATAGGGCTTTTTTTTTTTTGT 3' 
AP5 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCA 3' 
AP6 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCC 3' 
AP7 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCG 3' 
AP8 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAA 3' 
AP9 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAC 3' 
APIO 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAG 3' 
APll 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAT 3' 
AP12 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3' 
Figure 4.3. Sequences of twelve different 3' -oligo( dT 12) anchored primers (APs). 
Each AP primer contains three domains, including a T7 (17-mer) promoter sequence 
highlighted in blue for reamplification, an oligo( dT 12) highlighted in green for 
annealing to polyA tail of mRNA, and an anchoring base highlighted in red for 
dividing mRNA pool into subsets (adapted from fluoroDD manual, Beckman). 
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TMR-API + 5' ACGACTCACT ATAGGGCTTTTTT1TTTTTGA 3' 
TMR-AP2 + 5' ACGACTCACTATAGGGCTfTTTTTTTTTTGC 3' 
TMR-AP3 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTGG 3' 
TMR-AP4 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTGT 3' 
TMR-AP5 <}- 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCA 3' 
TMR-AP6 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCC 3' 
TMR-AP7 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCG 3' 
TMR-AP8 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAA 3' 
TMR-AP9 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAC 3' 
TMR-APIO + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAG 3' 
TMR-APll + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAT 3' 
TMR-AP12 + 5' ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3' 
Figure 4.4. Sequences of twelve different 3' -tetramethylrhodamine-labeled 
oligo(dT12) anchored primers (TMR-APs). Each TMR-AP primer has identical 
sequence which corresponds to the respective non-fluorescent-labeled anchored 
primer used for first-strand cDNA synthesis (adapted from fluoroDD manual, 
Beckman). The yellow star represents the fluorescent tag, TMR. 
38 
ARPl 5 ' ACAATTTCACACAGGACGACTCCAAG 3' 
ARP2 5' ACAATTTCACACAGGAGCTAGCATGG 3' 
ARP3 5' ACAATTTCACACAGGAGACCATTGCA 3， 
ARP4 5' ACAATTTCACACAGGAGCTAGCAGAC 3’ 
ARP5 5' ACAATTTCACACAGGAATGGTAGTCT 3， 
ARP6 5' ACAATTTCACACAGGATACAACGAGG 3， 
ARP7 5' ACAATTTCACACAGGATGGATTGGTC 3， 
ARP8 5' ACAATTTCACACAGGATGGTAAAGGG 3， 
ARP9 5' ACAATTTCACACAGGATAAGACTAGC 3， 
ARPIO 5' ACAATTTCACACAGGAGATCTCAGAC 3' 
ARPl 1 5' ACAATTTCACACAGGAACGCTAGTGT 3' 
ARP12 5' ACAATTTCACACAGGAGGTACTAAGG 3' 
ARP13 5' ACAATTTCACACAGGAGTTGCACCAT 3’ 
ARP14 5' ACAATTTCACACAGGATCCATGACTC 3， 
ARP15 5' ACAATTTCACACAGGACTTTCTACCC 3’ 
ARP16 5, ACAATTTCACACAGGATCGGTCATAG 3， 
ARP17 5, ACAATTTCACACAGGACTGCTAGGTA 3’ 
ARP18 5' ACAATTTCACACAGGATGATGCTACC 3' 
ARPl9 5' ACAATTTCACACAGGATTTTGGCTCC 3' 
ARP20 5，ACAATTTCACACAGGATCGATACAGG 3’ 
Figure 4.5. Sequences of twenty different 5'-arbitrary primers (ARPs). Each ARP 
primer contains a Ml3 (16-mer) reverse primer sequence highlighted in blue for 
reamplification, and a core annealing sequence h ighlighted in red for priming gene 
specific sequence in RT-PCR (adapted from fluoroDD manual, Beckman). 
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Table 4.1. Some of the possible differential gene expression patterns that can be 
found on both non-fluoroDD and fluoroDD gels 
( 
Differential PPARa (+/+) PPARa ( - / - ) G e n e s that are either up- or down-
gene regulated in PPARa (+/+) starved 
expression Fed Starved Fed Starved group compared to their 
pattern corresponding fed controls 
Up-regulated during starvation and A + - -
PPARa-dependent 
B + ++ + Up-regulated during starvation and 
PPARa-dependent 
Down-regulated during starvation but C + + + -
up-regulated by PPARa 
D ++ ++ ++ + Down-regulated during starvation but 
up-regulated by PPARa 
Down-regulated during starvation and E + - + + 
PPARa-dependent 
Down-regulated during starvation and F ++ + ++ ++ 
PPARa-dependent 
Up-regulated during starvation but G - - - + 
down-regulated by PPARa 
Up-regulated during starvation but H + + + ++ 
down-regulated by PPARa 
Up-regulated during starvation but 
丄 - + - + 
PPARa-independent 
Down-regulated during starvation but 
J + - + - PPARa-independent 
'+' indicates the presence of a band (cDNA) on fluoroDD gel, while ‘-，represents 
the corresponding band (cDNA) was not observed on the fluoroDD gel. The 
relative intensity of a gene expression among the four treatment groups is reflected 
by the number o f ' + ' . Those AP and ARP combinations, which generated either of 
the eight differential gene expression patterns (A-H) from preliminary non-
fluoroDD analysis, were used for subsequent fluoroDD analysis. 
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non-fluoro AP primers, which were cheaper than the fluoro AP primers, were used for 
RT-PCR for preliminary screening. 
！ 
4.6.1 Materials 
First-strand buffer, DTT, and SUPERSCRIPT™ II RNase H~ reverse 
transcriptase were purchased from Invitrogen™ (USA). Non-fluorescent labeled 3'-
oligo(dT) anchored primers, 5'-arbitrary primers, and dNTP mix (1:1:1:1) were 
synthesized and purchased from Gibco (USA). Taq polymerase and PGR buffer were 
obtained from Duncan (UK). 
4.6.2 Methods 
First-strand cDNA was reverse transcribed from 200 ng of freshly diluted and 
DNase I-treated total RNA in a final concentration of 0.2 iiM AP, Ix first-strand 
buffer, 25 |LIM dNTP mix (1:1:1:1), 10 mM DTT, and 2 U/jul of SUPERSCRIPT™ II 
RNase H reverse transcriptase (Appendix A, Table A3). For negative control of 
reverse transcription, SUPERSCRIPT™ II RNase H reverse transcriptase was 
excluded from the reaction mix. RT was performed in a thermal cycler and the PGR 
profile was as follows: 42�C for 5 min, 50�C for 50 min, 70�C for 15 min and hold at 
4°C. The synthesized first-strand cDNA was stored at -20°C. 
Non-fluorescent RT-PCR (Non-fluoroDD PGR) was performed by using 4 jul 
of first-strand cDNA synthesized in a final concentration Ix PGR buffer, 50 jiM 
dNTP mix (1:1:1:1), 0.35 |aM AP, 0.35 j^ M ARP and 0.05 U/jul of Taq polymerase 
(Appendix A, Table A4). RT-PCR was performed in a thermal cycler and the PGR 
profile was as follows: 95�C for 2 min, followed by 4 cycles of 92�C for 15 sec, 50�C 
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for 30 sec, 72�C for 2 min, and followed by 30 cycles of 92�C for 15 sec, 60�C for 30 
sec, 72°C for 2 min, and 72°C for 7 min and hold at 4°C. The amplified cDNA 
fragments were resolved on 1.5% agarose, 0.5x TBE gels with ethidium bromide 
staining. 
4.7 Reverse transcription (RT) and fluorescent PCR 
(fluoroDD PCR) 
The ARP-AP primer combinations which showed differential gene expression 
patterns of A-H (Table 4.1) in non-fluoroDD preliminary screenings were chosen for 
performing fluoroDD PCR. 
4.7.1 Materials 
HIEROGLYPH™ mRNA profile and fluoroDD kits were purchased from 
Beckman (USA). 
4.7.2 Methods 
Procedures for the first-strand cDNA synthesis (Appendix A, Table A3) and 
fluoroDD PCR (Appendix A, Table A5) were the same as that described in section 
4.6.2 except that APs and dNTP mix (1:1:1:1) for first-strand cDNA synthesis were 
obtained from HIEROGLYPH™ mRNA profile kit, while TMR-APs, ARPs and 
dNTP mix (1:1:1:1) for fluoroDD PCR were obtained from fluoroDD kit. The TMR-
labeled cDNA fragments were stored at -20°C. 
4.8 Fluorescent differential display 
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Following fluoroDD PCR, the TMR-labeled cDNA fragments were resolved 
on high-resolution fluoroDD gels and analyzed by fluorescent imaging and scanning 
to review differentially expressed cDNA fragments. 
4.8.1 Materials 
Notched and unnotched glass plates, spacers, 48-well comb, glass shield, HR-
1000丁 M 5.6% denaturing poly aery lamide gel, 0.5x TBE buffer, Ix TBE buffer, and 
TMR-labeled molecular weight DNA marker were purchased from Beckman (USA). 
Sodium hydroxide, ammonium persulfate, and TEMED were purchased from Sigma 
(USA). 
4.8.2 Methods 
A high resolution polyacrylamide fluoroDD gel was set by mixing 70 ml of 
5.6% denaturing HR-1000 gel with 320 jul of freshly prepared 10% ammonium 
persulfate and 32 |il TEMED. The gel was allowed to polymerize for overnight. 
Prior to loading samples to fluoroDD gel, a flat field baseline was performed for the 
gel in the GenomyxSC fluorescent imaging scanner (Genomyx, USA). 
FluoroDD gel electrophoresis was carried out in the GenomyxLR DNA 
electrophoresis system (Genomyx, USA). Upper and lower buffer chambers were 
filled with 125 ml of 0.5x and 250 ml of Ix TBE, respectively. Four microliters of 
samples and 1.2 |ul of TMR-labeled molecular weight DNA marker were mixed with 
2 and 1.5 |al fluoroDD loading dye, respectively. Samples and DNA marker were 
denatured and concentrated in a thermal cycler at 95°C for 4 min. The DNA marker 
and samples were loaded entirely onto the gel and run at 3000V, lOOW, 55°C for 3 to 
5 hr. After gel electrophoresis, the gel was dried in the GenomyxLR DNA 
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electrophoresis system at 50°C for 25 min and washed with 4 liters of distilled water. 
Drying and washing steps were repeated as mentioned in the above. The gel was 
dried and scanned in the GenomyxSC fluorescent imaging scanner. 
4.9 Excision of differentially expressed cDNA fragments 
cDNA fragments which showed differential gene expression patterns of A-H 
(Table 4.1) were excised from the gel for reamplification, subcloning, reverse dot blot 
analysis, sequencing and Northern blot analysis. 
4.9.1 Materials 
An excision workstation, a virtual grid, and an excision bridge were purchased 
from Genomyx (USA). Sterile blades were purchased from Swann-Morton® 
(England). 
4.9.2 Methods 
The computer-scanned image of the fluoroDD gel was aligned with a physical 
grid to accurately locate the positions of cDNA fragments on the fluoroDD gel before 
gel excision. The cDNA fragments were then excised with an excision workstation 
and sterile blades. To check the accuracy of cDNA fragment excision, the gel was re-
scanned after gel excision. DNA was eluted from the excised cDNA fragment in 25 
1^1 TE buffer [10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA (pH 7.5)] at 37�C for 1 hr 
and stored at -20�C. 
4.10 Reamplification of excised cDNA fragments 
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Excised cDNA fragments were reamplified before subcloning. Full-length T7 
promoter 22-mer (5'-GTAATACGACTCACTATAGGGC-3') and M13 reverse (-48) 
f 
24-mer (5'-AGCGGATAACAATTTCACACAGGA-3') primers were used for 
reamplification of cDNA fragments as partial sequences of T7 promoter (17-mer) and 
Ml3 reverse (16-mer) were present in the 3'-AP and 5'-ARP of each cDNA fragment, 
respectively. The sizes of the reamplified PCR products should be 13 bp longer than 
that occurred in fluoroDD gels because the Ml3 reverse and T7 promoter primers 
were lengthened by 8 and 5 nucleotides, respectively. 
4.10.1 Materials 
Full-length T7 promoter 22-mer and Ml3 reverse (-48) 24-mer primers in re-
amplification primer sub-kit 6 were purchased from Beckman (USA). Taq 
polymerase and PCR buffer were obtained from Duncan (UK). dNTP mix (1:1:1:1) 
was purchased from Gibco (USA). 
4.10.2 Methods 
Four microliters of DNA gel elute were reamplified in a final concentration of 
Ix PCR buffer, 20 ^M dNTP mix (1:1:1:1), 0.2 j^MMlS reverse (-48) 24-mer primer, 
0.2 i^M T 7 promoter 22-mer primer, and 0.05 U/|LI1 of Taq polymerase (Appendix A, 
Table A6). PCR was performed in a thermal cycler and the PCR profile was as 
follows: 95°C for 2 min, followed by 4 cycles of 92�C for 30 sec, 50�C for 30 sec, 
72�C for 2 min, followed by 25 cycles of 92�C for 30 sec, 60�C for 30 sec, 72�C for 2 
min, and 72°C for 7 min and hold at 4°C. Two microliters of reamplified PCR 
products were resolved on a 2% agarose, 0.5x TBE gel with ethidium bromide 
staining. 
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4.11 Subcloning of reamplified cDNA fragments 
Reamplified cDNA fragments were subcloned for reverse dot blot analysis, 
DNA sequencing and Northern blot analysis. The reamplified cDNA fragments 
containing 3’ A-overhang were subcloned by T/A cloning using either pT-Adv or 
pCR®II-TOPO® vector derived from AdvanTAge™ PCR or TOPO TA cloning kit, 
respectively. Phenol-chloroform extraction method (Ohyama, 1997) was used to 
screen for recombinant subclones, and the size of recombinant plasmid DNA should 
be larger than that of the pT-Adv (3.9 kb) or pCR®II-TOPO® (4.0 kb) vector alone. 
The size of inserts was confirmed by Eco?l digestion. Using pT-Adv vector, the size 
of DNA insert should be 18 bp longer than that of the reamplified cDNA fragments, 
as there were 8 nucleotide before and after the T/A cloning site and 10 nucleotides 
were extended after Ecom restriction digestion. For pCR®II-TOPO® vector, the size 
of the DNA insert should be lengthened by 20 bp, as there were 10 nucleotides before 
and after the T/A cloning site and 10 nucleotides were extended after EcoKi digestion. 
4.11.1 Materials 
AdvanTAge™ PCR cloning kit was purchased from Clontech (USA). TOPO 
TA cloning kit was obtained from Invitrogen (USA). Ampicillin was purchased from 
Sigma (USA). X-gal, IPTG, and sodium chloride were purchased from USB (USA). 
Restriction enzymes and buffers were purchased from New England Biolabs (UK). 




Subcloning was simply performed using AdvanTAge™ PCR or TOPO TA 
cloning kit. Using AdvanTAge™ PCR cloning kit, ligation reaction was made up of 
•f 
1 j^ l reamplified PCR product in a final concentration of Ix ligation buffer, 5 ng/jul of 
pT-Adv vector (Figure 4.6) and 4 U/|il of T4 DNA ligase. The mixture was incubated 
at 14�C for overnight. Alternatively, for TOPO TA cloning kit, ligation reaction was 
prepared by mixing 1 jul of reamplified PCR product in a final concentration of 0.2 M 
NaCl, 0.01 M M g C l 2 , and 0.17 ng/ul pCR®II-TOPO® vector (Figure 4.7). The 
mixture was incubated at room temperature for 5 min. TOP lOF E.coli competent 
cells were mixed with 2 of ligation mixture, and chilled on ice for 30 min. Heat 
shock was carried out in 42�C water bath for 90 sec. Competent cells were chilled on 
ice for 2 min and then incubated with 800 [xl LB medium at 37°C for 1 hr. After 
incubation, cells were centrifuged at 2,500 rpm at 4 � C for 8 min. Supernatant was 
discarded and cells were resuspended in 300 jul LB medium. Transformed cells were 
spread on LB agar plates containing 100 jug/ml ampicillin, 40 jal of 40 mg/ml X-Gal, 
and 40 |ul of 100 mM IPTG. The plates were placed inverted at 37°C incubator for 16 
hr. 
Individual white colony was inoculated in 3 ml of LB medium containing 100 
lag/ml ampicillin, and incubated in a 37�C shaker for 16 hr. Recombinant clones were 
screened by mixing an equal volume (30 of bacterial culture and phenol: 
chloroform: isoamyl alcohol (25:24:1). The mixture was vortexed vigorously and 
centrifuged at 14,000 rpm for 2 min. Twenty microliters of supernatant was resolved 
on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. 
The sizes of DNA inserts in recombinant clones were confirmed by EcoRl 
digestion. One milliliter of culture was centrifuged at 14,000 rpm for 1 min. 
Supernatant was discarded and cell pellet was resuspended in 17 \il autoclaved 
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Figure 4.6. The restriction map and multiple cloning site of pT-Adv vector used for 
subcloning of reamplified cDNA fragments (adapted from AdvanTAge™ PGR 
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Figure 4.7. The restriction map and multiple cloning site of PCR®II-TOPO® vector 
used for subcloning of reamplified cDNA fragments (adapted from TOPO cloning kit 
user manual). 
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distilled water. Bacterial cells were boiled for 1 min and centrifliged at 14,000 rpm 
for 1 min. Seventeen microliters of supernatant were digested with 10 units of Eco?l 
at 37�C for 2 hr. The EcoKi digests were then resolved on 2% agarose, 0.5x TBE gels 
with ethidium bromide staining. 
4.12 Reverse dot blot analysis of subcloned cDNA fragments 
Reverse dot blot analysis was used to screen out any false-positive cDNA 
subclones that co-migrated with the cDNA fragments and/or contaminated cDNA 
fragments during gel excision. In reverse dot blot analysis, differential gene 
expression patterns of cDNA fragments were analyzed by hybridizing 4 replicate 
blots dotted with an equal amount of cDNA subclones with 4 different DIG-labeled 
cDNA library probes prepared from the liver RNA of WT/Fed, WT/Starved, KO/Fed 
and KO/Starved mouse groups. To ensure the reliability of reverse dot blot analysis, 
two PPARa-dependent and fasting-responsive genes (cytochrome P450 4A14 and 
medium-chain acyl-CoA dehydrogenase) and one PPARa-independent and fasting-
responsive gene (glyceraldehyde-3-phosphate dehydrogenase) with known differential 
gene expression patterns, were dotted in the 4 blots as the gene expression controls. 
4.12.1 Materials 
Bio-Dot micro filtration apparatus was purchased from BIO-RAD (USA). 
Hybond-N+ membrane was purchased from Amersham Biosciences (England). Gel 
blotting paper was purchased from Schleicher & Schuell (Germany). Three MM filter 
paper was purchased from Whatman® (UK). Kapak SealPAK pouches were 
purchased from KAPAK® (USA). SMART™ PCR cDNA synthesis kit was 
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purchased from Clontech (USA). DIG Easy Hyb buffer, Tween 20, blocking reagent, 
anti-DIG-alkaline phosphatase antibody, DIG-Chem-Link labeling, nitro blue 
f 
tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) were 
purchased from Roche (Germany). MOPS was purchased from USB (USA). Glucose, 
potassium acetate, maleic acid and lysozyme were purchased from Sigma (USA). 
Glacial acetic acid was purchased from Merck (USA). 
4.12.2 Methods 
4.12.2.1 Mini-preparation of plasmid DNA from recombinant clones — alkaline 
lysis method 
Two milliliters of overnight cultures were centrifliged at 2,500 rpm for 8 min 
and supernatant was discarded. Cell pellet was resuspended in 100 |LI1 of Solution I 
[50 mM glucose, 25 mM Tris-HCl (pH 8.0) and 10 mM EDTA (pH 8.0)] containing 4 
mg/ml lysozyme and mixed by vortexing. Two hundred microliters of Solution II 
(0.2 N NaOH and 1% SDS) were added and mixed gently by inverting for several 
times. The mixture was allowed to stand at room temperature for 5 min. One 
hundred and fifty microliters of Solution III (3 M potassium acetate and 5 M glacial 
acetic acid) were added and mixed immediately by inverting for several times. The 
mixture was kept on ice for 5 min and centrifuged at 14,000 rpm for 5 min at 4°C. 
Supernatant was transferred to new tubes and mixed with equal volume of phenol: 
chloroform: isoamyl alcohol (25:24:1) by vortexing. The tubes were centrifuged at 
14,000 rpm for 2 min at room temperature. Three hundred microliters of supernatant 
were transferred to new tubes and mixed with 600 jal of absolute ethanol. After 5 min 
of incubation at room temperature, the tubes were centrifuged at 14,000 rpm for 8 min. 
Supernatant was discarded and DNA pellet was air-dried. DNA pellet was 
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resuspended in 150 |al autoclaved distilled water. At least 80 jug of DNA was 
required for each cDNA subclone for reverse dot blot analysis. 
4.12.2.2 Dot blot preparation 
Four identical blots were prepared for reverse dot blot analysis by using a Bio-
Dot® microfiltration apparatus. Each blot was first pre-wetted with distilled water in 
a glass tray and then each dot was rehydrated with 400 |li1 distilled water using the 
Bio-Dot® microfiltration apparatus. After rehydration, 5 or 10 |Lig of each 
recombinant cDNA fragment prepared in section 4.12.2.1 was diluted to a final 
volume of 150 \A in distilled water and then applied to each dot on the blot using the 
Bio-Dot® microfiltration apparatus. After the DNA samples were applied, 400 jLil of 
0.4 N sodium hydroxide was applied to wash each of the dotted DNA samples on the 
membrane twice. The membranes were disassembled from the apparatus and placed 
on top of 3 MM filter papers pre-soaked in denaturation solution (0.5 M NaOH and 
1.5 M NaCl) for 5 min, neutralization solution [IM Tris-HCl (pH 7.5) and 1.5 M 
NaCl] for 15 min, and 2x SSC solution (3 M sodium chloride and 0.3 M sodium 
citrate, pH 7.0) for 10 min. The membranes were air-dried and then sandwiched 
between 2 pieces of 3 MM filter paper and 1 piece of gel blotting paper for baking at 
80°C for 2 hr. The membranes were stored in scalable bags at room temperature. 
4.12.2.3 cDNA library and probe preparation 
Total RNA from four different groups of mice (WT/Fed, WT/Starved, KO/Fed 
and KO/Starved) was reverse transcribed and reamplified according to the instructions 
of S M A R T ™ PGR cDNA synthesis kit. One microgram of total RNA was reverse 
transcribed in a final concentration of Ix first-strand buffer, 2 mM DTT, 1 mM dNTP 
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mix, 1 laM 3' SMART CDS primer II A, 1 |aM SMART II oligonucleotide and 10 
U/|il PowerScript™ reverse transcriptase (Appendix A, Table Al). RT was 
A 
performed in a thermal cycler (GeneAmp® PCR system 9700) and the PCR profile 
was 42�C for 1 hr, 72�C for 7 min and hold at 4�C. First-strand cDNA was diluted to 
50 |al with 40 jiil TE buffer [10 mM Tris-HCl (pH7.5) and 1 mM EDTA (pH 7.5)] and 
stored at -20°C. 
Optimal number of PCR cycles was determined by setting two tubes for PCR 
for each sample. For each tube, 5 \i\ of diluted first-strand cDNA was amplified in a 
final concentration of Ix advantage 2 PCR buffer, 0.2 mM dNTP mix, 0.2 juM 5' PCR 
primer II A and 0.04 U/|ul advantage 2 polymerase mix (Appendix A, Table A8). 
PCR was performed in a thermal cycler (GeneAmp® PCR system 2400) and the PCR 
profile was as follows: 95°C for 1 min, followed by 24 cycles of 95°C for 15 sec, 
65°C for 30 sec, 68°C for 6 min, and hold at 4°C. One of the tubes was kept on ice 
after 15 cycles, while another one was allowed to continue the cycles. Aliquots were 
removed at 15, 18, 21 and 24 cycles and 5 jul of each aliquot was resolved on a 1.2% 
agarose, 0.5x TBE gel with ethidium bromide staining. After determining the optimal 
number of cycles, additional cycles were performed for the tube hold at 15 cycles as 
follows: 95�C for 1 min, followed by additional cycles of 95�C for 15 sec, 65�C for 30 
sec, 68°C for 6 min, and hold at 4°C. After addition of cycles, 5 |LI1 of PCR products 
was resolved on a 1.2% agarose, 0.5x TBE gel with ethidium bromide staining. 
Ninety microliters of PCR products were diluted to 200 jul with nuclease-free water, 
mixed with 200 |li1 of phenol: chloroform: isoamyl alcohol (25:24:1), and mixed 
thoroughly by vortexing. The mixture was centrifuged at 14,000 rpm for 15 min. 
One hundred and eighty microliters of supernatant were transferred to new tubes and 
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precipitated by mixing with 18 |li1 of 3 M sodium acetate and 360 jal of 100% ethanol 
at -80°C for overnight. After precipitation, the tubes were centrifiiged at 14,000 rpm 
( 
for 30 min, and supernatant was discarded. DNA pellet obtained was washed twice 
by 1 ml of 70% ethanol and centrifiiged at 14,000 rpm for 10 min after each washing. 
DNA pellet was air-dried and resuspended in 36 |li1 nuclease-free water. Purified 
cDNA library was stored at -20°C. Eighteen microliters of each of the purified cDNA 
libraries were labeled with 2 j^ l of DIG-Chem-Link reagent and incubated at 85�C for 
30 min. Labeling reaction was stopped with 5 |al of stop solution and the DIG-labeled 
cDNA libraries were stored at 4°C. 
4.12.2.4 Hybridization and signal detection 
Four identical blots prepared in section 4.12.2.2 were each pre-hybridized with 
25 ml DIG Easy Hyb buffer in scalable bags at 42°C for 2 hr. Twenty-five microliters 
of each of the four DIG-labeled cDNA libraries were boiled for 10 min and chilled on 
ice. Denatured probes were added to the scalable bag with pre-hybridization buffer, 
and the blots were hybridized separately at 42°C for overnight. The hybridized blots 
were washed in 2x SSC (3 M sodium chloride and 0.3 M sodium citrate, pH 7.0)/ 
0.1% SDS at room temperature for 5 min twice, 0.5x SSC/ 0.1% SDS at 60�C for 5 
min twice, and washing buffer [0.3% Tween 20 in maleic acid buffer (pH 7.5)] at 
room temperature for 5 min. The washed blots were then incubated in Ix blocking 
solution [Ix blocking solution in maleic acid buffer (pH 7.5)] for 1 hr with shaking at 
room temperature. Afterwards, the blots were incubated with anti-DIG-alkaline 
phosphatase antibody in a final concentration of 0.075 U/ml of Ix blocking solution 
for 1 hr with shaking at room temperature. The hybridized blots were washed in 
washing buffer twice and then equilibrated in detection buffer [0.1 M Tris-HCl (pH 
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9.5) and 0.1 M NaCl] for 5 min. The blots were allowed to develop color in 30 ml of 
detection buffer containing 150 and 112.5 jul o f N B T and BCIP, respectively. Color 
( 
development was terminated with autoclaved distilled water and the color intensity in 
each blot was quantified by a computer software, MultiAnalyst (BIO-RAD, USA). 
4.13 Sequencing of reverse dot blot-confirmed cDNA 
fragments 
cDNA subclones which showed matched differential gene expression patterns 
in both fluoroDD and reverse dot blot analyses were selected for DNA sequencing. 
DNA sequencing was performed by using CEQ dye terminator cycle sequencing kit, 
M13 forward (-20) (5 '-GTAAAACGACGGCCAG-3') and M13 reverse sequencing 
primers (5 '-CAGGAAACAGCTATGAC-3,). 
4.13.1 Materials 
QIAGEN® spin miniprep kit was purchased from QIAGEN (Germany). CEQ 
dye terminator cycle sequencing kit was purchased from Beckman (USA). Ml3 
forward (-20) and Ml3 reverse primers were obtained from Gibco (USA). EDTA and 
sodium acetate were purchased from Sigma (USA). 
4.13.2 Methods 
4.13.2.1 Mini-preparation of plasmid DNA from recombinant clones — Qiagen 
method 
Ten milliliters of overnight cultures were centrifuged at 2,500 rpm for 20 min. 
Supernatant was discarded and cell pellet was resuspended in 250 jul of Buffer PI 
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containing RNase A. Two hundred and fifty microliters of Buffer P2 were added and 
mixed by inverting 4-6 times. Three hundred and fifty microliters of Buffer P3 were 
added and mixed immediately by inverting 4-6 times. Samples were centrifuged at 
14,000 rpm for 10 min. Supernatant was applied to QIAprep spin columns in a 2-ml 
collection tube and centrifliged at 14,000 rpm for 1 min. The flow-through was 
discarded. The QIAprep spin columns were washed by adding 0.75 ml of Buffer PE 
and centrifuged at 14,000 rpm for 1 min. The flow through was discarded and the 
tubes were centrifliged for an additional 1 min to remove residual wash buffer. The 
QIAprep spin columns were transferred to clean tubes, incubated with 100 jul of 
nuclease-free water for 1 min and centrifliged at 14,000 rpm for 1 min to elute DNA. 
The DNA was stored at 4 � C and 20-40 jug of DNA was obtained for each cDNA 
subclone. 
4.13.2.2 DNA sequencing by CEQ dye terminator cycle sequencing 
DNA sequencing reaction was prepared by combining 100 fmol dsDNA in 6 
|ul sterile water with 2 |LI1 of lOx sequencing reaction buffer, 1 |ul of dNTP mix, 2 jul of 
ddUTP dye terminator, 2 \i\ of ddGTP dye terminator, 2 j^ l of ddCTP dye terminator, 
2 1^1 of ddATP dye terminator, 2 |ul of 1.6 juM Ml3 forward (-20) or Ml3 reverse 
primer, and 1 |LI1 of polymerase enzyme in a 0.2 ml thin-wall PCR tube. Reaction 
components were mixed by finger tapping and consolidated by brief centrifugation. 
PCR sequencing reaction was performed in a thermal cycler (GeneAmp® PCR system 
9700) and the PCR profile was as follows: 30 cycles of 96�C for 20 sec, 50°C for 20 
sec, 60°C for 4 min, and hold at 4°C. For the meantime, stop solution with final 
concentration of 1.5 M sodium acetate and 50 mM EDTA was freshly prepared. For 
each sample, PCR sequencing reaction was transferred to a 1.5 ml sterile tube 
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containing 4 )al of the freshly prepared stop solution and 1 of 20 mg/ml of glycogen, 
and then mixed vigorously by vortexing. To each sample, 60 [il cold 95% (v/v) 
ethanol/H20 was added and mixed by vortexing. Immediately, samples were 
centrifuged at 14,000 rpm at 4 � C for 20 min. All of the supernatant was decanted 
carefully. The pellet was rinsed with 200 jul cold 70% (v/v) ethanol/HsO twice. For 
each rinse, samples were centrifuged immediately at 14,000 rpm at 4°C for 25 min. 
After centrifugation, all of the supernatant was decanted carefully. Afterwards, tubes 
were wrapped with parafilms and holes were pinched on parafilms for solvent 
evaporation. The DNA pellet was vacuum dried for at least 40 min until all solvent 
was evaporated. To each tube, 40 ]il of sample loading buffer (from the Beckman 
sequencing kit) was added and the DNA pellet was allowed to rehydrate for 30 min 
before resuspended with a pipettor. The resuspended DNA samples were transferred 
to a 96-well polypropylene sample plate recommended for the CEQ automated DNA 
sequencer (Beckman). Each of the resuspended sample was overlayed with one drop 
of light mineral oil (provided by the sequencing kit). The sample plate was loaded 
into the CEQ DNA sequencer and DTCS-2 method was used for dsDNA plasmid 
sequencing using long capillary column. 
4.13.2.3 BLAST search against computer database 
After DNA sequencing, sequence homology was performed by searching the 
non-redundant, mouse and human ESTs using the Basic Local Alignment Search Tool 
databases (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). 
4.14 Northern blot analysis of sequenced cDNA fragments 
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The differential gene expression patterns of sequenced cDNA clones were 
further confirmed by Northern blot analysis. 
f 
4.14.1 Materials 
QIAGEN® plasmid midi and QIAquick® gel extraction kits were purchased 
from QIAGEN (Germany). DIG Easy Hyb, Tween 20, blocking reagent, anti-DIG-
alkaline phosphatase antibody, DIG-labeled RNA molecular weight marker I (0.39-
6.9 kb), DIG DNA labeling kit, nitro blue tetrazolium chloride (NBT) and 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP) were purchased from Roche (Germany). MOPS 
was purchased from USB (USA). Formaldehyde (37%) was purchased from Riedel-
de Haen (Germany). Hybond-N+ membrane was purchased from Amersham 
Biosciences (England). Gel blotting paper was purchased from Schleicher & Schuell 
(Germany). Three MM filter paper was purchased from Whatman® (UK). Kapak 
SealPAK pouches were purchased from KAPAK® (USA). Maleic acid was 
purchased from Sigma (USA). N,N-dimethylformamide was purchased from Fluka 
(Switzerland). 
4.14.2 Methods 
4.14.2.1 Midi-preparation of plasmid DNA from recombinant clones for probe 
preparation — Qiagen method 
One hundred milliliters of cultures were centrifuged at 6,000 rpm at 4°C for 20 
min. Supernatant was discarded and cell pellet was resuspended in 4 ml of buffer PI 
by vortexing. Four milliliters of buffer P2 were added and mixed by inverting 4-6 
times, and incubated at room temperature for 5 min. Four milliliters of buffer P3 
were added and mixed immediately by inverting 4-6 times, and incubated on ice for 
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30 min. Samples were centrifuged at 12,000 rpm at 4 � C for 30 min. Supernatant was 
applied to buffer equilibrated QIAGEN-tip 100 and allowed to enter the resin by 
f 
gravity. The QIAGEN-tip 100 was washed with 10 ml buffer QC twice by gravity. 
DNA was eluted with 5 ml buffer QF and precipitated by adding 3.5 ml isopropanoL 
Samples were mixed and centrifuged at 9,500 rpm at 4 � C for 30 min. Supernatant 
was discarded and DNA pellet was washed with 2 ml 70% ethanol, and centrifuged at 
9,500 rpm for 10 min. Supernatant was discarded and DNA pellet was air-dried, and 
resuspended in 150 |ul nuclease-free water. DNA was stored at 4°C, and about 100 fig 
of DNA was obtained for each cDNA subclone. 
4.14.2.2 DIG-labeled cDNA probe preparation 
The cDNA fragments were released from the cloning vectors for probe 
preparation. Recombinant plasmid DNA (~20 |ig) was digested with EcoRl at 37°C 
or BstXl at 55°C for overnight. Digested DNA was separated in 1.5% agarose�0.5x 
TBE preparative gels with ethidium bromide staining. Inserts of cDNA fragments 
were excised from the gel and purified using QIAquick® gel extraction kit. Gel slices 
were weighed and added with 3 gel volumes of buffer QG (1 g � 1 ml), and incubated 
at 50°C until completely dissolved. One gel volume of isopropanol was added and 
mixed. DNA was applied to QIAquik spin columns in 2-ml collection tubes and 
centrifliged at 14,000 rpm for 1 min. The flow-through was discarded. The QIAquik 
spin columns were incubated with 0.75 ml buffer PE for 5 min and centrifuged at 
14,000 rpm for 1 min. The flow-through was discarded and the QIAquik spin 
columns were centrifuged at 14,000 rpm for 1 min to remove residue wash buffer. 
The QIAquik spin columns were transferred to clean tubes, incubated with 200 jul 
nuclease-free water for 1 min and centrifliged at 14,000 rpm for 1 min to elute DNA. 
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To concentrate DNA for labeling, 200 jul of DNA eluted was mixed with 20 jul of 3 M 
sodium acetate (pH 5.2) and 400 jul of 100% ethanol, and incubated at -80�C for 
overnight precipitation of DNA. Samples were centrifuged at 14,000 rpm for 30 min 
and supernatant was discarded. DNA pellet obtained was washed by 70% ethanol and 
centrifuged at 14,000 rpm for 1 min. Supernatant was discarded carefully and 
washing steps were repeated twice. Eventually, DNA pellet was air-dried, 
resuspended in 17 jul of nuclease-free water, and stored at -80°C. 
Purified cDNA fragments were labeled by random prime labeling using the 
DIG DNA labeling kit. Fifteen microliters of DNA template (1000 - 2000 ng) was 
denatured by boiling for 15 min and chilled on ice for 10 min. Denatured DNA 
template was labeled with 2 jLil hexanucleotide mix, 2 jul dNTP mix and 1 jiil Klenow 
enzyme at 37°C for 20 hr. Labeling reaction was terminated with 2 |ul of 0.2 M 
EDTA (pH 8.0). Labeled probes were used immediately for hybridization or stored at 
-20°C until use. 
4.14.2.3 Formaldehyde-agarose gel electrophoresis 
Formaldehyde-agarose gel (1%) was prepared by mixing 1.5 g agarose with 
135 ml autoclaved distilled water, 15 ml lOx MOPS, and 2.7 ml 37% formaldehyde. 
Twenty or thirty micrograms of total RNA dissolved in 10 jil of 100% formamide was 
mixed with 10 jul of core mix A (5 of nuclease free water, 3 \i\ of 37% 
formaldehyde, and 2 i^l of lOx MOPS). Samples were incubated at 68�C water bath 
for 15 min and then cooled on ice for 10 min. After denaturation, 2.3 jul of core mix 
B (2 |Lil of 6X loading dye and 0.3 [xl of 1 mg/ml ethidium bromide) was added. Five 
microliters of DIG-labeled RNA molecular weight marker I (50 ng) was mixed with 5 
ILil 100% formamide, and 10 and 2.3 i^l of core mixes A and B, respectively. RNA 
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samples and RNA marker were loaded entirely onto a 1% formaldehyde-agarose gel 
and electrophoresed at 35V for 15 hr in Ix MOPS buffer. After gel electrophoresis, 
gels were washed in lOx SSC (3 M sodium chloride and 0.3 M sodium citrate, pH 7.0) 
with shaking for 45 min at room temperature. RNA was then transferred from the 
gels onto Hybond-N+ membranes in lOx SSC by upward capillary transfer for 
overnight. The next day, membranes were washed in 5x SSC for 10 min and dried at 
room temperature. Membranes were sandwiched between 2 pieces of 3 MM filter 
paper and gel blotting paper for baking at 80°C for 2 hr. Membranes were stored in 
scalable bags in a desiccator at room temperature. 
4.14.2.4 Hybridization and signal detection 
Membranes prepared in section 4.14.2.3 were pre-hybridized in 25 ml Dig 
Easy Hyb buffer in scalable bags at 42°C for 2 hr. Twenty microliters of labeled 
probes prepared in section 4.14.2.2 were boiled for 10 min and chilled on ice. 
Denatured probes were added to the pre-hybridization buffer for hybridization at 42°C 
in scalable bags for overnight. The hybridized membranes were washed in 2x SSC (3 
M sodium chloride and 0.3 M sodium citrate, pH 7.0)/ 0.1% SDS twice and in 0.5x 
SSC/ 0.1% SDS at 60°C twice. The membranes were washed in washing buffer 
[03% Tween 20 in maleic acid buffer (pH 7.5)] for 5 min and then incubated with Ix 
blocking solution [Ix blocking solution in maleic acid buffer (pH 7.5)] for 1 hr. 
Afterwards, the membranes were incubated with anti-DIG-alkaline phosphatase 
antibody in a final concentration of 0.075 U/ml of Ix blocking solution for 1 hr. The 
membranes were washed in washing buffer twice and then equilibrated in detection 
buffer [0.1 M Tris-HCl (pH 9.5) and 0.1 M NaCl] for 5 min. The membranes were 
allowed to develop color in 30 ml of detection buffer containing 150 and 112.5 jul of 
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NBT and BCIP, respectively. Color development was terminated with autoclaved 
distilled water and the signal intensity in Northern blots was quantified by 
( 
MultiAnalyst (BIO-RAD, USA). 
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Chapter 5 Results 
5.1 Confirmation of genotypes by PCR tail-genotyping 
Since there are no obvious phenotypic differences between the PPARa (+/+) 
and PPARa (-/-) mice, their genotypes were confirmed before used for treatment. In 
agreement to earlier study (Lee et al., 2002), the expected sizes for the PCR products 
were 191 and 1248 bp for PPARa (+/+) (Figure 5.1) and PPARa (-/-) (Figure 5.2) 
mice, respectively. 
5.2 Morphological observation 
It has been reported that fasting leads to accumulation of lipid in the liver of 
mice lacking PPARa expression, and results in fatty livers with a pale color compared 
to that of starved wild-type mice (Kersten et al., 1999; Leone et al., 1999; Hashimoto 
et al., 2000). In addition, hepatomegaly was observed in the liver of starved PPARa-
null mice (Leone et al., 1999). Consistent with the previous studies, both 
hepatomegaly and pale livers were observed in the starved PPARa-null mice in the 
present study (Figure 5.3A). There was a significant increase (1.35-fold) in the liver 
weight (as % body weight) in PPARa-null mice starved for 72 hr compared to their 
corresponding fed controls, whereas a significant decrease (15%) was obtained for 
starved wild-type mice (Figure 5.3B). These results indicated that PPARa is pivotal 
in regulating lipid homeostasis during starvation, as lipid accumulation and liver 
enlargement were observed in the liver of PPARa-null mice which lack PPARa 
expression. 
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PPARa (+/+) PPARa (-/-) 
Fed Starved (72 hr) Fed Starved (72 hr) 
B 
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1 4 r — L - n T  ^ 1 •Fed I i n ^ 
PPARa (+/+) PPARa (-/-) 
Figure 5.3. E ffect of 7 2-hr s tarvation o n 1 ivers of fed and s tarved P PARa (+/+) and 
PPARa (-/-) mice. (A) Gross morphology and color of livers. (B) Liver weight 
(expressed as % body weight). Data are expressed as means 土 S.D. (n=13-17). 
Independent Student's t tests were performed to evaluate the statistical significance 
between the fed and starved mice of the same genotype. < 0.01; < 0.001. 
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5.3 Serum P-hydroxybutyrate, triglyceride and cholesterol 
levels 
To study the role of PPARa in maintaining the lipid homeostasis during 
energy deprivation such as in fasting state, serum P-hydroxybutyrate, triglyceride, and 
cholesterol were measured in fed and starved wild-type and PPARa-null mice. 
During food deprivation, the capacity of fatty acid oxidation increases and 
ketone bodies such as p-hydroxybutyrate are generated to serve as energy fuel for 
extrahepatic tissues such as brain, muscle and kidney during starvation. Previous 
studies have shown that there is a dramatic increase in serum beta-hydroxybutyrate 
level in starved wild-type mice, but the increase in starved PPARa-null mice is much 
less mark (Kersten et al., 1999; Leone et al., 1999; Hashimoto et al., 2000). Similarly, 
the increases in serum beta-hydroxybutyrate levels for starved wild-type and PPARa-
null mice compared to their corresponding fed controls were 23.17- and 2.10-fold, 
respectively (Figure 5.4A). These results indicated that PPARa plays a critical role in 
ketone body formation such as P-hydroxybutyrate in the course of energy deprivation. 
In both wild-type and PPARa-null mice, fasting leads to decrease in plasma 
triglyceride levels (Hashimoto et al., 2000). Consistently, 72 hr-fasting in the present 
study resulted in 32% and 35% decreases in serum triglyceride levels in starved wild-
type and starved PPARa-null mice, respectively, compared to their corresponding fed 
controls (Figure 5.4B). The decreases in serum triglyceride levels in both wild-type 
and PPARa-null mice in response to starvation were not dependent on the presence of 
PPARa. 
It has been reported that fasting in healthy and nonobese human is 
accompanied by an increase in serum total cholesterol concentration and the increase 
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Figure 5.4. Effect of 72-hr starvation on (A) serum beta-hydroxybutyrate level; (B) 
serum triglyceride level; and (C) serum cholesterol level in fed and starved PPARa (+/+) 
and PPARa (-/-) mice. Data are expressed as means 土 S.D. (n二 13-17). Independent 
Student's t tests were performed to evaluate the statistical significance between the fed 
and starved mice of the same genotype. < 0.01; < 0.001. 
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jk 
is associated with weight loss (Savendahl and Underwood, 1999). Interestingly, 72-hr 
of fasting resulted in a 1.38-fold increase in serum total cholesterol level for wild-type 
mice compared to its fed control, but a 31% decrease for PPARa-null mice (Figure 
5.4C). The results appeared to dictate the essential role of PPARa in maintaining and 
elevating serum cholesterol level during fasting. 
5.4 RT and non-fluoroDD PGR 
According to the fluoroDD manual obtained from Beckman (USA), there are 
twelve different APs and twenty different ARPs, i.e. 240 different AP-ARP primer 
combinations, which can be used for performing RT-PCR. However, practically, not 
all of the AP-ARP primer combinations could give our desired differential gene 
expression patterns (A-H) as summarized in Table 4.1. Therefore, non-fluoroDD 
preliminary screenings using non-fluorescent APs, which are cheaper than the 
fluorescent TMR-APs, were used to screen for those AP-ARP primer combinations 
that would give the obvious differential gene expressions of A-H before carrying out 
fluoroDD RT-PCR. 
Totally, seventy-six AP-ARP primer combinations were screened by non-
fluoroDD (Figures 5.5a - 5.15b). Eighteen of the AP-ARP combinations including 
API & ARP6; AP2 & ARP7, ARP 12, ARP 18, and ARP 19; AP3 & ARP2, ARP 12, 
and ARP 17; AP4 & ARP6; AP5 & ARP2, ARP3, ARPIO, and ARP12; AP7 & 
ARP 17; AP9 & ARP3; APIO & ARP12; APl l & ARP12; and AP12 & ARP12 
(Table 5.1) produced differential gene expression patterns of A-H as shown in Table 
4.1. Eight of the AP-ARP combinations failed to give differential gene expressions 
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PPARa (+/+) PPARa (-/-) PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved Fed Starved Fed Starved 
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API & ARP4 
Figure 5.5a. Preliminary screening of API and ARPl, ARPS, and ARP4 primer 
combinations for differential gene expressions by non-fluoroDD. Total RNA of 
livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) 
was reverse transcribed using 3，-API, and amplified by PCR using 3'-API and 
three different 5'-ARPs (ARPl, ARPS, and ARP4). PCR products were resolved 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved 
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AP2 & ARPl 
Figure 5.6a. Preliminary screening of AP2 and ARPl primer combination for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (three mice per group) was reverse transcribed using 3'-AP2 and amplified by PGR using 3'-AP2 and 5'-ARPl. PGR 
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AP2 & ARP8 
Figure 5.6b. Preliminary screening of AP2 and ARPS, ARP7, and ARPS primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (three mice per group) was reverse transcribed using 3'-AP2 and amplified by PCR using 3'-AP2 and three 
different 5'-ARPs (ARP5, ARP7, and ARPS). PCR products were resolved on 1.5% 
agarose, 0.5X TBE gels with ethidium bromide staining. The (*) represents those 
AP-ARP primer combination which showed obvious PPARa-dependent and fasting-




PPARa (+/+) PPARa (-/-) PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved Fed Starved Fed Starved 
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AP2 & ARP18* AP2 & ARP19* 
Figure 5.6c. Preliminary screening of AP2 and ARP3, ARP 12, ARP 18, and ARP19 
primer combinations for differential gene expressions by non-fluoroDD. Total RNA 
of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per 
group) was reverse transcribed using 3'-AP2 and amplified by PCR using 3'-AP2 
and four different 5,-ARPs (ARP3, ARP12, ARP 18, and ARP 19). PCR products 
were resolved on 1.5% agarose, 0.5X TBE gels with ethidium bromide staining. The 
(*) represents those AP-ARP primer combinations which showed obvious PPARa-
dependent and fasting-responsive cDNA fragments (patterns A and B in Table 4.1) 
and were used for performing fluoroDD. 
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PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved 
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Figure 5.7a. Preliminary screening of AP3 and ARP2 and ARP12 primer 
combinations for differential gene expressions by non-fluoroDD. Total RNA of 
livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) 
was reverse transcribed using 3'-API and amplified by PGR using 3'-AP3 and two 
different 5,-ARPs (ARP2 and ARP12). PGR products were resolved on 1.5% 
agarose, 0.5X TBE gels with ethidium bromide staining. The (*) represents those 
AP-ARP primer combinations which showed obvious PPARa-dependent and 
fasting-responsive cDNA fragments (patterns B and F in Table 4.1) and were used 
for performing fluoroDD. 
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PPARa (+/+) PPARa (-/-) PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved Fed Starved Fed Starved 
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Figure 5.7b. Preliminary screening of AP3 and ARP 17, ARP 18, ARP 19，and ARP20 primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP3 and amplified by PCR using 3'-AP3 
and four different 5'-ARPs (ARP 17, ARP 18, ARP 19, and ARP20). PCR products 
were resolved on 1.5% agarose, 0.5X TBE gels with ethidium bromide staining. The 
(*) represents those AP-ARP primer combination which showed obvious PP ARa-
dependent and fasting-responsive cDNA fragments (pattern B in Table 4.1) and was 
used for performing fluoroDD. 
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PPARa (+/+) PPARa (-/-) PPARa (+/+) PPARa (-/-) 
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Figure 5.8. Preliminary screening of AP4 and ARP2, ARPS, and ARP6 primer 
combinations for differential gene expressions by non-fluoroDD. Total RNA of 
livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two or three mice per 
group) was reverse transcribed using 3'-AP4 and amplified by PGR using 3'-AP4 
and three different 5'-ARPs (ARP2, ARPS, and ARP6). PGR products were resolved 
on 1.5% agarose, 0.5X TBE gels with ethidium bromide staining. The (*) represents 
those AP-ARP primer combination which showed obvious PPARa-dependent and 
fasting-responsive cDNA fragments (pattern H in Table 4.1) and was used for 
performing fluoroDD. 
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PPARa (+/+) PPARa (-/-) 
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Figure 5.9a. Preliminary screening of AP5 and ARP2 and ARPS primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP5 and amplified by PCR using 3'-AP5 and two 
different 5'-ARPs (ARP2 and ARP3). PCR products were resolved on 1.5% 
agarose, 0.5X TBE gels with ethidium bromide staining. The (*) represents those 
AP-ARP primer combinations which showed obvious PPARa-dependent and 
fasting-responsive cDNA fragments (patterns B and D in Table 4.1) and were used 
for performing fluoroDD. 
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Figure 5.10. Preliminary screening of AP6 and ARP5, ARP6, ARP7, and ARPS primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP6 and amplified by PCR using 3’-AP6 and four 
different 5'-ARPs (ARPS, ARP6, ARP7, and ARPS). PCR products were resolved on 
1.5% agarose, 0.5X TBE gels with ethidium bromide staining. 
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Figure 5.11a. Preliminary screening of AP7 and ARPl3 primer combination for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP7 and amplified by PCR using 3'-AP7 and 5,-ARPl3. PCR 
products were resolved on a 1.5% agarose, 0.5X TBE gel with ethidium bromide 
staining. 
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Figure 5.11b. Preliminary screening of AP7 and ARP14, ARP15, ARP16, and ARP17 primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP7 and amplified by PCR using 3'-AP7 and four 
different 5'-ARPs (ARP14, ARP15, ARP16, and ARP17). PCR products were 
resolved on 1.5% agarose, 0.5X TBE gels with ethidium bromide staining. The (*) 
represents those AP-ARP primer combination which showed obvious PPARa-
dependent and fasting-responsive cDNA fragments (pattern B in Table 4.1) and was 
used for performing fluoroDD. 
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Figure 5.12. Preliminary screening of AP9 and ARP3 and ARP5 primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3'-AP9 and amplified by PCR using 3'-AP9 and two different 5'-
ARPs (ARP3 and ARP5). PCR products were resolved on 1.5% agarose, 0.5X TBE 
gels with ethidium bromide staining. The (*) represents those AP-ARP primer 
combination which showed obvious PPARa-dependent and fasting-responsive cDNA 
fragments (pattern B in Table 4.1) and was used for performing fluoroDD. 
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Figure 5.13. Preliminary screening of APIO and ARP9, ARPIO, ARPl l , and ARP 12 primer combinations for differential gene expressions by non-fluoroDD. Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (two mice per group) was reverse transcribed using 3，-APIO and amplified by PGR using 3，-APIO and four different 5'-ARPs (ARP9, ARPIO, ARPl l , and ARP12). PGR products were resolved 
on 1.5% agarose, 0.5X TBE gels with ethidium bromide staining. The (*) represents 
those AP-ARP primer combination which showed obvious PPARa-dependent and 
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Figure 5.14c. Preliminary screening of APl l and ARP13, ARP 14, ARP 15, and 
ARP 16 primer combinations for differential gene expressions by non-fluoroDD. 
Total RNA of livers of fed and starved PPARa (+/+) and PPARa (-/-) mice (three 
mice per group) was reverse transcribed using 3 ' -APll and amplified by PCR using 
3'-APll and four different 5'-ARPs (ARP13, ARP 14, ARP 15, and ARP 16). PCR 
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and these were due to inconsistent and/or no observable PGR products obtained after 
non-fluoroDD PGR. 
5.5 RT and fluoroDD PGR 
The eighteen AP-ARP primer combinations which showed the desired 
differential gene expression patterns (A-H) in non-fluoroDD preliminary screenings 
were used for performing fluoroDD RT-PCR. Eighteen fluoroDD gels were 
performed and named as gels D (AP3 & ARP 12), E (API & ARP6), G (AP12 & 
ARP 12), HH (AP5 & ARP12), JJ (AP5 & ARPIO), LL (AP4 & ARP6), MM (AP2 & 
ARP7), NN (APll & ARP12), 0 0 (AP9 & ARP3), PP (AP5 & ARP3), QQ (AP3 & 
ARP2), RR (AP3 & ARP 17), SS (AP7 & ARP 17), TT (APS & ARP2), UU (AP2 & 
ARP12), VV (AP2 & ARP18), WW (AP2 & ARP19), and XX (APIO & ARP12) 
(Figures 5.16 - 5.33). Sixty-two PPARa-dependent and fasting-responsive cDNA 
fragments (Dl, D2, D3, D4, E2, E3, Gl, HH2, HH3, JJl, JJ2, JJ3, JJ4, JJ5, LLl, LL4, 
MMl, MM2, MM3, MM4, MM5, NNl, 0 0 1 , 0 0 2 , 0 0 3 , 0 0 4 , 0 0 5 , 0 0 6 , 0 0 7 , 
0 0 8 , 0 0 9 , PPl, PP2, PP3, PP4, QQl, QQ3, QQ4, QQ5, QQ6, RRIO, RRl l , RR12, 
RR15, RR16, SSI, TT3, TT4, TT5, UUl, UU8, UU9, UUlO, VV5, VV6, W 7 , W 8 , 
WWl, WW2, XXI，XX3, and XX4) were identified and excised from the fluoroDD 
gels (Tables 5.2 — 5.9). Among the sixty-two differentially expressed cDNA 
fragments, thirty-four cDNA fragments (Dl, D3, Gl, HH2, LL4, MMl, MM2, MM4, 
NNl, 0 0 1 , 0 0 2 , 0 0 3 , 0 0 4 , 005, 0 0 6 , 0 0 8 , 0 0 9 , PPl, PP2, PP3, PP4, QQl, 
QQ3, QQ4, RRIO, RRl l , RR12, RR16, UUl, VV5, VV6, VV7, VV8, and XXI) 
were up-regulated in 72-hr starved PPARa (+/+) mice compared to their 
corresponding fed controls in a PPARa-dependent manner. Eighteen cDNA 
fragments (D2, E2, JJ5, 0 0 7 , QQ5, QQ6, RR15, SSI, TT3, TT4, TT5, UU8, UU9, 
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Figure 5.16. Fluorescent differential display (gel D) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each 
treatment group were reverse transcribed using 3,-API and amplified in duplicate by 
PCR using 3，-TMR-AP3 and 5'-ARP12. TMR-labeled PGR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.17. Fluorescent differential display (gel E) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each treatment group were reverse transcribed using 3'-API and amplified in duplicate by PGR using 
3'-TMR-APl and 5'-ARP6. TMR-labeled PGR products were resolved on a 5.6% 
denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive cDNA 
fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.18. Fluorescent differential display (gel G) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3'-AP12 and amplified in duplicate by 
PCR using 3'-TMR-AP12 and 5，-ARP 12. TMR-labeled PCR products were resolved on a 5.6% denaturing polyacrylamide gel. The PPARa-dependent and fasting-responsive cDNA fragment, indicated by an arrow, was excised from the gel and subjected to reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.19. Fluorescent differential display (gel HH) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each treatment group were reverse transcribed using 3'-AP5 and amplified in duplicate by 
PCR using 3'-TMR-AP5 and 5'-ARP12. TMR-labeled PGR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.20. Fluorescent differential display (gel J J) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each treatment group were reverse transcribed using 3,-AP5 and amplified in duplicate by PCR using 3'-TMR-AP5 and 5'-ARP10. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.21. Fluorescent differential display (gel LL) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each treatment group were reverse transcribed using 3,-AP4 and amplified in duplicate by PCR using 3'-TMR-AP4 and 5'-ARP6. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M，TMR-labeled molecular weight DNA marker. 
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Figure 5.22. Fluorescent differential display (gel MM) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from three mice of each 
treatment group were reverse transcribed using 3'-AP2 and amplified in duplicate by 
PCR using 3'-TMR-AP2 and 5'-ARP7. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PP ARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.23. Fluorescent differential display (gel NN) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3,-API 1 and amplified in duplicate by PCR using 3'-TMR-APl 1 and 5'-ARP12. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. The PPARa-dependent and fasting-
responsive cDNA fragment, indicated by an arrow, was excised from the gel and 
subjected to reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.24. Fluorescent differential display (gel 0 0 ) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3,-AP9 and amplified in duplicate by 
PCR using 3'-TMR-AP9 and 5'-ARP3. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.25. Fluorescent differential display (gel PP) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3'-AP5 and amplified in duplicate by 
PCR using 3'-TMR-AP5 and 5'-ARP3. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.26. Fluorescent differential display (gel QQ) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3，-AP3 and amplified in duplicate by PCR using 3,-TMR-AP3 and 5'-ARP2. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.27. Fluorescent differential display (gel RR) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3'-AP3 and amplified in duplicate by 
PCR using 3'-TMR-AP3 and 5'-ARP17. TMR-labeled PCR products were resolved 
in a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.28. Fluorescent differential display (gel SS) of liver cDNAs of fed and 
starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each 
treatment group were reverse transcribed using 3,-AP7 and amplified in duplicate by 
PCR using 3，-TMR-AP7 and 5'-ARP17. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. The PPARa-dependent and fasting-
responsive cDNA fragment, indicated by an arrow, was excised from the gel and 
subjected to reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.29. Fluorescent differential display (gel TT) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3'-APS and amplified in duplicate by 
PCR using 3'-TMR-AP5 and 5'-ARP2. TMR-labeled PCR products were resolved on 
a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.30. Fluorescent differential display (gel UU) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3'-AP2 and amplified in duplicate by 
PCR using 3'-TMR-AP2 and 5'-ARP12. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.31. Fluorescent differential display (gel VV) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3，-AP2 and amplified in duplicate by PCR using 3'-TMR-AP2 and 5，-ARP18. TMR-labeled PCR products were resolved on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive cDNA fragments, indicated by arrows, were excised from the gel and subjected to reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.32. Fluorescent differential display (gel WW) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3'-AP2 and amplified in duplicate by 
PCR using 3'-TMR-AP2 and 5'-ARPl9. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 
reamplification. M, TMR-labeled molecular weight DNA marker. 
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Figure 5.33. Fluorescent differential display (gel XX) of liver cDNAs of fed and starved PPARa (+/+) and PPARa (-/-) mice. Total RNAs from two mice of each treatment group were reverse transcribed using 3，-APIO and amplified in duplicate by PCR using 3'-TMR-AP10 and 5'-ARP12. TMR-labeled PCR products were resolved 
on a 5.6% denaturing polyacrylamide gel. PPARa-dependent and fasting-responsive 
cDNA fragments, indicated by arrows, were excised from the gel and subjected to 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































UUlO, WWl, WW2, XX3, and XX4) were down regulated in 72-hr starved PPARa 
(+/+) mice compared to their corresponding fed controls in a PPARa-dependent 
manner. Two cDNA fragments (E3 and MM3) were down-regulated in 72-hr starved 
PPARa (-/-) mice compared to their corresponding fed controls, but were up-
regulated by PPARa in starved PPARa (+/+) mice to the same levels as their 
corresponding fed controls. Eight cDNA fragments (D4, HH3, JJl, JJ2, JJ3, JJ4, LLl, 
and MM5) were up-regulated in 72-hr starved PPARa (-/-) mice compared to their 
corresponding fed controls, but were down-regulated by PPARa in starved PPARa 
(+/+) mice to the same levels as their corresponding fed controls. 
5.6 Reamplification of cDNA fragments 
To increase the quantity of cDNA fragments for subsequent steps, cDNA 
fragments were reamplified by PCR. The sixty-two differentially expressed cDNA 
fragments, excised from the eighteen fluoroDD gels, were first eluted in TE buffer 
and reamplified by PCR using Ml3 reverse (-48) and T7 promoter primers (Figures 
5.34 - 5.39). The sizes of reamplified PCR products were 13 bp longer than their 
corresponding cDNA fragments displayed on the fluoroDD gels, because the Ml3 
reverse and T7 promoter primers used for reamplification of cDNA fragments were 
lengthened by eight and five nucleotides, respectively (Tables 5.10 - 5.12). Among 
the sixty-two reamplified cDNA fragments, forty-seven (76%) of them (Dl, D3, D4, 
E2, HH2, HH3, JJ5, LL4, MMI, MM4, MM5, NNl, 0 0 1 , 0 0 2 , 0 0 3 , 0 0 4 , 0 0 6 , 
007 , 0 0 8 , 009，PPl, PP2, PP3, PP4, QQl, QQ3, QQ4, QQ5, QQ6, RRIO, RRl l , 
RR12, RR15, RR16, TT3, TT4, TT5, UUl, UU8, UU9, UUlO, VV7, VV8, WWl, 
WW2, XXI, and XX3) were resulted in single band product with expected sizes, 
whereas double bands were observed in PCR products reamplified from the other 
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Figure 5.34. Reamplification of cDNA fragments excised from fluoroDD gels D and E. The cDNA fragments excised from the gels were eluted in TE buffer and amplified by PCR using M13 reverse (-48) and T7 promoter primers. PCR products were resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 100 bp, 100 bp DNA marker. 
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Figure 5.35. Reamplification of cDNA fragments excised from fluoroDD gels G, HH, and JJ. The cDNA fragments excised from the gels were eluted in TE buffer and amplified by PCR using Ml3 reverse (-48) and T7 promoter primers. PCR products were resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 100 bp, 100 bp DNA marker. 
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Figure 5.36. Reamplification of cDNA fragments excised from fluoroDD gels LL, 
MM, NN, and 0 0 (fragments 0 0 1 - 006) . The cDNA fragments excised from the 
gels were eluted in TE buffer and amplified by PCR using Ml3 reverse (-48) and T7 
promoter primers. PCR products were resolved on 2% agarose, 0.5x TBE gels with 
ethidium bromide staining. 100 bp, 100 bp DNA marker. 
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Figure 5.37. Reamplification of cDNA fragments excised from fluoroDD gels 0 0 (fragments 0 0 7 - 009) , PP, QQ, RR, and SS. The cDNA fragments excised from the gels were eluted in TE buffer and amplified by PCR using Ml3 reverse (-48) and T7 promoter primers. PCR products were resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 100 bp, 100 bp DNA marker. 
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Figure 5.38. Reamplification of cDNA fragments excised from fluoroDD gels TT and UU. The cDNA fragments excised from the gels were eluted in TE buffer and amplified by PCR using Ml3 reverse (-48) and T7 promoter primers. PCR products were resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 50 bp, 50 bp DNA marker; 100 bp, 100 bp DNA marker. 
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twelve cDNA fragments including D2, E3, Gl , JJl, JJ2, JJ3, JJ4, 0 0 5 , SSI, VV5, 
VV6, and XX4. The presence of other extra PCR products might be due to 
( 
contamination of co-migrated and/or nearby cDNA fragments during gel excision 
from fluoroDD gels. Surprisingly, the sizes of reamplified PCR products of cDNA 
fragments LLl, MM2, and MM3 were smaller than that expected, and they might also 
be the product of contaminated cDNA fragments. 
5.7 Subcloning of reamplified cDNA fragments 
All of the sixty-two reamplified cDNA fragments were subcloned for mass 
production of cDNA for subsequent steps including reverse dot blot and Northern blot 
analyses, and DNA sequencing. The reamplified PCR products were subcloned in 
either pT-Adv (3.9 kb) or PCR®II-TOPO® (4.0 kb) vector. 
One to fifteen subclones were picked for each cDNA fragment. Subclones 
were first screened by phenol: chloroform: isoamyl alcohol (25:24:1) extraction 
(Appendix B, Figures B1 - B18). Those recombinant subclones, which were larger 
than the size of their cloning vectors, were further confirmed by EcoKi digestions 
(Figures 5.40 - 5.58). Theoretically, using pT-Adv vector, the size of inserts should 
be 18 bp longer than that of the reamplified cDNA fragments as there were eight extra 
nucleotides before and after T/A cloning site and ten nucleotides were extended after 
EcoRi digestion. For pCR®II-TOPO® vector, the size of inserts should be lengthened 
by 20 bp as there were ten extra nucleotides before and after the T/A cloning site in 
addition to ten nucleotides extended after EcoRl restriction digestion (Tables 5.13 -
5.28). 
Among the sixty-two cDNA fragments, twenty-nine cDNA fragments 
including Dl , D2, D3, D4, E3, Gl, HH2, JJ2, MM2, MM4, NNl, 0 0 1 , 0 0 3 , 0 0 4 , 
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Figure 5.40. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel D by EcoRI digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoRl enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 50 bp, 50 bp DNA marker; 100 bp, 100 bp DNA marker; 
PCR, reamplified PCR products of excised cDNA fragments. 
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Figure 5.41. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel E by EcoRl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoRI enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 50 bp, 50 bp DNA marker; 100 bp, 100 bp DNA marker; 
PCR, reamplified PCR products of excised cDNA fragments. 
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Figure 5.42. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gels G and HH by EcoRI digestion. Recombinant plasmid 
DNA was extracted by boiling and digested by EcoRl enzyme. After digestion, 
mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, reamplified PCR 
products of excised cDNA fragments. 
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Figure 5.43. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel JJ by FcoRI digestion. Recombinant plasmid DNA was extracted by boiling and digested by FcoRI enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, reamplified PCR 
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Figure 5.44. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gel LL by E c o ^ digestion. Recombinant plasmid DNA was 
extracted by boiling and digested by 五coRI enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker. 
136 
MMI MM2 
bp 100 bp 1 2 4 6 ^ 2 5 1 0 12 , 
J' �h 
MM3 MM4 MM5 
bp l O O b p l 3 6 8 9 2 3 5 8 9 3 6 7 9 10 
. -A! 
r l � H t ^ i r ‘ > ’ . “ ； 
I" �� —t 
r :賽•！覽 r 默 f e 屬 ‘ ， ； ’ 1 • vectors 
900 ： b • 等 繁 • H d 1 T , 
u： . r �聊 : - r ‘ ^ 卜 Inserts 
O U U ‘ < . "l^^r -'-'^'i "‘ , f r" v) - � ' ' ' < - ‘ ‘ , > / / - � Figure 5.45. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel MM by EcoRI digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoRI enzyme. After digestion, mixture 
was resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker. 
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Figure 5.46. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gel NN by FcoRI digestion. Recombinant plasmid DNA was 
extracted by boiling and digested by EcoRi enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, reamplified PCR 
products of excised cDNA fragments. 
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Figure 5.47. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel 0 0 (fragments 0 0 1 - 0 0 5 ) by EcoRl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoKi enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker. 
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Figure 5.48. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gel 0 0 (fragments 0 0 6 - 0 0 9 ) by EcoRl digestion. 
Recombinant plasmid DNA was extracted by boiling and digested by EcoRI enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker. 
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Figure 5.49. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel PP by FcoRI digestion. Recombinant plasmid DNA was extracted by boiling and digested by FcoRI enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker. 
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Figure 5.50. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel QQ (fragments QQl and QQ3) by EcoRl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoKi enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, 
reamplified PCR products of excised cDNA fragments. 
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Figure 5.51. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel QQ (fragments QQ4 - QQ6) by EcoKL digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoRI enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, 
reamplified PCR products of excised cDNA fragments. 
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Figure 5.52. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gel RR (fragments RRIO - RR12 and RR15) by EcoRl 
digestion. Recombinant plasmid DNA was extracted by boiling and digested by 
EcoRL enzyme. After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels 
with ethidium bromide staining. Recombinant subclones underlined were those 
containing inserts and selected for reverse dot blot analysis. 100 bp, 100 bp DNA 
marker; PCR, reamplified PCR products of cDNA fragments. 
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Figure 5.53. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gels RR (fragment RR16) and SS by EcoRl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoRi enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, 
reamplified PCR products of cDNA fragments. 
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Figure 5.54. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel TT by EcoBl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoKl enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 50 bp, 50 bp DNA marker; PCR, reamplified PCR products 
of cDNA fragments. 
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Figure 5.55. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel UU by EcoKi digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoKl enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, reamplified PCR 
products of cDNA fragments. 
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Figure 5.56. Screening for recombinant subclones containing cDNA fragments excised from fluoroDD gel VV (fragments VV5 - VV7) by EcoRl digestion. Recombinant plasmid DNA was extracted by boiling and digested by EcoBl enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, 
reamplified PCR products of cDNA fragments. 
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Figure 5.57. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gels VV (fragment VV8) and WW by EcoRL digestion. 
Recombinant plasmid DNA was extracted by boiling and digested by EcoRI enzyme. 
After digestion, mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium 
bromide staining. Recombinant subclones underlined were those containing inserts 
and selected for reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, 
reamplified PCR products of cDNA fragments. 
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Figure 5.58. Screening for recombinant subclones containing cDNA fragments 
excised from fluoroDD gel XX by FcoRI digestion. Recombinant plasmid DNA was 
extracted by boiling and digested by EcoRI enzyme. After digestion, mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing inserts and selected for 
reverse dot blot analysis. 100 bp, 100 bp DNA marker; PCR, reamplified PCR 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0 0 5 , 0 0 6 , 0 0 7 , QQl, QQ3, R R l l , RR16, SSI, TT5, UU8, VV5, VV6, WWl, 
WW2, and XX3 contained different subclones which showed different Ecom 
restriction patterns. These results indicated that more than one type of cDNA species 
were present in the original excised cDNA fragment, and this might be due to 
contamination of co-migrated and/or nearby cDNA fragments during gel excision 
from the fluoroDD gels. The inserts of recombinant cDNA subclones D2, D3, D4, E3, 
Gl, HH2, HH3, JJ2, NNl , 0 0 2 , 0 0 3 , 0 0 4 , 0 0 5 , 0 0 6 , 0 0 7 , PP2, PP3, QQl, QQ6, 
RR16, TT5, UU8, UU9, VV5, VV6, WWl, and XX3, were shorter than the expected 
sizes and these might be due to the presence of endogenous EcoKL sites in all of these 
inserts. Surprisingly, recombinant subclones of cDNA fragments JJ3, LL4, MMl, 
MM4, MM5, 0 0 2 , 0 0 4 , PP2, and PP4 resulted in no detectable inserts after Ecom 
digestion, and this might probably be due to the fact that they were not recombinant 
subclones or those inserts contained numerous ^coRI sites resulting in chopping off 
of the entire insert to very small and undetectable fragments after EcoBl digestion. In 
addition, recombinant subclones of cDNA fragments 0 0 5 and R R l l contained 
inserts larger than the expected sizes, and they might be the product of contaminated 
cDNA fragments. 
5.8 Reverse dot blot analysis of subcloned cDNA fragments 
To screen out any false-positive cDNA subclones that did not show 
differential gene expression patterns of A-H, reverse dot blot analysis was employed. 
For each cDNA fragment, several (1-12) recombinant subclones which displaying 
different or same restriction enzyme patterns were selected for reverse dot blot 
analysis to screen for the fasting-responsive and PPARa-dependent cDNA subclones. 
174 
The first step of reverse dot blot analysis was cDNA library construction. The 
optimal number of PCR cycles for cDNA library synthesis for the four treatment 
f 
groups (WT/Fed, WT/Starved, KO/Fed, and KO/Starved) was sixteen because there 
was no smearing of large sized PCR products at sixteen PCR cycles (Figure 5.59A). 
Therefore, sixteen PCR cycles were used for cDNA library construction for each of 
the treatment group (Figure 5.59B). 
To ensure the reliability of the reverse dot blot analysis, three differential gene 
expression controls including mouse cytochrome P450 4A14 (CYP4A14), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and medium-chain acyl-CoA 
dehydrogenase (MCAD) with known differential gene expression patterns were 
included in the reverse dot blot analysis. Both CYP4A14 and MCAD genes are up-
regulated in starved PPARa (+/+) group compared to their corresponding fed controls 
in a PPARa-dependent manner (Leon et al., 1999; Lee et al., 2002). In contrast, 
GAPDH is up-regulated in starved PPARa (+/+) group but in a PPARa-independent 
manner (Lee et al., 2002). The differential expression patterns of these three 
differential gene expression controls were re-confirmed in our laboratory by Northern 
blot analysis (Figure 5.60) before they were used in reverse dot blot analysis. 
The cDNA subclones derived from the sixty-two differentially expressed 
cDNA fragments were screened by reverse dot blot analysis (Figures 5.61a - 5.67b). 
As seen in these figures, the three differential gene expression controls exhibited the 
expected differential gene expression patterns among the four treatment groups 
(CYP4A14 in RDB-1, -3, -4, and -5; GAPDH in RDB-1, -2, -3, -4, -6 and -7; and 
MCAD in RDB-2). However, sometimes, the three differential gene expression 
controls could not exhibit the expected differential gene expression patterns 
(CYP4A14 in RDB-7; GAPDH in RDB-5; MCAD in RDB-1, -3, -4, -5, -6, and -7) 
175 
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Figure 5.59. Optimization of number of PCR cycles for cDNA library synthesis. 
Total RNA of livers of fed and starved PPARa (+/+) and PPAR (-/-) mice was 
reverse transcribed and amplified using SMART™ PCR cDNA synthesis kit. (A) 
The cDNA library for each treatment group was synthesized at 15, 18, 21, and 24 
PCR cycles, and resolved on a 1.2% agarose, 0.5X TBE gel with ethidium bromide 
staining. (B) The cDNA library for each treatment group was synthesized at the 
optimum 16 PCR cycles and was resolved on a 1.2% agarose, 0.5X TBE gel with 
ethidium bromide staining. 1 kb, 1 kb DNA marker. 
176 
PPARa (+/+) PPARa (-/-) 
Fed Starved Fed Starved 
bp M 1 2 3 4 5 6 7 8 9 10 11 12 
9661 M l 睡 麵 鍵 Mouse CYP4A14 zoo丄 F ^ 關 調 屬 丨 (-2547 bp) 
45.95 248.26 38.55 37.31 
^ ^ ^ ^ ^ 令 28S 
i I -I "I 暮丄‘“ i , I 4 '翼？ ‘‘ ； “ 
2661 i p m 
’ + Mouse MCAD 
丄 o 二丄 w w w ^ (-1846 bp) 
1 5 1 7 . 102.16 163.55 107.58 107.38 
|jj^ |PBilPPPmpiwp»mpwpmilW|PH||pnpiWi_,丨 _ 丨 W /^I -ye "^ Mityy ^ WttHUtg^�^ 28 S 
I、% f t H i l i 暴 - 4 - t�i 我'Ma 
1821 
1 5 1 7 參集赛賞麵、 4 1 1 I - I , - ： �I g g D b ^ ) 
1 0 4 9 168,59 179.41 158,83 169.36 
H I - ‘ ； ^ ” ： fef I + 18S 
Figure 5.60. Northern blot confirmation of CYP4A14, MCAD and GAPDH. Total 
liver RNAs (20 |ag) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) 
mice were fractionated on 1% agarose-formaldehyde gel and transferred to nylon 
membrane. The membrane was then hybridized separately with DIG-labeled probe of 
mouse CYP4A14, MCAD, and GAPDH prepared by random priming and the signal 
was detected by colorimetric method with reagents NBT and BCIP. The signal 
intensity was quantified by MultiAnalyst. Ethidium bromide stained RNA gel was 
used for normalization. M, RNA molecular weight marker I, digoxygenin-labeled 
(0.39-6.9 kb); CYP4A14, cytochrome P450 4A14; GAPDH, glyceraldehyde-3-




















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.61b. Alignment of the four blots in RDB-1. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+)，starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) group in reverse dot blot analysis (RDB-1) were aligned together for comparison of differential gene expression patterns. Differential gene expression controls which were up-regulated in WT/starved or KO/starved group are indicated by fl arrows. Differential gene expression controls including cytochrome P450 4A14 
(CYP4A14), medium-chain acyl-CoA dehydrogenase (MCAD), and 
glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) with known expression 
patterns were marked by solid squares. 
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Alignment of the four blots in RDB-1 
1 _ 2 3 4 5 6 7 8 9 1 0 1 1 1 2 
• • R i n . PPARa (+/+) / Fed 
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A _ 參 - , , P P A R a (-/-)/Fed 
⑩ 參 PPARa (-/-) / Starved 
MCAD D2#5 D4#6 E2#6 E3#1 [CYP 4A14 
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• PPARa (-/-) / Starved 
JJ4#9 JJ5#7 LL4#6 LL4#9 MM2#1 MM2#5 
• • • PPARa (+/+)/Fed 
E � • PPARa (+/+)/Starved 
# 鬱介二 S PPARa(-/-)/Fed ^ — i r 窜 零 PPARa (-/-)/Starved 
MM2#12 MM3#6 MM3#8 GAPDH MM4#3 MM4#5 
• • PPARa (+/+)/Fed 
P J ® PPARa (+/+) / Starved 
: : PPARa (-/-)/Fed 
PPARa (-/-) / Starved 
MM4#9 MM5#7 MM5#9 001#2 001#3 001#4 
• • • • • • • • PPARa (+/+)/Fed 
Q # # # # # # # # PPARa (+/+)/Starved 
• • • • • • • • PPARa (-/-)/Fed 
• • • • • • • • PPARa (-/-) / Starved 
001#6 001#8 003#7 005#4 005#7 005#9 
書 • PARa (+/+)/Fed 
H • _ 眷 _ PARa (+/+)/Starved 
• • 藥 PARa (-/-)/Fed 
• • • • PARa (-/-) / Starved 







































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.62b. Alignment of the four blots in RDB-2. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
group in reverse dot blot analysis (RDB-2) were aligned together for comparison 
of differential gene expression patterns. Positive cDNA subclones underlined and 
marked by dotted squares were those showing differential expression patterns A-H 
as shown in Table 4.1. Differential gene expression controls and positive cDNA 
subclones which were up-regulated in WT/starved or KO/starved group are 
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A . . 1 = = = I PPARa (-/-)/Fed 
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— — — — — — m m ^ ^ ― ^ ^ _ _ 
I • _ I _ _ PPARa (+/+)/Fed 
^ I 攀 攀 攀 介 I 參 _ PPAHa (+/+)/Starved B I • # 
I . I : : PPARa (-/-)/Fed 
j I • • PPARa (-/-) / Starved 
I QMl o m I Gl#9 Gl#10 Gl#ll Gl#12 
I—. I 
I I PPARa (+/+)/Fed 
I • • U • • 1 l • • 介 . _ f [ PPARa (+/+) / Starved 
！ I I PPARa (-/-) / Fed I I PPARa (-/-) / Starved 
Gl#15 I NN1#1 NN1#2 NN1#3 NN1#4 NN1#5 I 
！ I 
一 一 一 — 一 一 I J 
• • • • I ~ j # • • 鲁 ~ k P P A R a (+/+)/Fed 
• • • # • 介 丨 # • • ^ 刺 PPARa (+/+) / Starved • • • • I I • • • • PPARa (-/-)/Fed 
• • • • I < • • # • # # f ) PPARa (-/-)/Starved 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.63b. Alignment of the four blots in RDB-3. Corresponding cDNA subclones in 
each of the four dot blots hybridized with cDNA library probes of fed PPARa (+/+), 
starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) group in reverse dot 
blot analysis (RDB-3) were aligned together for comparison of differential gene 
expression patterns. Positive cDNA subclones underlined and marked by dotted squares 
were those showing differential expression patterns A-H as shown in Table 4.1. 
Differential gene expression controls and positive cDNA subclones which were up- or 
down-regulated in WT/starved or KO/starved group are indicated by ff and U arrows, 
respectively. Differential gene expression controls including cytochrome P450 4A14 
(CYP4A14), medium-chain acyl-CoA dehydrogenase (MCAD), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) with known expression patterns were marked by 
solid squares. 
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Alignment of the four blots in RDB-3 
1 一 一 5 一 」 8 9 10 11 12 
‘ � ‘ I f PPARa (+/+)/Fed 
® 緣’介 _ 春 f| �書 介 藥 春 ft _ 縢 ff PPARa (+/+) / Starved 
A , � '' , ‘ ‘ ‘ ’ I PPARa (-/-)/Fed 
fl • ‘ � '''' ‘‘ ‘ ‘ …丨丨 PPARa (-/-) / Starved 
MCAD 002#1 002#6 002#7 002#8 |  
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I I PPARa (+/+)/Fed 
^ j • • 介 ⑩ • _ 介 參 眷 介 響 _ 介 _ 眷介I PPARa (+/+)/Starved 
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一 一 一 一 —‘― — 一 一 L J 
I # # • • I PPARa (+/+)/Fed 
E I • 修 介 參 • J J • 鲁 JJ 播 fl 介 fl PPARa (+/+) / Starved 
j • • • • ' I PPARa (-/-)/Fed 
I 鲁 書 鲁 泰 f) I PPARa (-/-)/Starved 
I QQMIO 007#6 007#10 GAPDH 008#10 009#6 丨  
！ I 
一 一 ^ — — 一 一 一 一 一 L 1 
• • “ • I • — _ _ _ _ ,,, _ _ ___ ^ ^ ^ ^ ^ ^ 
I 介 介•• •丨丨 I PPARa (+/+)/Fed 
p j • • • • I • • I • 藝 I PPARa (+/+) / Starved 
I 争 1 I PPARa (-/-)/Fed 
I I • " 鲁 番 f f 奢 <^1丨介 PPARa (-/-) / Starved 
I PP3#3 PP3#13 I HH2#7 I LL1#7 LL1#11 I 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5 64b. Alignment of the four blots in RDB-4. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
group in reverse dot blot analysis (RDB-4) were aligned together for comparison 
of differential gene expression patterns. Positive cDNA subclones underlined and 
marked by dotted squares were those showing differential expression patterns A-H 
as shown in Table 4.1. Differential gene expression controls and positive cDNA 
subclones which were up- or down-regulated in WT/starved or KO/starved group 
are indicated by 介 and U arrows, respectively. Differential gene expression controls including cytochrome P450 4A14 (CYP4A14), medium-chain acyl-CoA 
dehydrogenase (MCAD), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) with known expression patterns were marked by solid squares. 
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Alignment of the four blots in RDB-3 
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D PPARa (-/-)/Fed 
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SS1#16 SS1#17 SS1#18 SS1#19 RR10#11 RR10#12 
PPARa (+/+)/Fed 
E • PPARa (+/+) / Starved 
PPARa (-/-)/Fed 
勢 崎 PPARa (-/-)/Starved 
RR10#13 RR10#14 RR10#15 RR11#16 RR11#17 RR11#19 
PPARa (+/+)/Fed 
p . PPARa (+/+)/Starved 
PPARa (-/-)/Fed � y PPARa (-/-) / Starved 
RR11#20 RR12#12 RR12#13 RR12#14 RR12#15 RR15#11 
^ PPARa (+/+)/Fed 
Q PPARa (+/+) / Starved 
-- ^ PPARa (-/-)/Fed 
m mr PPARa (-/-)/Starved 
RR15#17 RR15#18 RR15#19 RR15#20 RR16#16 RR16#17 
PPARa (+/+) / Fed 
0 0 f - PPARa (+/+)/Starved 
PPARa (-/-)/Fed 
介 PPARa (-/-) / Starved 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5 65b Alignment of the four blots in RDB-5. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
group in reverse dot blot analysis (RDB-5) were aligned together for comparison 
of differential gene expression patterns. Positive cDNA subclones underlined and 
marked by dotted squares were those showing differential expression patterns A-H 
as shown in Table 4.1. Differential gene expression controls cDNA subclones 
which were up- or down-regulated in WT/starved or KO/starved group are 
indicated by ff and li arrows, respectively. Differential gene expression controls 
including cytochrome P450 4A14 (CYP4A14), medium-chain acyl-CoA 
dehydrogenase (MCAD), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) with known expression patterns were marked by solid squares. 
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I 1 PPARa (-/-) / Starved 
I TT5#8 丨 UU8#3 UU9#3 























































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.66b. Alignment of the four blots in RDB-6. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
group in reverse dot blot analysis (RDB-6) were aligned together for comparison 
of differential gene expression patterns. Positive cDNA subclones underlined and 
marked by dotted squares were those showing differential expression patterns A-H 
as shown in Table 4.1. Differential gene expression controls cDNA subclones 
which were up-regulated in WT/starved or KO/starved group are indicated by ft 
arrows. Differential gene expression controls including medium-chain acyl-CoA 
dehydrogenase (MCAD) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) with known expression patterns were marked by solid squares. 
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Alignment of the four blots in RDB-3 
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• • I I I I PPARa (-/-)/Starved 
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Figure 5.67b. Alignment of the four blots in RDB-7. Corresponding cDNA 
subclones in each of the four dot blots hybridized with cDNA library probes of fed 
PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
group in reverse dot blot analysis (RDB-7) were aligned together for comparison 
of differential gene expression patterns. Differential gene expression controls 
which were up-regulated in WT/starved or KO/starved group are indicated by 介 arrows. Differential gene expression controls including cytochrome P450 4A14 
(CYP4A14), medium-chain acyl-CoA dehydrogenase (MCAD), and 
glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) with known expression 




Alignment of the four blots in RDB-7 
1 2 3 4 5 6 7 8 9 10 11 12 
‘ ’ 爆 r ^ • PPARa (+/+)/Fed 
_ 静 f �鲁 參 春 • _ M M M M M ^ L P P A R o c (+/+)/starved 
A • • • • 眷 拳 ⑩ _ 醣 _ PPARa (-/-)/Fed 
籲 ‘ 眷 f l � 眷 鲁 鲁藝 _ m 籲 眷 剩 P P A R a (-/-)/Starved MCAD QQ1#12 QQ1#23 QQ1#25 QQ1#27 GAPDH 
春 鲁 癱 • 眷 籲 PPARa (+/+)/Fed 
• • • • • • PPARa (+/+)/Starved 
單 零 響 哪 攀 PPARa (-/-)/Fed 
• • • • • 静 产 ^ PPARa (-/-) / Starved 
QQ1#31 QQ3#11 QQ3#12 QQ3#13 QQ3#14 QQ3#21 
鲁 . m m r ~ 一 P P A R a (+/+)/Fed 
C • • • • • • [ PPARa (+/+)/Starved 
• • m m PPARa (-/-)/Fed 
• • • * PPARa (-/-) / Starved 
QQ3#22 QQ3#23 QQ3#24 QQ3#25 RR12#11 CYP4A14 
205 
that CYP4A14 and MCAD were also slightly induced in starved PPARa (-/-) group 
compared to their corresponding fed controls besides the up-regulation in starved 
PPARa (+/+) group. In addition, GAPDH was induced solely in starved PPARa (+/+) 
group compared to their corresponding fed controls and PPARa (-/-) groups. The 
variation of patterns of differential gene expression controls in reverse dot blot 
analysis might be due to variation of quality of the cDNA library probe and depletion 
of the probe during recycling. Therefore, positive cDNA subclones displaying 
differential gene expression patterns of A-H were identified based on the relative 
densitometry readings of the blots among the treatment groups and the expression 
patterns of differential gene expression controls were also considered during the 
judgment (Tables 5.29a — 5.46b). 
The differential gene expression patterns (A-H, Table 4.1) of twenty-six 
cDNA fragments including Dl (subclone Dl#2)，D3 (subclone D3#3), Gl (subclones 
Gl#2, Gl#3, Gl#7, and Gl#8), LLl (subclones LL1#5, LLl#7, and LL7#11), MMl 
(subclone MM1#1), NNl (subclones NN1#1, NNl#2, NN1#3, NNl#4, and NN1#5), 
0 0 2 (subclones 002#1, 002#6, 002#7, 002#8, and 002#9), 0 0 3 (subclones 
003#2, 003#4, 003#8, and 003#9), 0 0 4 (subclones 004#3, 004#4, 004#6, 
004#8, and 004#10), 0 0 5 (subclones 005#2 and 005#13), 0 0 6 (subclones 
006#1, 006#2, 006#5, 006#8, 006#9, and 006#10), 0 0 7 (subclones 007#6 and 
007#10), 0 0 8 (subclone 008#10), 0 0 9 (subclones 009#6 and 009#8), PP3 
(subclones PP3#3, PP3#11, and PP3#13), QQ4 (subclones QQ4#14, QQ4#15, and 
QQ4#16), QQ5 (subclones QQ5#13, QQ5#14, QQ5#16, QQ5#17，and QQ5#18), 
QQ6 (subclones QQ6#13, QQ6#14, QQ6#18, and QQ6#20), TT3 (subclone TT3#9), 
TT4 (subclones TT4#5, TT4#8, and TT4#9), TT5 (subclones TT5#1, TT5#8, and 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(subclones VV5#2, VV5#3, and VV5#4), VV8 (subclones VV8#5 and VV8#6), 
WWl (subclones WW1#3, WWl#4, WW1#5, and WW1#7), and XXI (subclones 
f 
XX1#1, XX1#2, XX1#3, XX1#4, and XX1#9) were confirmed by reverse dot blot 
analyses. Interestingly, subclone D2#9 of cDNA fragment D2 was found to be up-
regulated by fasting in a PPARa-dependent manner in reverse dot blot analysis 
(Figures 5.66a and b), but it was down-regulated in the fluoroDD gel D (Figure 5.16). 
This contrasting result suggested that subclone D2#9 might be derived from 
contaminated/co-migrated cDNA fragments. Practically, cDNA subclones 007#6, 
WW1#3, WW1#4, WW1#5, and WWl#7 were considered as the positive cDNA 
subclones that they were down-regulated in starved PPARa (+/+) group in a PPARa-
dependent manner although the relative densitometry reading could not show this 
pattern. This is because the signal of these dots had exceeded the capacity of the 
densitometor. In spite of the fact that cDNA subclones LL1#5, LL1#7, and LL1#11 
were not perfectly matched with the fluoroDD pattern, they were also considered as 
the positive cDNA subclones as the induction in starved PPARa (-/-) group was much 
greater than that in starved PPARa (+/+) group. The differential gene expression 
patterns obtained for cDNA subclones HH3#1, HH3#5, JJ2#2, JJ2#10, JJ3#3, JJ3#5, 
JJ4#1, JJ4#2, JJ4#9, MM5#7 in RDB-1 might be false-positive and did not match 
with fluoroDD patterns as the differential gene expression control MCAD used in this 
reverse dot blot analysis was also slightly induced in starved PPARa (-/-) group. 
Therefore, up-regulation of those cDNA subclones in starved PPARa (-/-) group 
might be due to the artifact of the cDNA library probe. In contrast, cDNA subclone 
002#9 was considered as positive cDNA subclone and matched with fluoroDD 
pattern. The cDNA subclone 002#9 was induced in starved PPARa (+/+) group 
242 
compared to their corresponding fed controls, the slight induction in starved PPARa 
(-/-) group might due to the artifact of the cDNA library probe. 
5.9 Sequencing of reverse dot blot-confirmed cDNA 
fragments 
DNA sequencing was performed to identify the cDNA fragments. One to five 
positive cDNA subclones of cDNA fragments showing obvious differential gene 
expression patterns of A-H in reverse dot blot analysis were selected for DNA 
sequencing. Plasmid DNA of each cDNA sudclone was digested by E c o ^ to check 
for the presence of correct sized insert before DNA used for sequencing (Figures 5.68 
-5.73). Fifty-two positive cDNA subclones derived from twenty-three differentially 
expressed cDNA fragments were sequenced (Tables 5.47 - 5.54; Appendix C, Cl . l — 
C54.3). 
Thirteen PPARa-dependent and fasting-responsive genes were identified from 
the twenty-three cDNA fragments. It is interesting to note that some genes occurred 
repetitively in cDNA fragments derived from the same or different fluoroDD gels 
(Figure 5.74). These genes, in the ascending order of abundance, included mouse 
betaine-homocysteine methyltransferase (Bhmt) (fragment D2), mouse cathepsin L 
(Ctsl) (fragment LLl), a mouse EST with homology to mouse hypothetical protein 
MMT-7 gene (fragment D3), mouse 3-hydroxyl-3-methylglutaryl-Co synthase II 
(HMG-CoAS) (fragment VV8), mouse L-speciflc multifunctional beta-oxidation 
protein (L-PBE) (fragment 004) , mouse medium-chain acyl-CoA dehydrogenase 
(MCAD) (fragment QQ4), mouse phytanoyl-CoA hydroxylase (Phyh) (fragment 
003) , mouse 2-hydroxyphytanoyl-CoA lyase (Hpcl) (fragments 0 0 8 and 009) , 
243 
D1 D2 D3 
bp 100 bp PCR 2 PCR 9 PCR 3 
誦丨： 
LL1 MM1 
bp 1 kb PCR 5 7 11 PCR 1 
上 一 一 — 一 f W f f ^ 
；： :；：： 
Figure 5.68. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gels D, LL, and MM by EcoBl 
digestion before DNA sequencing. Recombinant plasmid DNA was purified by 
QIAprep spin miniprep kit and digested by EcoRi enzyme. Digestion mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing insert of correct size and 
used for sequencing. 100 bp, 100 bp DNA marker; 1 kb, 1 kb DNA marker; PCR, 
reamplified PCR products of excised cDNA fragments. 
244 
0 0 2 0 0 3 0 0 4 
bp 100 bp PCR 6 9 PCR 4 9 PCR 3 4 8, 
I ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ (3.9 kb) 
800 ：匿 f ^ P ^ P ^ i P P ^ ^ 、 
0 0 4 0 0 5 
bp 100 bp PCR 10 bp 100 bp PCR 2 13 
M- Vector B ^ l w • Vectors 
(3.9 kb) I U l l l l ^ (3.9 kb) 
1000 f ^ W • Insert 二 二膠 l ^ M 800 600 - ^ U H a a Inserts 
Figure 5.69. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gel 0 0 (fragments 0 0 2 - 0 0 5 ) 
by FcoRI digestion before DNA sequencing. Recombinant plasmid DNA was 
purified by QIAprep spin miniprep kit and digested by FcoRI enzyme. Digestion 
mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing insert of correct size and 
used for sequencing. 100 bp, 100 bp DNA marker; PCR, reamplified PCR products 
of excised cDNA fragments. 
245 
f 
0 0 6 0 0 7 0 0 8 0 0 9 PP3 
bp 100 bp PCR 2 8 10 PCR 3 6 10 PCR 10 PCR 6 8 PCR 3 13 
政r ‘ L ^ W -.^ -r ；^"： ^'v. .r：： irfr：! 
� I ” f产,织’:/•、‘ “ 、，I ""If f • Vectors 
： 丨 : : 一 
Figure 5.70. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gels 0 0 (fragments 0 0 6 - 0 0 9 ) 
and PP by FcoRI digestion before DNA sequencing. Recombinant plasmid DNA was 
purified by QIAprep spin miniprep kit and digested by FcoRI enzyme. Digestion 
mixture was resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing insert of correct size and 
used for sequencing. 100 bp, 100 bp DNA marker; PCR, reamplified PCR products 
of excised cDNA fragments. 
246 
QQ4 QQ5 QQ5 
bp 100 bp PCR 14 15 PCR 14 16 bp 100 bp PCR 17 
%： . ‘V^  ‘ . ‘ ；^ 
� � , > > ‘ , H 
• —— ‘, ？. 
] • V t ^ Vector 
QQ6 
bp 100 bp PCR 13 14 E . V 咖 
(4.0 kb) 1 i 一 
Figure 5.71. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gel QQ by EcoRI digestion 
before DNA sequencing. Recombinant plasmid DNA was purified by QIAprep spin 
miniprep kit and digested by EcoRI enzyme. Digestion mixture was resolved on 2% 
agarose, 0.5x TBE gels with ethidium bromide staining. Recombinant subclones 
underlined were those containing insert of correct size and used for sequencing. 100 




bp 50 bp PCR 5 8 9 PCR 1 8 9 
mi^f ; “ f ~ i. f . 
P, ' • >-,)•、 （ •H-jsMass^  ^  "^srf J^ MfHtll,* i'^ 
I ' , , ？ , ^ •• ‘ , ‘ — , l ift'' . , U » •i-VR 
I. '-'v,： ‘ . ‘ - ', ‘ % “ i ‘, ‘'rv … . ‘ - � � - “ ‘ . 
_ ^ , ‘’卜"：'’:、‘， 
.. ‘ 务 Vectors 
i 漆 
UUl 
bp 1 kb PCR 1 4 
I ' ‘ 
I L勒 ‘ J 
f , ’I …鍾 
I ‘ t 一 J • Vectors 
(4.0 kb) ：：翻〜 
Figure 5.72. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gels TT and UU by EcoRI 
digestion before DNA sequencing. Recombinant plasmid DNA was purified by 
QIAprep spin miniprep kit and digested by BcoRI enzyme. Digestion mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing insert of correct size and 
used for sequencing. 50 bp, 50 bp DNA marker; 1 kb, 1 kb DNA marker; PCR, 
reamplified PCR products of excised cDNA fragments. 
248 
V V 5 V V 8 
bp 100 bp PCR 1 2 3 4 PCR 5 6 
^ ― — — 
P M- Vectors 
fe (4.0 kb) 
W W l X X I 
bp 1 kb PCR 3 4 5 7 PCR 1 2 3 4 9 
I ‘ 保 礙 勢 傳 二 滿 ： p 义 i ) i" 
• O&n •5>»4亡 lie,, ^ 》々 ‘),，‘ -rC ， “4 t 1 - . 1 
I 神 s 驗 ： i J ；； jx I 
Figure 5.73. Checking for correct sized insert for purified recombinant plasmid DNA 
containing cDNA fragments excised from fluoroDD gels VV, WW, and XX by 
EcoRl digestion before DNA sequencing. Recombinant plasmid DNA was purified 
by QIAprep spin miniprep kit and digested by EcoKL enzyme. Digestion mixture was 
resolved on 2% agarose, 0.5x TBE gels with ethidium bromide staining. 
Recombinant subclones underlined were those containing insert of correct size and 
used for sequencing. 100 bp, 100 bp DNA marker; 1 kb, 1 kb DNA marker; PCR, 
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mouse serine protease inhibitor 1-3 (Spil-3) (fragments 0 0 7 and WWl), rat 
argininosuccinate lyase (ASL) (fragments 0 0 2 , 0 0 3 , and 0 0 4 ) , mouse cytochrome f 
P450 4A14 (CYP4A14) (fragments 0 0 4 , 0 0 5 , 0 0 6 . and PP3), mouse major urinary 
protein II (MUPII) (fragments QQ5, QQ6, TT4, and TT5), and mouse cytochrome 
P450 4A10 (CYP4A10) (fragments Dl , MMl, UUl, VV5, and XXI). The existence 
of two genes for cDNA fragment 0 0 3 and three genes for cDNA fragment 0 0 4 , 
which displayed distinct EcoKl digestion patterns, confirmed the existence of co-
migrated cDNA fragments. The highest abundant gene is mouse CYP4A10 (20.83%), 
whereas the least abundant genes include mouse Bhmt, Ctsl, EST, HMG-CoAS, L-
PBE, MCAD, Phyh (4.17%). 
5.10 Northern blot analysis of sequenced cDNA fragments 
The differential gene expression patterns of the twenty-four sequenced cDNA 
fragments were further confirmed by Northern blot analysis. For those cDNA 
fragments which corresponded to the same gene, only one cDNA fragment was 
chosen as probe for Northern blot confirmation (Tables 5.55 - 5.58). The 28S and 
18S RNA stained with ethidium bromide gels were used for loading normalization. 
The differential gene expression patterns of all of the thirteen cDNA 
fragments including clone D2#9 (mouse betaine homocysteine methyltransferase, 
Figure 5.75), clone D3#3 (mouse EST with homology to mouse hypothetical protein 
MMT-7 gene, Figure 5.76)，clone LL1#7 (mouse cathepsin L, Figure 5.77), clone 
MM1#1 (mouse cytochrome P450 4A10, Figure 5.78), clone 002#6 (rat 
argininosuccinate lyase, Figure 5.79), clone 003#9 (mouse phytanoyl-CoA 
hydroxylase, Figure 5.80), 004#10 (mouse L-specific multifunctional beta-oxidation 
protein, Figure 5.81), clone 008#10 (mouse 2-hydroxyphytanoyl-CoA lyase, Figure 
262 
Table 5.55. Summary of Northern blot analysis of subclones of cDNA fragments from fluoroDD 
gels D, LL, MM, and 0 0 
f 
Northern blot 
Subclone Gene FluoroDD Reverse dot blot Matched with 
no. homology pattern pattern Pattern fluoroDD and 
reverse dot 
blot patterns 
Mouse CYP4A10 ‘ c Dl#2 (2077 bp) - + - - + ++ + + Not performed* 
Matched with 
A /r 1 ^ • , 如. reverse dot Mouse betame homocysteine 
D2#9 methyltransferase (Bhmt) ++ + + + + + + ++ + + + ++ + + blot pattern but u \ do not match (2131 bp) with fluoroDD 
pattern 
Mouse EST with homology 
D3#3 to mouse h3^pothetical + ++ + + + ++ 十 + + ++ 十 + Yes 
protein MMT-7 gene 
(2184 bp)  
Matched with 
reverse dot 
LL1#7 Mouse cathepsin L (Ctsl) + + + ++ + ++ + ++++ + ++ + ++++ blot pattern but 
(1374 bp) do not match 
with fluoroDD 
pattern 
LL1#11 Mouse Cffjiye^ps^)!^ (Ctsl) ~ + + + + + . + + + ++ Not performed* 
MM1#1 - + - - + +十 + + - + - - ^ (2077 bp)  
Rat argininosuccinate lyase 
002#6 (ASL) - + - - + ++ + + + ++ + + Yes 
(1574 bp) 
Rat argininosuccinate lyase 
002#9 (ASL) - + - - + ++ + + Not performed* 
(1574 bp)  
Mouse phytanoyl-CoA 
003#4 hydroxylase (Phyh) - + - - + ++ + + Not performed* 
(1419 bp)  
Mouse phytanoyl-CoA 
003#9 hydroxylase (Phyh) - + - - + ++ + + + ++ + + Yes 
(1419 bp)  
Rat argininosuccinate lyase 
004#3 (ASL) - + - - + ++ + + Not performed* 
(1574 bp)  
- 0 0 4 # 4 M � :二 A 1 4 _ + 一 _ + 十+ + + Not performed* (2547 bp)  Mouse L-specific 
004#10 multifunctional beta- . + _ . + ++ + + + ++ + + Yes 
oxidation protein (L-PBE) 
(3097 bp)  
^Northern blots were not performed because same gene was confirmed once. 
263 
( 
Table 5.56. Summary of Northern blot analysis of subclones of cDNA fragments from fluoroDD 
gels 0 0 and PP 
Northern blot 
Subclone Gene FluoroDD Reverse dot blot Matched with 
no. homology pattern pattern Pattern fluoroDD and 
reverse dot 
blot patterns 
Rat argininosuccinate lyase 
004#3 (ASL) - + - - + ++ + + Not performed* 
(1574 bp)  
r^ r^ A+iA Mouse CYP4A14 , 丄 ^ . 004#4 (2547 bp) - + - - + ++ + + Not performed* 
Mouse L-specific 
r^r^.n-tr. multifuiictional beta- , , , 、， 004#10 . , ‘ . ,T d d t ^ � - + - - + ++ + + + ++ + + Yes oxidation protein (L-PBE) 
(3097 bp)  
005#13 十 + ++++ ++ ++ + ++ + + Not performed* 
Mouse CYP4A14 丄 丄丄丄丄丄 . . ^ . 
006#2 (2547 bp) - + - - + ++ + + Not performed* 
…，加 Mouse CYP4A14 , , ^ 
006#8 (2547 bp) - + - - + ++ + + Not performed* 
… … A Mouse CYP4A14 , , , , , , . . ^ ^ 006#10 (2547 bp) - + - - + ++ + + Not performed* 
Mouse serine protease 
007#6 inhibitor 1-3 (Spil-3) + - + + ++ + + + + + Not performed* 
(1366 bp)  
Mouse serine protease 
007#10 inhibitor 1-3 (Spil-3) + - + + ++ + + + + + Not performed* 
(1366 bp)  
Mouse 2-hydroxyphytanoyl-
008#10 CoA lyase (Hpcl-pending) - + - - + ++ + + - + - - Yes 
(1982 bp)  
Mouse 2-hydroxyphytanoyl-
009#6 CoA lyase (Hpcl-pending) + ++ + + + ++ + + Not performed* 
(1982 bp)  
Mouse 2-hydroxyphytanoyl-
009#8 CoA lyase (Hpcl-pending) + ++ + + + ++ + + Not performed* 
(1982 bp)  
“ P P 3 # 3 Mouse CYP4A14 _ + _ _ + … + - + - - ^ 
(2547 bp)  
PP3#13 Mouse CYP4A14 . + . . + ++ + + Not performed* (2547 bp)  
^Northern blots were not performed because same gene was confirmed once. 
264 
Table 5.57. Summary of Northern blot analysis of subclones of cDNA fragments from fluoroDD 
gels QQ, TT, and UU 
Northern blot 
Subclone Gene FluoroDD Reverse dot blot Matched with 




QQ4#14 C o A ^ h g ^ n a s e + ++ + + + ++ + + + ++ + + Yes 
(1846 bp)  
Mouse medium-chain acyl-
QQ4#15 CoA^h红贾enase 十 ++ + 十 + ++ + + Not performed* 
(1846 bp)  Mouse major urinary protein 
QQ5#14 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
QQ5#17 II (MUP II) ++ + ++ ++ ++ + ++ ++ ++ + + + + + Yes 
(872 bp)  
Mouse major urinary protein 
QQ6#13 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
QQ6#14 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
TT4#5 (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
TT4#8 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
TT4#9 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
TT5#1 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
Mouse major urinary protein 
TT5#9 II (MUP II) ++ + ++ ++ ++ + ++ ++ Not performed* 
(872 bp)  
~UU1#1 ^ " Z v v Z T ' - + - - + ++ + + Notperfonned* 
~~UU1#4 ^ 7 2 0 7 7 ™ ^ ^ - + - - + ++ + + Not performed* 
*Northem blots were not performed because same gene was confirmed once. 
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Table 5.58. Summary of Northern blot analysis of subclones of cDNA fragments from fluoroDD 
gels VV, WW, and XX 
Northern blot 
Subclone Gene FluoroDD Reverse dot blot Matched with 
no. homology Pattern pattern Pattern fluoroDD and 
reverse dot 
blot patterns 
Mouse rYP4A 10 
VV5#2 (20冗p) + ++ + + + ++ + + Not performed* 
VV5#3 M�u(�o!^7Y二AlO + ++ + + + ++ + + Not performed* 
.r^rcn. Mouse CYP4A10 � t , r 
VV5#4 (2077 bp) + ++ + + + ++ + + Not performed* Mouse 3-hydroxy-3-
VV8#5 m e _ 2 g l ( u # g " J o � & f t h a s e + ++ + + + ++ + + Not performed* (2011 bp)  Mouse 3-hydroxy-3-
methylgl=iji，々， thase + ++ + + + ++ + + + ++ + + Yes 
2 (HMG-CoAS) 
(2011 bp)  
Mouse serine protease 
WW1#3 inhibitor 1-3 (Spil-3) ++ + ++ ++ ++ + ++ ++ Not performed* 
(1366 bp)  
Mouse serine protease 
WW1#4 inhibitor 1-3 (Spil-3) ++ + ++ ++ ++ + ++ ++ ++ + ++ ++ Yes 
(1366 bp)  
Mouse serine protease 
WW1#7 inhibitor 1-3 (Spil-3) ++ + ++ ++ ++ + ++ ++ Not performed* 
(1366 bp)  
. X X 1 # 2 ^ " Z l v v Z T ^ - + - - + ++ + + Not performed* 
“XX1#3 ^ 7 2 0 7 7 ™ ' ' - + - - + ++ + + Not performed* 
“XX1#9 M o : o品4 ) A 1 0 _ + - _ + ++ + + Not performed* 
^Northern blots were not performed because same gene was confirmed once. 
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Figure 5.75. Northern blot and reverse dot blot analyses of clone D2#9 (mouse 
Bhmt). (A) Northern blot analysis of clone D2#9 (mouse Bhmt). Total liver RNAs 
(30 |Lig) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone D2#9 (mouse 
Bhmt) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-6) of clone D2#9 (mouse Bhmt). Four identical blots 
(Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 j^ g) of 
cDNA subclone D2#9 on nylon membranes (duplicate dots per sample per blot). The 
four blots were hybridized with cDNA library probes prepared from total liver RNAs 
of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
mice, respectively, and the signal was detected by colorimetric method with reagents 
NBT and BCIP. The signal intensity was quantified by MultiAnalyst. M, RNA 
molecular weight marker I，digoxygenin-labeled (0.39-6.9 kb); Bhmt, betaine homocysteine methytransferase. 
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Figure 5.76. Northern blot and reverse dot blot analyses of clone D3#3 (mouse EST). 
(A) Northern blot analysis of clone D3#3 (mouse EST). Total liver RNAs (20 jug) 
from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone D3#3 (mouse 
EST) prepared by random priming and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
Ethidium bromide stained RNA gel was used for normalization. (B) Reverse dot blot 
analysis (RDB-6) of clone D3#3 (mouse EST). Four identical blots (Blots 1, 2, 3, and 
4) were prepared by dotting recombinant plasmid DNA (10 |Lig) of cDNA subclone 
D3#3 on nylon membranes (duplicate dots per sample per blot). The four blots were 
hybridized with cDNA library probes prepared from total liver RNAs of fed PPARa 
(+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) mice, 
respectively, and the signal was detected by colorimetric method with reagents NBT 
and BCIP. The signal intensity was quantified by MultiAnalyst. M, RNA molecular 
weight marker I，digoxygenin-labeled (0.39-6.9 kb). 
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Figure 5.77. Northern blot and reverse dot blot analyses of clone LLl#7 (mouse Ctsl). 
(A) Northern blot analysis of clone LLl#7 (mouse Ctsl). Total liver RNAs (30 )ag) 
from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone LLl#7 (mouse 
Ctsl) prepared by random priming and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
Ethidium bromide stained RNA gel was used for normalization. (B) Reverse dot blot 
analysis (RDB-3) of clone LL1#7 (mouse Ctsl). Four identical blots (Blots 1, 2, 3, 
and 4) were prepared by dotting recombinant plasmid DNA (10 |ag) of cDNA 
subclone LLl#7 on nylon membranes (duplicate dots per sample per blot). The four 
blots were hybridized with cDNA library probes prepared from total liver RNAs of 
fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved PPARa (-/-) 
mice, respectively, and the signal was detected by colorimetric method with reagents 
NBT and BCIP. The signal intensity was quantified by MultiAnalyst. M, RNA 
molecular weight marker I, digoxygenin-labeled (0.39-6.9 kb); Ctsl, cathepsin L. 
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Figure 5.78. Northern blot and reverse dot blot analyses of clone MM1#1 (mouse 
CYP4A10). (A) Northern blot analysis of clone MM1#1 (mouse CYP4A10). Total 
liver RNAs (20 j^ g) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) 
mice were fractionated on 1% agarose-formaldehyde gel and transferred to nylon 
membrane. The membrane was then hybridized with DIG-labeled probe of clone 
MM1#1 (mouse CYP4A10) prepared by random priming and the signal was detected 
by colorimetric method with reagents NBT and BCIP. The signal intensity was 
quantified by MultiAnalyst. Ethidium bromide stained RNA gel was used for 
normalization. (B) Reverse dot blot analysis (RDB-6) of clone MM1#1 (mouse 
CYP4A10). Four identical blots (Blots 1, 2, 3, and 4) were prepared by dotting 
recombinant plasmid DNA (10 )ig) of cDNA subclone MM1#1 on nylon membranes 
(duplicate dots per sample per blot). The four blots were hybridized with cDNA 
library probes prepared from total liver RNAs of fed PPARa (+/+), starved PPARa 
(+/+), fed PPARa (-/-), and starved PPARa (-/-) mice, respectively, and the signal 
was detected by colorimetric method with reagents NBT and BCIP. The signal 
intensity was quantified by MultiAnalyst. M, RNA molecular weight marker I, 
digoxygenin-labeled (0.39-6.9 kb); CYP4A10, cytochrome P450 4A10. 
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Figure 5.79. Northern blot and reverse dot blot analyses of clone 002#6 (mouse 
ASL). (A) Northern blot analysis of clone 002#6 (mouse ASL). Total liver RNAs 
(20 |ag) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone 002#6 (mouse 
ASL) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-3) of clone 002#6 (mouse ASL). Four identical blots 
(Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 )ag) of 
cDNA subclone 002#6 on nylon membranes (duplicate dots per sample per blot). 
The four blots were hybridized with cDNA library probes prepared from total liver 
RNAs of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved 
PPARa (-/-) mice, respectively, and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
M, RNA molecular weight marker I, digoxygenin-labeled (0.39-6.9 kb); ASL, 
argininosuccinate lyase. 
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Figure 5.80. Northern blot and reverse dot blot analyses of clone 003#9 (mouse 
Phyh). (A) Northern blot analysis of clone 003#9 (mouse Phyh). Total liver RNAs 
(20 |Lig) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone 003#9 (mouse 
Phyh) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-3) of clone 003#9 (mouse Phyh). Four identical 
blots (Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 
jj^ g) of cDNA subclone 003#9 on nylon membranes (duplicate dots per sample per 
blot). The four blots were hybridized with cDNA library probes prepared from total 
liver RNAs of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved 
PPARa (-/-) mice, respectively, and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
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Figure 5.81. Northern blot and reverse dot blot analyses of clone 004#10 (mouse L-
PBE). (A) Northern blot analysis of clone 004#10 (mouse L-PBE). Total liver RNAs 
(20 |Lig) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone 004#10 (mouse 
L-PBE) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-3) of clone 004#10 (mouse L-PBE). Four identical 
blots (Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 
|Lig) of cDNA subclone 004#10 on nylon membranes (duplicate dots per sample per 
blot). The four blots were hybridized with cDNA library probes prepared from total 
liver RNAs of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved 
PPARa (-/-) mice, respectively, and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
M, RNA molecular weight marker I, digoxygenin-labeled (0.39-6.9 kb); L-PBE, L-
specific multifunctional beta-oxidation protein. 
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5.82), clone PP3#3 (mouse cytochrome P450 4A14, Figure 5.83), clone QQ4#14 
(mouse medium-chain acyl-CoA dehydrogenase, Figure 5.84)，QQ5#17 (mouse major 
urinary protein II, Figure 5.85), clone VV8#6 (mouse 3-hydroxy-3-methyglutary 1-
CoA synthase 2, Figure 5.86), and clone WW1#4 (mouse serine protease inhibitor 1-3, 
Figure 5.87) were confirmed by Northern blot analyses. Mouse EST (D3#3), 
CYP4A10, CYP4A14, MCAD, HMG-CoAS, Hpcl, L-PBE, Bhmt, Phyh, and ASL 
were induced by fasting in a PPARa-dependant manner, while mouse MUP II and 
Spil-3 were suppressed by PPARa in response to food deprivation (Figure 5.88). 
Finally, mouse Ctsl, which was induced during fasting, was dramatically suppressed 
by PPARa during food deprivation. 
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Figure 5.82. Northern blot and reverse dot blot analyses of clone 008#10 (mouse 
Hpcl). (A) Northern blot analysis of clone 008#10 (mouse Hpcl). Total liver RNAs 
(30 jag) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice were 
fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone 008#10 (mouse 
Hpcl) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-3) of clone 008#10 (mouse Hpcl). Four identical 
blots (Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 
|Lig) of cDNA subclone 008#10 on nylon membranes (duplicate dots per sample per 
blot). The four blots were hybridized with cDNA library probes prepared from total 
liver RNAs of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved 
PPARa (-/-) mice, respectively, and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
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Figure 5.83. Northern blot and reverse dot blot analyses of clone PP3#3 (mouse 
CYP4A14). (A) Northern blot analysis of clone PP3#3 (mouse CYP4A14). Total 
liver RNAs (30 |ug) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) 
mice were fractionated on 1% agarose-formaldehyde gel and transferred to nylon 
membrane. The membrane was then hybridized with DIG-labeled probe of clone 
PP3#3 (mouse CYP4A14) prepared by random priming and the signal was detected by 
colorimetric method with reagents NBT and BCIP. The signal intensity was 
quantified by MultiAnalyst. Ethidium bromide stained RNA gel was used for 
normalization. (B) Reverse dot blot analysis (RDB-3) of clone PP3#3 (mouse 
CYP4A14). Four identical blots (Blots 1, 2, 3, and 4) were prepared by dotting 
recombinant plasmid DNA (10 jag) of cDNA subclone PP3#3 on nylon membranes 
(duplicate dots per sample per blot). The four blots were hybridized with cDNA 
library probes prepared from total liver RNAs of fed PPARa (+/+), starved PPARa 
(+/+), fed PPARa (-/-), and starved PPARa (-/-) mice, respectively, and the signal 
was detected by colorimetric method with reagents NBT and BCIP. The signal 
intensity was quantified by MultiAnalyst. M, RNA molecular weight marker I, 
digoxygenin-labeled (0.39-6.9 kb); CYP4A14, cytochrome P450 4A14. 
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Figure 5.84. Northern blot and reverse dot blot analyses of clone QQ4#14 (mouse 
MCAD). (A) Northern blot analysis of clone QQ4#14 (mouse MCAD). Total liver 
RNAs (30 jug) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice 
were fractionated on 1% agarose-formaldehyde gel and transferred to nylon 
membrane. The membrane was then hybridized with DIG-labeled probe of clone 
QQ4#14 (mouse MCAD) prepared by random priming and the signal was detected by 
colorimetric method with reagents NBT and BCIP. The signal intensity was 
quantified by MultiAnalyst. Ethidium bromide stained RNA gel was used for 
normalization. (B) Reverse dot blot analysis (RDB-4) of clone QQ4#14 (mouse 
MCAD). Four identical blots (Blots 1, 2，3, and 4) were prepared by dotting recombinant plasmid DNA (10 jag) of cDNA subclone QQ4#14 on nylon membranes 
(duplicate dots per sample per blot). The four blots were hybridized with cDNA 
library probes prepared from total liver RNAs of fed PPARa (+/+), starved PPARa 
(+/+), fed PPARa (-/-), and starved PPARa (-/-) mice, respectively, and the signal 
was detected by colorimetric method with reagents NBT and BCIP. The signal 
intensity was quantified by MultiAnalyst. M, RNA molecular weight marker I， digoxygenin-labeled (0.39-6.9 kb); MCAD, medium-chain acyl-CoA dehydrogenase. 
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Figure 5.85. Northern blot and reverse dot blot analyses of clone QQ5#17 (mouse 
MUP II). (A) Northern blot analysis of clone QQ5#17 (mouse MUP II). Total liver 
RNAs (20 |ig) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice 
were fractionated on 1% agarose-formaldehyde gel and transferred to nylon 
membrane. The membrane was then hybridized with DIG-labeled probe of clone 
QQ5#17 (mouse MUP II) prepared by random priming and the signal was detected by 
colorimetric method with reagents NBT and BCIP. The signal intensity was 
quantified by MultiAnalyst. Ethidium bromide stained RNA gel was used for 
normalization. (B) Reverse dot blot analysis (RDB-4) of clone QQ5#17 (mouse MUP 
II). Four identical blots (Blots 1, 2, 3, and 4) were prepared by dotting recombinant 
plasmid DNA (10 |ig) of cDNA subclone QQ5#17 on nylon membranes (duplicate 
dots per sample per blot). The four blots were hybridized with cDNA library probes 
prepared from total liver RNAs of fed PPARa (+/+), starved PPARa (+/+), fed 
PPARa (-/-), and starved PPARa (-/-) mice, respectively, and the signal was detected 
by colorimetric method with reagents NBT and BCIP. The signal intensity was 
quantified by MultiAnalyst. M, RNA molecular weight marker I, digoxygenin-
labeled (0.39-6.9 kb); MUP II, major urinary protein II. 
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Figure 5.86. Northern blot and reverse dot blot analyses of clone VV8#6 (mouse 
HMG-CoAS). (A) Northern blot analysis of clone VV8#6 (mouse HMG-CoAS). 
Total liver RNAs (20 |ag) from three mice of fed and starved PPARa (+/+) and 
PPARa (-/-) mice were fractionated on 1% agarose-formaldehyde gel and transferred 
to nylon membrane. The membrane was then hybridized with DIG-labeled probe of 
clone VV8#6 (mouse HMG-CoAS) prepared by random priming and the signal was 
detected by colorimetric method with reagents NBT and BCIP. The signal intensity 
was quantified by MultiAnalyst. Ethidium bromide stained RNA gel was used for 
normalization. (B) Reverse dot blot analysis (RDB-6) of clone VV8#6 (mouse HMG-
CoAS). Four identical blots (Blots 1, 2, 3, and 4) were prepared by dotting 
recombinant plasmid DNA (10 jug) of cDNA subclone VV8#6 on nylon membranes 
(duplicate dots per sample per blot). The four blots were hybridized with cDNA 
library probes prepared from total liver RNAs of fed PPARa (+/+), starved PPARa 
(+/+), fed PPARa (-/-), and starved PPARa (-/-) mice, respectively, and the signal 
was detected by colorimetric method with reagents NBT and BCIP. The signal 
intensity was quantified by MultiAnalyst. M, RNA molecular weight marker I, 
digoxygenin-labeled (0.39-6.9 kb); HMG-CoAS, 3-hydroxy-3-methylglutaryl-CoA 
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Figure 5.87. Northern blot and reverse dot blot analyses of clone WWl#4 (mouse 
Spil-3). (A) Northern blot analysis of clone WWl#4 (mouse Spil-3). Total liver 
RNAs (20 |Lig) from three mice of fed and starved PPARa (+/+) and PPARa (-/-) mice 
was fractionated on 1% agarose-formaldehyde gel and transferred to nylon membrane. 
The membrane was then hybridized with DIG-labeled probe of clone WWl#4 (mouse 
Spil-3) prepared by random priming and the signal was detected by colorimetric 
method with reagents NBT and BCIP. The signal intensity was quantified by 
MultiAnalyst. Ethidium bromide stained RNA gel was used for normalization. (B) 
Reverse dot blot analysis (RDB-5) of clone WWl#4 (mouse Spil-3). Four identical 
blots (Blots 1, 2, 3, and 4) were prepared by dotting recombinant plasmid DNA (10 
i^g) of cDNA subclone WWl#4 on nylon membranes (duplicate dots per sample per 
blot). The four blots were hybridized with cDNA library probes prepared from total 
liver RNAs of fed PPARa (+/+), starved PPARa (+/+), fed PPARa (-/-), and starved 
PPARa (-/-) mice, respectively, and the signal was detected by colorimetric method 
with reagents NBT and BCIP. The signal intensity was quantified by MultiAnalyst. 
M, RNA molecular weight marker I, digoxygenin-labeled (0.39-6.9 kb); Spil-3, serine 














































































































































































































































































































































































Chapter 6 Discussion 
6.1 PPARa and hepatic lipid metabolism during fasting 
PPARa appears to play a critical role in adaptive responses to maintain 
energy homeostasis during energy deprivation such as fasting and diabetes. The 
indispensable role of PPARa in regulating energy homeostasis is stressed by severe 
hepatomegaly, hepatic steatosis, hypoglycemia, hypoketonemia, elevated fatty acid 
levels and hypothermia in PPARa-null mice fasted for 24, 48 or 72 hr compared with 
their corresponding wild-type controls (Kersten et al., 1999; Leone et al., 1999; 
Hashimoto et al., 2000). 
In addition, PPARa plays a pivotal role in adaptive responses to energy 
deprivation through transcriptional regulation of genes involved in energy 
homeostasis, in particular fatty acid oxidation. Genes involved in mitochondrial p-
oxidation such as medium-chain acyl-CoA dehydrogenase (Leone et al,, 1999), 
ketogenesis such as 3-hydroxy-3-methylglutaryl-CoA synthase (Le May et al,, 2000), 
peroxisomal (3-oxidation such as bifunctional protein and 3-ketoacyl-CoA thiolase 
(Kroetz et al., 1998), and microsomal co-oxidation such as cytochrome P450 4A1, 
cytochrome P450 4A2, cytochrome P450 4A3 (Kroetz et al,, 1998; Leone et al., 
1999), cytochrome P450 4A14 (Lee et al., 2002) are up-regulated during fasting in a 
PPARa-dependent manner. Apart from transcriptional activation, PPARa also 
regulates constitutive expression of genes encoding several mitochondrial fatty acid 
metabolizing enzymes. The gene expression levels of very long-chain acyl-CoA 
dehydrogenase, long-chain acyl-CoA dehydrogenase, short-chain specific 3-ketoacyl-
CoA thiolase, and long-chain acyl-CoA synthase are lower in PPARa-null mice 
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compared to their corresponding wild-type control mice (Aoyama et al., 1998; 
Watanabe et al., 2000). 
These results indicate the importance of PPARa in maintaining lipid 
homeostasis during energy deprivation. However, the complex network of PPARa-
dependent signaling pathways in regulating hepatic fatty acid oxidation during energy 
deprivation is still not clear, as the underlying molecular mechanism of fasting-
induced PPARa-dependent novel genes such as fasting induced adipose factor 
(Kersten et al., 2000) and a novel gene B3 (Lee et al., 2002) is still uncertain. 
The aim of present study is to identify the spectrum of PPARa-dependent 
genes involved in regulation of hepatic lipid homeostasis during fasting by the 
method of fluorescent differential display. Identification of novel PPARa-dependent 
and fasting-responsive genes may provide implications for the mechanism, 
significance and consequence of such regulations by PPARa. 
6.2 Enlargement of liver in starved PPARa-null mice 
The pivotal role of PPARa involved in hepatic lipid metabolism during 
fasting is further confirmed by the sole morphological change in the liver of starved 
mice lacking PPARa expression compared to their corresponding fed controls. 
Fasting leads to accumulation of lipid in the liver of PPARa-null mice, and results in 
fatty livers with a pale color compared to that of starved wild-type mice (Kersten et 
al., 1999; Leone et al., 1999; Hashimoto et al., 2000). In addition, hepatomegaly was 
observed in the liver of starved PPARa-null mice (Leone et al., 1999). Consistently, 
both hepatomegaly and pale livers were observed in the starved PPARa-null mice in 
the present study. There was a significant increase (1.35-fold) in the liver weight (as 
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% body weight) in PPARa-null mice starved for 72 hr compared to their 
corresponding fed controls, whereas a significant decrease (15%) was obtained for 
f 
starved wild-type mice. These results indicated that PPARa plays an important role 
in regulating hepatic lipid homeostasis during starvation, as lipid accumulation and 
liver enlargement were observed in the liver of PPARa-null mice, which lack PPARa 
expression. 
6.3 Alteration of serum P-hydroxybutyrate, triglyceride and 
cholesterol levels by PPARa during fasting 
Serum P-hydroxybutyrate, triglyceride, and cholesterol were measured in fed 
and starved wild-type and PPARa-null mice to study the effect of PPARot on those 
metabolites during energy deprivation. 
In adaptive to food deprivation, the capacity of fatty acid oxidation increases 
and ketone bodies such as P-hydroxybutyrate are generated to serve as energy fuel for 
extrahepatic tissues such as brain, muscle and kidney during starvation. Previous 
studies have shown that there is a dramatic increase in serum beta-hydroxybutyrate 
level in starved wild-type mice, but the increase in starved PPARa-null mice is much 
less mark (Kersten et al., 1999; Leone et al,, 1999; Hashimoto et al., 2000). In 
accordance with the previous studies, a dramatic increase in serum beta-
hydroxybutyrate levels were obtained for starved wild-type (23.17-fold) and a less 
marked increase was observed in starved PPARa-null mice (2.10-fold) compared to 
their corresponding fed controls. The small increase of serum P-hydroxybutyrate in 
starved PPARa-null mice might be due to the impairment of PPARa-dependent 
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induction of the HMG-CoA synthase gene, which is involved in ketogenesis during 
fasting, in the absence of PPARa (Le May et al., 2000). 
( 
Fasting leads to decrease in plasma triglyceride levels in both wild-type and 
PPARa-null mice (Hashimoto et al., 2000). Consistently, 72 hr-fasting in the present 
study resulted in 32% and 35% decreases in serum triglyceride levels in starved wild-
type and starved PPARa-null mice, respectively, compared to their corresponding fed 
controls. These results indicated that decrease in serum triglyceride levels in 
response to starvation was PPARa-independent as both wild-type and PPARa-null 
mice showed the same level of decrease. 
It has been reported that fasting in healthy and nonobese human is 
accompanied by an increase in serum total cholesterol concentration and the increase 
is associated with weight loss (Savendahl and Underwood, 1999). Interestingly, 72 hr 
of fasting resulted in a 1.38-fold increase in serum total cholesterol level for wild-type 
mice compared to their corresponding fed controls, but a 31% decrease for PPARa-
null mice. The results appeared to dictate the essential role of PPARa in maintaining 
and elevating serum cholesterol level during fasting. However, the molecular and 
functional consequence of this change is uncertain. 
6.4 Identification of PPARa-dependent and fasting-
responsive genes by fluorescent differential display 
and PPARa-null mice 
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PPARa-dependent and fasting-responsive genes were identified by the 
method of fluorescent differential display by comparing the gene expression level 
( 
between livers of fed and starved PPARa wild-type and PPARa-null mice. Non-
fluoroDD preliminary screening, which is a fast and economic method, was employed 
to screen out AP-ARP primer combinations that would give obvious differential gene 
expressions of A-H as summarized in Table 4.1 before carrying out fluoroDD PCR as 
not all of the AP-ARP primer combinations (240 combinations) could give the 
differential gene expression patterns A-H. Eighteen out of seventy-six primer 
combinations screened showed the differential gene expression patterns and were 
used for performing fluoroDD PCR. Sixty-two differentially expressed cDNA 
fragments were excised from eighteen fluoroDD gels performed and were used for 
reamplification and subcloning. It is tricky that some of the cDNA fragments 
resulted in extra PCR products in addition to the expected PCR products after 
reamplification. In addition, after subcloning, some of the reamplified cDNA 
fragments resulted in more than a single type of cDNA subclones which displaying 
different restriction pattern in restriction enzyme analysis. These results indicated 
that the excised cDNA fragments might contain other cDNA species, which might be 
derived from co-migrated and/or contaminated nearby cDNA fragments during gel 
excision, and this had greatly increased the chance of getting false-positive 
differentially expressed cDNA fragments. 
With a view to screen out false-positive cDNA subclones, cDNA subclones 
showing the same or different restriction patterns were screened by reverse dot blot 
analysis. To ensure the reliability of the reverse dot blot analysis, three differential 
gene expression controls including mouse cytochrome P450 4A14 (CYP4A14), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and medium-chain acyl-CoA 
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dehydrogenase (MCAD) with known differential gene expression patterns were 
included in reverse dot blot analysis. Both CYP4A14 and MCAD genes are up-
f 
regulated in starved PPARa (+/+) group compared to their corresponding fed controls 
in a PPARa-dependent manner. In contrast, GAPDH is up-regulated in starved 
PPARa (+/+) group but in a PPARa-independent manner. It is important to include 
those differentially expressed genes as controls in reverse dot blot analysis, as they 
are useful in realizing the performance or reliability of reverse dot blot analysis. The 
reverse dot blot analyses in which the three differential gene expression controls 
exhibited the expected pattern were chosen for screening out the false-positive cDNA 
subclones. However, the differential gene expression patterns of the three controls 
were sometimes slightly varied from their corresponding Northern blot patterns. 
Those variations include an induction of CYP4A14 and MCAD in starved PPARa (-
/-) group compared to their corresponding fed controls besides the up-regulation in 
starved PPARa (+/+) group. Whereas GAPDH was down-regulated in fed PPARa (-
/-) group compared to their corresponding starved groups and wild-type groups. As a 
result, for those reverse dot blot analyses, careful judgment is required in selecting 
positive cDNA subclones based on the patterns of differential gene expression 
controls. The variation in patterns of differential gene expression controls in reverse 
dot blot analyses might be due to the variation of quality between the cDNA library 
probes and depletion of the probes during recycling, which result in reduced 
efficiency in reverse dot blot analysis. cDNA subclones obtained from sixty-two 
differentially expressed cDNA fragments were screened by reverse dot blot analysis, 
and twenty-six cDNA fragments (41.94%) obtained with positive cDNA subclones 
displaying differential gene expression patterns A-H. 
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Fifty-two positive cDNA subclones derived from twenty-three differentially 
expressed cDNA fragments were sequenced and then thirteen PPARa-dependent and 
f 
fasting-responsive genes were identified after sequencing. They, in ascending order 
of abundance, included mouse betaine-homocysteine methyltransferase (Bhmt) 
(fragment D2), mouse cathepsin L (Ctsl) (fragment LLl), a mouse EST with 
homology to mouse hypothetical protein MMT-7 gene (fragment D3), mouse 3-
hydroxyl-3-methylglutaryl-Co synthase II (HMG-CoAS) (fragment VV8), mouse L-
specific multifunctional beta-oxidation protein (L-PBE) (fragment 004) , mouse 
medium-chain acyl-CoA dehydrogenase (MCAD) (fragment QQ4), mouse 
phytanoyl-CoA hydroxylase (Phyh) (fragment 003) , mouse 2-hydroxyphytanoyl-
CoA lyase (Hpcl) (fragments 0 0 8 and 009) , mouse serine protease inhibitor 1-3 
(Spil-3) (fragments 0 0 7 and WWl), rat argininosuccinate lyase (ASL) (fragments 
0 0 2 , 0 0 3 , and 004) , mouse cytochrome P450 4A14 (CYP4A14) (fragments 0 0 4 , 
0 0 5 , 0 0 6 . and PP3), mouse major urinary protein II (MUPII) (fragments QQ5, QQ6, 
TT4, and TT5), and mouse cytochrome P450 4A10 (CYP4A10) (fragments Dl, MMl, 
UUl, VV5, and XXI). The number of genes identified were thirteen rather than 
twenty-four as some of those genes occurred repetitively in the cDNA fragments. 
Among those genes, the highest abundant gene is mouse CYP4A10 (20.83%), 
whereas the least abundant genes include mouse Bhmt, Ctsl, EST, HMG-CoAS, L-
PBE, MCAD, Phyh (4.17%). All of the genes were successfully confirmed in 
Northern blot analysis. 
Practically, the method of fluorescent differential display is powerful in 
identifying novel genes such as the mouse EST (clone D3#3) in the present study, but 
the limitation is that abundant genes such as mouse CYP4A10 will greatly increase 
the cost as well as the labor. 
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6.4.1 Roles of PPARa-dependent and fasting-responsive genes 
Using fluorescent differential display method, thirteen PPARa-dependent and 
fasting-responsive genes were identified in the present study. The thirteen PPARa-
dependent and fasting-responsive genes identified, in ascending order of abundance, 
included mouse betaine homocysteine methyltransferase (Bhmt), mouse cathepsin L 
(Ctsl), mouse EST with homology to mouse hypothetical protein MMT-7 gene (clone 
mouse 3-hydroxy-3-methyglutaryl-CoA synthase 2 (HMG-CoAS) (Le May et 
al., 2000), mouse L-specific multifunctional beta-oxidation protein (L-PBE) 
(Hashimoto et al., 2000), mouse medium-chain acyl-CoA dehydrogenase (MCAD) 
(Leone et al., 1999; Wan et al., 2000), mouse phytanoyl-CoA hydroxylase (Phyh), 
mouse 2-hydroxyphytanoyl-CoA lyase (Hpcl), mouse serine protease inhibitor 1-3 
(Spil-3), rat argininosuccinate lyase (ASL), mouse cytochrome P450 4A14 
(CYP4A14) (Lee et al., 2002), mouse major urinary protein II (MUP II), and mouse 
cytochrome P450 4A10 (CYP4A10). PPARa-dependent genes up-regulated during 
fasting including the mouse EST (clone D3#3), medium-chain acyl-CoA 
dehydrogenase (MCAD), L-specific multifunctional beta-oxidation protein (L-PBE), 
phytanoyl-CoA hydroxylase (Phyh), 2-hydroxyphytanoyl-CoA lyase (Hpcl), 
cytochrome P450 4A10 (CYP4A10), cytochrome P450 4A14 (CYP4A14), 3-
hy droxy-3-methy Iglutaryl-Co A synthase (HMG-CoAS), betaine-homocysteine 
methyltransferase (Bhmt), and argininosuccinate lyase (ASL). Serine protease 
inhibitor 1-3 (Spil-3) and major urinary protein II (MUP II) were PPARa-dependent 
and down-regulated during starvation. Interestingly, up-regulation of mouse 
cathepsin L (Ctsl) during fasting was dramatically down-regulated by PPARa. 
Collectively, in response to fasting, PPARa stimulates hepatic fatty acid oxidation by 
transcriptional up-regulation of genes involved in mitochondrial p-oxidation (MCAD), 
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peroxisomal a- (Phyh and Hpcl) and p-oxidation (L-PBE), microsomal co-oxidation 
(CYP4A10 and CYP4A14) and ketogenesis (HMG-CoAS) (Table 6.1). In addition, 
PPARa also play a role in regulating protein metabolism (Bhmt, Ctsl, ASL, and Spil-
3) during energy deprivation. However, the functional consequence of transcriptional 
alteration of a certain genes (mouse EST clone D3#3 and MUP II) by PPARa during 
fasting is still uncertain, especially the novel cDNA subclone. 
6.4.1.1 Lipid metabolism 
In response to fasting, PPARa stimulates mitochondrial P-oxidation by 
mediating the induction of medium-chain acyl-CoA dehydrogenase (MCAD), the 
first enzyme of mitochondrial P-oxidation (Figure 6.1) (Leone et al., 1999; Wan et al,, 
2000). Consistently, hepatic MCAD was one of the fasting-induced and PPARa-
dependent genes identified by fluoroDD in the present study. Mitochondrial P-
oxidation is a key route for the oxidation of short- (�Cg), medium- (C8-C12), and long-
(C14-C20) chain fatty acids generating acetyl-CoA and contributes to energy 
production via oxidative phosphorylation generating ATP (Eaton et al., 1996; Reddy 
et al., 2001). Oxidation of fatty acids to acetyl-CoA by mitochondrial p-oxidation for 
production and secretion of ketone bodies for extrahepatic tissues such as brain, 
muscle and kidney to serve as an important energy fuel is favored during starvation. 
Besides, MCAD contains a functional PPRE (Devchand et al” 1999) and hence it 
might be a direct PPARa target gene induced during fasting. Human MCAD gene 
spans 44 kb and contains 12 exons (Zhang et al., 1992), and in mouse, MCAD gene 
spans 25 kb and is composed of 12 exons as well (Tolwani et al., 1996). MCAD 
carries a phosphate group, which has no detectable effect on the catalytic activity of 







































































































































































































































































































































































































































































































































Fatty acid + CoA 
广 ATP A c y l - C o A synthetase 
^ ^ AMP + PPi 
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I 3 -Hydroxyacyl-Co A 
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Figure 6.1. The schematic pathway of fatty acid P-oxidation in mitochondria (Reddy et al., 2001). 
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rats, MCAD mRNA is highly expressed in aorta, heart and brown fat, and to a lesser 
extent in liver, kidney and duodenum, and to a least extent in brain, placenta, ovary, 
f 
testes and skeletal muscle (Mainline et al., 1993). MCAD deficiency is a common 
inherited defect in fatty acid oxidation in humans, and patients are at risk for 
outcomes such as hypoglycemia, hepatomegaly and sudden death (Wang et al., 1999). 
Deficiency of MCAD is mainly associated with a point mutation that A replaces G at 
nucleotide position 985 of the MCAD mRNA coding region leading to substitution of 
a glutamic acid for a lysine at amino acid position 304 of the mature protein (Kelly et 
al., 1990). In addition to A985G mutation, G to A mutation at nucleotide position 
583 is also associated with severe MCAD deficiency causing hypoglycemia or 
sudden neonatal death (Brackett et al., 1994). Recently, newborn screening for 
MCAD deficiency has been employed and suggested for being included in the routine 
neonatal screening program (Alluri et al,, 2002). Collectively, mitochondrial P-
oxidation is stimulated during fasting through induction of MCAD gene expression 
mediated by PPARa. 
Hepatic mitochondrial 3 -hydroxy-3-methylglutaryl-CoA synthase (HMG-
CoAS), the key enzyme of ketogenesis (Figure 6.2), has been demonstrated to be 
induced by fasting in a PPARa-dependent manner (Le May et al., 2000), and this is 
farther supported by the result that hepatic mitochondrial HMG-CoAS was identified 
as a fasting-induced and PPARa-dependent gene in current study. Ketogenesis is 
responsible for generation of ketone bodies as energy fuel for extrahepatic tissues, in 
particular, during starvation, and this is illustrated by the dramatic elevation of P-
hydroxybutyrate levels of fasted wild-type mice. The critical role of PPARa in 
regulating ketogenesis is manifested by the impaired elevation of p-hydroxybutyrate 
levels in fasted PPARa-deficient mice as compared to fasted wild-type mice (Kersten 
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2 Acetyl CoA • 
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Figure 6.2. Ketone bodies formation in liver (Stryer, 1995). 
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et aL, 1999; Leone et al., 1999; Hashimoto et al., 2000). Collectively, these results 
reveal that PPARa plays a prominent role in stimulating ketogenesis through 
f 
transcriptional activation of mitochondrial HMG-CoAS gene in response to fasting. 
Mitochondrial HMG-CoAS might be a direct target of PPARa as a functional PPRE 
has been identified in the upstream region of the gene (Meertens et al., 1998). 
Interestingly, in addition to its role as a ketogenic enzyme, mitochondrial HMG-
CoAS protein also acts as a transcription co-activator of PPARa that activates the 
expression of the HMG-CoAS gene itself (Meertens et al., 1998). Mitochondrial 
HMG-CoAS mRNA is highly expressed in liver and colon, and to a lesser extent in 
testis, heart, skeletal muscle and kidney (Mascaro et al., 1995). A recessive disorder 
of ketogenesis of mitochondrial HMG-CoAS deficiency has been reported in children 
with hypoglycaemic hypoketotic coma during fasting periods (Aledo et al., 2001). 
As a result, in adaptive response to fasting, mitochondrial ketogenesis is activated by 
PPARa-mediated up-regulation of HMG-CoAS. 
Consistent with previous study, L-specific multifunctional beta-oxidation 
protein (L-PBE) was up-regulated by fasting in a PPARa-dependent manner in the 
present study (Hashimoto et al., 2000). Very-long-chain fatty acids (>C20) are 
almost exclusively (3-oxidized in peroxisomes as mitochondria are devoid of very-
long-chain acyl-CoA synthetase (Reddy et al,, 1994; Uchiyama et al,, 1996). Long-
chain fatty acids, dicarboxylic acids, eicosanoids, bile acids and xenobiotics are also 
metabolized by the peroxisomal P-oxidation system (Mannaerts et al., 2000; Reddy et 
al” 1994). The second and third steps of peroxisomal p-oxidation are catalyzed by 
PBE (Figure 6.3). Both L-PBE and D-PBE, which are responsible for the 
peroxisomal-inducible classical straight-chain and the noninducible branched-chain 
fatty acid P-oxidation systems respectively, are induced by fasting via PPARa 
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Figure 6.3. The schematic pathway of straight-chain fatty acid P-oxidation in peroxisomes (Reddy et a/., 2001). 
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(Hashimoto et al., 2000). These results imply that PPARa enhances peroxisomal p-
oxidation by stimulating PBE during starvation. A functional PPRE has been 
f 
identified for PBE, and PBE PPRE contains three regulatory motifs including DRl 
and DR2 sequences. Transcriptional regulation of PBE by PPAR and RXR is via the 
DRl element whereas auxiliary factors modulate expression via DR2 region in 
HepG2 cells (Bardot et al., 1995). Surprisingly, PBE is capable of acting as a 
cofactor in activating the AF-1 domain of PPARa. Thus, PBE, a PPARa-responsive 
gene, interacts with this nuclear hormone receptor to autoregulate its own nuclear 
transcription (Juge-Aubry et al., 2001). Peroxisomal P-oxidation was activated in the 
course of energy deprivation via PPARa-dependent up-regulation of L-PBE gene 
expression. 
In this study, it was found that fasting induced both phytanoyl-CoA 
hydroxylase (Phyh) and 2-hydroxyphantanoyl-CoA lyase (Hpcl), which are 
responsible for the first and second steps of peroxisomal a-oxidation respectively 
(Figure 6.4), through PPARa. Recently, phytanic acid a-oxidation pathway has been 
proved to be localized in peroxisomes (Jansen et al., 2001). Phytanic acid is a phytol-
derived branched-chain fatty acid present in dietary products and is first metabolized 
by a-oxidation as the methyl group in the 3-position blocks p-oxidation, which 
leading to shortening of the chain by one carbon atom yielding pristanic acid and 
carbon dioxide, (Wanders et al., 2001). Pristanic acid is then further oxidized by 
peroxisomal and mitochondrial P-oxidation (Verhoeven et al., 1998). Previously 
study has illustrated that pristanic acid and phytanic acid are naturally occurring 
PPARa ligands (Zomer et al., 2000) and Hpcl is induced by PPARa after peroxisome 
proliferator treatment (Lee et al., 2002). In contrast, it has been suggested that 
activation of Phyh by phytanic acid is independent of PPARa (Zomer et al., 2000). 
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Figure 6.4. The schematic pathway of phytanic acid a-oxidation in peroxisomes (Wanders 
et al., 2000). 
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Results obtained in current study indicated that, in addition to mitochondrial and 
peroxisomal p-oxidation, peroxisomal a-oxidation might also be induced as an 
adaptive response to starvation via PPARa. 
Hepatic cytochrome P450 4A10 (CYP4A10) and cytochrome P450 4A14 
(CYP4A14) were identified to be fasting-responsive genes induced by PPARa. The 
initial step of oo-oxidation is co-hydroxylation of fatty acid in smooth endoplasmic 
reticulum catalyzed by CYP4A isoforms (Figure 6.5) (Johnson et al., 1996). CYP4A 
isoforms are active in co-hydroxylation of medium- and long-chain fatty acids and 
fatty acid derivatives such as arachidonic acid, prostaglandin and other eicosanoids 
(Roman et aL, 1993; Johnson et al., 1996). CYP4A isoforms appear to play a 
significant role in fatty acid metabolism as induction of CYP4A expression has been 
reported in states of altered nutrient metabolism, such as obesity (Enriquez et al., 
1999), diabetes (Kroetz et al., 1998; Enriquez et al., 1999) and fasting (Kroetz et al., 
1998; Lee et al,, 2002). Moreover, it has been reported that the known PPARa target 
gene, CYP4A10 and CYP4A14, are induced in the liver of streptozotocin-induced 
diabetic mouse (Sakuma et al., 2001). Recently, hepatic CYP4A1, CYP4A2 and 
CYP4A3 have also been demonstrated to be induced by fasting through PPARa 
(Kroetz et al., 1998; Leone et al., 1999; Hashimoto et aL, 2000), and a functional 
PPRE has been identified for CYP4A1 (Aldridge et al,, 1995). Based on these results, 
PPARa plays a significant role in stimulating co-oxidation through transcriptional 
activation of a variety of CYP 4A isoforms in the period of food deprivation. 
6.4.1.2 Protein metabolism 
In spite of the crucial role of PPARa involved in lipid metabolism, PPARa 
also play an indispensable role in protein metabolism (Kersten et al., 2001). The 
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expression level of argininosuccinate synthase and argininosuccinate lyase (ASL), 
enzymes involved in urea cycle, is lower in fasted wild-type mice than that of fasted 
PPARa-null mice (Kersten et al., 2001). Reduced synthesis of urea in fasted wild-
type mice as compared with fasted PPARa-deficient mice is in agreement with lower 
plasma urea in fasted wild-type mice than in PPARa-null mice, while there is no 
difference between them under fed condition (Kersten et al., 2001). These data 
appears to indicate that PPARa has an inhibitory effect on urea synthesis in the 
period of food deprivation. However, in contrast to these observations, ASL 
identified in the present study was slightly induced by fasting in a PPARa-dependent 
manner in mouse liver instead. Actually, the same type of wild-type and PPARa-null 
mice on SV129 background have been used in previous and present studies, but the 
major difference between them is the duration of food deprivation. In previous study, 
mice have been fasted for 24 hr instead of a longer period of 72 hr used in the present 
study. Practically, protein metabolism varies in the course of starvation that there is 
an initial decrease in protein utilization followed by a period of protein sparing that 
ends with a marked increase in nitrogen excretion (Belkhou et al., 1994). Thus, the 
contradiction in the regulation of ASL in fasting by PPARa might probably be 
attributed to the differences in the duration of food deprivation. It appears that ASL 
was suppressed and then induced in the course of starvation through PPARa. 
It is quit surprising that cathepsin L (Cstl), an ubiquitously expressed member 
of the papain family contributing to the terminal degradation of proteins in the 
lysosome, induced by fasting was dramatically suppressed by PPARa, despite the 
fact that the activity of Ctsl are significantly increased during starvation in rat 
(Inubushi et ah, 1996). Ctsl gene spans 8.5 kb and contains 8 exons (Ishidoh et al,, 
1989). In addition to proteolysis in the lysosomes, Ctsl is critical for cardiac 
300 
morphology and function, as Ctsl null mice develop pathomorphological, histological, 
and cardiac alternations that closely resemble human dilated cardiomyopathy 
! 
(Stypmann et al., 2002). Besides, Ctsl is essential for epidermal homeostasis, regular 
hair follicle morphogenesis and cycling (Roth et al., 2000). Furthermore, Ctsl is 
associated with MHC class Il-mediated antigen presentation in epithelial cells of the 
thymus (Reinheckel et al,, 2001). However, the underlying mechanism of PPARa-
mediated suppression of fasting-induced Ctsl expression in response to fasting is 
unclear. 
During fasting serine protease inhibitor 1-3 (Spil-3) was suppressed in a 
PPARa-dependent manner. Serine protease inhibitors (serpins) are a family of 
structurally related proteins that regulate the activity of serine proteases involved in 
diverse physiological processes such as coagulation, fibrinolysis, complement 
activation, apoptosis, inflammation, angiogenesis, neoplasia and viral pathogenesis 
(Janciauskiene, 2001). It has been reported that Spi-3 is induced by endotoxin in 
ocular tissues, suggesting that Spi-3 may have a crucial role in preventing some 
degenerative proteolysis induced by inflammatory stimuli (Takamiya et al,, 2001). 
Besides, expression of Spi-3 mRNA is induced by the cytokine interleukin-1 beta, 
which is dependent of gene transcription, protein synthesis and activation of NF-
kappaB but not nitric oxide formation (Chen et al., 1999). However, the functional 
consequence of PPARa-mediated suppression of Spil-3 during food deprivation is 
unknown. 
In the present study, betaine-homocysteine methyltransferase (Bhmt) was 
induced by fasting via PPARa. Bhmt is a zinc metalloenzyme that involved in the 
pathway of choline and methionine metabolism (Heil et al., 2000; Millian et al., 
1998). Recently, the gene encoding for Bhmt has been cloned, and it is composed of 
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8 exons and 7 introns (Garrow, 1996; Neece et al., 2000). Bhmt is mainly expressed 
in the liver and kidney cortex of humans, pigs and rats (Sunden et al., 1997; Delgado-
Reyes et al., 2001). Expression of Bhmt mRNA is devoid in brain, heart, skeletal 
muscle, pancreas, spleen and placenta in humans (Sunden et al., 1997). Previous 
studies have shown that Bhmt is regulated by dietary factors that it is increased in 
adaptation from a high protein diet to a low protein diet (Finkelstein et al., 1984) and 
methionine-deficient diet with supplemental betaine (Park et al., 1999). However, the 
significance of transcriptional activation of Bhmt by PPARa in the period of food 
deprivation is uncertain. 
6.4.1.3 Other functions 
In addition to regulation of genes involved in lipid and protein metabolism, 
PPARa also plays an obligatory role in regulating transcription of other genes. In the 
present study, PPARa mediated the suppression of major urinary protein II (MUP II) 
gene in response to fasting. Major urinary proteins (MUPs) belong to a superfamily 
of ligand-binding proteins and represent the major urinary proteins secreted by the 
liver and filtered by the kidney for excretion in urine of adult male mice, the 
homologous proteins in rats are referred as ot2u-globulins (Cavaggioni et al., 2000). 
Six mouse major urinary proteins (MUP I-VI), encoded by distinct genes, have been 
described and they show distinct expression in liver as well as in various exocrine 
glands such as mammary, parotid, sublingual, lachrymal and submaxillary gland 
(Shahan et al., 1987). MUPs appears to play a role in chemosensory signaling among 
rodents as they act as carriers of odorant molecules (Hurst et al,, 1998; Lehman-
McKeeman et al., 1998). A previous study has shown that a iu-globulin gene is a 
PPARa-target gene and is suppressed by the treatment of peroxisome proliferators 
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via PPARa (Motojima et al., 1997). Besides, MUP synthesis decreases early in 
mouse liver tumor formation, and this has been suggested to be used as a tumor 
f 
marker in mouse hepatocarcinogenesis (Dragani et al., 1989). However, the 
mechanism and significance of PPARa-mediated suppression of MUP II in the period 
of starvation is unclear. 
One of the cDNA subclones identified in current study did not share 
homology with any known genes, but matched with the mouse EST. This novel 
cDNA clone D3#3 (fragment D3), sharing homology with mouse hypothetical protein 
MMT-7 gene, was induced during fasting in a PPARa-dependent manner. The size 
of transcript verified in Northern blot analysis was similar to the complete cDNA size 
of MMT-7 gene. However, the function of PPARa-mediated induction of the mouse 
EST remains to be elucidated. 
In summary, PPARa plays an essential regulatory role in transcription of 
certain genes during fasting and most of them are involved in lipid and protein 
metabolism (Figure 6.5). By the method of fluorescent differential display, thirteen 
PPARa-dependent and fasting-responsive genes identified include, in ascending 
order of abundance, mouse betaine homocysteine methyltransferase (Bhmt), mouse 
cathepsin L (Ctsl), mouse EST with homology to mouse hypothetical protein MMT-7 
gene (clone D3#3), mouse 3-hydroxy-3-methyglutaryl-CoA synthase 2 (HMG-CoAS), 
mouse L-specific multifunctional beta-oxidation protein (L-PBE), mouse medium-
chain acyl-CoA dehydrogenase (MCAD), mouse phytanoyl-CoA hydroxylase (Phyh), 
mouse 2-hydroxyphytanoyl-CoA lyase (Hpcl), mouse serine protease inhibitor 1-3 
(Spil-3), rat argininosuccinate lyase (ASL), mouse cytochrome P450 4A14 
(CYP4A14), mouse major urinary protein II (MUP II), and mouse cytochrome P450 

























































































































































































































































































































































































































































































































PPARa involved in lipid metabolism during energy deprivation. However, PPARa-
mediated adaptation to food deprivation might be more complex as functional 
consequences of modification of certain known and novel genes are still uncertain. 
Thus, identification of more PPARa-dependent and fasting-responsive genes and 
functional analysis of identified genes are necessary to study the complex 
physiological role of PPARa involved in lipid metabolism induced by starvation in 
future. 
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Chapter 7 Conclusions 
PPARa plays an essential regulatory role in transcription of certain genes during 
fasting. By the method of fluorescent differential display, thirteen PPARa-dependent 
and fasting-responsive genes were identified and they included, in a ascending order of 
abundance, mouse betaine homocysteine methyltransferase (Bhmt), mouse cathepsin L 
(Ctsl), mouse EST with homology to mouse hypothetical protein MMT-7 gene (clone 
D3#3), mouse 3 -hydroxy-3 -methyglutaryl-CoA synthase 2 (HMG-CoAS), mouse L-
specific multiflinctional beta-oxidation protein (L-PBE), mouse medium-chain acyl-CoA 
dehydrogenase (MCAD), mouse phytanoyl-CoA hydroxylase (Phyh), mouse 2-
hydroxyphytanoyl-CoA lyase (Hpcl), mouse serine protease inhibitor 1-3 (Spil-3), rat 
argininosuccinate lyase (ASL), mouse cytochrome P450 4A14 (CYP4A14), mouse major 
urinary protein II (MUP II), and mouse cytochrome P450 4A10 (CYP4A10). Among the 
thirteen genes, the mouse EST (clone D3#3), medium-chain acyl-CoA dehydrogenase, L-
specific multifunctional beta-oxidation protein, phytanoyl-CoA hydroxylase, 2-
hydroxyphytanoyl-CoA lyase, cytochrome P450 4A10, cytochrome P450 4A14, 3-
hydroxy-3 -methyIglutaryl-CoA synthase, betaine-homocysteine methyltransferase, and 
argininosuccinate lyase were induced by fasting in a PPARa-dependant manner, while 
mouse major urinary protein II and serine protease inhibitor 1-3 were suppressed by 
PPARa in response to food deprivation. Finally, mouse cathepsin L, which was induced 
by fasting, was suppressed by PPARa during fasting. Collectively, in response to fasting, 
PPARa stimulates hepatic fatty acid oxidation by transcriptional up-regulation of genes 
involved in mitochondrial P-oxidation (MCAD), peroxisomal a- (Phyh and Hpcl) and P-
oxidation (L-PBE), microsomal co-oxidation (CYP4A10 and CYP4A14) and ketogenesis 
(HMG-CoAS). In addition, PPARa also play a role in regulating protein metabolism 
� 307 
(Bhmt, Ctsl, ASL, and Spil-3) during energy deprivation. However, the functional 
consequence of transcriptional alteration of a certain genes (mouse EST clone D3#3 and 
MUP II) by PPARa during fasting is still uncertain, especially the novel cDNA subclone. 
In conclusion, PPARa plays an essential regulatory role in transcription of certain 
genes during fasting and most of them are involved in lipid and protein metabolism. 
These results might shed some light on the physiological role of PPARa involved in lipid 
metabolism during energy deprivation. However, PPARa-mediated adaptation to food 
deprivation might be more complex as functional consequences of modification of certain 
known and novel genes are still uncertain. 
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Chapter 8 Future studies 
8.1 Further identification of fasting-responsive and PPARa-
dependent genes 
The complex signaling pathway of PPARa-mediated transcriptional regulation of 
genes in adaptation to fasting is still uncompleted as the significance and consequence of 
alteration of a certain gene remains to be explored, in particular the mouse EST. Further 
identification of novel or unknown PPARa-dependent genes in response to starvation 
might provide a more prudent and comprehensive role of PPARa in mediating adaptive 
response to energy deprivation as in starvation. 
8.2 Characterization of the mouse EST 
The function of the mouse EST (clone D3#3), which was up-regulated by PPARa 
during fasting, is unknown, and so it is necessary to characterize the mouse EST. To 
characterize the EST, construction of flill-length cDNA, expression of the full-length 
cDNA, immunohistochemical study, and tissue distribution of the protein will be 
conducted. Finally, the function of the novel gene in vivo will be further characterized 
via the construction of gene-targeted knockout mice. 
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Appendix A: Protocol for reaction preparation 
Table Al . PCR tail-genotyping 
Reagent Stock Final Per reaction Per 20 reactions 
concentration concentration (|li1) (|il) 
Sterile H2O - - 19.125 382.5 
PCR buffer 10 x 1 x 2.5 50 
dNTP mix (1:1:1:1) 10 mM (each) 0.05 mM (each) 0.125 2.5 
Forward primer (Fl) 10 i^M 0.35 |iM 0.875 17.5 
Reverse primer (R3) 10 |iM 0.35 [iM 0.875 17.5 
Taq polymerase 5 U/^ il 0.1 U尔 1 0.5 10 
Ten-fold diluted tail DNA 1 
Total 25 480 
Table A2. DNase I treatment of total RNA 
Reagent Stock Final Per reaction Per 8.5 reactions 
concentration concentration (1^ 1) ()j,l) 
Sterile H2O - - ^ 229.5 
Tris-HCl (pH 7.5) 1 M 50 mM 5 42.5 
MgCl2 25 mM 10 mM 40 340 
RNase-free DNase 1 10 U/[il 0.3 U/|il 3 25.5 
Total RNA (50 lag) 2 i^g/^ il 0.5 iig/[i\ 25 -
Total 100 637.5 
Table A3. Reverse transcription (RT) for both non-fluoroDD and fluoroDD PCR 
Reagent Stock Final Per reaction Per 9 reactions 
concentration concentration (jil) (jil) 
DNase I treated total RNA 0.1 |ig尔 1 0.01 2 -
3'-AP 2 laM 0.2 [iM 2 -
Nuclease-free water - - 7.8 70.2 
First-strand buffer 5x Ix 4 36 
dNTP mix (1:1:1:1) 250 (iM (each) 25 |iM (each) 2 18 
DTT 100 mM 10 mM 2 18 
SUPERSCRIPT™ II RNase H" 200 卵 2 卵 0.2 1.8 
reverse transcriptase 
Total 20 144 
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Table A4. Non-fluoroDD PCR 
Reagent Stock Final Per reaction Per 17 reactions 
concentration concentration (1^ 1) ( i^l) 
First-strand cDNA - - 4 -
Nuclease-free water - - 0.45 7.65 
PCR buffer lOx Ix 1 17 
dNTP mix (1:1:1:1) 250 |aM (each) 50 liU (each) 2 34 
5'-ARP 2(iM 0.35 _ 1.75 29.75 
3，-AP 0.35 pM 0.7 11.9 
Taq polymerase 5 U/jal 0.05 U/^ il 0.1 1.7 
Total 10 102 
Table A5. FluoroDD PCR 
Reagent Stock Final Per reaction Per 17 reactions 
concentration concentration (jil) (fil) 
First-strand cDNA 4 
Nuclease-free water - - 0.45 7.65 
PCR buffer lOx Ix 1 17 
dNTP mix (1:1:1:1) 250 juM (each) 50 (iM (each) 2 34 
5'-ARP 2 |liM 0.35 i^M 1.75 29.75 
3'-TMR-AP 5 |iM 0.35 ^M 0.7 11.9 
Taq polymerase 5 U/^1 0.05 U/|_il 0.1 1.7 
Total 10 102 
Table A6. Reamplification of cDNA fragments 
Reagent Stock Final Per reaction Per 10 reactions 
concentration concentration (|li1) ()i1) 
Nuclease-free water - - 8.2 82 
PCR buffer lOx Ix 2 20 
dNTP mix (1:1:1:1) 250 |iM (each) 20 [xM (each) 1.6 16 
T7 promoter 22-mer primer 2 |aM 0.2 [xM 2 20 
Ml3 reverse (-48) 24-mer primer 2 \iM 0.2 juM 2 20 
Taq polymerase 5 U尔 1 0.05 U尔 1 0.2 2 
DNA gel elute _ - 4 -
Total 20 160 
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Table A7. Reverse transcription in cDNA library synthesis for reverse dot blot 
analysis 
Reagent Stock Final Per reaction 
concentration concentration (fil) 
Total RNA 0.5 \xgl\x\ 0.1 昭尔 1 2 
3' SMART CDS primer II A 10 1 \iM 1 
SMART II oligonucleotide 10 [xM 1 pM 1 
First-strand buffer 5x Ix 2 
dNTP mix (1:1:1:1) 10 mM (each) 1 mM (each) 1 
DTT 20 mM 2 mM 1 
Powerscript reverse transcriptase 100 U/pi 10 U/|il 1 
Nuclease-free water - - 1 
Total 10 
Table A8. RT-PCR in cDNA library synthesis for reverse dot blot analysis 
Reagent Stock Final Per reaction Per 8.5 reactions 
concentration concentration (f^l) (|ul) 
Diluted first-strand cDNA - - 5 -
Nuclease-free water - - 79 671.5 
Advantage 2 PCR buffer lOx Ix 10 85 
dNTP mix (1:1:1:1) 10 mM (each) 0.2 mM (each) 2 17 
5' PCR primer IIA 10 ^M 0.2 |aM 2 17 
Advantage 2 polymerase mix 2 U/fil 0.04 U/pi 2 17 
Total 100 807.5 
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Appendix B: Phenol-chloroform extraction for recombinant subclones 
Dl D2 
kb SM 2 2 8 2 5 7 9 2 3 
50 . N n ^ ^ f l ^ R 1 j Plasmid D N A 
D3 
kb SM 3 10 11 
||L|J|||^l|AgMl • Genomic D N A 
H t ^ f f l • P — A 
D4 
kb SM 5 6 7 
M L ^ ^ ^ ^ A ^ J • Genomic D N A 
4：? Plasmid D N A 
Figure Bl. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel D. Reamplified c D N A fragments were 
ligated to pT-Adv vector (3.9 kb) and transformed into E. coli. After transformation, 
individual white colonies (2 — 5) were picked randomly. Plasmid D N A was extracted 
from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and resolved 
on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those subclones 
underlined, containing recombinant D N A larger than 3.9 kb vector D N A alone, were 
selected for EcoBl digestion. SM, 1 kb supercoil D N A marker. 
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E2 
1 2 S M kb 
Genomic D N A •• - - • 
Plasmid D N A 4 9 
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Figure B2. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel E. Reamplified c D N A fragments were 
ligated to pT-Adv vector (3.9 kb) and transformed into E. coli. After transformation, 
individual white colonies (10 — 11) were picked randomly. Plasmid D N A was 
extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and 
resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 3.9 kb vector D N A 
alone, were selected for EcoRI digestion. SM, 1 kb supercoil D N A marker. 
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G1 
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Figure B3. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gels G and HH. Reamplified cDNA 
fragments from gels G and H H were ligated to pCR®II-TOPO® (4.0 kb) or pT-Adv 
vectors (3.9 kb), respectively, and transformed into E. coli. After transformation, 
individual white colonies (10 — 15) were picked randomly. Plasmid D N A was 
extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and 
resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 3.9 or 4.0 kb vector 
D N A alone (V), were selected for FcoRI digestion. SM, 1 kb supercoil D N A marker. 
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JJl JJ2 
V I 2 3 4 5 6 7 8 9 10 1 2 3 4 5 V 
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Figure B4. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel JJ. Reamplified c D N A fragments were 
ligated to pT-Adv vector (3.9 kb) and transformed into E. coli. After transformation, 
individual white colonies (10) were picked randomly. Plasmid D N A was extracted 
from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and resolved 
on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those subclones 
underlined, containing recombinant D N A larger than 3.9 kb vector D N A alone (V), 
were selected for EcdRl digestion. 
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Figure B5. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel LL. Reamplified cDNA fragments were 
ligated to pT-Adv vector (3.9 kb) and transformed into E. coli. After transformation, 
individual white colonies (10 — 15) were picked randomly. Plasmid D N A was 
extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and 
resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 3.9 kb vector D N A 
alone (V), were selected for EcoKl digestion. 
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Figure B6. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel M M . Reamplified cDNA fragments 
were ligated to pT-Adv vector (3.9 kb) and transformed into E, coli. After 
transformation, individual white colonies (7 - 15) were picked randomly. Plasmid 
D N A was extracted from overnight culture by phenol:chloroform:isoamyl alcohol 
(25:24:1) and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide 
staining. Those subclones underlined, containing recombinant D N A larger than 3.9 
kb vector D N A alone (V), were selected for &6>RI digestion. 
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Figure B7. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gels N N and 0 0 (fragments 001 - 004). 
Reamplified c D N A fragments were ligated to pCR®II-TOPO® (4.0 kb) or pT-Adv 
vectors (3.9 kb), respectively, and transformed into E. coli. After transformation, 
individual white colonies (10 - 12) were picked randomly. Plasmid D N A was 
extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) and 
resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 3.9 or 4.0 kb vector 
D N A alone (V), were selected for EcoKL digestion. 
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Figure B8. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel 0 0 (fragments 005 - 007). 
Reamplified c D N A fragments were ligated to pT-Adv vector (3.9 kb) and 
transformed into E. coli. After transformation, individual white colonies (10 - 15) 
were picked randomly. Plasmid D N A was extracted from overnight culture by 
phenolxhloroformiisoamyl alcohol (25:24:1) and resolved on 0.6% agarose, 0.5x 
TBE gels with ethidium bromide staining. Those subclones underlined, containing 
recombinant D N A larger than 3.9 kb vector D N A alone (V), were selected for EcoRI 
digestion. 
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Figure B9. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel 0 0 (fragments 008 and 009). 
Reamplified cDNA fragments were ligated to pT-Adv vector (3.9 kb) and 
transformed into E, coli. After transformation, individual white colonies (10) were 
picked randomly. Plasmid D N A was extracted from overnight culture by 
phenol:chloroform:isoamyl alcohol (25:24:1) and resolved on 0.6% agarose, 0.5x 
TBE gels with ethidium bromide staining. Those subclones underlined, containing 
recombinant D N A larger than 3.9 kb vector D N A alone (V), were selected for EcoRL 
digestion. 
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Figure BIO. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel PP. Reamplified c D N A fragments were 
ligated to pT-Adv vector (3.9 kb) and transformed into E. coli. After transformation, 
individual white colonies (10 — 15) were picked randomly. Plasmid D N A was 
extracted from overnight culture by phenolxhloroformiisoamyl alcohol (25:24:1) and 
resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 3.9 kb vector D N A 
alone (V), were selected for EcoKl digestion. 
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Figure Bll. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel Q Q (fragments QQl and QQ3). 
Reamplified cDNA fragments were ligated to pCR®II-TOPO® vector (4.0 kb) and 
transformed into E. coli. After transformation, individual white colonies (13 — 14) 
were picked randomly. Plasmid D N A was extracted from overnight culture by 
phenol:chloroform:isoamyl alcohol (25:24:1) and resolved on 0.6% agarose, 0.5x 
TBE gels with ethidium bromide staining. Those subclones underlined, containing 
recombinant D N A larger than 4.0 kb vector D N A alone (V), were selected for 五coRI 
digestion. 
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Figure B12. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel Q Q (fragments QQ4 - QQ6). 
Reamplified c D N A fragments were ligated to pCR®II-TOPO® vector (4.0 kb) and 
transformed into E. coli. After transformation, individual white colonies (10) were 
picked randomly. Plasmid D N A was extracted from overnight culture by 
phenol:chloroform:isoamyl alcohol (25:24:1) and resolved on 0.6% agarose, 0.5x 
TBE gels with ethidium bromide staining. Those subclones underlined, containing 
recombinant D N A larger than 4.0 kb vector D N A alone (V), were selected for EcoRI 
digestion. 
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Figure B13. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel RR. Reamplified c D N A fragments were 
ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. coli. After 
transformation, individual white colonies (10) were picked randomly. Plasmid D N A 
was extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) 
and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 4.0 kb vector D N A 
alone (V), were selected for EcoRI digestion. 
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Figure B14. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gels SS and TT. Reamplified cDNA 
fragments were ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. 
coli. After transformation, individual white colonies (10) were picked randomly. 
Plasmid D N A was extracted from overnight culture by phenol:chloroform:isoamyl 
alcohol (25:24:1) and resolved on 0.6% agarose, 0.5x TBE gels with ethidium 
bromide staining. Those subclones underlined, containing recombinant D N A larger 
than 4.0 kb vector D N A alone (V), were selected for E c o ^ digestion. 
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Figure B15. Phenol-chloroform extraction for recombinant subclones containing 
c D N A fragments excised from fluoroDD gel UU. Reamplified cDNA fragments 
were ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. coli. After 
transformation, individual white colonies (2 - 10) were picked randomly. Plasmid 
D N A was extracted from overnight culture by phenol:chloroform:isoamyl alcohol 
(25:24:1) and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide 
staining. Those subclones underlined, containing recombinant D N A larger than 4.0 
kb vector D N A alone (V), were selected for FcoRI digestion. 
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Figure B16. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel W . Reamplified cDNA fragments 
were ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. coli. After 
transformation, individual white colonies (5 - 12) were picked randomly. Plasmid 
d n a was extracted from overnight culture by phenol:chloroform:isoamyl alcohol 
(25:24:1) and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide 
staining. Those subclones underlined, containing recombinant D N A larger than 4.0 
kb vector D N A alone (V), were selected for EcoKl digestion. 
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Figure B17. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel W W . Reamplified cDNA fragments 
were ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. coli. After 
transformation, individual white colonies (10) were picked randomly. Plasmid D N A 
was extracted from overnight culture by phenol:chloroform:isoamyl alcohol (25:24:1) 
and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide staining. Those 
subclones underlined, containing recombinant D N A larger than 4.0 kb vector D N A 
alone (V), were selected for EcoRI digestion. 
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Figure B18. Phenol-chloroform extraction for recombinant subclones containing 
cDNA fragments excised from fluoroDD gel XX. Reamplified cDNA fragments 
were ligated to pCR®II-TOPO® vector (4.0 kb) and transformed into E. coli. After 
transformation, individual white colonies (10—12) were picked randomly. Plasmid 
D N A was extracted from overnight culture by phenol:chloroform:isoamyl alcohol 
(25:24:1) and resolved on 0.6% agarose, 0.5x TBE gels with ethidium bromide 
staining. Those subclones underlined, containing recombinant D N A larger than 4.0 
kb vector D N A alone (V), were selected for £coRI digestion. 
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Cl.l: DNA sequence of cDNA subclone Dl#2 using M13 forward -20 primer and the sequence of 3’-AP3 
1 t t a c g a c t c a c t a t a g g g c g a a t t g g g c c c t c t a n n a t g c a t g c t c g g a n c g g c c g c c a g 
61 TGTGATGGAT ATCTGCAGAA TTCGGCTGTA a t a c g a c t c a c t a t a g g g c t t t t t t t t t t t A P S 
1 2 1 GGATGACACT GGGAACTTTA TTGCAGAAAG GAGGGAAGAT GGAGAAACTC GTGTGAGGAT 
1 8 1 TAATCAGGTA GAAAGAGACT ATGCAGGGTA GATTTAGATG AACACATTAG GTAACTGTCA 
2 4 1 TGTGAAAATG ATACTAAGCT GAATAATGTC TTCACCAATN GNATNGTNTN CAGGCCTTGG 
3 0 1 ATTTTGGAGA CCATGGTACA TATTGAATGA TTCNCTNCAT NAA 
C1.2: Sequence alignment of cDNA subclone Dl#2 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
Dltt2 ：123 a t g a c a c t g q q a a c t t t a t t q c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a t t a 182 
iimimiiiiiiiimiiiiiiiiiiiimiimmmimiiiiiii ii 
M o u s e C Y P 4 A 1 0 ：2075 a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a t a 2016 
D 1 # 2 ：183 a t c a q g t a g a a a g a q a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a t g 242 
M M M M M I M M M M M M M M M M M M M M M M M M M M M I M M M 
M o u s e CYP4A10 ： 2015 a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a t g 1956 
D 1 # 2 ：243 t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c c a a t n g n a t n g t n t n c a g g c c t t g g a t 302 
iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii I I I I i i m i m m M o u s e C Y P 4 A 1 0 ：1955 t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t 1902 
D l # 2 ：303 t t t g g a g a c c a t g g t a c a t a t t g a a t g a t t c 333 
iiiiiiimiiiiimiiimiiiiiii 
M o u s e C Y P 4 A 1 0 ：1901 t t t g g a g a c c a t g g t a c a t a t t g a a t g a t t c 1 8 7 1 
C1.3: Summary of sequence alignment of cDNA subclone Dl#2 with mouse CYP4A10 
- FluoroDD gel D (AP3 + ARPl2) Subcloning Sequencing 
Differential display pattern Size of insert 
Fragment "； Subclone released by d • Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) ^o. cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Dl ^ Ml3 forward Mouse CYP4A10 
(975 bp) I _ I + I _ I _ —20 (2077 bp) 199/211 (94o/o) 
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C2.1: DNA sequence of cDNA subclone Dl#2 using M13 reverse primer and the sequence of 5’-ARP12 
1 G C C A A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G 
6 1 G C T T A G C G G A TAACAATTTC ACACAGGAGG TACTAAGGCT C T A C C C A C C T G T C C C A G G T A A R P 12 
1 2 1 T T G T C A G A G A A C T C A G T A C A T C T G T C A C C T T C C C T G A T G G A C G C T C T T T A C C C A A A G G T G 
1 8 1 T C C A G G T C A C A C T C T C C A T T T A T G G T C T C C A C C A C A A C C C G A A G G T G T G G C C A A A T C C A G 
2 4 1 A G G T G T T T G A C C C T T C C A G G T T T G C A C C N A G A C N N N T C C N N C C C G G A N C C A C A N G C C A C T 
3 0 1 C A T T N C C C T G C C C T T C T C A G G A G G A G C C A G G A A N C T G G G C C A N T T T G G G G G G A 
C2.2: Sequence alignment of cDNA subclone Dl#2 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
：93 c t a a g g c t c t a c c c a c c t g t c c c a g g t a t t g t c a g a g a a c t c a g t a c a t c t g t c a c c t t c 152 I M M M M I M M M M M M M M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I 1 1 1 1 1 
M o u s e C Y P 4 A 1 0 ：1164 c t a a g g c t c t a c c c a c c t g t c c c a g g c a t t g t c a g a g a a c t c a g t a c a t c t g t c a c c t t c 1223 
Dltt2 ：153 c c t g a t g g a c g c t c t t t a c c c a a a g g t g t c c a g g t c a c a c t c t c c a t t t a t g g t c t c c a c 212 M M M M M M I M M M M M M M M M M M M M M M M M M M M M M M I 
M o u s e C Y P 4 A 1 0 ：1224 c c t g a t g g a c g c t c t t t a c c c a a a g g t g t c c a g g t c a c a c t c t c c a t t t a t g g t c t c c a c 1283 
：213 c a c a a c c c g a a g g t g t g g c c a a a t c c a g a g g t g t t t g a c c c t t c c a g g t t t g c a c c 268 M M M I M I M M I M M M M M M M M M M M M M M M M I M M M I I M o u s e C Y P 4 A 1 0 ： 1284 c a c a a c c c g a a g g t g t g g c c a a a t c c a g a g g t g t t t g a c c c t t c c a g g t t t g c a c c 1339 
C2.3: Summary of sequence alignment of cDNA subclone Dl#2 with mouse CYP4A10 
FluoroDD gel D (AP3 + A R P 12) Subcloning Sequencing 
Differential display pattern Size of insert 
Fragment 77； Subclone released by „ . Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) ^o. £coRI cut ？匪®^ (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
W] ‘ ^ Mouse CYP4A10 
- D1#2 1020 M l 3 reverse (2077 bp) 175/176 (94%) 
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C3.1: DNA sequence of cDNA subclone D2#9 using M13 forward -20 primer and the sequence of 5'-ARP12 
1 A A N N T G T A N N A N C G A C T C A C T A T A G G G G C G A A T T G G G G C C C T C T A G A T G C A T G C T C G A G C 
6 1 G G C C G C C A G T G T G A T G G A T A T C T G C A G A A T T C G G C T T A G C GGATAACAAT TTCACACAGG ARP 12 
1 2 1 AGGTACTAAG G G A G C A G C C G A G C T G A T G C A G C A G A A G G A G G C C A C T A C T G A G C A G C A G C T 
1 8 1 G A G A G A G C T C T T T G A A A A A C A A A A A T T C A A G T C T G C A C A G T A G C C A C A G G C A A C A G T T T G 
2 4 1 G G G T A A A T C C C C T C C A T G N C C T G G G G C C T C A N A T G T G T G C C C C C G G A A A N A N G A N N N A A A 
3 0 1 A G G N A T N G G G G C C T T G A A A A A G T T C A G N T N G T N N N T G T G T N A A T A C C A G C C T A C A C C C T N 
3 6 1 A T N G N A T N A G G N G G T T G C C C T 
C3.2: Sequence alignment of cDNA subclone D2#9 with mouse Bhmt by BLAST searching 
with the National Center for Biotechnology Information database 
D2tt9 ：128 a a g g g a g c a g c c g a g c t g a t g c a g c a g a a g g a g g c c a c t a c t g a g c a g c a g c t g a g a g a g 187 l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
M o u s e B h m t ：1458 a a g g g a g c a g c c g a g c t g a t g c a g c a g a a g g a g g c c a c t a c t g a g c a g c a g c t g a g a g a g 1517 
D 2 # 9 ：188 c t c t t t g a a a a a c a a a a a t t c a a g t c t g c a c a g t a g c c a c a g g c a a c a g t t t g g g g t a a a 247 M M M M M I M M M M M M I I M M M I 1 1 1 1 1 1 1 1 1 1 I I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
M o u s e B h m t ：1518 c t c t t t g a a a a a c a a a a a t t c a a g t c t g c a c t g t a g c c a c a g g c a a c a g t t t g g g g t a a a 1577 
D 2 # 9 ： 248 t c c c 2 5 1 M M M o u s e B h m t ：1578 t c c c 1 5 8 1 
C3.3: Summary of sequence alignment of cDNA subclone D2#9 with mouse Bhmt 
FluoroDD gel D (AP3 + A R P 12) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment Subclone released by „ . Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) N o . EcoRlJ Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved  
Mouse betaine 
TO M13 forward homocysteine 4e.60 
++ + ++ ++ D2#9 650 .20 methyltransferse 123/124(99%) 
(700 bp) “ (Bhmt) pseudogene 、 ) 
(2131 bp)  
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C4.1: DNA sequence of cDNA subclone D3#3 using M13 forward -20 primer and the sequence of 5'-ARP12 
1 T G A T A G C G A C T C A C T A T A G G G G C G A A T T G G G G C C C T C T A N N T G C A T G C T C G A G C G G C C G C 
6 1 C A G T G T G A T G G A T A T N C T G C A G A A T T C G G C T T A G C G G A T A ACAATTTCAC ACAGGAGGTA ARP12 
1 2 1 C T A A G G G C A A G C G T G G T G T T G A C T A T G A G A C C C T C A A A A A T G C C T T C G T G G A A G C C T C T A 
1 8 1 T G T C G G T G A T C A T G A A A C T G T T C C C A C A G C T G G A G G G C A A G G T G G A G A G T G T G A C T G G A G 
2 4 1 G G T C A C C A C T G A C C N N A A C C C N C A A G N N C T N A T T C T G G C T G C A C C C C G A G G A G C T A C C T A 
3 0 1 T G G A G C T G A N C C A T N G A A A C C C T T T T T G G G G C T 
C4.2: Sequence alignment of cDNA subclone D3#3 with mouse hypothetical protein MMT-7 by BLAST 
searching with the National Center for Biotechnology Information database 
D3tt3 ：123 a a q q q c a a q c q t g q t g t t g a c t a t g a g a c c c t c a a a a a t g c c t t c g t g g a a g c c t c t a t g 182 
M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M 
M o u s e M M T - 7 ：1541 a a g g g c a a g c g t g g t g t t g a c t a t g a g a c c c t c a a a a a t g c c t t c g t g g a a g c c t c t a t g 1600 
D3tt3 ：183 t c g q t g a t c a t g a a a c t g t t c c c a c a g c t g g a g g g c a a g g t g g a g a g t g t g a c t g g a g g g 242 
M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M 
M o u s e M M T - 7 ：1601 t c g g t g a t c a t g a a a c t g t t c c c a c a g c t g g a g g g c a a g g t g g a g a g t g t g a c t g g a g g g 1660 
D 3 # 3 ：243 t c a c c a c t g a c c 254 
llllllllllll 
M o u s e M M T - 7 ：1661 t c a c c a c t g a c c 1672 
C4.3: Summary of sequence alignment of cDNA subclone D3#3 with mouse hypothetical protein MMT-7 
FluoroDD gel D (AP3 + ARP 12) Subcloning Sequencing 一 
Differential display pattern Size of insert 
Fragment 77"~~~ Subclone released by d • Sequence homology E-value 
No PPARa (+/+) PPARa (-/-) N o. £ c o R I cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Mouse EST with 
, homology to mouse 2e-67 
D3 + ++ + + D3#3 600 M U tomard hypothetical protein 132/132 
(560 bp) MMT-7 gene (100%) 
(2184 bp)  
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C5.1: DNA sequence of cDNA subclone D3#3 using M13 reverse primer and the sequence of 3’-AP3 
1 A C C N A G C T T G G G T A C C G A G C T C G G A T C G C A C T A G T N A A C G G C C G C C A G T G T G C T G G A A T G 
6 1 T C G G C T T G T A ATACGACTCA CTATAGGGCT TTTTTTTTTT G G G A A A C A A A A T G G T T T T T G A P 3 
1 2 1 T T T A T A T G T G C A A G G A A T T G C T G T A G G A G G G A G G A C A C C A C G A G A A G T T G G G G A G G T G C C 
1 8 1 T T T C C T C T G G C T C T T C T C T G A A C G G A C T A C A T C T T C T T C T T T T G T G C C T T G A C C T T T G A G 
2 4 1 C C A A G A G C C T G C A G A T C T G A G T A C A A G T T C C C G T T T N T C A A G G N A N N G G G C N A C T N G C T G 
3 0 1 C A C C A G C A A N N G C C C C C T G C A N G N C C C C C A T N C C A G N C C C C A C C A A G N G G T T N N G A A A 
C5.2: Sequence alignment of cDNA subclone D3#3 with mouse hypothetical protein MMT-7 by BLAST searching 
with the National Center for Biotechnology Information database 
D 3 # 3 ：182 t t c c t c t q q c t c t t c t c t q a a c q g a c t a c a t c t t c t t c t t t t g t g c c t t g a c c t t t g a g c 2 4 1 
M M M M M M M I M M M M M M M M M M M M M M M M M M M I M M M 
M o u s e M M T - 7 ：2184 t t c c t c t g g c t c t t c t c t g a a c g g a c t a c a t c t t c t t c t t t t g t g c c t t g a c c t t t g a g c 2 1 2 5 
D 3 # 3 ：242 c a a g a g c c t g c a g a t c t g a g t a c a a g t t c c 2 7 1 M M M M M M M M M M M I M M M I M o u s e M M T - 7 ：2124 c a a g a g c c t g c a g a t c t g a g t a c a a g t t c c 2 0 9 5 
C5.3: Summary of sequence alignment of cDNA subclone D3#3 with mouse hypothetical protein MMT-7 
FluoroDD gel D (AP3 + A R P 12) Subcloning Sequencing 
Differential display pattern Size of insert 
Fraement ； Subclone released by „ . Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) ^o. EcoRI out P ^ e r (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Mouse EST with 
M13 homology to 3e-42 
D3 + ++ + + D3#3 600 mouse hypothetical on/cm nniw、 
(560 bp) reverse protein M M T - 7 gene 90/90 (100/o) 
(2184 bp)  
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C6.1: DNA sequence of cDNA subclone LL1#7 using M13 reverse primer and the sequence of 3,-AP4 
1 T N C N A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G 
6 1 G C T T G T A A T A CGACTCACTA TAGGGCTTTT TTTTTTGTAC A C A C A C T G A G C T A A A A T T T A AP4 
1 2 1 T T T T T A A G A G G T A A A G A A A G T T T T A T A C A A C C T T T A T A T A A A A C A A A T A T T C C A G A C T C A 
1 8 1 G A A T T A A G C A C T A A G T T T T C A A T A T T A T A A A G C T G T T T A T A A C A G G A G T T T T A A G T A G T G 
2 4 1 G T A A A C A T T T A A C C C C C A T T G T T A A A A A T G G C A A C C A G A A T T C A A A T C A T G A C C T T G G A T 
3 0 1 N C C T C N A N A T T G N A T T T N C C A A N A G 
C6.2: Sequence alignment of cDNA subclone LL1#7 with mouse Ctsl by BLAST searching 
with the National Center for Biotechnology Information database 
L L 1 # 7 ：99 a c a c a c a c t g a g c t a a a a t t t a t t t t t a a g a g g t a a a g a a a g t t t t a t a c a a c c t t t a t a 158 M M M M I M M M M M M M M M M M M M M M M M M M M M M I i l l l l l 
M o u s e C t s l ： 1 3 7 2 a c a c a c a c t g a g c t a a a a t t t a t t t t t a a g a g g t a a a g a a a g t t t t a t a c a a c c t t t a t a 1313 
LLlft7 ：159 t a a a a c a a a t a t t c c a g a c t c a g a a t t a a g c a c t a a g t t t t c a a t a t t a t a a a g c t g t t t 218 M M M I M I M I M I M M I M I M M M M M M M M M M M M M M I M M M I 
M o u s e C t s l ：1312 t a a a a c a a a t a t t c c a g a c t c a g a a t t a a g c a c t a a g t t t t c a a t a t t a t a a a g c t g t t t 1253 
LLltt7 ：219 a t a a c a g g a g t t t t a a g t a g t g g t a a a c a t t t a a c c c c c a t t g t t a a a a a t g g c a a c c a g 278 M M I M I M M M M M M M M l l l l l l l l l M i l l 1 1 1 1 1 1 1 1 1 1 1 1 I I I 
M o u s e C t s l ： 1 2 5 2 a t a a c a g g a g t t t t a a g t a g t g g t - a a c a t t t a a - - c c c a t - - g t a a a a a t g g c a a - c a g 1199 
L L 1 # 7 ： 2 7 9 a a t t c a a a t c a t g a c 293 i i i i i i i i i i i im M o u s e C t s l ：1198 a a t t c a a a t c a t g a c 1184 C6.3: Summary of sequence alignment of cDNA subclone LLl#7 with mouse Ctsl 
— FluoroDD gel LL (AP4 + ARP6) Subcloning Sequencing 
Differential display pattern Size of insert 
Fragment Subclone released by „ . Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) no. £coRI cut ?匪er (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Mouse cathepsin L 7e gQ 
^ ^ ^ f o i p )十 + + ++ LL1#7 800 + 300 M13 reverse ^^(C^sO^^ 188/19； (96%) 
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C7.1: DNA sequence of cDNA subclone LL1#11 using M13 forward -20 primer and the sequence of 5，-ARP6 
1 TTACACTCAC TATAGGGCGA ATTGGGCCCT CTAGAATGCA TGCTCGNAGC GGCCGCCATG 
6 1 TGATGGATAT CTGCAGAATT CGGCTTAGCG GATAACAATT TCACACAGGA TACAACGAGG ARP6 
1 2 1 A A T A C A G C A A C G G G C A G C A C G G C T T T T C C A T G G A G A T G A A C G C C T T T G G T G A C A T G A C C A 
1 8 1 A T G A G G A A T T C A G G C A G G T G G T G A A T G G C T A T C G C C A C C A G A A G C A C A A G A A G G G G A G G C 
2 4 1 T T T T T C A G G A C C G C T G A T G C T T A A G A T C C C C A A G T C T G T G G A C T G G A G A G A A A A G G G T T G 
3 0 1 T G T G A C T C C T G T G A A G A A C C A G G G C C A G T G C G G G T C T T G T T G G G C G T T T A G C G C A T C G G G 
3 6 1 T T G C C T A G A A G G A C A G A T G T T C C T T A A G A C C G G C A A A C T G A T C T C A C T G A G T G A A C A G A A 
4 2 1 C C T T G T G G A C T G T T C T C A C G C T C A A G G C A A T C A G G G C T G T A A C G G A G G C C T G A T G G A T T T 
4 8 1 T G C T T T C C A G T A C A T T A A G G A A A A T G G A G G T C T G G A C T C C G A G G A G T C T N A C C C C T A T G A 
5 4 1 A G C A A A N G A C N G A T C T T N T A A A T A C A G A G C C G A G T T C G C T G T G G C T A A T G A C A C A G G G T T 
6 0 1 C G T G N A T N T C C C T C A G C A A G A N A A A G C C C T C A T G A N G G C T G T G G C G A C T A T G G G G G C T A T 
6 6 1 N N C T G T N G C T A T G N A C G C A G C C A T T C G T T T T T T 
C7.2: Sequence alignment of cDNA subclone LL1#11 with mouse Ctsl by BLAST searching 
with the National Center for Biotechnology Information database 
LLlttll :112 a c a a c g a g g a a t a c a g c a a c g g g c a g c a c g g c t t t t c c a t g g a g a t g a a c g c c t t t g g t g 171 
m m iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 
M o u s e C t s l ：253 a c a a c g g g g a a t a c a g c a a c g g g c a g c a c g g c t t t t c c a t g g a g a t g a a c g c c t t t g g t g 312 
LLlttll :172 a c a t g a c c a a t g a g g a a t t c a g g c a g g t g g t g a a t g g c t a t c g c c a c c a g a a g c a c a a g a 231 M I M M M M M M M I M M I M M M M M M M M M M M M I I I I I I I I I I I I I 
M o u s e C t s l ：313 a c a t g a c c a a t g a g g a a t t c a g g c a g g t g g t g a a t g g c t a t c g c c a c c a g a a g c a c a a g a 372 
LLlftll :232 a g g g g a g g c t t t t t c a g g a - c c g c t g a t g c t t a a g a t c c c c a a g t c t g t g g a c t g g a g a g 290 
iiimimiiiiiiiii iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii M o u s e C t s l ：373 a g g g g a g g c t t t t t c a g g a a c c g c t g a t g c t t a a g a t c c c c a a g t c t g t g g a c t g g a g a g 432 
LLlttll :291 a a a a g g g t t g t g t g a c t c c t g t g a a g a a c c a g g g c c a g t g c g g g t c t t g t t g g g c g t t t a 350 
l l l l l l l l l l l l l l l l l l l l l l l ' l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l 
M o u s e C t s l :433 a a a a g g g t t g t g t g a c t c c t g t g a a g a a c c a g g g c c a g t g c g g g t c t t g t t g g g c g t t t a 492 
LLlftll :351 g c g c a t c g g g t t g c c t a g a a g g a c a g a t g t t c c t t a a g a c c g g c a a a c t g a t c t c a c t g a 410 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l M 
M o u s e C t s l ：493 g c g c a t c g g g t t g c c t a g a a g g a c a g a t g t t c c t t a a g a c c g g c a a a c t g a t c t c a c t g a 552 
LLlttll :411 g t g a a c a g a a c c t t g t g g a c t g t t c t c a c g c t c a a g g c a a t c a g g g c t g t a a c g g a g g c c 470 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M I I 
M o u s e C t s l ：553 g t g a a c a g a a c c t t g t g g a c t g t t c t c a c g c t c a a g g c a a t c a g g g c t g t a a c g g a g g c c 612 
LLlftll :471 t g a t g g a t t t t g c t t t c c a g t a c a t t a a g g a a a a t g g a g g t c t g g a c t c c g a g g a g t c t n 530 
i m i m m m i i i i m i i i m i m i m m i i i i i m m iiiiiim 
M o u s e C t s l ：613 t g a t g g a t t t t g c t t t c c a g t a c a t t a a g g a a a a t g g a g g t c t g g a c t c g g a g g a g t c t t 672 
LLlttll :531 a c c c c t a t g a a g c a a a n g a c n g a t c t t n t a a a t a c a g a g c c g a g t t c g c t g t g g c t a a t g 590 
M M M M M M M M I I I l l l l l i 11 111 11 1 1 1 1 11 11 I I I I 丨丨丨 11 丨 I 丨丨丨丨 I 丨 
M o u s e C t s l ：673 a c c c c t a t g a a g c a a a g g a c g g a t c t t g t a a a t a c a g a g c c g a g t t c g c t g t g g c t a a t g 732 
LLlttll •591 a c a c a q q g t t c g t q n a t n t c c c t c a g c a a g a n a a a g c c c t c a t g a n g g c t g t g g c g a c t a 650 
imiTimim i丨1111丨i丨i丨111 imiiii丨丨i丨丨丨丨丨丨丨丨丨m 
M o u s e C t s l ：733 a c a c a g g g t t c g t g g a t a t c c c t c a g c a a g a g a a a g c c c t c a t g a a g g c t g t g g c g a c t g 792 
LLlftll :651 t g g g g g c t a t n n c t g t n g c t a t g n a c g c a 679 l l l l l M M M M m i l l M i l l M o u s e C t s l ：793 t g g g g c c t a t t t c t g t t g c t a t g g a c g c a 821 C7.3： Summary of sequence alignment of cDNA subclone LL1#11 with mouse Ctsl 
FluoroDD gel LL (AP4 + ARP6) Subcloning 一 Sequencing  
Differential display pattern Size of insert 
PT-aament Subclone released by p Sequence homology E-value 
h a ^ ^ n t PPARa (+/+) PPARa (-/-) ^o. EcoRl cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Ml3 forward Mouse cathepsin L q 
LLl + + + ++ LL1#11 800 + 300 ^^^^ (Ctsl) 552/569 (97%) 
(1250 bp) ^ (1374 bp) I 、 ， 
351 
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C8.1: DNA sequence of cDNA subclone MM1#1 using M13 forward -20 primer and the sequence of 3'-AP2 
1 TTTACGACTC ACTATAGGGC GAATTGGGCC CTCTAGATGC ATGCTCGAGC GGCCGCCAGT 
6 1 G T G A T G G A T A T C T G C A G A A T T C G G C T T G T A ATACGACTCA CTATAGGGCT TTTTTTTTTT A P 2 
1 2 1 GCATGACACT GGGAACTTTA TTGCAGAAAG GAGGGAAGAT GGAGAAACTC GTGTGAGGAT 
1 8 1 TAATCAGGTA GAAAGAGACT ATGCAGGGTA GATTTAGATG AACACATTAG GTAACTGTCA 
2 4 1 TGTGAAAATG ATACTAAGCT GAATAATGTC TTCACAATGA TGTTCAGGCC TTGGATTTTG 
3 0 1 GAGACCATGG TACATATTGA ATGATTCCTC ATAATTCAGA AGGAACTTAG TAGGTTAGAT 
3 6 1 TGAATAAGAT ACATNTAGAT GGGAAAACTA TCTTGGAGCT TTTAGGGATC NTTAATGATG 
4 2 1 TCATAAGCAT CTGTAAAAGG TAAGGACATT AGAAGAGAGG GGATGAGGAN GGTGCTGGCT 
4 8 1 TTGAAGCANG GGAATATTCC AGTGCCAAGG ANTGATGATC TATACTGAAC AGAGGATGAG 
5 4 1 AGGACTCTCT GGANTATNCT CCTGAAANAA GTANGTCACA NCCACAACTT TGNCTTCCTN 
6 0 1 CAGTGAAACT CTTCTCANAC NTNGNANCNC ACAACAGANT CAGTGNAGCT CTTGANATGT 
6 6 1 ANGTANATCC ATNNTTGACT CNCCCNAGTN NGCTAGNGCA TGNNACNNNN NN 
C8.2: Sequence alignment of cDNA subclone MM1#1 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
MMlttl :121 g c a t q a c a c t q q g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a t 180 
i m i i m m i i i i m m m m m i m m m m i m m m m l l l l l 1 1 1 1 1 1 1 1 1 1 1 1 1 
M o u s e C Y P 4 A 1 0 ： 2 0 7 7 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a 2 0 1 8 
MMlttl :181 t a a t c a g g t a g a a a q a q a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 240 
m m i i i i m i m i m m m m m m m m m m m i l l l l l i i 
Mouse CYP4A10 ：2017 t a a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 1958 
MMlttl :241 t q t q a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t t t t g 300 
i i i i m m i i m i m m m i l l l l l l l l l l l l l l   
M o u s e C Y P 4 A 1 0 ： 1 9 5 7 t g t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t t t t g 1 8 9 8 
M M l t t l ： 3 0 1 q a q a c c a t q g t a c a t a t t q a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 3 6 0 
i i i i m m i i m i l i i i i i i i i i i m i l m m m i l    
M o u s e C Y P 4 A 1 0 ： 1 8 9 7 g a g a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 1 8 3 8 
MMlttl :361 t q a a t a a g a t a c a t n t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c n t t a a t g a t g 420 
i i m i m i m m m imimiimiii i imiimimmii m m i i i i i … � 
M o u s e C Y P 4 A 1 0 ： 1 8 3 7 t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c - t t a a t g a t g 1 7 7 9 
MM1#1 :421 t c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a n g g t g c t g g c t 480 
M M I M M M M M M M I M I M M M l l l l l I M M M M M … 
M o u s e C Y P 4 A 1 0 ： 1 7 7 8 t c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a g g g t g c t g g c t 1 7 1 9 
顺1#1 :481 t t q a a g c a n g q g a a t a t t c c a g t g c c a a g g a n t g a t g a t c t a t a c t g a a c a g a g g a t g a g 540 
I M l l l l l I l l l l l l l l l l l l l l l l l l l I 1 … 
M o u s e C Y P 4 A 1 0 ： 1 7 1 8 t t g a a g c a g g g g a a t a t t c c a g t g c c a a g g a a t g a t g a t c t a t a c t g a a c a g a g g a t g a g 1 6 5 9 
MMI#1 •541 a q q a c t c t c t q q a n t a t n c t c c t g a a a n a a g t a n g t c a c a n c c a c a a c t t t g n c t t c c t n 600 
l l l l l l l l l l l l l I I I I I I l l l l l I 111 I l l l l l I I M M M I I N i 
M o u s e C Y P 4 A 1 0 ： 1 6 5 8 a g g a c t c t c t g g a g t a t t c t t c t g a a a a a g g t a g g t c a c a c c a a c a a c t t a g - c t t t c t c 1 6 U U 
MM1#1 ：601 c a q t g a a a c t c t t c t c a n a c n t n g n a n c - n c a c a a c a g a n t c a g t g n a g c - t c t t g a n a t 658 
I l l l l l l l l l l l l l l 1 M M I M l l l l l I I 
M o u s e C Y P 4 A 1 0 ： 1 5 9 9 c a g t g a a a c t c t t c t c a g a c a t t g g a g c t c c a c a a c a g t a t c a g t g g a g c t t c t t g a g a t l b 4 U 
MMlftl : 6 5 9 g t a n g t a n a t c c 6 7 0 I I I I I I M M M o u s e C Y P 4 A 1 0 : 1 5 3 9 g t a g g t a g a t c c 1 5 2 8 C8.3: Summary of sequence alignment of cDNA subclone MM1#1 with mouse CYP4A10 
FluoroDD gel M M (AP2 + A R P 7 ) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment Subclone released by p Sequence homology E-value 
hra^ent p p A R a (+/+) P P A R a (-/-) ^o. EcoRI cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
^TT^ M l 3 forward Mouse C Y P 4 A 1 0 ~ 0 
( 二 “ ) - + - - M M 1 # 1 1400 .20 (2077 bp) 520/552 (94。/。） 
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C9.1: DNA sequence of cDNA subclone MM1#1 using M13 reverse primer and the sequence of 5'-ARP7 
1 GCCAGCTTGN GTACCGAGCT CGGATCCACT AGTAACGGCC GCCAGTGTGC TGGAATGCGG 
6 1 CTTAGCGGAT AACAATTTCA CACAGGATGG ATTGGTCAAG CTGAGAAAGG ATCAGCTGCA ARP7 
1 2 1 GGATGAGGGA GAGCTGGAAA AGATCAAGAA GAAGAGACGT TTGGATTTTC TGGATATCCT 
1 8 1 TTTATTTGCC AGAATGGAGA ATGGGGACAG CATGTCTGAC AAGGACCTAC GTGCTGAGGT 
2 4 1 GGACACATTC ATGTTCGAGG GCCATGACAC CACAGCCAGT GGAGTCTCCT GGATCTCCTA 
3 0 1 T G C T C T G G C C A C A C A C C C T G A T C A C C A A C A G A G A T G C A G A G A G G A A G T T C A G A G C C T C C T 
3 6 1 GGGGGATGGA TCCTCTATCA CCTGGGATCA CCTAGACCAC ATTCCCTATA CCACAATGTG 
4 2 1 CATCAAGGAG GCCCTAAGGC TCTACCCACC TGTCCCAGGC ATTGTCAGAG AACTCAGTAC 
4 8 1 ATCTGTTACC TTCCCTGATG GACGCTCTNT ACCCAAAGGT GTCCANGTCA AGAGGATGAG 
5 4 1 TTATGGTCTC CACCACNACC CGAAGGTGTN GCCNAATNCA GANGTGTNTG ANCCTNNCAN 
6 0 1 GTTTGCACCA GACTCTNNCC GANNAGCCAC TCATNNCTGC CCTCTCAGGA NGANCAGGAA 
6 6 1 CTGCATNNGG AACANTTGCN ATGANTGANC TGANAA 
C9.2: Sequence alignment of cDNA subclone MM1#1 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
MMlttl :86 q a t g g a t t g g t c a a g c t g a g a a a g g a t c a g c t g c a g g a t g a g g g a g a g c t g g a a a a g a t c 145 ？I mi   
M o u s e C Y P 4 A 1 0 ： 8 1 6 g a t g g a g t g a t c a a g c t g a g a a a g g a t c a g c t g c a g g a t g a g g g a g a g c t g g a a a a g a t c 8 7 5 
MM1#1 :146 a a q a a q a a q a g a c g t t t g q a t t t t c t g g a t a t c c t t t t a t t t g c c a g a a t g g a g a a t g g g 205 
M I M I M I I I M M M I M M M M M M M M I l l l l l M M M _ 
M o u s e C Y P 4 A 1 0 ：876 a a g a a g a a g a g a c g t t t g g a t t t t c t g g a t a t c c t t t t a t t t g c c a g a a t g g a g a a t g g g 9 3 5 
MMlttl :206 q a c a q c a t q t c t g a c a a g g a c c t a c g t g c t g a g g t g g a c a c a t t c a t g t t c g a g g g c c a t 265 
I M I I M I I M I I M M I I M M M M M M M M M I M M M I I I I I I I I l l l l l l I ! _ 
M o u s e C Y P 4 A 1 0 ： 9 3 6 g a c a g c a t g t c t g a c a a g g a c c t a c g t g c t g a g g t g g a c a c a t t c a t g t t c g a g g g c c a t 9 9 5 
MMlitl :266 q a c a c c a c a q c c a q t q g a g t c t c c t g g a t c t c c t a t g c t c t g g c c a c a c a c c c t g a t c a c 325 
〒丨iiimiTiiiiiiimimiiiim  
M o u s e C Y P 4 A 1 0 ： 9 9 6 g a c a c c a c a g c c a g t g g a g t c t c c t g g a t c t t c t a t g c t c t g g c c a c a c a c c c t g a t c a c 1 0 5 5 
MMlttl :326 c a a c a g a g a t g c a g a g a g g a a g t t c a g a g c c t c c t g g g g g a t g g a t c c t c t a t c a c c t g g 385 M M I I I I M I M M M M M M M M M M I M M I I l l l l l l I I l l ， … 
M o u s e C Y P 4 A 1 0 ： 1 0 5 6 c a a c a g a g a t g c a g a g a g g a a g t t c a g a g c c t c c t g g g g g a t g g a t c c t c t a t c a c c t g g l l l b 
M M 1 # 1 ： 3 8 6 q a t c a c c t a q a c c a c a t t c c c t a t a c c a c a a t g t g c a t c a a g g a g g c c c t a a g g c t c t a c 4 4 5 
iiiiiiiiiiiiii iiiiiiiiiiiiimmiimiiimimiimiji 丨丨…� 
M o u s e C Y P 4 A 1 0 ： 1 1 1 6 g a t c a c c t a g a c c a g a t t c c c t a t a c c a c a a t g t g c a t c a a g g a g g c c c t a a g g c t c t a c 1 1 / b 
MMlttl •446 c c a c c t q t c c c a q g c a t t q t c a q a g a a c t c a g t a c a t c t g t t a c c t t c c c t g a t g g a c g c 5 0 5 
‘ M I M I I M M I I I M M M M M M M M M M M l l l l l 1 1 1 1 1 1 1 1 1 1 1 丄 l l l l l l 
M o u s e C Y P 4 A 1 0 ： 1 1 7 6 c c a c c t g t c c c a g g c a t t g t c a g a g a a c t c a g t a c a t c t g t c a c c t t c c c t g a t g g a c g c 1 2 j b 
MMlftl ：506 t c t n t a c c c a a a g g t g t c c a n g t c a c a c t c t c c a t t t a t g g t c t c c a c c a c n a c c c g a a g 5 6 5 
111 iimm〒〒iTmi 丨丨 ，)。； 
M o u s e C Y P 4 A 1 0 ：1236 t c t t t a c c c a a a g g t g t c c a g g t c a c a c t c t c c a t t t a t g g t c t c c a c c a c a a c c c g a a g 1 2 9 5 
M M 1 # 1 ：566 q t q t n q c c n a a t n c a g a n g t g t n t g a n c c t n n c a n g t t t g c a c c a g a c t c t n n c c g a - n n 624 
l l l l 111 I I I M M M M M l I M M ，？巧 
M o u s e C Y P 4 A 1 0 ： 1 2 9 6 g t g t g g c c a a a t c c a g a g g t g t t t g a c c c t t c c a g g t t t g c a c c a g a c t c t c c c c g a c a c 1 3 5 5 
MMittl ：625 a q c c a c t c a t n n c t g c c c - t c t c a g g a n g a - n c a g g a a c t g c a t 6 6 6 iTiiimii iiim iiiiiiii II iiiiiMimi 
M o u s e C Y P 4 A 1 0 ： 1 3 5 6 a g c c a c t c a t t c c t g c c c t t c t c a g g a g g a g c c a g g a a c t g c a t 1 3 9 9 C9.3： Summary of sequence alignment of cDNA subclone MM1#1 with mouse CYP4A10 
FluoroDD gel M M (AP2 + ARP7) Subcloning Sequencing  
Differential display pattern Size of insert 
Pragment ： ~ Subclone released by p Sequence homology E-value 了 P P A R a (+/+) P P A R a (-/-) ^o. EcoKl cut P ^ e r (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
Mouse CYP4A10 0 - + - I - I M M 1 # 1 1400 Ml3 reverse (2077 bp) 556/584 (95%) 
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ClO.l: DNA sequence of cDNA subclone 002#6 using M13 forward -20 primer and the sequence of 3，-AP9 
1 A A T G A T T A C G A C T C A C T A T A G G G G C G A A T T G G G G C C C T C T A G A T G C A T T G C T C G A G C G G C 
6 1 CGCCAGTGTG A T G G A T A T C T GCAGAATTCG GCTTGTAATA CGACTCACTA TAGGGCTTTT AP9 
1 2 1 T T T T T T T T A C G G T T T C T T C A G G G C T C C A C T T T A T T G G G G A G C A G C T T T G G G T G G G C G G G A 
1 8 1 T C T A G G G C T C C T G G G C T T G C A G T A G G G C C C G C A C C T G C C T G A T C T G C C A T T C G A C A C T G G 
2 4 1 A T T T C G C T G T G C C A C C C A A G G C A C T G T A C T G T T C C A C G C T G T G A C T G T A G T C C C A C A C G T 
3 0 1 G A C T C A C A T C A C C T G A G A A C A G G G G A C T G A T G G T C T G C A G C T C C T G T A G C G A C A G C A G G T 
3 6 1 T G A G A G C C A C T C C T T T A G T C T C C G C C A T G A A C A C A G C T T T C C C T G A G G C C T C G T G G G C C T 
4 2 1 G G C G G A G T G G C A T C C C T T T G C G G A C C A G G T A G T A G G C G A N G T C C G T G G C C A G C A T G T C A G 
4 8 1 G G C T G A G C G C N T G T N T C A T G T N C T C A C G A T G A A T C T G C N A T G T A N N G A T G A C T C C A G T G G 
5 4 1 C C A C T N G G A G G A C A G C T A T C A T N G T G T C A G A C A C T N C A A N A C A G N C N C C C T G T C T N N C T G 
6 0 1 T A A G T C N T G N T T G T A G G T G C T N G A A N G T C C C T G A A G G G T C A T C A G G A N T N C G G C C N C C C G 
6 6 1 T N C A N N A C A C A C G N C N G C C C T G N C T C C G N A T C A G C C T C A N G C T G T C N N G N N N N N 
C10.2: Sequence alignment of cDNA subclone Q02#6 with rat ASL by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇2tt6 ： 1 9 8 t q c a q t a q q q c c c g c a c c t g c c t g a t c t g c c a t t c g a c a c t g g a t t t c g c t g t g c c a c c c 2 5 7 
M i l l i i i i i i i i i i i i i i i i i i i i i i i i i II m m 
R a t A S L ： 1 5 2 9 t g c a g c a g g g c c c g c a c c t g g c t g a t c t g c c a c t c a a c a c t g g a c t g t g c t g t g c c a c c c 1 4 7 0 
〇〇2ft6 ： 2 5 8 a a q q c a c t g t a c t g t t c c a c g c t g t g a c t g t a g t c c c a c a c g t g a c t c a c a t c a c c t g a g 3 1 7 
i i f h i t i i i i i I I I I I I I I I I I i i i i i i i i m i l I I I I I I I � 
R a t A S L ： 1 4 6 9 a a g g c t g t g t a c t g c t c c a c g c t g t g g c t g t a g t c c c a c a c g a g a t t c a c g t c a c t c g a g 1 4 1 0 
〇〇2tt6 ：318 a a c a q g g q a c t g a t g g t c t g c a g c t c c t g t a g c g a c a g c a g g t t g a g a g c c a c t c c t t t a 3 7 7 
iiii〒fpfimi iiiiiimiiiiii m m iiiii 。 
R a t A S L ： 1 4 0 9 a a c a g g g g a c t g a c g g t c t g c a g c t c c t g a a g t g a c a g c t g g t t g a g a g c c a c c c c t t t c 1 3 5 0 
〇〇2:t^ 6 ： 3 7 8 q t c t c c g c c a t g a a c a c a g c t t t c c c t g a g g c c t c g t g g g c c t g g c g g a g t g g c a t c c c t 4 3 7 
M M M M I I M M M M M M I M M M I M I M M I I I I I I I I M M M M M _ 
R a t A S L ：1349 a t c t c t g c c a c g a c c a c a g c t t t c c c t g a g g c c t c g t g g g c c t g g c g g a a t g g c a t c c c t 1 2 9 0 
〇〇2#6 : 4 3 8 t t q c q g a c c a g q t a q t a g g c g a n g t c c g t g g c c a g c a t g t c a g g g c t g a g c g c n t g t n t c 4 9 7 
l l l l l l l l l l l l l l l l l l l l I 111 I I M M I M I I I M I I M M M I I I I I I ” ) � 
R a t A S L ：1289 t t g c g g a c c a g g t a g t a g g c a a g g t c g g t a g c c a g c a t g t c a g g g c t g a g t g c c t g t g c c 1 2 3 0 
002#6 - 4 9 8 a t q t n c t c a c g a t g a a t c t g c n a t g t a n n g a t g a c t c c a g t g g c c a c t n g g a g g a c a g c t 5 5 7 
M M i m m i i i i i i i i i M M I I I I I I I I I I I I I I I …， 
R a t A S L ：1229 a t g t t c t c a c g a t g a a t c t g c a g t g t a g a g a t g a c t c c a g t g g c t a c t t g g a g g a c a g c t 1 1 7 0 
002#6 ：558 a t c a t n g t q t c a g a c a c t n c - a a n a c a g n c n c c c t g t c t n n c t g t a a g t c n t g n t t g t a g 616 
I I I I I I I I I I I I 1 I M i l l I l i m i M I M I N I 川。 
R a t A S L ：1169 g t c a t g g t g t c a g a c a c t t c a a a c a c a g c c t c c t t g t c t t c c t g t a a g t c c t t g t t g t a g 1 1 1 0 
0〇2tt6 ： 6 1 7 g t g c t n g a a n g t c c c t g a a g g g t c a t c a g g a 6 4 7 I I I I I I I m m i i i i i i i i i i i i i R a t A S L ： 1 1 0 9 g t g c t t g g a a g t c c c t t g a g g g t c a t c a g g a 1 0 7 9 C10.3: Summary of sequence alignment of cDNA subclone 002#6 with rat ASL 
一 FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing 一 
Differential display pattern Size of insert 
Fraement ： ~ Subclone released by p Sequence homology E-value 
hra^ent p p A R a (+/+) P P A R a (_/_) n o . EcoKl cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved M  
Rat argininosuccinate „ 190 
二。) - + I - - 00 观 700.230 
354 
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Cl l . l : DNA sequence of cDNA subclone 002#9 using M13 reverse primer and the sequence of 5,-ARP3 
1 T G C C A A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T G C 
6 1 G G C T T A G C G G ATAACAATTT CACACAGGAG ACCATTGCAG G C A A C C C T C T G G G T G T G G A C ARP3 
1 2 1 C G G G A G C T A C T C C G T G C A G A A C T G A A C T C C C G C G G G C C A T C A C T C T C A A C A G C A T G G A T G 
1 8 1 C C A C C A G T G A G A G A G A C T T T G T G G C T G A G T T C C T G T T T T G G G C T T C T C T G T G T A T G A C C C 
2 4 1 A C C T C A G C A G G A T G G C A G A G G A C C T A A T T C T C T A T G G T A C C A A G G A A T T C A G C T T T G T G C 
3 0 1 A A C T C T C A G A T G C C T A C A G C A C C G G A A G C A G C T T G A T G C C C C A G A A G A A A A A C C C A G A C A 
3 6 1 G C C T G G A G C T G A T C C G G A G C A A G G C G G G C C G A G T G T N T G G A C G G T G T G C C G G A C T C C T G A 
4 2 1 T G A C C C T C A A G G G A C T N N C A A G C A C C T A C A A C A A G G A C T T A C A N G A A G A C A A G G A G G C T G 
4 8 1 T G T T T G A N G T G T C T G A C A C C A T G A T A G C T G T C C T N N A G C G G N C A C T G G A G T C A T C T C T A C 
5 4 1 A T T G C A G A T T C A T C G T G A G A N C N T G A A A C A G G C N C T C A G C N N T G A C A T G C T G G C A C G G A C 
6 0 1 N C N N C T A C T A N C T G G T C G C A A G G N A G C A T T C G C A G C C C A C A G C T C N N G A A G C T G T T C T G C 
6 6 1 A G A C T A G G N N G G C T C A N C N N N 
CI 1.2: Sequence alignment of cDNA subclone 002#9 with rat ASL by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇2tt9 ：92 c c a t t g c a g g c a a c c c t c t g g g t g t g g a c c g g g a g c t a c t c c g t g c a g a a c t g a a c t c c c 1 5 1 
immiiiiiimiiiiiiiiiiiimmi i iii iiiiiiiiiiiiiii 
R a t A S L ：758 c c a t t g c a g g c a a c c c t c t g g g t g t g g a c c g g g a g t t c c t c t g t g c a g a a c t g a a c t t t g 8 1 7 
〇〇2ft9 ：152 g c q g g c c a t c a c t c t c a a c a g c a t g g a t g c c a c c a g t g a g a g a g a c t t t g t g g c t g a g t t 2 1 1 
II iiii II iiiiiiii iiiiiiiiiiiiii i i i i i m m i i i i m m i 
R a t A S L ：818 g a g - - c c a t t a c g c t c a a c a g t a t g g a t g c c a c c a g c g a g a g a g a c t t c g t g g c t g a g t t 8 7 5 
〇〇2tt9 .212 c c t g t t t t g g g c t t c t c t g t g t a t g a c c c a c c t c a g c a g g a t g g c a g a g g a c c t a a t t c t 2 7 1 
iiiiiiiiimimimi I I I I I I I I M M M M M M I M M I M M I M M 
R a t A S L ：876 c c t g t t t t g g g c t t c t c t g t g c a t g a c c c a t c t c a g c a g g a t g g c a g a a g a c c t g a t t c t 9 3 5 
〇〇2tt9 .272 c t a t q g t a c c a a g g a a t t c a g c t t t g t g c a a c t c t c a g a t g c c t a c a g c a c c g g a a g c a g 3 3 1 
I I I M M I M I M M M M I ' l l l l l l l l I I I I I 111 I I I I 111 I I I 1丨丨 1 1 1 1 1 1 1 
R a t A S L ：936 c t a c g g t a c c a a g g a a t t c a a c t t t g t g c a g c t c t c c g a t g c c t a c a g c a c c g g a a g c a g 9 9 5 
〇〇2tt9 - 332 c t t g a t g c c c c a g a a g a a a a a c c c a g a c a g c c t g g a g c t g a t c c g g a g c a a g g c g g g c c g 3 9 1 
iiiiimiiiiiiiiimiiiiiiimi i i i i i i i i i m m m i i m M M 
R a t A S L ：996 c t t g a t g c c c c a g a a g a a a a a c c c a g a c a g c t t g g a g c t g a t c c g g a g c a a g g c g c g c c g 1 0 5 5 
〇〇2tt9 - 392 a g t g t n t g g a c g g t g t g c c g g a c t c c t g a t g a c c c t c a a g g g a c t n n c a a g c a c c t a c a a 4 5 1 M i l l m m m i i i i i i i i i i i i i i i i i i i i i i i i i i i i miiiiiimi 
R a t A S L ：1056 a g t g t t t g g a c g g t g c g c a g g a c t c c t g a t g a c c c t c a a g g g a c t t c c a a g c a c c t a c a a 1 1 1 5 
〇〇2:t^ 9 :452 c a a g g a c t t a c a n g a a g a c a a g g a g g c t g t g t t t g a n g t g t c t g a c a c c a t g a t a g c t g t 5 1 1 M I M M M M I M M M M M M M M M M M M M  
R a t A S L ：1116 c a a g g a c t t a c a g g a a g a c a a g g a g g c t g t g t t t g a a g t g t c t g a c a c c a t g a c a g c t g t 1 1 7 5 
002#9 • 5 1 2 c c t - n n a g c g q n c a c t g g a g t c a t c t c t a c a t t g c a g a t t c a t c g t g a g a n c n t g a a a c a 5 7 0 
111 I I I M M I M M M I M M M I I II丨丨丨丨丨丨丨I M丨丨丨 
R a t A S L ：1176 c c t c c a a g t a g c c a c t g g a g t c a t c t c t a c a c t g c a g a t t c a t c g t g a g a a c a t g g c a c a 1 2 3 5 
〇〇2tt9 ：571 g g c n c t c a g c n n t g a c a t g c t g g c 5 9 4 
III m i l l i i i i i i i i i i i i R a t A S L ： 1 2 3 6 g g c a c t c a g c c c t g a c a t g c t g g c 1 2 5 9 CI 1.3: Summary of sequence alignment of cDNA subclone 002#9 with rat ASL 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencii^  
Differential display pattern Size of insert 
Framient Subclone released by p Sequence homology E-value 
了 P P A R a (+/+) P P A R a (-/-) N o . E c o m cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
— Rat argininosuccinate 0 
0 0 2 + _ _ 0〇2#9 700 + 230 M l 3 reverse lyase (ASL) 458/504 
(900 bp) (1574 bp) (90o/o) 
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C12.1: DNA sequence of cDNA subclone 003#4 using M13 forward -20 primer and the sequence of 5,-ARP3 
1 T T A C G A C T C A C T A T A G G G G C G A A T T G G G G C C C T C T A G A T G C A T G C T C G A G C G G C C G C C A G 
6 1 T G T G A T G G A T A T G C T G C A G A A T T C G G C T T A G C G G A T A A . C A ATTTCACACA GGAGACCATT ARP3 
1 2 1 G C A A C C T A A T T G T T T G T G C T T G G A C A G C C A T G G A G C A C A T T G A C A G A A A C A A C G G T T G T C 
1 8 1 T G G T T G T G C T C C C A G G T A C C C A C A A A G G C A C T C T G A A G C C A C A T G A T T A C C C C A A G T G G G 
2 4 1 A G G G A G G T G T T A A C A A A A T G T A C C A T G G C A T C C A A G A C T A T G A C C C C A A C A G C C C C C G G G 
3 0 1 T C C A C C T A G T G A T G G A A A A G G G C G A T A C T G T T T T C T T C C A C C C T C T G C T C A T C C A T G G A T 
3 6 1 C T G G T C G G A A C A A A A C T C A A G G C T T C C G G A A A G C A A T T T C C T G C C A C T T C G G C A G C T C T G 
4 2 1 A C T G C C A G T G T A T C G A T G T G A G C G G C A C C A G T C A A G A A A A T A T T G C A A G G G A N G T T G C C G 
4 8 1 A G A T G G C A G A G A A A A G T A T G G A T T C C A G G A G T C A T G G A C T T A N N G A C A C T N G G A T A T N N C 
5 4 1 G A A N C C G A C T N G T G A A N G G A G A A A G A A T A A N C A T T T G A A N C A G C C C N T T C A N G A G T G A G G 
6 0 1 T A C T G G N A T G A T A G T C T G A N G C A G G A N C A T C G A N A N T T C G A N T A C A C T G A N C T A C A C G A G 
6 6 1 G A T G C A T N N C N C T C T N N C C N T A N N N T G A N A N A 
C12.2: Sequence alignment of cDNA subclone 003#4 with mouse Phyh by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇3#4 ：121 g c a a c c t a a t t g t t t g t g c t t g g a c a g c c a t g g a g c a c a t t g a c a g a a a c a a c g g t t g t c 1 8 0 
llllllllllllllllllllllllllllllllllllllllllllllllllllllllllll 
M o u s e P h y h ：596 g c a a c c t a a t t g t t t g t g c t t g g a c a g c c a t g g a g c a c a t t g a c a g a a a c a a c g g t t g t c 6 5 5 
〇〇3#4 ：181 t q q t t q t g c t c c c a g g t a c c c a c a a a g g c a c t c t g a a g c c a c a t g a t t a c c c c a a g t g g g 2 4 0 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l i l l l l l l l l M 
M o u s e P h y h ：656 t g g t t g t g c t c c c a g g t a c c c a c a a a g g c a c t c t g a a g c c a c a t g a t t a c c c c a a g t g g g 7 1 5 
〇〇3#4 ：241 a q g g a g g t g t t a a c a a a a t g t a c c a t g g c a t c c a a g a c t a t g a c c c c a a c a g c c c c c g g g 3 0 0 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l i 
M o u s e P h y h ：716 a g g g a g g t g t t a a c a a a a t g t a c c a t g g c a t c c a a g a c t a t g a c c c c a a c a g c c c c c g g g 7 7 5 
〇〇3#4 - 3 0 1 t c c a c c t a g t g a t g g a a a a g g g c g a t a c t g t t t t c t t c c a c c c t c t g c t c a t c c a t g g a t 3 6 0 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 丨 I I I 
M o u s e P h y h ：776 t c c a c c t a g t g a t g g a a a a g g g c g a t a c t g t t t t c t t c c a c c c t c t g c t c a t c c a t g g a t 8 3 5 
〇〇3tt4 ：361 c t g q t c q g a a c a a a a c t c a a g g c t t c c g g a a a g c a a t t t c c t g c c a c t t c g g c a g c t c t g 4 2 0 
l i l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i M M 
M o u s e P h y h ：836 c t g g t c g g a a c a a a a c t c a a g g c t t c c g g a a a g c a a t t t c c t g c c a c t t c g g c a g c t c t g 8 9 5 
0〇3#4 . 4 2 1 a c t g c c a g t g t a t c g a t g t g a g c g g c a c c a g t c a a g a a a a t a t t g c a a g g g a n g t t g c c g 4 8 0 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l M M I I 
M o u s e P h y h ：896 a c t g c c a g t g t a t c g a t g t g a g c g g c a c c a g t c a a g a a a a t a t t g c a a g g g a a g t t g t c g 9 5 5 
0 0 3 # 4 : 4 8 1 a q a t q q c a q a g - a a a a g t a t g g a t t c c - a g g a g t c a t g g a c - t t a n n g a c a c t n g g a t a t 5 3 7 
I I M I I I M M l l l l l l l l l l M M M l l l l l l 
M o u s e P h y h ：956 a g a t g g c a g a g a a a a a g t a t g g a t t c c a a g g a g t c a t g g a c t t t a a g g a c a c t t g g a t a t 1 0 1 5 
003tt4 .538 n n c q a a n c c g a c t n g t q a a n g g a g a a a g a a t a a n c a t t t g a a n c a g c c c n t t c a n g a g t g 5 9 7 
• M M M M M M i l l l l l l l l l l M l I I M M M M 丨丨丨丨丨 
M o u s e P h y h ：1016 t t c g a a g c c g a c t t g t g a a a g g a g a a a g a a t a a a c a t t t g a a a c a g c c c - t t c a a g a g t g 1 0 7 4 
0 0 3 # 4 .598 a q q t a c t g g n a t g a t a g t c t g a n g c a g g a n c a t c g a n a n t t c g a n t a c a 646 
l l l l l l l l l l l l l l l l l l l I I M M M I M M I M M 
M o u s e P h y h ： 1 0 7 5 a g g t a c t g g g a t g a t a g t c t g a g a c a g g a g c a t c g a g a g t t c g a g t a c a 1 1 2 3 C12.3: Summary of sequence alignment of cDNA subclone 003#4 with mouse Phyh 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning ~ Sequencing  
Differential display pattern Size of insert 
Fragment 1 Subclone released by p Sequence homology E-value 
P P A R a (+/+) P P A R a (-/-) ^o. BcoRI cut Prmer (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
Mouse phytanoyl-
M l 3 forward C o A hydroxylase 0 
』s03 - 003#4 920 .20 (Phyh) 505/529 (95%) 
(885 bp) (1419 bp)  
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C13.1: DNA sequence of cDNA subclone 003#9 using M13 reverse primer and the sequence of 5,-ARP3 
1 T G C C A A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T G C 
6 1 G G C T T A G C G G ATAACAATTT CACACAGGAG ACCATTGCAG G C A A C C C T C T G G G T G T G G A C A R P 3 
1 2 1 C G G G A G C T A C T C C G T G C A G A A C T G A A C T T T G G G G C C A T C A C T C T C A A C A G C A T G G A T G C C 
1 8 1 A C C A G T G A G A G A G A C T T T G T G G C T G A G T T C C T G T T T T G G G C T T C T C T G T G T A T G A C C C A C 
2 4 1 C T C A G C A G G A T G G C A G A G G A C C T A A T T C T C T A T G G T A C C A A G G A A T T C A G C T T T G T G C A A 
3 0 1 C T C T C A G A T G C C T A C A G C A C C G G A A G C A G C T T G A T G C C C C A G A A G A A A A A C C C A G A C A G C 
3 6 1 C T G G A G C T G A T C C G G A G C A A G G C G G G C C G A G T G T T T G G A C G G T G T G C C G G A C T C C T G A T G 
4 2 1 A C C C T C A A G G G A C T T C C A A G C A C C T A C A A C G A G G A C T T A C A G G A A G A C A A G G A G G C T G T G 
4 8 1 T T T G A A G T G T C T G A C A C C A T G A T A G C T G T C C T C C A A G T G G G C A C T G G A G T C A T C T C T A C G 
5 4 1 T T G C A G A T T C A T C G T G A G A A C A T G A A A C A G G C G C T C A G C C C T G A C A T G C T G G C A C G G A C N 
6 0 1 C G N C T A C T A C C T G G T C G C A A N N G A T G C A T T C G C A G N C N C G A G C T A N N N N N C G G T C T G C G A 
6 6 1 A T A G G N N G C T A C T G 
C13.2: Sequence alignment of cDNA subclone 003#9 with rat ASL by BLAST 
searching with the National Center for Biotechnology Information database 
〇〇3#9 ： 9 2 c c a t t g c a g g c a a c c c t c t g g g t g t g g a c c g g g a g c t a c t c c g t g c a g a a c t g a a c t t t g 1 5 1 
iiiiiiiiiiiimimiiiiiiiiimiiii i iii i i i i i m i m m i i i 
R a t A S L ： 7 5 8 c c a t t g c a g g c a a c c c t c t g g g t g t g g a c c g g g a g t t c c t c t g t g c a g a a c t g a a c t t t g 8 1 7 
0 0 3 # 9 ： 1 5 2 q q q c c a t c a c t c t c a a c a g c a t g g a t g c c a c c a g t g a g a g a g a c t t t g t g g c t g a g t t c c 2 1 1 
I iiiii II Miiiiii iiiiiiiiiiiiii Imil丨iiiii丨 
R a t A S L ： 8 1 8 g a g c c a t t a c g c t c a a c a g t a t g g a t g c c a c c a g c g a g a g a g a c t t c g t g g c t g a g t t c c 8 7 7 
0 0 3 # 9 : 2 1 2 t q t t t t g g q c t t c t c t g t g t a t g a c c c a c c t c a g c a g g a t g g c a g a g g a c c t a a t t c t c t 2 7 1 
M M M M M M I M M M M I I I I I I 1 1 1 1 1 1 1 1 1 1 I I I I I I 丨 I I I I I l l l l l l l 
R a t A S L ： 8 7 8 t g t t t t g g g c t t c t c t g t g c a t g a c c c a t c t c a g c a g g a t g g c a g a a g a c c t g a t t c t c t 9 3 7 
003#9 ：272 a t q q t a c c a a q g a a t t c a g c t t t g t g c a a c t c t c a g a t g c c t a c a g c a c c g g a a g c a g c t 3 3 1 
I m i i i i i i i m i i i 1 1 1 1 1 1 1 1 1 M i l l I I l l l l l l l I i m i m m i m 
R a t A S L ： 9 3 8 a c g g t a c c a a g g a a t t c a a c t t t g t g c a g c t c t c c g a t g c c t a c a g c a c c g g a a g c a g c t 9 9 7 
0 〇 3 粘 ： 3 3 2 t q a t g c c c c a g a a g a a a a a c c c a g a c a g c c t g g a g c t g a t c c g g a g c a a g g c g g g c c g a g 3 9 1 
i M i i i 
R a t A S L ： 9 9 8 t g a t g c c c c a g a a g a a a a a c c c a g a c a g c t t g g a g c t g a t c c g g a g c a a g g c g c g c c g a g 1 0 5 7 
o o ^ t i g . 3 9 2 t q t t t q q a c q g t g t g c c g q a c t c c t g a t g a c c c t c a a g g g a c t t c c a a g c a c c t a c a a c g 4 5 1 
• i i M i i i M i i i i II m m 11 m i  
R a t A S L ： 1 0 5 8 t g t t t g g a c g g t g c g c a g g a c t c c t g a t g a c c c t c a a g g g a c t t c c a a g c a c c t a c a a c a 1 1 1 7 
0 0 3 # 9 -452 a q g a c t t a c a g g a a g a c a a g g a g g c t g t g t t t g a a g t g t c t g a c a c c a t g a t a g c t g t c c 511 
Ra t A S L :1118 a g g a c t t a c a g g a a g a c a a g g a g g c t g t g t t t g a a g t g t c t g a c a c c a t g a c a g c t g t c c 1177 
0 0 3 # 9 : 5 1 2 t c c a a q t q g g c a c t g g a g t c a t c t c t a c g t t g c a g a t t c a t c g t g a g a a c a t g a a a c a g g 5 7 1 
lllllll I llllllllllllllllll lllllll I 
R a t A S L ： 1 1 7 8 t c c a a g t a g c c a c t g g a g t c a t c t c t a c a c t g c a g a t t c a t c g t g a g a a c a t g g c a c a g g 1 2 3 7 
〇〇3#9 ：572 c g c t c a g c c c t g a c a t g c t g g c 593 
I i m m i i m i i m m R a t A S L -.12 3 8 c a c t c a g c c c t g a c a t g c t g g c 1259 C13.3: Summary of sequence alignment of cDNA subclone 003#9 with rat ASL 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing _ _ 
Differential display pattern Size of insert 
Fragment " ~ Subclone released by p^ - ^^ Sequence homology E-value 
PPARa (+/+) PPARa (-/-) N o. BCORI cut Pnmer (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
Rat argininosuccinate • 
003 + - - 003#9 700 + 230 M13 reverse lyase (ASL) 472/502 (94%) 
(885 bp) (1574 bp) ^  
357 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C14.1: DNA sequence of cDNA subclone 004#3 using M13 forward -20 primer and the sequence of5,-ARP3 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G G A G C G G C C G C C A G 
6 1 T G T G A T G G A T A T C T G C A G A A T T C G G C T T A G CGGATAACAA TTTCACACAG GAGACCATTG ARP3 
1 2 1 C A G G C A A C C C T C T G G G T G T G G A C C G G G A G C T A C T C C G T G C A G A A C T G A A C T T T G G G G C C A 
1 8 1 T C A C T C T C A A C A G C A T G G A T G C C A C C A G T G A G A G A G A C T T T G T G G C A G G A T G G C A G A G G A 
2 4 1 C C T A A T T C T C T A T G G T A C C A A G G A A T T C A G C T T T G T G C A A C T C T C A G A T G C C T A C A G C A C 
3 0 1 C G G A A G C A G C T T G A T G C C C C A G A A G A A A A A C C C A G A C A G C C T G G A G C T G A T C C G G A G C A A 
3 6 1 G G C G G G C C G A G T G T T T G G A C G G T G T G C C G G A C T C C T G A T G A C C C C T C A A G G G A C T T C C A A 
4 2 1 G C A C C T A C A A C A A G G A C T T A C A G G A A G A C A A N G A G G C T G T G T T T G A A G T G T C T G A C A C C A 
4 8 1 T G A T A G C T G T C C T C C A C G T G G C C A C T G G A G T C A T C T C T A C A T T G C A G A T T C A T C G T G A G A 
5 4 1 A C A T G A A N N A G G C G C T C A G C C C T G A C A T G C T G G C C A C N G A C C T C N C C T A C T A C C T G G T C C 
6 0 1 G C A A N N G A T G C C A T N N C G C C A G G C C C A C G A N G C C T C A G G G C A N C T G T G T N C A T G G C A G A G 
6 6 1 A C T A N N G A N T G C T C T C A C C T G C T G T N C T A N G G A N C T G N N 
C14.2: Sequence alignment of cDNA subclone 004#3 with rat ASL by BLAST 
searching with the National Center for Biotechnology Information database 
004#3 •225 q c a q q a t q q c a g a g q a c c t a a t t c t c t a t g g t a c c a a g g a a t t c a g c t t t g t g c a a c t c t 2 8 4 
l l l l l l l l l l l l l I I I M l i m i l l l l l l l l l l l l l l l l l l l l l l l l l l l M M • 
R a t A S L ：911 g c a g g a t g g c a g a a g a c c t g a t t c t c t a c g g t a c c a a g g a a t t c a a c t t t g t g c a g c t c t 9 7 0 
0〇4#3 : 2 85 c a q a t q c c t a c a g c a c c g g a a g c a g c t t g a t g c c c c a g a a g a a a a a c c c a g a c a g c c t g g 3 4 4 
I M l I N ， 。 ？ 。 
R a t A S L ：971 c c g a t g c c t a c a g c a c c g g a a g c a g c t t g a t g c c c c a g a a g a a a a a c c c a g a c a g c t t g g 1 0 3 0 
〇04tt3 : 3 45 a g c t g a t c c g g a g c a a g g c g g g c c g a g t g t t t g g a c g g t g t g c c g g a c t c c t g a t g a c c c 4 0 4 M I M I M M M M M M M 1 1 1 1 1 1 1 I I I 1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 I N M M 
R a t A S L : 1 0 3 1 a g c t g a t c c g g a g c a a g g c g c g c c g a g t g t t t g g a c g g t g c g c a g g a c t c c t g a t g a c c c 1 0 9 0 
〇04#3 :405 c t c a a q g g a c t t c c a a g c a c c t a c a a c a a g g a c t t a c a g g a a g a c a a n g a g g c t g t g t t t 4 6 4 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l I M M M i l l M l 
R a t A S L ：1091 - t c a a g g g a c t t c c a a g c a c c t a c a a c a a g g a c t t a c a g g a a g a c a a g g a g g c t g t g t t t 1 1 4 9 
0 0 4 # 3 :465 g a a g t g t c t g a c a c c a t g a t a g c t g t c c t c c a c g t g g c c a c t g g a g t c a t c t c t a c a t t g 524 
I M I M M M M M I M M l l l l l l l l l l l l 11 1 1 1 1 111111丄 11 I M 11 i I ^ ^ ^ ^ 
R a t A S L : 1 1 5 0 g a a g t g t c t g a c a c c a t g a c a g c t g t c c t c c a a g t a g c c a c t g g a g t c a t c t c t a c a c t g 1 2 0 9 
004#3 ：525 c a q a t t c a t c g t g a g a a c a t g a a n n a g g c g c t c a g c c c t g a c a t g c t g g c c a c n g a c c t c 584 
I I I M M M M M M M M M M M 111 I I I 111 I I I I N I丄 1 1 1 J 丨 M i l l ” � 
R a t A S L ：1210 c a g a t t c a t c g t g a g a a c a t g g c a c a g g c a c t c a g c c c t g a c a t g c t g g c t a c c g a c c t t 1 2 6 ^ 
〇〇4#3 ：585 n c c t a c t a c c t g g t c c g c - a a n n g a t g c c a t n n c g c c a g g c c c a c g a n g c c t c a g g g 6 4 0 
i i i m i m f h m i ii iiiiiiii 丨丨丨丨丨 
R a t A S L ：1270 g c c t a c t a c c t g g t c c g c a a a g g g a t g c c a t t c c g c c a g g c c c a c g a g g c c t c a g g g 1 3 2 6 C14.3: Summary of sequence alignment of cDNA subclone 004#3 with rat ASL 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning ~ Sequencing  
Differential display pattern Size of insert 
Fragment Subclone released by p Sequence homology E-value 
Fra葛 =ent p p A R a (+/+) P P A R a (-/-) n o . ECORI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
A^rn f 7" Rat argininosuccinate 164 
0 0 4 _ + _ - 004#3 720 + 210 M l 3 forward lyase (ASL) sggM；? (92%) 
(850 bp) (1574 bp) 、 ‘ 
358 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C15.1: DNA sequence of cDNA subclone OQ4#3 using M13 reverse primer and the sequence of 3,-AP9 
1 T G C C A A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C 
6 1 GGCTTGTAAT ACGACTCACT ATAGGGCTTT TTTTTTTTAC GCTTGTCTCG GTTTCTTCAG AP9 
1 2 1 G G C T C C A C T T T A T T G G G G A G C A G C T T T G G G T G G G C G G G A T C T A G G G C T C C T G G G C T T G C A 
1 8 1 G T A G G G C C C G C A C C T G C C T G A T C T G C C A T T C G A C A C T G G A T T T C G C T G T G C C A C C C A A G G 
2 4 1 C A C T G T A C T G T T C C A C G C T G T G A C T G T A G T C C C A C A C G T G A C T C A C A T C A C C T G A G A A C A 
3 0 1 G G G G A C T G A T G G T C T G C A G C T C C T G T A G C G A C A G C A G G T T G A G A G C C A C T C C T T T A G T C T 
3 6 1 C T G C C A T G A A C A C A G C T T G C C C T G A G G C C T C G T G G G C C T G G C G G A A T G G C A T C C C T T T G C 
4 2 1 G G A C C A G G T A G T A G G C G A G G T C C G T G G C C A G C A T G T C A G G G C T G A G C G C C T G T T T C A T G T 
4 8 1 T C T C A C G A T G A A T C T G C A A T G T A G A G A T G A C T C C A G T G G C C A C T T G G A G G A C A G C T A T C A 
5 4 1 T G G T G T C A G A C A C T T C A A A C A C A G C C T C C T T G T C T T C C T G T A A G T N C T G N T N G T A G G T G C 
6 0 1 T N G G A A G T C C C T N G A G G G T C A T C A G G A G T N C G G C A C A C C G T C C N A A C A C T C G G N C C G C C N 
6 6 1 T G N C T C G G A T C A G C T C A N G C T G T 
C15.2: Sequence alignment of cDNA subclone 004#3 with rat ASL by BLAST 
searching with the National Center for Biotechnology Information database 
〇〇4#3 ：177 t g c a g t a g g g c c c g c a c c t g c c t g a t c t g c c a t t c g a c a c t g g a t t t c g c t g t g c c a c c c 236 
IIIII IIIIIIIIIIIIII IIIIIIIIIII 11 IIIIIIII I iimiiiim 
R a t A S L ：1529 t g c a g c a g g g c c c g c a c c t g g c t g a t c t g c c a c t c a a c a c t g g a c t g t g c t g t g c c a c c c 1 4 7 0 
〇〇4#3 :237 a a g g c a c t g t a c t g t t c c a c g c t g t g a c t g t a g t c c c a c a c g t g a c t c a c a t c a c c t g a g 296 
I I I I I M M I I I i i m m m i i i m i m i i m I I M M M M M I 
R a t A S L ：1469 a a g g c t g t g t a c t g c t c c a c g c t g t g g c t g t a g t c c c a c a c g a g a t t c a c g t c a c t c g a g 1 4 1 0 
〇〇4#3 :297 a a c a g g g g a c t g a t g g t c t g c a g c t c c t g t a g c g a c a g c a g g t t g a g a g c c a c t c c t t t a 356 
iiiiiiiimii iiiiiiiiiiiiiii II m m iiiiiimmi iiiii 
R a t A S L ：1409 a a c a g g g g a c t g a c g g t c t g c a g c t c c t g a a g t g a c a g c t g g t t g a g a g c c a c c c c t t t c 1350 
〇〇4#3 ：357 g t c t c t q c c a t g a a c a c a g c t t g c c c t g a g g c c t c g t g g g c c t g g c g g a a t g g c a t c c c t 416 
iiiiimi II IIIIIIII i i m i m i i i m i i i i i m i i m i i i i i i m 
R a t A S L ：1349 a t c t c t g c c a c g a c c a c a g c t t t c c c t g a g g c c t c g t g g g c c t g g c g g a a t g g c a t c c c t 1290 
〇〇4#3 ：417 t t g c g g a c c a g g t a g t a g g c g a g g t c c g t g g c c a g c a t g t c a g g g c t g a g c g c c t g t t t c 476 
l l l l l l l l l l l l l l l l l l l l M i l l I I l l l l l l l l l l l l l l l l l l l l 丨 I I I I I I 
R a t A S L ：1289 t t g c g g a c c a g g t a g t a g g c a a g g t c g g t a g c c a g c a t g t c a g g g c t g a g t g c c t g t g c c 1 2 3 0 
〇〇4#3 .477 a t g t t c t c a c g a t g a a t c t g c a a t g t a g a g a t g a c t c c a g t g g c c a c t t g g a g g a c a g c t 536 
M I M I M M M M M M M M I 11111 11 11 11111 11111 I 11111111 丨丨丨丨丨丨丨 
R a t A S L :1229 a t g t t c t c a c g a t g a a t c t g c a g t g t a g a g a t g a c t c c a g t g g c t a c t t g g a g g a c a g c t 1170 
〇〇4#3 •537 a t c a t g g t g t c a g a c a c t t c a a a c a c a g c c t c c t t g t c t t c c t g t a a g t n c t g n t n g t a g 596 
M I M M M M M M I M M M 1 1 1 1 1 1 1 1 1 1 1 M I M M 
R a t A S L ： 1169 g t c a t g g t g t c a g a c a c t t c a a a c a c a g c c t c c t t g t c t t c c t g t a a g t c c t t g t t g t a g 1110 
004#3 •597 g t g c t n g q a a g t c c c t n g a g g g t c a t c a g g a g t n c g g c a c a c c g t c c n a a c a c t c g g n c c 656 
I I I I I M M M M M M M M M I M M M I I I M M I I I M M M I 
R a t A S L :1109 g t g c t t g g a a g t c c c t t g a g g g t c a t c a g g a g t c c t g c g c a c c g t c c a a a c a c t c g g c g c 1050 
〇〇4#3 ：657 g c c n t g n c t c g g a t c a g c t c 676 
III II IIIIIIIIIII R a t A S L ：1049 g c c t t g c t c c g g a t c a g c t c 1030 C15.3: Summary of sequence alignment of cDNA subclone 004#3 with rat ASL 
FluoroDD gel 0 0 (AP9 + ARP3) Subdoning “ Sequencing  
Differential display pattern Size of insert Fragment Subclone released by p Sequence homology E-value h r a g ^ n t PPARa (+/+) PPARa (-/-) ^ o . E c o m cut P^mer (Transcript size) (% Identity) Fed Starved Fed Starved ^  
Rat argininosuccinate e 171 
0 0 4 + - - 0 0 4 # 3 720 + 210 M13 reverse lyase (ASL) 449/500 (89%) 
(850 bp) _ (1574 bp) � ) 
359 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C16.1: DNA sequence of cDNA subclone 004#4 using M13 forward -20 primer and the sequence of 5,-ARP3 
1 T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G G A G C G G C C G C C A G T 
6 1 G T G A T G G A T A TCTGCAGAAT TCGGCTTAGC GGATAACAAT TTCACACAGG AGACCATTGC ARP3 
1 2 1 A C T G A C A G A G G A A G A T A T A T T T T A G A G G G A G A C A C T T G T A C C T T T C T C T C C C T T C A G T T A 
1 8 1 T T A G A C T C T T G G G A C A A T G G A C A T C A T G A A T T A A A A C G T T C T T A G A A A T C A C A T G C T G G G 
2 4 1 A G A A A A T T A A C A C T A A A A T C T G G T A C C A G C C A G A G G A A G G A A C T T G A C T C A A A A T A A G A G 
3 0 1 A T T T T T A G G T A T T T C T G T C T G T C T C A T A G T T A A A A T T A A T G T T T T C C T G C T T T C T G G C A T 
3 6 1 A T G C C T C A T C T T T T C T A T G A A G T A G T A A T A C T G A T A C A G A A A G G T A G A G A G A A A T G A A T A 
4 2 1 G T T T T T G C T A C T T T G G G C C A A A C T G T G A A A A A A T C C A T T T T A T T T C A T C A A T T T C T G T T T 
4 8 1 C C C A A T T T C A T T T A A G A C A C A G G A A A A C T A C T C A G C A T G A A C T T T G G G G A G C C A G A G C A G 
5 4 1 T N N T G N C A A T N C A N N G A N G C A T G T N G C C A T C T G G T C C N A C T G T T A G A N T G T G N A G A A T C T 
6 0 1 C A G C T C T G A N A N G T G T C T C T G C T T N G A C T C T G A G C T G G T G T G T A N A A T C A G G T N G C G T N N 
6 6 1 T G T G A G C T A N G A N T T C T G A C T N A N N C G G 
C16.2: Sequence alignment of cDNA subclone OQ4#4 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇4tt4 ：113 a c c a t t q c a c t g a c a g a q q a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 172 
M M M I M M M M M M M M M M M M l l l l l I I   
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1882 
0 0 4 ^ 4 •173 t t c a q t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 232 
iiii〒imii〒imiiiiiiiiimiimimiiiimimmiiiiiM M 
M o u s e C Y P 4 A 1 4 ：1883 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 1942 
〇〇4#4 ：233 a t q c t q q q a q a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 292 
iiTi丨腦iiimiiiiiimmiimiiimimmimiiiiiiiiii 
M o u s e C Y P 4 A 1 4 ：1943 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2002 
0 0 4 # 4 ：293 a a t a a q a q a t t t t t a q g t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 352 
l l l l l l l l l l l l l l l l I M M M M M M M I M M I I I I I I I I I I M M M M M i M 
M o u s e C Y P 4 A 1 4 ： 2 0 0 3 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 2062 
0 0 4 # 4 ：353 t c t q q c a t a t q c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 412 
I M M M M I I M I M M M M M I M M I M M M 111 1 1 1 1 1 1 1 1 1 1 1 1 
M o u s e C Y P 4 A 1 4 ： 2 0 6 3 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 2122 
0 0 4 # 4 .413 a a t q a a t a q t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t 472 
M I I M M M M M M M M I M M M l l l l l I �只， 
M o u s e C Y P 4 A 1 4 ：2123 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t ^^丄 
0 0 4 # 4 :473 t t c t q t t t c c c a a t t t c a t t t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t t g g g g a g c 532 
M M I M M M M I M M M M M M M I M M M 1 1 1 1 1山 1 1 1 1 1 1 1 
M o u s e C Y P 4 A 1 4 ：2183 t t c t g t t t c c c a a t t t c a t t t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t t g g g g a g c 2242 
0 0 4 # 4 :533 c a q a g c a g t n n t g n c a a t n c a n n g a n g c a t g t n g c c a t c t g g t - c c n a c t g t t a g a n t g t 591 
l l l l l l l l l I I M M I I I I I l l l l l I I I I M l i M I I I I I , … 
M o u s e C Y P 4 A 1 4 :2243 c a g a g c a g t t t t g g c a a t c c a g g g a a g c a t g t t g c c a t c t g g t c c c t a c t g t t a g a a t g t 」U 2 
〇〇4#4 ：592 g 592 
M o u s e C Y P 4 A 1 4 :2303 g 2303 C16.3: Summary of sequence alignment of cDNA subclone Q04#4 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment " ~ Subclone released by p Sequence homology E-value 
= PPARa (+/+) PPARa (-/-) ^ o . E c o m cut Primer (Transcript size) (% Identity) Fed Starved Fed Starved ^  
™ M l 3 forward Mouse C Y P 4 A 1 4 0 
二 p ) + 0 0 4 # 4 560 + 200 .^p (2547 bp) 469/481 (97。/。） 
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C17.1: DNA sequence of cDNA subclone 004#4 using M13 reverse primer and the sequence of3'-AP2 
1 C C N A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T N C G G 
6 1 CTTGTAATAC GACTCACTAT AGGGCTTTTT TTTTTTACAT GTCATGTGAT TTTAATAGGA AP9 
1 2 1 A T T C T C C A A A T C A C T A A A G T G A A T A A T C A G A G T A C T C T A A A C A A A T A A G A C C G G G T T A A A 
1 8 1 G T C A G A A A A C T C C T T A G C T T C A C A A A A A A C G C C A A C C T G C A T T T C T A C A C A A C C A G C T C A 
2 4 1 G G A G T C A A A A G C A G A G A A C A A C C T C T C A G G A G C T G A G A A T T C T A C C A C A T T C T A A C A G T A 
3 0 1 G G G A C C A G A T G G C A A C A T G C T T C C C T G G A T T G C C A A A A C T G C T C T G G C T C C C C A A A G T T C 
3 6 1 A T G C T G A G T A G T T T T C C T G T G T C T T A A A T G A A A T T G G G A A A C A G A A A T T G A T G A A A T A A A 
4 2 1 A T G G A T T T T T T C A C A G T T T G G C C C A A A G T A G C A A A A A C T A T T C A T T T C T C T C T A C C T T T C 
4 8 1 T G T A T C A G T A T T A C T A C T T C A T A G A A A A G A T G A N G C A T A T G C C A G A A N G C A N G A A A A C A T 
5 4 1 T A N T N N T A N C T A T G A G A C A G A C A G A A A T A C C T A A A A A T C T C T N A T N N T G A G T C A N G T C C N 
6 0 1 T N C N C T G G C T G N A C A G A T T N A G T G T N A N T T N T C C A G C A T G T G A T T C T A N A C G T T N A N T C A 
6 6 1 T G A T G T C A T G T N C A G A N N A T 
C17.2: Sequence alignment of cDNA subclone 004#4 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
oo4±l:4 • 98 c a t q t c a t q t q a t t t t a a t a q g a a t t c t c c a a a t c a c t a a a g t g a a t a a t c a g a g t a c t c 157 
• I I I I M M I ？ I I I I I I I I I m i l l l l l l l l l l l M l I I I I I M I I M M I 
M o u s e C Y P 4 A 1 4 : 2 4 9 1 c a t g t c a t g g g a t t t t a a t g g g a a t t c t c c a a a t c a t t a a g g g g a a t a t t c - g a g t a a t t 2 4 3 3 
0 0 4 # 4 • 1 5 8 t - a a a c a a a t a a g a c c g g g t t a a a g t c a g a a a a c t c c t t a g c t t c a c a a a a a a c g c c a a c 2 1 6 
I m i l l l l i m i l l l l l l l M I I I I I I I I I I M M I I I M M I I I I I � 
M o u s e C Y P 4 A 1 4 : 2 4 3 2 t t a a a c a a a t a a g a c c g g g t t a a a t t c a g a a a a t t c t t t a g g t t c a c a a a a a a c g c c a a c 2 3 7 3 
0 0 4 # 4 : 2 1 7 c t q c a t t t c t a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 2 7 6 
丨〒mil I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M M I I I I I I I I I I I I I I ， ” ？ 
M o u s e C Y P 4 A 1 4 ：2372 t t g c a t t t t a a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 2 3丄3 
〇〇4#4 ： 2 7 7 q a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 336 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I I I I l l l l l 
M o u s e C Y P 4 A 1 4 : 2 3 1 2 g a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 
0 0 4 # 4 . 3 3 7 a a c t q c t c t g q c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 3 9 6 
l I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I M M M I I N I I I I 
M o u s e C Y P 4 A 1 4 : 2 2 5 2 a a c t g c t c t g g c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 2丄 
0 0 4 # 4 :397 g g a a a c a g a a a t t g a t g a a a t a a a a t g g a t t t t t t c a c a g t t t g g c c c a a a g t a g c a a a a 4 5 6 
M M I I I I M I M I M M M M M M M M M I M I I I I I I I I M M M M I l l l l l I I 。 ” ？ 
M o u s e C Y P 4 A 1 4 : 2 1 9 2 g g a a a c a g a a a t t g a t g a a a t a a a a t g g a t t t t t t c a c a g t t t g g c c c a a a g t a g c a a a a 2 1 3 3 
0 0 4 # 4 -457 a c t a t t c a t t t c t c t c t a c c t t t c t g t a t c a g t a t t a c t a c t t c a t a g a a a a g a t g a n g c 516 
. l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M I I l l l l i M l N 
M o u s e C Y P 4 A 1 4 : 2 1 3 2 a c t a t t c a t t t c t c t c t a c c t t t c t g t a t c a g t a t t a c t a c t t c a t a g a a a a g a t g a g g c 2 0 7 3 
0 0 4 # 4 •517 a t a t g c c a g a a n g c a n g a a a a c a t t a n t n n t a n c t a t g a g a c a g a c a g a a a t a c c t a a a a 576 
l l l l l l l l l l l 111 l l l l l l l l l l I 11 I I I I M M M M M M M 1 I M l 
M o u s e C Y P 4 A 1 4 : 2 0 7 2 a t a t g c c a g a a a g c a g g a a a a c a t t a a t t t t a a c t a t g a g a c a g a c a g a a a t a t c t a a a a 2 0 l i 
〇 〇 4 # 4 ： 577 a t c t c t n a t n n t g a g t c a 594 IIIIIIII iiimi 
M o u s e C Y P 4 A 1 4 :2〇12 a t c t c t t a t t t t g a g t c a 1 9 9 5 C17.3： Summary of sequence alignment of cDNA subclone 004#4 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning S e q u e n c j ^  
Differential display pattern Size of insert 
Fnmment 1 Subclone released by p Sequence homology E-value Fragment p p A R a (+/+) PPARa (-/-) ^ o . E c o m cut Pnmer (Transcript size) (% Identity) Fed Starved Fed Starved (bp)  ^ Mouse CYP4A14 0 0 0 4 _ + _ - 0 0 4 # 4 560 + 200 M13 reverse (2547 bp) 470/498 (94%) (850 bp) -I — 
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C18.1: DNA sequence of cDNA subclone 004#10 using M13 forward -20 primer and the sequence of3,-AP9 
1 A G G C G A A T G G G C C C T A A T G C A T G C T C G A G C G G C G C C A G T G T G A T G G A T A T C T G C A G A A T T 
6 1 C G G C T T G T A A TACGACTCAC TATAGGGCTT TTTTTTTTTT A C C A T C A T T A A T T T T A T T A A AP9 
1 2 1 C T T C A T T G A G A T A G A A T A T A T A T A T A T A T A T G T A T A T A T A T A T A T G T T G T G T G T A T A T A C 
1 8 1 A C A C A C A C T A C A T A G T T C A C T T T G A A C C A T T G A A C T C A A T G T G T T A C A G A T A C A C C A C T A 
2 4 1 A A G T A A T T T T A G A A A A G T T T A T C A A A C T C C A A A G A T A C T C T G T A T T A A T C A G C A G T A A T T 
3 0 1 T T A A C T T A A A A C A A T T A T A G C C T T G G G C T A C T C A T C T A C A T T G T T C T C A G A T C T G T A T A T 
3 6 1 T C T G G A A T T T A T A T C C A C A T C C A T A T G A C A T G T G G C C T T C T T T G G G C T G C C T C C T C T T A G 
4 2 1 T C A G A G C A A T G C T G C A A C A C A G A C A C C A T G G T G G C A T C A T G T T C C G T C A C A C A G C T G A A A 
4 8 1 T G T G T G A C T T G T A T G T C C A A T G A C C A C T T A T 
C18.2a: Sequence alignment of cDNA subclone 004#10 with rat PBE by BLAST searching 
with the National Center for Biotechnology Information database 
O O 4 # 1 0 •196 t t c a c t t t q a a c c a t t q a a c t c a a t g t g t t a c a g a t a c a c c a c t a a a g t a a t t t t a g a a a 2 5 5 M M M M I I M M M M M M M M M M M M M I I I I I I I I I I M i l l 
R a t P B E ： 3 0 2 0 t t c a c t t t g a a c c a t t g a a c t c a a t g t g t t a c a g a t c c a c c a c t a g a g t a a t t t t a g a a a 2 9 6 1 
〇〇4#10 :256 a q t t t a t c a a a c t c c a a a g a t a c t c t g t a t t a a t c a g c a g t a a t t t t 3 0 2 
I I I I I I I I iimmiiiiim I I I 丨丨丨丨丨 
R a t P B E ：2960 a t t t t a t c a g c t c c c a a a g a t a c t c t g t a c t a a t c a g t a g t g a t t t t 2 9 1 4 C18.3a: Summary of sequence alignment of cDNA subclone 004#10 with rat PBE 
— FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing 
Differential display pattern Size of insert 
Fragment ~ S u b c l o n e released by ^ • _ Sequence homology E-value 了 P P A R a (+/+) PPARa (-/-) No . £coRI cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Rat peroxisomal 
enoyl-
noz i 一 M13 forward CoA:hydratase-3- 2e-28 (g50bp) + 0 0 4 # 1 0 900 .20 hydroxyacyl-CoA 97/107 (90%) 
bifunctional enzyme 
(PBE) (3097 bp)  
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C18.1: DNA sequence of cDNA subclone 004#10 using M13 forward -20 primer and the sequence of3’-AP9 
1 A G G C G A A T G G G C C C T A A T G C A T G C T C G A G C G G C G C C A G T G T G A T G G A T A T C T G C A G A A T T 
6 1 C G G C T T G T A A TACGACTCAC TATAGGGCTT TTTTTTTTTT A C C A T C A T T A A T T T T A T T A A A P 9 
1 2 1 C T T C A T T G A G A T A G A A T A T A T A T A T A T A T A T G T A T A T A T A T A T A T G T T G T G T G T A T A T A C 
1 8 1 A C A C A C A C T A C A T A G T T C A C T T T G A A C C A T T G A A C T C A A T G T G T T A C A G A T A C A C C A C T A 
2 4 1 A A G T A A T T T T A G A A A A G T T T A T C A A A C T C C A A A G A T A C T C T G T A T T A A T C A G C A G T A A T T 
3 0 1 T T A A C T T A A A A C A A T T A T A G C C T T G G G C T A C T C A T C T A C A T T G T T C T C A G A T C T G T A T A T 
3 6 1 T C T G G A A T T T A T A T C C A C A T C C A T A T G A C A T G T G G C C T T C T T T G G G C T G C C T C C T C T T A G 
4 2 1 T C A G A G C A A T G C T G C A A C A C A G A C A C C A T G G T G G C A T C A T G T T C C G T C A C A C A G C T G A A A 
4 8 1 T G T G T G A C T T G T A T G T C C A A T G A C C A C T T A T 
C18.2b: Sequence alignment of cDNA subclone 004#10 with mouse L-PBE by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇4#10 ： 1 6 6 q t t q t q t g t a t a t a c a c a c a c a c t a c a t a g t t c a c t t t g a a c c a t t g a a c t c a a t g t g t t 2 2 5 
I I I I I I I I I M I M M M M I M M M M M M M M M I   
M o u s e L - P B E ： 1 5 8 1 g t t g t g t g t a t a t a c a c a c a c a c t a c a t a g t t c a c t t t g a a c c a t t g a a c t c a a t g t g t t 1522 
O O 4 # 1 0 ： 2 2 6 a c a q a t a c a c c a c t a a a g t a a t t t t a g a a a a g t t t a t c a a a c t c c a a a g a t a c t c t g t a t 2 8 5 
M M M M M M M M M I M M M M I M M M I I l l l l l I I M I I I … � 
M o u s e L - P B E ： 1 5 2 1 a c a g a t a c a c c a c t a a a g t a a t t t t a g a a a a g t t t a t c a a a c t c c a a a g a t a c t c t g t a t 1 4 6 2 
004ttlO • 2 8 6 t a a t c a q c a q t a a t t t t a a c t t a a a a c a a t t a t a g c c t t g g g c t a c t c a t c t a c a t t g t t 3 4 5 
11II111II11IIIII11II111111111111111111111111111 M I Ml M III II 
M o u s e L - P B E ： 1 4 6 1 t a a t c a g c a g t a a t t t t a a c t t a a a a c a a t t a t a g c c t t g g g c t a c t c a t c t a c a t t g t t 1 4 0 2 
004社l〇 • 346 c t c a q a t c t q t a t a t t c t g g a a - t t t a t a t c c a c a t c c a t a t g a c a t g t g g c c t t c t t t g 4 0 4 
• M M I I M I I M I m i l I I I I M M M M M I M I I I I I I I I I I I I M M M M I M 
M o u s e L - P B E ： 1401 c t c a g a t c t g t a t a t t c t g g a a t t t t a t a t c c a c a t c c a t a t g a c a t g t g g c c t t c t t t - 1 3 4 3 
0 0 4 ^ 1 0 . 4 0 5 q q c t q c c t c c t c t t a g t c a g a g c a a t g c t g c a a c a c a g a c a c c a t g g t g g c a t c a t g t t c 4 6 4 
• l l l l l l l l l M M l l l l l m i l M M I l i l l l l l M I ” AS 
M o u s e L - P B E ： 1 3 4 2 g g c t g c c t c c t c t t a g t c a g a g c a a t g c t g c a a c a c a - c g a c c a t g g t - g c a t c a t g t t c 丄^dab 
〇〇4#10 : 4 6 5 c g t c a c a c a g c t g a a a t g t g t g a c t t g t a t g t c c a 4 9 9 
i i i i i i i i i i i i i i m i i m i m m m m 
M o u s e L - P B E ： 1 2 8 4 c g t c a c a c a g c t g a a a t g t g t g a c t t g t a t g t c c a 1 2 5 0 Cl8.3b: Summary of sequence alignment of cDNA subclone 004#10 with mouse L-PBE 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning S e q u e n c ^  
Differential display pattern Size of insert 
p,agment 1 Subclone released by p Sequence homology E-value 牠^ent PPARa (+/+) PPARa (-/-) ^ o . EcoRl cut P r m e r (Transcript size) (% Identity) Fed Starved Fed Starved ^  
Mouse L-specific 
M l 3 forward multifunctional beta- e-164 
, + 0 0 4 # 1 0 900 .20 oxidation protein (L- 329/335 (98%) 
(850 bp) PBE) (3097 bp)  
363 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C19.1: DNA sequence of cDNA subclone Q05#13 using M13 forward -20 primer and the sequence of3，-AP9 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A T G C A T G C T C G A G C G G C C G C C A G T G 
6 1 T G A T G G A T A T CTGCAGAATT CGGCTTGTAA TACGACTCAC TATAGGGCTT TTTTTTTTTA AP9 
1 2 1 C A T G T C A T G T G A T T T T A A T A G G A A T T C T C C A A A T C A C T A A A G T G A A T A A T C A G A G T A C T C 
1 8 1 T A A A C A A A T A A G A C C G G G T T A A A G T C A G A A A A C T C C T T A G C T T C A C A A A A A A C G C C A A C C 
2 4 1 T G C A T T T C T A C A C A A C C A G C T C A G G A G T C A A A A G C A G A G A A C A A C C T C T C A G G A G C T G A G 
3 0 1 A A T T C T A C C A C A T T C T A A C A G T A G G G A C C A G A T G G C A A C A T G C T T C C C T G G A T T G C C A A A 
3 6 1 A C T G C T C T G G C T C C C C A A A G T T C A T G C T G A G T A G T T T T C C T G T G T C T T A A A T G A A A T T G G 
4 2 1 G A A A C A G A A A T N G A T G A A A T A A A A T G G A T T T T T T C A C A G T N T G G C C C A A A G T A G C A A A A A 
4 8 1 C T A T T C A T T T C T C T C T A C C T T T C T A T A T C A G T A T T A C T A C T T C A T A G A A A A G A T G A G G C A 
5 4 1 T A T G C C A G A A A G C A G G C A G A C A T N A A T T T T A A C T A T G A G A C A G A C A G G A N T A T C T A A N A N 
6 0 1 T C T C T T A T T T T G A G T C A A G T C C C T C C T C T G G C T G G T A C A G A T T N A G T G T T A A T T T C T N C A 
6 6 1 G C A T G T G A T T C T A N A C G T T N A N T C A T G A T G T C A T G T C C A C C 
C19.2: Sequence alignment of cDNA subclone 005#13 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
〇05#13 : 1 2 1 c a t g t c a t g t g a t t t t a a t a g g a a t t c t c c a a a t c a c t a a a g t g a a t a a t c a g a g t a c t c 1 80 
l l l l l l l l l l l l l l l l l l M M M M M M M M I I I 1 M i l l I I I I I 丨 I ^^^^ 
M o u s e C Y P 4 A 1 4 : 2 4 9 1 c a t g t c a t g g g a t t t t a a t g g g a a t t c t c c a a a t c a t t a a g g g g a a t a t t c - g a g t a a t t 
〇〇5#13 : 1 8 1 t - a a a c a a a t a a g a c c g g g t t a a a g t c a g a a a a c t c c t t a g c t t c a c a a a a a a c g c c a a c 2 3 9 
I i i i i m m f m m i i m iiiiiiii ii M M iiimiimimiii 
M o u s e C Y P 4 A 1 4 : 2 4 3 2 t t a a a c a a a t a a g a c c g g g t t a a a t t c a g a a a a t t c t t t a g g t t c a c a a a a a a c g c c a a c 2 3 7 3 
0 0 5 # 1 3 :240 c t g c a t t t c t a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 2 9 9 
l l l l l l l I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M M I M I M M l 
M o u s e C Y P 4 A 1 4 ：2372 t t g c a t t t t a a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 2 3丄」 
0 0 5 # 1 3 :300 g a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 3 5 9 
〒 | | | | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 丄 1 1 丄 厂 1 1 1 1 1 丄 山 丄 2 2 5 3 
M o u s e C Y P 4 A 1 4 : 2 3 1 2 g a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 
0 0 5 # 1 3 :360 a a c t g c t c t g g c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 4 1 9 
l l l l l l l l l l l M M M M M M M I I M M M l I M I I H I 
M o u s e C Y P 4 A 1 4 : 2 2 5 2 a a c t g c t c t g g c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 
0 0 5 # 1 3 :420 ggaaac:agaaatiigatgaaataaaatggat:ttttt:cacagtiit^gg〒〒〒aaag1^ag〒予aaa 4 7 9 
I IIIII IIII11 Ill lllllll 
M o u s e C Y P 4 A 1 4 : 2 1 9 2 g g a a a c a g a a a t t g a t g a a a t a a a a t g g a t t t t t t c a c a g t t t g g c c c a a a g t a g c a a a a 2 1 3 3 
0 0 5 # 1 3 :480 a c t a t t c a t t t c t c t c t a c c t t t c t a t a t c a g t a t t a c t a c t t c a t a g a a a a g a t g a g g c 5 3 9 
I i i i i i i i i i i i i i i i i i i i i i m I I I m i l l l l l l l l l l l l i i i i M i i I I I I I ？。73 
M o u s e C Y P 4 A 1 4 : 2 1 3 2 a c t a t t c a t t t c t c t c t a c c t t t c t g t a t c a g t a t t a c t a c t t c a t a g a a a a g a t g a g g c 2 0 7 3 
• 。 • : 5 4 。 丨 n m n m 而 〒 n i n r n m m m m 丨 丨 丨 m m T m m n 
M o u s e C Y P 4 A 1 4 : 2 0 7 2 a t a t g c c a g a a a g c a g g a a a a c a t t a a t t t t a a c t a t g a g a c a g a c a g a a a t a t c t a a a a 2 0 1 3 
0〇5#i3 ：600 n t c t c t t a t t t t g a g t c a a g - t c c c t c c t c t g g c t g g t a c 6 3 8 
i i i m m i i m i m i iii iiimm丄丨丨丄丨丨 ^ ^^^ 
M o u s e C Y P 4 A 1 4 ：2012 a t c t c t t a t t t t g a g t c a a g t t c c t t c c t c t g g c t g g t a c 1 9 7 3 C19.3: Summary of sequence alignment of cDNA subclone 005#13 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing  
Differential display pattern Size of insert 
» P P A R a (./.) P P A R a ( T T P 薩 ： ( « ) 
Fed Starved Fed Starved ^  
™ ；;~~7： M l 3 forward Mouse CYP4A14 0 
0〇5 ++ ++++ ++ ++ 005#13 560 + 200 _2o (2547 bp) 491/520 (94%) 
(720 bp) J    
364 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C20.1: DNA sequence of cDNA subclone 0 0 5 # 1 3 using M13 reverse primer and the sequence of 5,-ARP3 
1 GCCNAGCTTG NGTACCGAGC TCGGATCCAC TAGTAACGGC CGCCAGTGTG CTGGAATTCG 
6 1 G C T T A G C G G A TAACAATTTC ACACAGGAGA CCATTGCACT G A C A G A G G A A G A T A T A T T T T ARPS 
1 2 1 AGAGGGAGGC ACTTGTACCT TTCTCTCCCT TCAGTTATTA GACTCTTGGG ACAATGGACA 
1 8 1 TCATGAATTA AAACGTTCTT AGAAATCACA TGCTGGGAGA AAATTAACAC TAAAATCTGG 
2 4 1 TACCAGCCAG AGGAAGGAAC TTGACTCAAA ATAAGAGATT TTTAGATATT CCTGTCTGTC 
3 0 1 TCATAGTTAA AATTAATGTC TTCCTGCTTT CTGGCATATG CCTCATCTTT TCTATGAAGT 
3 6 1 AGTAATACTG ATATAGAAAG GTAGAGAGAA ATGAATAGTT TTTGCTACTT TGGGCCAAAC 
4 2 1 TGTGAAAAAA TNCATTTTAT NTCATCAATT TCTGTNTNNC AATTTCATNT AAGACACAGG 
4 8 1 AAAACTACTC AGCATGAACT TGGGNGAGCC AGAGCAGTTT GGGCANTCAG GGAAGCATGT 
5 4 1 TGCATCTGNT CCTACTGTAG ANTGTGTAGA NTCTCAGCTC TGAGAGTGTC TCTGCTTTGA 
6 0 1 CTCTGANCTG NTGTGTNNAA TGCAGGTGGC TTNNTGGTNA GCTANGANTN NTGACTNACC 
6 6 1 NGTNTATNGT AAANTACTGA TNTNNNTANN ATNGGG 
C20.2: Sequence alignment of cDNA subclone 0 0 5 # 1 3 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
0 〇 5 # 1 3 ： 9 0 a c c a t t q c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g g c a c t t g t a c c t t t c t c t c c c 1 4 9 
M M M I M M M M M M M M M I I I I I l l M M l l I 1 1 1 1 M l 111 I I M l 
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1 8 8 2 
〇 0 5 # 1 3 ： 1 5 0 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 2 0 9 
i i i i � i i i i i i � m i i i i i i l l l l l l l l I I I I I I m i l l l l l l l l l M i l l M l 
M o u s e C Y P 4 A 1 4 ：1883 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 
0 0 5 # 1 3 ： 2 1 0 a t q c t q q g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2 6 9 
i i � i m ? i � i i i i i i i m i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i川 u I I I 
M o u s e C Y P 4 A 1 4 ：1943 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a Z U 0 2 
〇〇5#13 :270 a a t a a g a g a t t t t t a g a t a t t c c t g t c t g t c t c a t a g t t a a a a t t a a t g t c t t c c t g c t t 3 2 9 
I I M I I I I M M M M I M M 111 M I 111 111 I M l 1 1 1 1 I N M 1 I M l I 
M o u s e C Y P 4 A 1 4 :2〇03 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 2 0 6 2 
005#13 -330 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a t a g a a a g g t a g a g a g a 389 
11IIIII ^^^^ 
M o u s e C Y P 4 A 1 4 : 2 0 6 3 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 2 1 2 2 
0 0 5 # 1 3 -.3 9 0 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t n c a t t t t a t n t c a t c a a t 4 4 9 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M l M l l l l l l l l l l 
M o u s e C Y P 4 A 1 4 : 2 1 2 3 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t 
0 0 5 # 1 3 :450 t t c t g t n t n n c a a t t t c a t n t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t g g g n g a g c 5 0 9 
l l l l l l I l l l l l l l l l M M M M M M I M M I I I M M M M I M I I M M ” � 
M o u s e C Y P 4 A 1 4 :2183 t t c t g t t t c c c a a t t t c a t t t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t t g g g g a g c 2 2 4 2 
0 0 5 # 1 3 ： 5 1 0 c a q a q c a q t t t g g g c a n t - c a g g g a a g c a t g t t g c 5 4 3 
M I M M M M M M I 1丨1丨丨1丨丨丨丨|丨丄尸I乃？？ 
M o u s e C Y P 4 A 1 4 ：2243 c a g a g c a g t t t t g g c a a t c c a g g g a a g c a t g t t g c 2 2 " C20.3: Summary of sequence alignment of cDNA subclone 0 0 5 # 1 3 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning ~ Sequencing  
Differential display pattern Size of insert 
p,agment Subclone released by p — S e q u e n c e homology E-value 
F r a ^ ^ n t p p A R a (+/+) PPARa (-/-) N o . ECORI cut Pnmer (Transcript size) (% Identity) 
Fed Starved Fed Starved W -
— 二 Mouse CYP4A14 0 ( 7二p ) ++ ++++ ++ ++ 0 0 5 # 1 3 560 + 200 M13 reverse (2547 bp) 440/455 (96%) 
365 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C21.1: DNA sequence of cDNA subclone 006#2 using M13 forward -20 primer and the sequence of 3,-AP9 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A N A T G C A T G C T C G G A G C G G C C G C C A T G 
6 1 TGATGGATAT CTGCAGAATT CGGCTTGTAA TACGACTCAC TATAGGGCTT TTTTTTTTTT AP9 
1 2 1 A C A T G T C A T G T G A T T T T A A T A G G A A T T C T C C A A A T C A C T A A A G T G A A T A A T C A G A G T A C T 
1 8 1 C T A A A C A A A T A A G A C C G G G T T A A A G T C A G A A A A C T C C T T A G C T T C A C A A A A A A C G C C A A C 
2 4 1 C T G C A T T T C T A C A C A A C C A G C T C A G G A G T C A A A A G C A G A G A A C A A C C T C T C A G G A G C T G A 
3 0 1 G A A T T C T A C C A C A T T C T A A C A G T A G G G A C C A G A T G G C A A C A T G C T T C C C T G G A T T G C C A A 
3 6 1 A A C T G C T C T G G C T C C C C A A A G T T C A T G C T G A G T A G T T T T C C T G T G T C T T A A A T G A A A T T G 
4 2 1 G G A A A C A G A A A T N G A T G A A A T A A A A T G G A T T T T T T C A C A G T T T G G C C C A A A G T A G C A A A A 
4 8 1 A C T A T T C A T T T C T C T C T A C C T T T C T G T A T C A G T A T T A C T A C T N C A T A G A A N A G A T G A G G C 
5 4 1 A T A T G C C A G A A A G C A G G A A A N C A T N A N T T T N A A C T A T G A G A C A G A C A G A A A T A T C T A A N A 
6 0 1 N N T C T N A T T N G G A G T C A G T C C C T C C N C T G G C T G T A C A G A T T T A G T G T A N T T T C T C C A G C A 
6 6 1 T G T G A T T C T A N A C G T T T A A T C A T G A T T C A T G T C N A A N T N A T A C N A N G G G 
C21.2: Sequence alignment of cDNA subclone 006#2 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇6#2 ：122 c a t q t c a t q t q a t t t t a a t a g g a a t t c t c c a a a t c a c t a a a g t g a a t a a t c a g a g t a c t c 181 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l I I I I I I I M I I I I I M I 
M o u s e C Y P 4 A 1 4 ：2491 c a t g t c a t g g g a t t t t a a t g g g a a t t c t c c a a a t c a t t a a g g g g a a t a t t c - g a g t a a t t 2433 
0〇6#2 ：182 t - a a a c a a a t a a g a c c g g g t t a a a g t c a g a a a a c t c c t t a g c t t c a c a a a a a a c g c c a a c 240 I i m i i i i m i i i i i i i i i i i i i i i i i i i I I M M i i i i i i i i i i i i i i i i i i 
M o u s e C Y P 4 A 1 4 ： 2 4 3 2 t t a a a c a a a t a a g a c c g g g t t a a a t t c a g a a a a t t c t t t a g g t t c a c a a a a a a c g c c a a c 2373 
0〇6#2 ：241 c t q c a t t t c t a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 300 
l l l l l l l M M M M M M M M M M M M M M M M M M M M M M M M M 
M o u s e C Y P 4 A 1 4 ： 2 3 7 2 t t g c a t t t t a a c a c a a c c a g c t c a g g a g t c a a a a g c a g a g a a c a a c c t c t c a g g a g c t g a 2313 
〇〇6tt2 ： 3 0 1 q a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 360 
M M M I M M M M M M M M M M M M M M M M M I M M M M M M M M I I 
M o u s e C Y P 4 A 1 4 ：2312 g a a t t c t a c c a c a t t c t a a c a g t a g g g a c c a g a t g g c a a c a t g c t t c c c t g g a t t g c c a a 2253 
〇〇6tt2 ：361 a a c t g c t c t q g c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 420 
llllllllllll llllllllllllllllmilmiiiimmmm 
M o u s e C Y P 4 A 1 4 ： 2252 a a c t g c t c t g g c t c c c c a a a g t t c a t g c t g a g t a g t t t t c c t g t g t c t t a a a t g a a a t t g 2193 
〇〇6tt2 ：421 q q a a a c a g a a a t n q a t g a a a t a a a a t g g a t t t t t t c a c a g t t t g g c c c a a a g t a g c a a a a 480 
？〒iiiiiimi    
M o u s e C Y P 4 A 1 4 ：2192 g g a a a c a g a a a t t g a t g a a a t a a a a t g g a t t t t t t c a c a g t t t g g c c c a a a g t a g c a a a a 2133 
〇〇6#2 ：481 a c t a t t c a t t t c t c t c t a c c t t t c t g t a t c a g t a t t a c t a c t n c a t a g a a n a g a t g a g g c 540 
l l l l l l l l l l l l l I I I I I I I I I I I I I m i i i m i m i l I i m m i m i i m � � ” 
M o u s e C Y P 4 A 1 4 ：2132 a c t a t t c a t t t c t c t c t a c c t t t c t g t a t c a g t a t t a c t a c t t c a t a g a a a a g a t g a g g c 2 0 7 3 
.〇〇6tt2 ：541 a t a t g c c a g a a a q c a q g a a a n c a t n a n t t t n a a c t a t g a g a c a g a c a g a a a t a t c t a a 598 
I I I l l l l l l l I I i m i M i l l 
M o u s e C Y P 4 A 1 4 ：2072 a t a t g c c a g a a a g c a g g a a a a c a t t a a t t t t a a c t a t g a g a c a g a c a g a a a t a t c t a a 2015 C21.3: Summary of sequence alignment of cDNA subclone 006#2 with mouse CYP4A14 
FluoroDD gel 00 (AP9 + ARP3) Subcloning Sequencing .一 Differential display pattern Size of insert 
Fragment ^ , , 、~ Subclone released by p Sequence homology E-value 
X PPARa (+/+) P P A R a (-/-) ^o. EcoRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
006 M l 3 forward Mouse CYP4A14~ 0 
( : ; 、 - 。06#2 550+ 190 _20 454/478 (94%) 
366 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C22.1: DNA sequence of cDNA subclone 006#8 using M13 forward -20 primer and the sequence of 5，-ARP3 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G N A G C G G C C G C C A T 
6 1 G T G A T G G A T A T C T G C A G A A T T C G G C T T A G C GGATAACAAT TTCACACAGG AGACCATTGC ARP3 
1 2 1 A C T G A C A G A G G A A G A T A T A T T T T A G A G G G A G A C A C T T G T A C C T T T C T C T C C C T T C A G T T A 
1 8 1 T T A G A C T C T T G G G A C A A T G G A C A T C A T G A A T T A A A A C G T T C T T A G A A A T C A C A T G C T G G G 
2 4 1 A G A A A A T T A A C A C T A A A A T C T G G T A C C A G C C A G A G G A A G G A A C T T G A T T C A A A A T A A G A G 
3 0 1 A T T T T T A G A T A T T T C T G T C T G T C T C A T A G T T A A A A T T A A T G T T T T C C T G C T T T C T G G C A T 
3 6 1 A T G C C T C A T C T T T T C T A T G A A G T A G T A A T A C T G A T A C A G A A A G G T A G A G A G A A A T G A A T A 
4 2 1 G T T T T T G C T A C G A A T T C C A G C A C A C T G G C G G C C G T T A C T A G T G G A T C C G A G C T C G G T A C C 
4 8 1 A A G C T T G G C G T A A T C A T G G T C A T A G C T G T T T C C T G T G T G A A A T N G T N A T C C G C T C A C A A T 
5 4 1 T C C A C A C N A C A T A C G A G C C G G A N G C A T A A A G T G T A A G C N N G G G N G C C T A T G A G T G A G C T A 
6 0 1 C T A C A T N A N T G C G T G C N C T A C T G C C G C N T T C A G T N G G N A A C N G T C T G C A N C N C A T A N G A T 
6 6 1 N G C A C G C C N N G A A N N G 
C22.2: Sequence alignment of cDNA subclone Q06#8 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇6ft8 ：113 a c c a t t q c a c t g a c a q a g g a a q a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 172 
M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M 
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1882 
〇〇6ft8 ：173 t t c a q t t a t t a q a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 232 
l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l i 
M o u s e C Y P 4 A 1 4 ：1883 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 1942 
〇〇6ft8 ：233 a t g c t g g q a q a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a t t c a a 292 
I I 丫 m i i m i i i m i i i i i i i i i i i i i m i i i m i i i m m m i i i i MM 
M o u s e C Y P 4 A 1 4 ：1943 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2002 
〇〇6tt8 ：293 a a t a a q a g a t t t t t a q a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 352 
M M M M M M I M M M M M M M M M M M M M M M M M M M I M M M I I 
M o u s e C Y P 4 A 1 4 ： 2003 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 2062 
0〇6#8 ：353 t c t q q c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 412 
llllllllllllllllllllllllllllllllllllllllllllllllllllllllllll 
M o u s e C Y P 4 A 1 4 ： 2063 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 2122 
〇〇6#8 ：413 a a t g a a t a g t t t t t g c t a c 4 3 1 i imiiiiimiiim M o u s e C Y P 4 A 1 4 ：2123 a a t g a a t a g t t t t t g c t a c 2 1 4 1 
C22.3: Summary of sequence alignment of cDNA subclone Q06#8 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment ~ Subclone released by ^ Sequence homology E-value 
X PPARa (+/+) PPARa (-/-) ^ 0 . EcoRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
“ ~ M13 forward Mouse C Y P 4 A 1 4 ~ e-176 
( 7 = p �- 006#8 390 .20 (2547 bp) 318/319(99%) 
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C23.1: DNA sequence of cDNA subclone 006#10 using M13 reverse primer and the sequence of 5,-ARP3 
1 T G C C A G C T T G G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A T T C G G C 
6 1 T T A G C G G A T A ACAATTTCAC ACAGGAGACC ATTGCACTGA C A G A G G A A G A T A T A T T T T A G ARP3 
1 2 1 A G G G A G A C A C T T G T A C C T T T C T C T C C C T T C A G T T A T T A G A C T C T T G G G A C A A T G G A C A T C 
1 8 1 A T G A A T T A A A A C G T T C T T A G A A A T C A C A T G C T G G G A G A A A A T T A A C A C T A A A A T C T G G T A 
2 4 1 C C A G C C A G A G G A A G G A A C T T G A C T C A A A A T A A G A G A T T T T T A G A T A T C T C T G T C T G T C T C 
3 0 1 A T A G T T A A A A T T A A T G T N A T A A N A G C T A C C C C G N C A T A T G C C C C C C C C C C A A A A A T A T A G 
3 6 1 A N N G T T A A G T T A A T T A A C T N G A N T A A C A A G A A A A A A G N G G T N A N G A A A G A A A G A A A A A A A 
4 2 1 T N G A A A A T T T A A G T T N N T T T T T T N N G N C C T A A A C T T T T T T T G G G G G G N C C C N A A A A A N C N 
4 8 1 T N G N T N G N A A A A A A A A A A T T C C C N A T T T T T T T N A N T N N T C C A A T T C A A A N T T T T C N T G G T 
5 4 1 T T T N C C C N N A N T T T T C A A T T T T A N N N A C N N A A A N G A A A N A A C T A C N N C A N G C N A N N N N N A 
6 0 1 N N T T T N G G G G G N A G N C C A A N A A G C C A N G N C N T T T T G G G G C A A A N T N N C C A A G G G G G A 
C23.2: Sequence alignment of cDNA subclone 006#10 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇6#10 :88 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 147 
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1882 
〇〇6ttl0 :148 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 207 M M I M I M I I M M M M M M M M M M M M M M M M M M M I I  
M o u s e C Y P 4 A 1 4 ：1883 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 1942 
〇〇6ttl0 :208 a t q c t q g q a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 267 
M I M I I I I I M M M M M M M I M M M I I I I I I M i l M M I I I  
M o u s e C Y P 4 A 1 4 ：1943 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2002 
〇〇6ftl0 :268 a a t a a q a g a t t t t t a g a t a t c t c t g t c t g t c t c a t a g t t a a a a t t a a t g t 317 
l l l l l l l l l l l l l l l l l l l l M M M M M M M M M M M I M M M 
M o u s e C Y P 4 A 1 4 ： 2 0 0 3 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t 2052 C23.3: Summary of sequence alignment of cDNA subclone 006#10 with mouse CYP4A14 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing 
Differential display pattern Size of insert 
Fragment Subclone released by „ . Sequence homology E-value 
l ^ r P P A R a (+/+) P P A R a (-/-) ^ o . £coRI cut Pr霞 r (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
^ r ^ Mouse CYP4A14 e ^ 
( 7 = p ) - + - - 006#10 5 5 0 + 190 M l 3 reverse ^2547 bp) 229/230 (99%) 
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C24.1: DNA sequence of cDNA subclone 007#6 using M13 reverse primer and the sequence of 5，-ARP3 
sequence 
1 G C N N A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G 
6 1 G C T T A G C G G A TAACAATTTC ACACAGGAGA CCATTGCAGC A C G C T G T C C A G C T G G G T G C T ARP3 
1 2 1 G C T G A T G G A T T A T G C A G G C A A T G C C A C T G C T G T C T T C C T T C T G C C C G A T G A T G G G A A G A T 
1 8 1 G C A G C A T C T G G A G C A A A C T C T C A G C A A G G A G C T C A T C T C T A A G T T C C T G C T A A A C A G G C G 
2 4 1 C A G A A G G T T A G C C C A G A T C C A C T T C C C C A G A C T G T C C A T C T C T G G A G A A T A T A A C T T G A A 
3 0 1 G A C A C T C A T G A G T C C A C T G G G C A T C A C C C G A A T C T T C A A C A A T G G G G C T G A C C T C T C C G G 
3 6 1 A A T C A C A G A G G A G A A T G C T C C C C T G A A G C T C A G C C A G G C T G T G C A T A A G G C T G T G C T G A C 
4 2 1 C A T C G A T G A G A C A G G A A C A G A A G C T G C A G C A G T C A C A G T C T T A C T A G C C G T N C C T T A T T C 
4 8 1 T A T G C C C C C T A T C C T G C G C T T C G A C C A C C C T T T C C T T T N A T A A T A T N T G A A G A N C A C A C T 
5 4 1 C A G A G C C C C T C T T T G T G G N A A A G T G N A G A T C C A C A C A T A A T G A C A C C T A G A T G T C A T C C T 
6 0 1 C N T C T G A N T G G T N C T N C A T N A A C C A G G C T G N C T N C T G T G C T G A T C T C N G T A A N N A N N A G C 
6 6 1 N N T N T A T G A T A C A A A 
C24.2: Sequence alignment of cDNA subclone 007#6 with mouse Spil-3 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇7tt6 ：90 a c c a t t q c a q c a c g c t g t c c a g c t g g g t g c t g c t g a t g g a t t a t g c a g g c a a t g c c a c t g 149 
mmtiiiiiiiiiiimiiiiiiiiiiiiiiiiiiimimiiiiiiiiimi 
M o u s e S p i l - 3 ：776 a c c a t t g c a g c a c g c t g t c c a g c t g g g t g c t g c t g a t g g a t t a t g c a g g c a a t g c c a c t g 835 
〇〇7tt6 ：150 c t q t c t t c c t t c t q c c c g a t g a t g g g a a g a t g c a g c a t c t g g a g c a a a c t c t c a g c a a g g 209 
M I I M M I I l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l I  
M o u s e S p i l - 3 ：836 c t g t c t t c c t c c t g c c c g a t g a t g g g a a g a t g c a g c a t c t g g a g c a a a c t c t c a g c a a g g 895 
〇07#6 ：210 a q c t c a t c t c t a a g t t c c t g c t a a a c a g g c g c a g a a g g t t a g c c c a g a t c c a c t t c c c c a 269 
I I I I M M M l l l l l l l l l l l l l l l l l l M M M M M M M M M M M I M M M 
M o u s e S p i l - 3 ：896 a g c t c a t c t c c a a g t t c c t g c t a a a g a g g c c c a g a a g g t t a g c c c a g a t c c a c t t c c c c a 955 
〇〇7#6 ：270 q a c t q t c c a t c t c t q q a q a a t a t a a c t t g a a g a c a c t c a t g a g t c c a c t g g g c a t c a c c c 329 
I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
M o u s e S p i l - 3 ：956 g a c t g t c c a t c t c t g g a g a a t a t a a c t t g a a g a c a c t c a t g a g t c c a c t g g g c a t c a c c c 1015 
〇〇7#6 ：330 q a a t c t t c a a c a a t g g g g c t g a c c t c t c c g g a a t c a c a g a g g a g a a t g c t c c c c t g a a g c 389 
I m i 
M o u s e S p i l - 3 ：1016 g g a t c t t c a a c a a t g g g g c t g a c c t c t c c g g a a t c a c a g a g g a g a a t g c t c c c c t g a a g c 1075 
〇〇7:tt6 ： 390 t c a q c c a g g c t g t g c a t a a g g c t g t g c t g a c c a t c g a t g a g a c a g g a a c a g a a g c t g c a g 449 
M I I M I I I M M M M M I M I I M M M 1 …口 
M o u s e S p i l - 3 ：1076 t c a g c c a g g c t g t g c a t a a g g c t g t g c t g a c c a t g g a t g a g a c a g g a a c a g a a g c t g c a g 1135 
〇〇7#6 :45〇 c a q t c a c a g t c t t a c t a g c c q t n c c t t a t t c t a t g c c c c c t a t c c t g c g c t t c g a c c a c c 509 
I I I l l l l l l l l l l l l l l l l l 111 M l I N I , , , , 
M o u s e S p i l - 3 ：1136 c a g c t a c a g t c t t a c t a g c c g t t c c t t a t t c t a t g c c c c c t a t c g t g c g c t t c g a t c a c c 1195 
0 0 7 # 6 ：510 c t t t c c - t t t n a t a a t a t n t g a a g a n c a c a c t c a g a g - c c c c t c t t t g t g g n a a a 562 
m m III iiiim m m ，，⑶ 
M o u s e S p i l - 3 ：1196 c t t t c c t t t t c a t a a t a t t t g a a g a a c a c a c t c a g a g c c c c c t c t t t g t g g g a a a 1250 C24.3: Summary of sequence alignment of cDNA subclone 007#6 with mouse Spil-3 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing _ 
Differential display pattern Size of insert 
Fragment T T T ~ Subclone released by p Sequence homology E-value 
^ ^ P P A R a (+/+) P P A R a (-/-) ^ o . 份oRI cut P ^ e r (Transcript size) (% Identity) Fed Starved Fed Starved ^  
Mouse serine n m � protease inhibitor 1-3 0 二U/ + - + + 007#6 680 M13 reverse 彻丨1-3) 458/475 (96%) 
(635 bp) (1366 bp)  
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C25.1: DNA sequence of cDNA subclone 007#10 using M13 forward -20 primer and the sequence of 3,-AP9 
1 T T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G N A G C G G C C G C C A 
6 1 T G T G A T G G A T ATCTGCAGAA T T C G G C T T G T AATACGACTC ACTATAGGGC TTTTTTTTTT AP9 
1 2 1 T T A C T G T A G C A T C A G G C A C G A G C C A G G C C A G C C T G T G T T T A A T G G A A G G A A C C C A A T T C A 
1 8 1 G A A G G A A G G A T G A C A T T T T A G G G T G G T C A T T T A T G N T G T G G G A T C T A C C A C T T T T C C C A C 
2 4 1 A A A G A T G G G G C T C T G A G T G T G T T C T T C A A A T A T T A T G A A A A G G A A A G G G T G G T C G A A G C G 
3 0 1 C A G G A T A G G G G G C A T A G A C G T A G G A A C C A T T T G T A A G A C T G T A A C T G C T G C A G C T T C T A T 
3 6 1 T C C T G T C T C A T C G A T G G T C A G C A C A G C C T T A T G C A C A G C C T G G C T G A G C T T C A G G G G A G C 
4 2 1 A T T C T C C T C T G T G A T N C C G G A G A G G T C A G C C C C A T T G T T G A A G A N N C G G G T G A T G N N A G T 
4 8 1 G G A C T C A T G A G T G T C T T C A A G T T A T A T T C T C C A G A N A T N G A C A G T C T G G G G N A N G T N G G A 
5 4 1 T C T G G G N C T N A C C C T T C T G C N N N C N G N T N T A G C C A G G N A N C N T N A N A G A A T G A G C C T C C N 
6 0 1 T N A C T G N A G A G T T N N G C T C C A G A T G C T G C A T T T T C C C A T T N T C N N N N N N A G G N A N N C G C A 
6 6 1 G T N N N T N G N N G A T A N T C C T C G C G C N N C N G N N N N N N G N T C T G C A N G G 
C25.2: Sequence alignment of cDNA subclone Q07#10 with mouse Spil-3 by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇7#10 :124 c t g t a g c a t c a g g c a c g a g c c a g g c c a g c c t g t g t t t a a t g g a a g g a a c c c a a t t c a g a a 183 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l i l 
M o u s e S p i l - 3 ：1358 c t g t a g c a t c a g g c a c g a g c c a g g c c a g c c t g t g t t t a a t g g a a g g a a c c c a a t t c a g a a 1299 
〇〇7#1〇 ： 1 8 4 g g a a g g a t g a c a t t t t a g g g t g g t c a t t t a t g n t g t g g g a t c t a c c a c t t t t c c c a c a a a 2 4 3 i i i m i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i 
M o u s e S p i l - 3 ：1298 g g a a g g a t g a c a t c t t a g g g t g g t c a t t t a t g - t g t g g g a t c t a c c a c t t t t c c c a c a a a 1240 
〇〇7ttlO :244 g a t g g g g c t c t g a g t g t g t t c t t c a a a t a t t a t g a a a a g g a a a g g g t g g t c g a a g c g c a g 303 I I i m i i i i m i m i i i i m i i m i i i i i i i i i i m m i i I I I I I I I I I I 
M o u s e S p i l - 3 ：1239 g a g g g g g c t c t g a g t g t g t t c t t c a a a t a t t a t g a a a a g g a a a g g g t g a t c g a a g c g c a c 1180 
〇〇7ftl0 :304 g a t a g g g g g c a t a g a c g t a g g a a c c a t t t g t a a g a c t g t a a c t g c t g c a g c t t c t a t t c c 363 l l l l l m i m i 11 I l l l l l I i i i i i i i i i i i i i i i i i i i i i i i i i M M 
M o u s e S p i l - 3 ：1179 g a t a g g g g g c a t a g a a t a a g g a a c g g c t a g t a a g a c t g t a g c t g c t g c a g c t t c t g t t c c 1120 
〇〇7#10 :364 t q t c t c a t c g a t g g t c a g c a c a g c c t t a t g c a c a g c c t g g c t g a g c t t c a g g g g a g c a t t 423 
i m i i m iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 
M o u s e S p i l - 3 ：1119 t g t c t c a t c c a t g g t c a g c a c a g c c t t a t g c a c a g c c t g g c t g a g c t t c a g g g g a g c a t t 1060 
〇〇7#10 :424 c t c c t c t g t g a t n c c g g a g a g g t c a g c c c c a t t g t t g a a g a n n c g g g t g a t g - n n a g t g g 482 
I M M I M M M M M M M M M M M M M M M M M l l l l l l l l l M i l l 
M o u s e S p i l - 3 ：1059 c t c c t c t g t g a t t c c g g a g a g g t c a g c c c c a t t g t t g a a g a t c c g g g t g a t g c c c a g t g g 1000 
〇〇7#10 :483 a c t c a t g a g t g t c t t c a a g t t a t a t t c t c c a g a n a t n g a c a g t c t g g g g 5 3 1 
i i i m m i i i m m i i i i i i m m m ii iiiiiiiiiiii 
M o u s e S p i l - 3 ：999 a c t c a t g a g t g t c t t c a a g t t a t a t t c t c c a g a g a t g g a c a g t c t g g g g 9 5 1 0 C25.3: Summary of sequence alignment of cDNA subclone Q07#10 with mouse Spil-3 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing 
Differential display pattern Size of insert 
Fraement ： ~ Subclone released by p Sequence homology E-value 
^ ^ PPARa (+/+) PPARa (-/-) ^ o . EcoRl cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Mouse serine 
n n 7 M l 3 forward protease inhibitor 1-3 e-177 
+ _ + + 007#10 680 .20 (Spil-3) 386/409 (95%) 
� PJ (1366 bp)  
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C26.1: DNA sequence of cDNA subclone 008#10 using M13 forward -20 primer and the sequence of 5，-ARP3 
1 T T A N C A C T C A C T A T A G G G C G A A T T G G G C C C T C T T A G A A T G C A T G C T C G N A G C G G C C G C C A 
6 1 G T G T G A T G G A TATCTGCAGA ATTCGGCTTA G C G G A T A A C A ATTTCACACA GGAGACCATT ARP3 
1 2 1 G C A G C C G C T C T A G T G G C T A A A G A C A G A A G T C C T G G G C A G C G G G T C A T C T G T G T G G A A G G T 
1 8 1 G A C A G T G C C T T C G G A T T T T C T G G C A T G G A A G T G G A G A C C A T C T G C A G G T A C A A C T T G C C A 
2 4 1 A T C A T A C T C T T G G T A G T A A A C A A T A A T G G A A T T T A C C A A G G T T T T G A C G C T G A C A C C T G G 
3 0 1 G A A A A A A T G C T A C A T T T T C A A G A A G C T G C T A C A A C T G T C C C T C C T A A T G T G C C T C T T G C C 
3 6 1 A A A C T C G C A T T A T G A G C A G G T C A T G A C C G C A T T T G G A G G C A A A G G G T A T T T T G T A C G A A C 
4 2 1 A C C A G A A G A G C T C C A A C A C T C G C T G A G G C A G G C T C T G C A A G A C A C A A G T A A A C C C T G C C T 
4 8 1 T C T C A A C A T T A T G A T T G A G C C A C A A A G T A C G C G C A A G G C C C A G G A T N T T C A C T G G C T C A C 
5 4 1 C C G T N C T A A C A T G T G A A T A A A C T A C T N G A T G G T N A T G A G G A A T T T C T C T N T C C G C A G G T A 
6 0 1 G A N N N A C N N N C A T A G C A A A T N A C A T A G T G C T A A A T C G T A T N N A A A A N A C A C N T T A A N N G T 
6 6 1 A T T N N A T N G T A A A A A A A N A A G C N N T A T N N N G A G T N G N N T N A C N A G C N N N 
C26.2: Sequence alignment of cDNA subclone 008#10 with mouse Hpcl by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇8ttl0 : 116 c c a t t q c a g c c g c t c t a g t g g c t a a a g a c a g a a g t c c t g g g c a g c g g g t c a t c t g t g t g g 1 7 5 
M M I I M M M M M M M M M M M M M M l l l l l I I I I    
M o u s e ：1392 c c a t t g c a g c c g c t c t a g t g g c t a a a g a c a g a a g t c c t g g g c a g c g g g t c a t c t g t g t g g 1 4 5 1 
H p c l - p e n d i n g 
〇〇8ttio : 1 7 6 a a g g t g a c a g t g c c t t c g g a t t t t c t g g c a t g g a a g t g g a g a c c a t c t g c a g g t a c a a c t 2 3 5 M M M ， … 
M o u s e ：1452 a a g g t g a c a g t g c c t t c g g a t t t t c t g g c a t g g a a g t g g a g a c c a t c t g c a g g t a c a a c t 1 5 1 1 
H p c l - p e n d i n g 
〇〇8ftl〇 ：236 t q c c a a t c a t a c t c t t g g t a g t a a a c a a t a a t g g a a t t t a c c a a g g t t t t g a c g c t g a c a 2 9 5 
iTiiiimiiiimiiiiiiiiiiiiiiiimimimmmiiiiiimii ⑶ 
M o u s e ：1512 t g c c a a t c a t a c t c t t g g t a g t a a a c a a t a a t g g a a t t t a c c a a g g t t t t g a c g c t g a c a 1 5 7 1 
H p c l - p e n d i n g 
O O 8 # 1 0 :296 c c t q q g a a a a a a t g c t a c a t t t t c a a g a a g c t g c t a c a a c t g t c c c t c c t a a t g t g c c t c 3 5 5 
M I I I I M M M I I M I M M M I I I I M I M l i l l I I I I I I I I I M M I I M 
M o u s e ：1572 c c t g g g a a a a a a t g c t a c a t t t t c a a g a a g c t g c t a c a a c t g t c c c t c c - a a t g t g c c t c 1 6 3 0 
H p c l - p e n d i n g 
O O 8 # 1 0 ：356 t t q c c a a a c t c g c a t t a t g a g c a g g t c a t g a c c g c a t t t g g a g g c a a a g g g t a t t t t g t a 4 1 5 
l l l l l l l l l l l l l l l l i l l M M M I I I I M I l l l l l M M M M M M I M 
M o u s e ：1631 t t g c c a a a c t c g c a t t a t g a g c a g g t c a t g a c t g c a t t t g g a g g c a a a g g g t a t t t t g t a 1 6 ^ 0 
H p c l - p e n d i n g 
〇08ttio :416 c g a a c a c c a g a a g a g c t c c a a c a c t c g c t g a g g c a g g c t c t g c a a g a c a c a a g t a a a c c c 4 7 5 I I M M M M M M M M M M M M M M M M I，？^ 
M o u s e ： 1 6 9 1 c g a a c a c c a g a a g a g c t c c a a c a c t c g c t g a g g c a g g c t c t g c a a g a c a c a a g t a a a c c c 丄/bu 
H p c l - p e n d i n g 
O O 8 # 1 0 :476 t g c c t t c t c a a c a t t a t g a t t g a g c c a c a a a g t a c g c g c a a g g c c c a g g a t n t t c a c t g g 5 3 5 
I i l l M l 11 
M o u s e ：1751 t g c c t t c t c a a c a t t a t g a t t g a g c c a c a a a g t a c g c g c a a g g c c c a g g a t t t t c a c t g g 1 8 1 0 
H p c l - p e n d i n g 
oosttlO . 536 c t c a c c c q t n c t a a c a t g t g a a t a a a c t a c t n g a t g g t n a t g a g g a a t t t 5 8 5 
i i m i i i i M I 
M o u s e ：1811 c t c a c c c g t t c t a a c a t g t g a a t a a a c t a c t t g a t g g t t a t g a g g a a t t t 1 8 6 0 
H p c l - p e n d i n g 
C26.3: Summary of sequence alignment of cDNA subclone 008#10 with mouse Hpcl 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning 一 Sequencing  
Differential display pattern Size of insert Praement " ~ Subclone released by p^- ^^ Sequence homology E-value hra葛 p p A R a (+/+) P P A R a (-/-) ^ o . £coRI cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
Mouse 
A / i n f H 2-hydroxyphytanoyl- q 
0 0 8 - + - - 0 0 8 # 1 0 680 M m o r w a r d CoA lyase 464/470 (98%) 
(615 bp) -川 (Hpcl-pending) ^ (1982 bp)  
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C27.1: DNA sequence of cDNA subclone 009#6 using M13 forward -20 primer and the sequence of 3,-AP9 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A T G C A T G C T C G A A G C G G C C G C C A G T 
6 1 G T G A T G G A T A T C T G C A G A A T T C G G C T T A G C G G A T A A C A A T T T C A C A C A G N N N N C C A T T G C 
1 2 1 A G G T A C A A C T T G C C A A T C A T A C T C T T G G T A G T A A A C A A T A A T G G A A T T T A C C A A G G T T T T 
1 8 1 G A C G C T G A C A C C T G G G A A A A A A T G C T A C A T T T T C A A G A A G C T G C T A C A A C T G T C C C T C C A 
2 4 1 A T G T G C C T C T T G C C A A A C T C G C A T T A T G A G C A G G T C A T G A C T G C A T T T G G A G G C A A A G G G 
3 0 1 T A T T T T G T A C G A A C A C C A G A A G A G C T C C A A C A C T C G C T G A G G C A G G C T C T G C A A G A C A C A 
3 6 1 A G T A A A C C C T G C C T T C T C A A C A T T A T G A T T G A G C C A C A A A G T A C G C G C A A G G C C C A G G A T 
4 2 1 T T T C A C T G G C T C A C C C G T T C T A A C A T G T G A A T A A A C T A C T T G A T G G T T A T G A G G A A T T T T 
4 8 1 C T C T T C C C C G C A A G G T A G A A T N T A C T T T T C A T A G C A A A A T N A N C A T A G T G C T A A A N T G G T 
5 4 1 A T T T T A A A A T A C A C T N T A A N T G G T A T T T N A T A G T A A A A A A AAAAGCCCTA TAGTGAGTGT A P 9 
6 0 1 A T A T C A N G C N G N N N C A N C A C A C T G G N G N C N G T A C T A N N G N A T C N A G C T C N N T A N C 腿 G C N 
6 6 1 N N N N G T A T N C N T N N N N N A N C G G N T N T C N N G G N T G A N N 
C27.2: Sequence alignment of cDNA subclone OQ9#6 with mouse Hpcl by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇9tt6 ： 1 1 8 t q c a q q t a c a a c t t q c c a a t c a t a c t c t t g g t a g t a a a c a a t a a t g g a a t t t a c c a a g g t 1 7 7 
I I M I I M M M M M M M M I M M M l l l l l l l I I I I M I I I M M M I I I l l l l l l 
M o u s e ：1499 t g c a g g t a c a a c t t g c c a a t c a t a c t c t t g g t a g t a a a c a a t a a t g g a a t t t a c c a a g g t 1 5 5 8 
H p c l - p e n d i n g 
〇〇9tt6 ：178 t t t q a c q c t q a c a c c t q g g a a a a a a t g c t a c a t t t t c a a g a a g c t g c t a c a a c t g t c c c t 2 3 7 
M I I M I M I M M I M I M M M M I M I I M M I M l l l l ^ � 
M o u s e ：1559 t t t g a c g c t g a c a c c t g g g a a a a a a t g c t a c a t t t t c a a g a a g c t g c t a c a a c t g t c c c t 1 6 1 8 
H p c l - p e n d i n g 
0 0 9 # 6 .238 c c a a t q t q c c t c t t q c c a a a c t c g c a t t a t g a g c a g g t c a t g a c t g c a t t t g g a g g c a a a 2 9 7 
IIIII �。 
M o u s e ：1619 c c a a t g t g c c t c t t g c c a a a c t c g c a t t a t g a g c a g g t c a t g a c t g c a t t t g g a g g c a a a 1 6 7 8 
H p c l - p e n d i n g 
〇〇9tt6 ：298 q q q t a t t t t q t a c q a a c a c c a g a a g a g c t c c a a c a c t c g c t g a g g c a g g c t c t g c a a g a c 3 5 7 
I I I I I I I I I I I I I I   Mouse ：1679 g g g t a t t t t g t a c g a a c a c c a g a a g a g c t c c a a c a c t c g c t g a g g c a g g c t c t g c a a g a c 
H p c l - p e n d i n g 
〇〇9#6 ：358 a c a a g t a a a c c c t g c c t t c t c a a c a t t a t g a t t g a g c c a c a a a g t a c g c g c a a g g c c c a g 4 1 7 
M M I M M I M M M M M I M M M M M M M I M I I I I I ^ 彻 
M o u s e ：1739 a c a a g t a a a c c c t g c c t t c t c a a c a t t a t g a t t g a g c c a c a a a g t a c g c g c a a g g c c c a g 1 7 9 8 
H p c l - p e n d i n g 
0 0 9 # 6 :418 q a t t t t c a c t q g c t c a c c c g t t c t a a c a t g t g a a t a a a c t a c t t g a t g g t t a t g a g g a a t 4 7 7 
m m 
M o u s e ：1799 g a t t t t c a c t g g c t c a c c c g t t c t a a c a t g t g a a t a a a c t a c t t g a t g g t t a t g a g g a a t 1 8 5 8 
H p c l - p e n d i n g 
009社6 - 478 t t t c t c t t c c c c q c a a g g t a q a a t n t a c t t t t c a t a g c a a a a t n a n c a t a g t g c t a a a n t 5 3 7 
• I I I I I I I I L L L L L L L L L I I I I I 1 L L L L L L L L L I M M M M M 
M o u s e ： 1 8 5 9 t t t c t c t t t c c c g c a a g g t a g a a t t t a c t t t t c a t a g c a a a a t t a c c a t a g t g c t a a a a t 1 9 1 8 
H p c l - p e n d i n g 
0〇9#6 ：538 q q t a t t t t a a a a t a c a c t n t a a n t g g t a t t t n a t a g t 5 7 4 
l l l l l l l l i l l l l l l l M l I M M M M i l l 。 ； ； 
M o u s e ：1919 t g t a t t t a a a a a t a c a c t t t a a a t t g t a t t t t a t a g t 1 9 5 5 
H p c l - p e n d i n g 
C27.3: Summary of sequence alignment of cDNA subclone Q09#6 with mouse Hpcl 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment 77：~ Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) ^ 0 . EcoRl cut P rmer (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
— Mouse 
2-hydroxyphytanoyl- • 
0 0 9 + ++ + + 0 0 9 # 6 560 M l 3 forward CoA lyase 446/457 (97%) 
(510 bp) - � (Hpcl-pending) � (1982 bp)  
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C28.1: DNA sequence of cDNA subclone 009#8 using M13 reverse primer and the sequence of 3,-AP9 
1 T N C C A A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T G C 
6 1 G G C T T G T A A T ACGACTCACT ATAGGGCTTT TTTTTTTTAC T A A A A A A T A C A A T T T A A A G T A P 9 
1 2 1 G T A T T T T T A A A T A C A A T T T T A G C A C T A T G G T A A T T T T G C T A T G A A A A G T A A A T T C T A C C T 
1 8 1 T G C G G G A A A G A G A A A A T T C C T C A T A A C C A T C A A G T A G T T T A T T C A C A T G T T A G A A C G G G T 
2 4 1 G A G C C A G T G A A A A T C C T G G G C C T T G C G C G T A C T T T G T G G C T C A A T C A T A A T G T T G A G A A G 
3 0 1 G C A G G G T T T A C T T G T G T C T T G C A G A G C C T G C C T C A G C G A G T G T T G G A G C T C T T C T G G T G T 
3 6 1 T C G T A C A A A A T A C C C T T T G C C T C C A A A T G C A G T C A T G A C C T G C T C A T A A T G C G A G T T T G G 
4 2 1 C A A G A G G C A C A T T G G A G G G A C A G T T G T A G C A G C T T C T N G A A A A T G T A G C A N N T T T T N N C A 
4 8 1 N G T G T C A G C G T C A A A A C C T N G G T A A A T T C C A T T A T T G T N T A C T A C C A A G A G T A T G A T G G G 
5 4 1 C A A G T T G T A C G T G C N A T N G T C T N C T G T G T G A A A T G G T N A T N C G C T A A G C N G A N T T C T G C A 
6 0 1 G A T A T N C A T C A C A C T G N C G G G C G C T C G A G C A T G C A T C T A G A G G G C C C A A T T C G C C C T A T A 
6 6 1 G T G A G T T N T A T N A C A N T N A C T G G C N G T N T T T T A C A N C G T T G T G A C T G N N A N A N C C T G G C G 
C28.2: Sequence alignment of cDNA subclone 009#8 with mouse Hpcl by BLAST searching 
with the National Center for Biotechnology Information database 
〇09#8 ：99 a c t a a a a a a t a c a a t t t a a a g t g t a t t t t t a a a t a c a a t t t t a g c a c t a t g g t a a t t t t g 1 5 8 
M M 11111111111111111111111111111 丨 m 11111 m 1111 丨 111111111 
M o u s e ：1955 a c t a t a a a a t a c a a t t t a a a g t g t a t t t t t a a a t a c a a t t t t a g c a c t a t g g t a a t t t t g 1 8 9 6 
H p c l - p e n d i n g 
0 0 9 # 8 ：159 c t a t q a a a a g t a a a t t c t a c c t t g c g g g a a a g a g a a a a t t c c t c a t a a c c a t c a a g t a g t 2 1 8 
I I M I M M M I M M M M M M M M M M M M I M M M I l l l l l l l l l 
M o u s e ： 1 8 9 5 c t a t g a a a a g t a a a t t c t a c c t t g c g g g a a a g a g a a a a t t c c t c a t a a c c a t c a a g t a g t 1 8 3 6 
H p c l - p e n d i n g 
0 0 9 # 8 ：219 t t a t t c a c a t g t t a g a a c g g g t g a g c c a g t g a a a a t c c t g g g c c t t g c g c g t a c t t t g t g 2 7 8 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I I I I I I I l l l l l i M 
M o u s e ：1835 t t a t t c a c a t g t t a g a a c g g g t g a g c c a g t g a a a a t c c t g g g c c t t g c g c g t a c t t t g t g 1 7 7 6 
H p c l - p e n d i n g 
〇〇9tt8 : 2 7 9 g c t c a a t c a t a a t g t t g a g a a g g c a g g g t t t a c t t g t g t c t t g c a g a g c c t g c c t c a g c g 3 3 8 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I M I I , , , , 
M o u s e ： 1 7 7 5 g c t c a a t c a t a a t g t t g a g a a g g c a g g g t t t a c t t g t g t c t t g c a g a g c c t g c c t c a g c g 1 7 1 6 
H p c l - p e n d i n g 
0 0 9 # 8 ：339 a q t q t t q q a g c t c t t c t g g t q t t c g t a c a a a a t a c c c t t t g c c t c c a a a t g c a g t c a t g a 3 9 8 
I I I I M I I I I M M M M M i l l ， … 
M o u s e ：1715 a g t g t t g g a g c t c t t c t g g t g t t c g t a c a a a a t a c c c t t t g c c t c c a a a t g c a g t c a t g a 1 6 5 6 
H p c l - p e n d i n g 
〇〇9#8 :399 c c t g c t c a t a a t g c g a g t t t g g c a a g a g g c a c a t t g g a g g g a c a g t t g t a g c a g c t t c t n 4 5 8 
M M I M M M M M M M M M M M M l l l l l 1 1 11 I M 1 1 1 1 1 1 M l M M I N 11 
M o u s e ：1655 c c t g c t c a t a a t g c g a g t t t g g c a a g a g g c a c a t t g g a g g g a c a g t t g t a g c a g c t t c t t 1 5 9 6 
H p c l - p e n d i n g 
0 0 9 # 8 :459 g a a a a t g t a g c a n n t t t t n n c a n g t g t c a g c g t c a a a a c c t n g g t a a a t t c c a t t a t t g t 518 
l l l l l l l l l l l l M M I I l l l l l l l l l l l l l l l I I I i l M I I N I I I I I N N … 6 
M o u s e ：1595 g a a a a t g t a g c a t t t t t t c c c a g g t g t c a g c g t c a a a a c c t t g g t a a a t t c c a t t a t t g t 1 5 3 6 
H p c l - p e n d i n g 
〇〇9#8 ： 5 1 9 n t a c t a c c a a g a g t a t g a t g g g c a a g t t g t a c 5 5 0 M M M M M M M M M M M M M M M … 
M o u s e ：1535 t t a c t a c c a a g a g t a t g a t t g g c a a g t t g t a c 1 5 0 4 
H p c l - p e n d i n g 
C28.3: Summary of sequence alignment of cDNA subclone 009#8 with mouse Hpcl 
FluoroDD gel 0 0 (AP9 + ARP3) Subcloning “ Sequencing  
Differential display pattern Size of insert 
Fmement Subclone released by p Sequence homology E-value 了 PPARa (+/+) PPARa (-/-) ^ o . E c o ^ cut P rmer (Transcript size) (% Identity) 
Fed Starved Fed Starved M  
Mouse 
2-hydroxyphytanoyl- 0 
0 0 9 + ++ + + 0 0 9 # 8 560 M l 3 reverse CoA lyase 442/452 (97%) 
(510 bp) (Hpcl-pendmg) 
(1982 bp)  
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C29.1: DNA sequence of cDNA subclone PP3#3 using M13 forward -20 primer and the sequence of 5,-ARP3 
1 T T T A C A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C N N A G C G G C C G C C A T 
6 1 GTGATGGATA TCTGCAGAAT TCGGCTTAGC GGATAACAAT TTCACACAGG AGACCATTGC ARP3 
1 2 1 A C T G A C A G A G G A A G A T A T A T T T T A G A G G G A G A C A C T T G T A C C T T T C T C T C C C T T C A G T T A 
1 8 1 T T A G A C T C T T G G G A C A A T G G A C A T C A T G A A T T A A A A C G T T C T T A G A A A T C A C A T G C T G G G 
2 4 1 A G A A A A T T A A C A C T A A A A T C T G G T A C C A G C C A G A G G A A G G A A C T T G A C T C A A A A T A A G A G 
3 0 1 A T T T T T A G A T A T T T C T G T C T G T C T C A T A G T T A A A A T T A A T G T T T T C C T G C T T T C T G G C A T 
3 6 1 A T G C C T C A T C T T T T C T A T G A A G T A G T A A T A C T G A T A C A G A A A G G T A G A G A G A A A T G A A T A 
4 2 1 G T T T T T G C T A C T T T G G G C C A A A C T G T G A A A A A A T C C A T T T T A T T T C A T C A A T T T C T G T T T 
4 8 1 C C C A A T T T C A T T T A A G A C A C A N G A A A C T A C T C A G C A T G A A C T N T G N G G A G C N A G A G C A G T 
5 4 1 T T T G G C A A T C C A G G G A N G C A T G T N G C C A T C T G G T C C C T A C T G T T A G A N T G T G N T A G A A T T 
6 0 1 C T C A G C T C C T G A G A G G T T G T T C T C T G C N T T T G A C T C N G A G C T G N T N G T G T N A A A T C A N G T 
6 6 1 N G C G T T T T N G T N A N C T A G G A T T N N T G A C T T T 
C29.2: Sequence alignment of cDNA subclone PP3#3 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
PP3±t3 .113 a c c a t t q c a c t q a c a g a q g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1 7 2 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M 
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1 8 8 2 
P P 3 # 3 .173 t t c a q t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 2 3 2 
l l l l l l l l l … 
M o u s e C Y P 4 A 1 4 ：1883 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 1 9 4 2 
P P 3 # 3 - 233 a t q c t q q q a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2 9 2 
iiTii 〒〒？丨〒||111丨||||11丨111111111111111111111丨11丨1丨1川11!111 
M o u s e C Y P 4 A 1 4 ：1943 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 20iJZ 
pp^+ti . 2 9 3 a a t a a q a q a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 3 5 2 
• iiiii〒i〒iiiimiiiiiiiiiiiiiiimmiiiiiii!!ii ⑴ ! m i y m 
M o u s e C Y P 4 A 1 4 :2〇〇3 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 2 0 6 2 
P P 3 # 3 •353 t c t q q c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 4 1 2 
M M l M M I I M M I M M M M M M M M I M M M I l l l l l l l l l M M M I l l l l 
M o u s e C Y P 4 A 1 4 -.2063 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 2 1 2 2 
P P 3 # 3 : 4 1 3 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t 4 7 2 
m〒iiii?iimiiiiiiiiiimiimiiiiiiiii!m山 I Ml 丄丄 
M o u s e C Y P 4 A 1 4 : 2 1 2 3 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t 2丄 
PP3社3 .473 t t c t q t t t c c c a a t t t c a t t t a a g a c a c a n g - a a a c t a c t c a g c a t g a a c t n t g n g g a g c 5 3 1 
M M I M M I M M M M M M M I I I I I I M M M M 丨丨丨丨丨丄丨丨 1 1 ! � � 2 2 4 2 
M o u s e C Y P 4 A 1 4 : 2 1 8 3 t t c t g t t t c c c a a t t t c a t t t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t t g g g g a g c 
P P 3 # 3 :532 nagagcagttttggcaatccagggangcatgtngccatctggt ^〒〒〒Ya〒1^g1^t^agant^g1^ 5 9 1 I I I I M I M M I M M M M M M I I I l l l l l l l l l l l I 
M o u s e C Y P 4 A 1 4 : 2 2 4 3 c a g a g c a g t t t t g g c a a t c c a g g g a a g c a t g t t g c c a t c t g g t c c c t a c t g t t a g a a t g t 2 3 U 2 
P P 3们 ：592 g n t a g a a t t c t c a g c t c c t g a g a g g t t g t t c t c t g c n t t t g a c t c 6 3 6 I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I I M I M M M o u s e C Y P 4 A 1 4 : 2 3 〇 3 g g t a g a a t t c t c a g c t c c t g a g a g g t t g t t c t c t g c t t t t g a c t c 2 3 4 / C29.3: Summary of sequence alignment of cDNA subclone PP3#3 with mouse CYP4A14 
FluoroDD gel PP (APS + ARP3) Subcloning S e q u e n ^  
Differential display pattern Size of insert 
Fragment Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) ^ o . EcoRI cut (Transcript size) (% Identity) Fed Starved Fed Starved ^  ^ M l 3 forward Mouse CYP4A14 0 
( 7 二 + PP3#3 560 + 220 ― � (2547 bp) 515/525 (98%) 
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C30.1: DNA sequence of cDNA subclone PP3#13 using M13 reverse primer and the sequence of 5，-ARP3 
1 T G C C A G C T T G N G T A C C G A G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A T T C G G 
6 1 C T T A G C G G A T AACAATTTCA CACAGGAGAC CATTGCACTA A C A G A G G A A G A T A T A T T T T A ARP3 
1 2 1 G A G G G A G A C A C T T G T A C C T T T C T C T C C C T T C A G T T A T T A G A C T C T T G G G A C A A T G G A C A T 
1 8 1 C A T G A A T T A A A A C G T T C T T A G A A A T C A C A T G C T G G G A G A A A A T T A A C A C T A A A A T C T G G T 
2 4 1 A C C A G C C A G A G G A A G G A A C T T G A C T C A A A A T A A G A G A T T T T T A G A T A T T T C T G T C T G T C T 
3 0 1 C A T A G T T A A A A T T A A T G T T T T C C T G C T T T C T G G C A T A T G C C T C A T C T T T T C T A T G A A G T A 
3 6 1 G T A A T A C T G A T A C A G A A A G G T A G A G A G A A A T G A A T A G T T T T T G C T A C T T T G G G C N A A A C T 
4 2 1 G T G A A A N N A T C C A T T T T A T T T C A T C A A T N T C T G T T T C C C A A N T T C A T N T A A G A C A C A G G A 
4 8 1 N A A C T A C T C A G C A T G A A C T T T G G G G A G C C A G A G C A G T T T T G G C A A T N C A N N G A N G C A T G T 
5 4 1 N G C C A T C T G G T C C C T A C T G T N A G A N T G T G N A G A N T C T C A G C T C T G A G A G T G T C T C T G C T T 
6 0 1 T G A C T C T G A G C T G N T G T G T A N A A T C A G T C G C C T N C T G T A N C T A N G A N T T C T A C T N A C C N G 
6 6 1 N T T A T N G T A A A N T A C C 
C30.2: Sequence alignment of cDNA subclone PP3#13 with mouse CYP4A14 by BLAST searching 
with the National Center for Biotechnology Information database 
p:P3#13 ：89 a c c a t t q c a c t a a c a q a q g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 148 
imiifiiii i m i i i i i i i i i i m m m m i l m i i i i i i i i m m m 
M o u s e C Y P 4 A 1 4 ：1823 a c c a t t g c a c t g a c a g a g g a a g a t a t a t t t t a g a g g g a g a c a c t t g t a c c t t t c t c t c c c 1882 
PP3社13 •149 t t c a q t t a t t a g a c t c t t q g q a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 208 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
M o u s e C Y P 4 A 1 4 ： 1 8 8 3 t t c a g t t a t t a g a c t c t t g g g a c a a t g g a c a t c a t g a a t t a a a a c g t t c t t a g a a a t c a c 1 9 4 2 
P P 3 # 1 3 -209 a t q c t q q q a q a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 268 
M I M I I I I I I M M M M M I I M M M l l l l l l l l l l l l I I I I I I I I I I I M M M M � � 
M o u s e C Y P 4 A 1 4 ： 1 9 4 3 a t g c t g g g a g a a a a t t a a c a c t a a a a t c t g g t a c c a g c c a g a g g a a g g a a c t t g a c t c a a 2 0 0 2 
PP34±i3 .269 a a t a a q a q a t t t t t a q a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 328 
iim〒i〒iiimiiiiiiiimiiiiiiiiiiiiiiiiii 川 山I … m 
M o u s e C Y P 4 A 1 4 :2〇〇3 a a t a a g a g a t t t t t a g a t a t t t c t g t c t g t c t c a t a g t t a a a a t t a a t g t t t t c c t g c t t 2062 
P P 3 # 1 3 .329 t c t q q c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 388 
91” 
M o u s e C Y P 4 A 1 4 ：2063 t c t g g c a t a t g c c t c a t c t t t t c t a t g a a g t a g t a a t a c t g a t a c a g a a a g g t a g a g a g a 2 1 2 2 
P P 3 # 1 3 :389 a a t g a a t a g t t t t t g c t a c t t t g g g c n a a a c t g t g a a a n n a t c c a t t t t a t t t c a t c a a t 448 
M I I M M M M I M M M M M M l l l l l I I I I I I I M M M 1 U N I ^^^^ 
M o u s e C Y P 4 A 1 4 : 2 1 2 3 a a t g a a t a g t t t t t g c t a c t t t g g g c c a a a c t g t g a a a a a a t c c a t t t t a t t t c a t c a a t 2丄yj 
PP34+13 .449 n t c t q t t t c c c a a n t t c a t n t a a g a c a c a g g a n a a c t a c t c a g c a t g a a c t t t g g g g a g c 508 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 丄 m m i i i i i i i , � 
M o u s e C Y P 4 A 1 4 :2183 t t c t g t t t c c c a a t t t c a t t t a a g a c a c a g g a a a a c t a c t c a g c a t g a a c t t t g g g g a g c 
P P 3 # 1 3 :509 c a q a q c a g t t t t g g c a a t n c a n n g a n g c a t g t n g c c a t c t g g t c c c t a c t g t n a g a n t g t 568 
M I I I M I M M M M M I I I I M M M 丨 丨 丨 丨 J 丨 丨 丨 • 
M o u s e C Y P 4 A 1 4 ：2243 c a g a g c a g t t t t g g c a a t c c a g g g a a g c a t g t t g c c a t c t g g t c c c t a c t g t t a g a a t g t 2 i Q 2 
P P 3 # 1 3 :569 g 569 I 
M o u s e C Y P 4 A 1 4 :2303 g 230 3 C30.3: Summary of sequence alignment of cDNA subclone PP3#13 with mouse CYP4A14 
FluoroDD gel PP (APS + ARP3) Subcloning 一 Sequencing  
Differential display pattern Size of insert 
Fragment Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) n o . ECORI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp) . 
——^ Mouse CYP4A14 0 
(72^bp) “ + _ - PP3#13 560 + 220 M l 3 reverse (2547 bp) 466/481 (96。/。） 
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C31.1: DNA sequence of cDNA subclone 004#14 using M13 forward -20 primer and the sequence of 5，-ARP2 
1 A T G T A T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A N A A T G C A T G C C G A G C G G C C G C C 
6 1 A G T G T G A T G G A T A T C T G C A G A A T T C G C C C T T A G C G G A T A A . CAATTTCACA CAGGAGCTAG A R P 2 
1 2 1 C A T G G C A G C G G C G T T C C G C A G A G G C T G C A G G G T C C T G A G A A G T G T T T C T C A T T T T G A G T G 
1 8 1 T C G A A C A C A A C A C T C G A A A G C G G C T C A C A A G C A G G A G C C C G G A T T A G G G T T T A G T T T T G A 
2 4 1 G T T G A C G G A A C A G C A G A A A G A G T T T C A A G C A A C T G C C C G C A A G T T T G C C A G A G A G G A G A T 
3 0 1 T A T C C C C G T C G C C C C G G A A T A T G A C A A A A G C G G G G A G T A C C C G T T C C C T C T C A T C A A A A G 
3 6 1 A G C C T G G G A A C T C G G C T T G A T C A A C G C G C A C A T T C C G G A A A G T T G C G G T G G T C T T G G C C T 
4 2 1 G G G A A C G T C G A T G C T T G T T T A A T T A C C G A A G A G T A G G C G T A T G G G T G T A C A G G G G T G C A A 
4 8 1 C T G C T A T T G A A G C A A C A T T C T T G G G G C A A T G C C T G T G A T T C T T G C T G G A A A A T G A A C C A C 
5 4 1 A A A A A A A A A A G C C C A 
C31.2: Sequence alignment of cDNA subclone QQ4#14 with mouse MCAD by BLAST searching 
with the National Center for Biotechnology Information database 
0 0 4 訂 4 ：121 c a t q q c a q c g g c g t t c c g c a g a g g c t g c a g g g t c c t g a g a a g t g t t t c t c a t t t t g a g t g 180 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 丨 I I I I I I I I I I I I I 
M o u s e M C A D ：7 c a t g g c a g c a g c g t t c c g c a g a g g c t g c a g g g t c c t g a g a a g t g t t t c t c a t t t t g a g t g 6 6 
〇〇4ttl4 ：181 t c q a a c a c a a c a c t c g a a a g c g g c t c a c a a g c a g g a g c c c g g a t t a g g g t t t a g t t t t g a 2 4 0 
IIIIIIII  
M o u s e M C A D ：67 t c g a a c a c a a c a c t c g a a a g c g g c t c a c a a g c a g g a g c c c g g a t t a g g g t t t a g t t t t g a 126 
〇〇4#14 : 2 4 1 q t t q a c g q a a c a g c a g a a a g a g t t t c a a g c a a c t g c c c g c a a g t t t g c c a g a g a g g a g a t 3 0 0 
, , , 
M o u s e M C A D ： 1 2 7 g t t g a c g g a a c a g c a g a a a g a g t t t c a a g c a a c t g c c c g c a a g t t t g c c a g a g a g g a g a t 1 8 6 
0 0 4 ^ 1 4 - 3 0 1 t a t c c c c q t c q c c c c g g a a t a t q a c a a a a g c g g g g a g t a c c c g t t c c c t c t c a t c a a a a g 3 6 0 
• l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l I M M � “ 
M o u s e M C A D ： 1 8 7 t a t c c c c g t c g c c c c g g a a t a t g a c a a a a g c g g g g a g t a c c c g t t c c c t c t c a t c a a a a g 2 4 6 
0 0 4 # 1 4 ：361 a q c c t q q g a a c t c g q c t t g a t c a a c g c g c a c a t t c c g g a a a g t t g c g g t g g t c t t g g c c t 4 2 0 
I I M I I I I M M M M M I M I I M M M M M I M M M I I I I • 
M o u s e M C A D : 2 4 7 a g c c t g g g a a c t c g g c t t g a t c a a c g c g c a c a t t c c g g a a a g c t g c g g t g g c c t t g g c c t 3 0 6 
0 0 4 # 1 4 : 4 2 1 q q q a a c q - t c g a t q c t t g t t t a a t t a c c g a a g a g t a g g c g t a t g g g t g t a c a g g g g t g c - 4 7 8 
iiiiMi iiiiiiiiiiiiiiiiiiiiiiiiiii I IIIIIIII m m m i l m i … 
M o u s e M C A D :307 g g g a a c g t t c g a t g c t t g t t t a a t t a c c g a a g a g t t g g c g t a t g g g t g t a c a g g g g t g c a 3 6 6 
0 0 4 # 1 4 :479 a a c t g c t a t t g a a g c a a c a t t c - t t g g g g c - a a t g c c t g t g a t t c t t g c t g g a a a 5 3 1 
l l l l l l l l l l l l l l l l l M M M M M l l l l l l l l I I 丨丨丨MINI N l l l l • 
M o u s e M C A D : 3 6 7 a a c t g c t a t t g a a g c a a - a t t c t t t g g g g c a a a t g c c t g t g a t t c t t g c t g g a a a 4 2 0 C31.3: Summary of sequence alignment of cDNA subclone QQ4#14 with mouse MCAD 
_ FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment 1 7 7； S u b c l o n e released by p Sequence homology E-value 
Z PPARa (+/+) PPARa (-/-) ^ o . EcoRl cut P r m e r (Transcript size) (% Identity) Fed Starved Fed Starved W  Mouse medium-chain acyl-CoA q 
QQ4 + ++ + + QQ4#14 500 9。广ar dehydrogenase 406/415 (91%) (470 bp) -20 (MCAD) ^ ) 
(1846 bp)  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C32.1: DNA sequence of cDNA subclone 004#15 using M13 reverse primer and the sequence of 5'-ARP2 
1 T A T T A G T C C C C T A T A T A N A T C A A G C T A T G C A T C A A G C C T G G T A C T A C T C G G A T C C A C T A G 
6 1 T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G A T A ACAATTTCAC ACAGQAGCTA ARP2 
1 2 1 GCATGGCAGC G G C G T T C C G C A G A G G C T G C A G G G T C C T G A G A A G T G T T T C T C A T T T T G A G T 
1 8 1 G T C G A A C A C A A C A C T C G A A A G C G G C T C A C A A G C A G G A G C C C G G A T T A G G G T T T A G T T T T G 
2 4 1 A G T T G A C T G T G A A C A G C A G A A A G A G T T T C A A G C A A C T G C C C G C A A G T T T T G C C A G A G A G T 
3 0 1 G A G A T T A T C C C C G T C G C C C C G G A A T A T G A C A A A A A G C G G G G A G T A A C C C G T T C C C T C T C A 
3 6 1 T C A A A A G A G C C T G G G A A C T C G G C T T G A T C A A A C G C G C A C A T T C C G G A A A A G T T G C G G T G G 
4 2 1 T C T T G G C C T G G G A A C G T N C G A T G C 
C32.2: Sequence alignment of cDNA subclone QQ4#15 with mouse MCAD by BLAST searching 
with the National Center for Biotechnology Information database 
0〇4ttl5 ：122 c a t q q c a g c q g c q t t c c q c a g a g g c t g c a g g g t c c t g a g a a g t g t t t c t c a t t t t g a g t g 181 
I M I I M I I I I M M M M M M M M M M M M M M M M M I I I I l l l l _ 
M o u s e M C A D ：7 c a t g g c a g c a g c g t t c c g c a g a g g c t g c a g g g t c c t g a g a a g t g t t t c t c a t t t t g a g t g 66 
004ttl5 ：182 t c q a a c a c a a c a c t c g a a a g c g g c t c a c a a g c a g g a g c c c g g a t t a g g g t t t a g t t t t g a 241 
M I M M M M M M M M M M M M I M M M l l l l l i M i l l 
M o u s e M C A D ：67 t c g a a c a c a a c a c t c g a a a g c g g c t c a c a a g c a g g a g c c c g g a t t a g g g t t t a g t t t t g a 126 
0 0 4似 5 ：242 q t t q a c t q t g a a c a q c a g a a a g a g t t t c a a g c a a c t g c c c g c a a g t t t t g c c a g a g a g t g 301 
l l l l l i M M M M M M M M I M M M M M M I M M M l l l l l l l l l l l l I � � 
M o u s e M C A D ：127 g t t g a c - - g g a a c a g c a g a a a g a g t t t c a a g c a a c t g c c c g c a a g - t t t g c c a g a g a g - g 182 
〇〇4ttl5 ：302 a q a t t a t c c c c g t c g c c c c g g a a t a t g a c a a a a a g c g g g g a g t a a c c c g t t c c c t c t c a t 361 
I〒丨miiiiiiimmmimm iiiiiiiiiiiii _ 
M o u s e M C A D ：183 a g a t t a t c c c c g t c g c c c c g g a a t a t g a c - a a a a g c g g g g a g t - a c c c g t t c c c t c t c a t 240 
0〇4ftl5 ：362 c a a a a g a q c c t g g g a a c t c g g c t t g a t c a a a c g c g c a c a t t c c g g a a a a g t t g c g g t g g t 4 2 1 
M M I I I I M M M M M I M I M M M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 M M ，。。 
M o u s e M C A D :241 c a a a a g a g c c t g g g a a c t c g g c t t g a t c - a a c g c g c a c a t t c c g g - a a a g c t g c g g t g g c 298 
Q Q 4似 5 :422 c t t g g c c t g g g a a c g t n c g a t g c 444 l l l l l l l l l l l l l l l l I I M I I M o u s e M C A D ： 299 c t t g g c c t g g g a a c g t t c g a t g c 321 C32.3: Summary of sequence alignment of cDNA subclone OQ4#15 with mouse MCAD 
FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment 77：~ Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) ^ o . EcoRl cut P ^ e r (Transcript size) (% Identity) Fed Starved Fed Starved ^  Mouse medium-chain acyl-CoA e-134 
QQ4 + ++ + + O04#15 500 M l 3 reverse dehydrogenase ^in/193 (9^%) (470 bp) ^ ^ (MCAD) J i u / J / J ^yo/o； 
(1846 bp)  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C33.1: DNA sequence of cDNA subclone QQ5#14 using M13 forward -20 primer and the sequence of 
3，-AP3 
1 A A T G A A T A C C A C T C A C T A T A G G G C G A A T G G G C C C T C T A N C A T G C A T G C T C G A G C G G C G C C 
6 1 A G T G T G A T G G A T A T C T G C A G A A T T C G C C C T T G T A A T A C G A CTCACTATAG GGCTTTTTTT A P 3 
1 2 1 TTTTTGGGTG C A A G G G T A A T C A T T T A T T G A A C A G G A A G A G G A A G A A A T T C A T G A A A A A T T 
1 8 1 G T C A T G G G T A T A T C A A A G A G A A A T T T A A A G A A G T C T T T G A T T C T T G A T G A G G T A T C C T A G 
2 4 1 G T A A C A T G T G G A T A G A C T G G A A T T G G A C T T C T C A G T G A G A C A G G A T G G A A T G C A G A T C A C 
3 0 1 A G A A T T T A T A C T G G G G A T G C T G T A T G G A T A G G A A G G G A T G A T G G T G G A G T C C T G G T G G A G 
3 6 1 A A G T C T C C C A A T C A A A C A C T G G A G G C T C A G C C A T T C T T C A T T T C T C G G G G G C C T G A G G C A 
4 2 1 G C G G A T T G G C T T G G A T A G G G T C A A A T G A A T T A A T T T T C T C T A A G G A T T C C A T G C T A C T C C 
4 8 1 T G T G T G A A A T T G T A A T C C C G C C T A A A G G G C G A A A T T C C C A G G C A C A C C T G G C G 
C33.2: Sequence alignment of cDNA subclone QQ5#14 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇5|^14 ：128 q t q c a a g g q t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g g 187 
I I I M I I I I M M M M M M M M M I M M M I I I I I I I I I I l l l l l l l l l l l l l l l l 
M o u s e M U P 工工 ：869 g t g c a a g g g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g g 810 
005ttl4 ：188 q t a t a t c a a a q a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a t 247 
I M M M M I I I I M M M M M M M M l l l l l I I I I I I I I I I I I I丨丨丨丨丨 _ 
M o u s e M U P II :809 g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a t 750 
〇〇5#14 ：248 q t q q a t a q a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t t 307 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I _ 
M o u s e M U P II :749 g t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t t 690 
0 0 5 # 1 4 ：308 a t a c t g g g g a t g c t q t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g g a g a a g t c t c 367 
iiiiitiiimiiiiimiiiiimiiiimimiiimiiii iiiiii丄i丄⑶ 
M o u s e M U P II :689 a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t - g a g a a g t c t -
〇〇5ttl4 ：368 c c a a t c a a a c a c t g g a g g c t c a - g c c a t t c t t c a t t 402 I I I I I I I I I I I I I I I I I I I 1. I I I I I I I I I I I I I 
M o u s e M U P 工工 ：631 c c a c t c - a a c a c t g g a g g c t c a g g c c a t t c t t c a t t 597 C33.3: Summary of sequence alignment of cDNA subclone QQ5#14 with mouse MUP II 
FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment 77：~ Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) ^ o . BcoRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
A41-5 f Mouse major urinary 131 
QQ5 ++ + ++ ++ QQ5#14 430 M13 torward p^ t^ein II (MUP II) 271/276 (98%) 
(395 bp) ；^  (872 bp) 2/1/2/0(^8/0； 
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C34.1: DNA sequence of cDNA subclone 005#17 using M13 reverse primer and the sequence of 5’-ARP2 
1 T T G T G A C C T A T A G A A T A C T C A G C T A T G C A T C A A G C T T G T G T A C G A G C T C G G A T C A C T A G T 
6 1 A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G A T A A CAATTTCACN CAGGAGCTAG ARP2 
1 2 1 CATGGAATCC T T A G A G A A A A T A T C A T T G A C C T A T C C A A T G C C A A T C T G C T G C C T C C A G T G 
1 8 1 C C C G A G A A T G A A G A A T G T G C C T G A G C C T A C C A G T G T T G A G T G T G A G A C T T C T C A C C A G G A 
2 4 1 C T C C C A A C C A T T C A A T C C C C T T T C C C T A T T C C C A G G G G G G G G A T T C C C C A A G G T T A T A A A 
3 0 1 A T T T C C T G G T G G A A T T C T T 
C34.2: Sequence alignment of cDNA subclone Q05#17 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
：119 a g c a t q g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c t g c t g c c t c c a g 178 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 口Q� 
M o u s e M U P 工工 ：531 a g c a t g g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c - g c t g c c t c c a g 5 8 9 
0〇5打7 ：179 t q c c c q a q a a t g a a g a a t g t g c c t g a g c c t a c c a g t g t t g a g t g t g a g a c t t c t c a c c a g 2 3 8 
I M I I I I M M I M M M l l l l l l l l l l M M M I M M M _ 
M o u s e M U P II :590 - g c c c g a g a a t g a a g a a t g - g c c t g a g c c t - c c a g t g t t g a g t g - g a g a c t t c t c a c c a g 6 4 5 
Q Q 5 # 1 7 ： 2 3 9 g a c t c c 2 4 4 M M M M o u s e M U P II g a c t c c 6 5 1 C34.3: Summary of sequence alignment of cDNA subclone QQ5#17 with mouse MUP II 
- FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing : 
Differential display pattern Size of insert 
Fraement T T " ~ Subclone released by p Sequence homology E-value 
^ ^ PPARa (+/+) PPARa (-/-) ^ o . £coRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
Mouse major urinary 6e 40 
QQ5 ++ + + + + + 0 0 5 # 1 7 430 M l 3 reverse protein II (MUP II) l o i / n ^ ; /-Qf^ o/) 
(395 bp) (872 bp) 灼/o) 
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C35.1: DNA sequence of cDNA subclone QQ6#13 using M13 forward -20 primer and the sequence of3’-AP3 
1 C T A T A G G C G A A T T G G G C C C T C T A A T G C A T G C T C G A G C G G C C G C C A G T G T G A T G G A T A T C T 
6 1 G C A G A A T T C G C C C T T G T A A T ACGACTCACT ATAGGGCTTT TTTTTTTTTG G G T G C A A G G G A P 3 
1 2 1 T A A T C A T T T A T T G A A C A G G A A G A G G A A G A A A T T C A T G A A A A A T T T T C A T G G G T G T A T C A A 
1 8 1 A G A G A A A T T T A A A G A A G T C T T T G A T T C T T G A T G A G G T A T C C T A G G T A A C A T G T G G A T A G A 
2 4 1 C T G G A A T T G G A C T T C T C A G T G A G A C A G G A T G G A A T G C A G A T C A C A G A A T T T A T A C T G G G G 
3 0 1 A T G C T G T A T G G A T A G G A A G G G A T G A T G G T G G A G T C C T G T G A G A A G G T C T C C A C T C A A C A C 
3 6 1 T G G A G G C T C A G C C C A T T C T T C A T T C T C G G G G C C T G A G G C A G C G A T T T G G C A T T G G A T A G G 
4 2 1 T C A A T G A T A T T T T C T C T A A G G A T T C C A T G C T A C T C C T G T G T G A A A T T G T T A T C C G C T A A G 
4 8 1 G G C G A A T T C C A G A C A C A C T G G C G G C C G T N A C T A G T G G A T C C G A G A C T C G G T A C C C A A G C T 
5 4 1 T G A T G C A T A G C T T G A G T A T C T A T G A T G T C A C C C T A A A A A T A G C A T T G G G C G T A A A T C A T G 
6 0 1 G A 
C35.2: Sequence alignment of cDNA subclone QQ6#13 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
〇〇6#13 ：112 q t q c a a q g g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t t t c a t g g 1 7 1 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M l l l l 
M o u s e M U P I I g t g c a a g g g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g g 8 1 0 
〇〇6ttl3 ：172 q t q t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a t 2 3 1 
綱 I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
M o u s e M U P I I : 8 0 9 g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a t 7 5 0 
0〇6ttl3 ：232 q t q q a t a g a c t g q a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t t 2 9 1 
l l l l l l l l l l l l l l l l M M M M M M M M M M I M i l l I M M M i l l I I M I M l 咖 
M o u s e M U P I I : 7 4 9 g t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t t 6 9 0 
0 0 6 # 1 3 :292 a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t - g t g a g a a g g t c t c 3 5 0 
l l l l l l l l l l l l l l l l I I I I I [ m i l M M I M M M i l l 口 1 
M o u s e M U P 工工 ：689 a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g a g a a - g t c t c 6 3 1 
006ttl3 : 3 5 1 c a c t c a a c a c t g g a g g c t c a g c c c a t t c t t c a t t c t c g g g g c c t g a g g c a g c g a t t t g g c 4 1 0 i i i i i i i i i i i i i i i m i i i l l l l l l l l l l l l l l l l l l M i l l I I I … 
M o u s e M U P 工工 ：630 c a c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c t g g a g g c a g c g a - t t g g c 5 7 2 
〇〇6ttl3 : 4 1 1 a t t g q a t a g g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 4 5 1 
I I I I l l l l l l l l l l l l l l l l l l l l l l l l l I I 111 I I m i l 
M o u s e M U P 工工 ：571 a t t g g a t a g g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 5 3 1 C35.3: Summary of sequence alignment of cDNA subclone OQ6#13 with mouse MUP II 
FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing 二 _ Differential display pattern Size of insert 
Fragment “ S u b c l o n e released by p Sequence homology E-value 
Mag^en t p p A R a (+/+) PPARa (-/-) N o . EcoRl cut (Transcript size) (% Identity) 
Fed Starved Fed Starved M  
f J Mouse major urinary 1^3 
Q Q 6 ++ + ++ ++ QQ6#13 430 Mntorward protein II ( M U P II) 332/3；! (97%) 
(385 bp) -20 (872 bp) � ) 
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C36.1: DNA sequence of cDNA subclone QQ6#14 using M13 reverse primer and the sequence of 5,-ARP2 
1 A T T A G T G A C C T A T A T N T A C T C A A G C T A T G C A T C A A G C T T G G T A C G A G C T C G G A T C A C T A G 
6 1 T A A C G G C C G C C A G T G T G C T G G A A T T C T G C C C T T A G C G G A T AACAATTTCA CGCAGGAGCT ARP2 
1 2 1 AGCATGGAAT C C T T A G A G A A A A T A T C A T T G A C C T A T C C A A T G C C A A T C G C T G C C T C C A G G 
1 8 1 C C C G A G A A T G A A G A A T G G C C T G A G C C T C C A G T G T T G A G T G G A G A C T T C T C A C C A G G A C T C 
2 4 1 C A C C A T C A T C C C T T C C T A T C C A G T G G G G G C A T C C C C A G T A T A A A T T C T G T G A T C T G C A T T 
3 0 1 T C C A T C C T G T C T C A C T G A G A A A G T C C G A T T C C A G T C T A T C C A C A T G T T A C C T A G G G A T A C 
3 6 1 C T C A T C A A G A A T C A A A G A C T T C T T T A A A A T T T T T C C T T T T G A T A T A A C C C A T T G A C A A A A 
4 2 1 T A T T T C A C T G C A A T T T C T T T C C C T C C T T C C T G G T T C 
C36.2: Sequence alignment of cDNA subclone OQ6#14 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
0Q6ttl4 :121 a g c a t q g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 180 
iTiiiffiiiiiiiiiiii lllllll m m i i m i m m m i I丨丨丨 IIIIIIII _ 
M o u s e M U P 工工 ：531 a g c a t g g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 590 
006ttl4 ：181 c c c g a q a a t g a a g a a t g g c c t g a g c c t c c a g t g t t g a g t g g a g a c t t c t c a c c a g g a c t c 240 
llllllllllllllllllllllllllllllllllllllllllilllllMIIMMMM “ 。 
M o u s e M U P II :591 c c c g a g a a t g a a g a a t g g c c t g a g c c t c c a g t g t t g a g t g g a g a c t t c t c a c c a g g a c t c 650 
0 0 6 # 1 4 .241 c a c c a t c a t c c c t t c c t a t c c a g t g g g g g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a t t 300 
. M M M I M M M M I M M M 1 1 1 1 1 1 I 1111 M l M l M M I M l 11111 I • 
M o u s e M U P 工工 ：651 c a c c a t c a t c c c t t c c t a t c c a - - t a c a g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a - t 70/ 
0 0 6 # 1 4 .301 t c c a t c c t g t c t c a c t g a g a a a g t c c g a t t c c a g t c t a t c c a c a t g t t a c c t a g g g a t a c 360 
M M M M I M I M M I M l l l l l l i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 ! I M I N 
M o u s e M U P II :708 t c c a t c c t g t c t c a c t g a g - a a g t c c a a t t c c a g t c t a t c c a c a t g t t a c c t a - g g a t a c 76b 
006ttl4 ： 3 6 1 c t c a t c a a q a a t c a a a g a c t t c t t t a a a 388 
I I I I I I 1 I I I I I I 1 I I I I 111 I I 111 I I 
M o u s e M U P 工工 ：766 c t c a t c a a g a a t c a a a g a c t t c t t t a a a 793 C36.3: Summary of sequence alignment of cDNA subclone QQ6#14 with mouse MUP II 
FluoroDD gel QQ (AP3 + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert 
Fragment 77：~ Subclone released by p Sequence homology E-value 
PPARa (+/+) PPARa (-/-) ^ o . £coRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved ^  
Mouse major urinary e-115 
QQ6 ++ + ++ ++ QQ6#14 430 M l 3 reverse protein II (MUP II) 258/268 (96%) 
(385 bp) (872 bp) ^  
381 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C37.1: DNA sequence of cDNA subclone TT4#5 using M13 forward -20 primer and the sequence of 3，-AP5 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G A A G C G G C C G C C A G 
6 1 T G T G A T G G A T ATCTGCAGAA T T C G C C C T T G TAATACGACT CACTATAGGG CTTTTTTTTT AP5 
1 2 1 T T C A G T G C A A G G G T A A T C A T T T A T T G A A C A G G A A G A G G A A G A A A T T C A T G A A A A A T T G C C 
1 8 1 A T G G G T A T A T C A A A G A A A A A T T T A A A G A A G T C T T T G A T T C T T G A T G A G G T A T C C T A G G T A 
2 4 1 A C A T G T G G A T A G A C T G G A A T T G G A C T T C T C A G T G A G A C A G G A T G G A A T G C A G A T C A C A G A 
3 0 1 A T T T A T A C T G G G G A T G C T G T A T G G A T A G G A A G G G A T G A T G G T G G A G T C C T G G T G A G A A G T 
3 6 1 C T C C A C C T C A A C A C T G G A G G C T C A G G C C A T T C T T C A T T C T C G G G C C C T G G A G G C A G C G A T 
4 2 1 T G G C A T T G G A T A G G T C A A T G A T A T T T T C T C T A A G G A T T C C A T G C T A G C C T C C T G T G T G A A 
4 8 1 A T N G T T A T C C G C T A A N N G C G A A T T C C A G C A C A C T G G C N G C C G T T A N T A G T G G A T C C G A G C 
5 4 1 T C N G T A C C A A G C N T G A T G C A T A N C T G A G T A T N C T A T A G T G T A C C T A A A T A G C T G G G C G T A 
6 0 1 A T A T G G T A T N N N N G T N N C N G T G T G A N A T G T A T C G N N C N N A T T C C N N N A N N T C N A N C N G A A 
6 6 1 N N T N G N G T N N G N N G G G N T G C N A T G A G T G N C 
C37.2: Sequence alignment of cDNA subclone TT4#5 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
T T 4 # 5 •124 a q t q c a a q q g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g c c a t g 1 8 3 
i〒i〒iiiffhiiimiiiiimiiimmiimiiiiiiimm丄丄ijiji 口” 
M o u s e M U P 工工 ：870 a g t g c a a g g g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g 8 1 1 
T T 4 # 5 ：184 q q t a t a t c a a a g a a a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a 2 4 3 
M M M M M I I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M M M M 
M o u s e M U P 1 1 :810 g g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a 7 5 1 
T T 4 # 5 :244 t q t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t 3 0 3 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l I M M M I M I I � 
M o u s e M U P 1 1 :750 t g t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t 6 9 1 
T T 4 # 5 :304 t a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g a g a a g t c t c 3 6 3 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M M l l l l l l l l I I 
M o u s e M U P 工工 ：690 t a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g a g a a g t c t c 6 3 1 
T T 4 # 5 :364 c a c c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c c t g g a g g c a g c g a t t g g 4 2 3 
11 M I M M M M M M M M M M M M M I I I I I I I I I l l l l l l l 11 ^^^ 
M o u s e M U P 工工 ：630 c a - c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g - c c t g g a g g c a g c g a t t g g 5 7 3 
T T 4 # 5 : 4 2 4 c a t t q g a t a g q t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 4 6 5 
iiiiMiiiiimimiiiiimmmii丨丨11丄11!；” 
M o u s e M U P 工工 ：572 c a t t g g a t a g g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 5 3 1 C37.3: Summary of sequence alignment of cDNA subclone TT4#5 with mouse MUP II 
FluoroDD gel TT (APS + ARP2) Subcloning Sequencing _ _ 
Differential display pattern Size of insert Fnmment Subclone released by p ^ — r Sequence homology E-value 
Fra^ ent ppARa (+/+) PPARa (-/-) ^0. Ecom cut Primer (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp) — 
A^n r 7" Mouse major urinary 170 
TT4 ++ + ++ 竹 TT4#5 430 M l 3 forward protein II (MUP II) 333/342(98%) 
(385 bp) -乂u (872 bp) ^ 1_ 
382 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C38.1: DNA sequence of cDNA subclone TT4#8 using M13 forward -20 primer and the sequence of5，-ARP2 
1 N N T T T A C A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G G A G C G G C C G C C 
6 1 AGTGTGATGG ATATCTGCAG AATTCGCCCT TAGCGGATAA CAATTTCACA CAGGAGCTAG ARP2 
1 2 1 C A T G G A A T C C T T A G A G A A A A T A T C A T T G A C C T A T C C A A T G C C A A T C G C T G C C T C C A G G C C 
1 8 1 C G A G A A T G A A G A A T G G C C T G A G C C T C C A G T G T T G A G T G G A G A C T T C T C A C C A G G A C T C C A 
2 4 1 C C A T C A T C C C T T C C T A T C C A T A C A G C A T C C C C A G T A T A A A T T C T G T G A T C T G C A T T C C C A 
3 0 1 T C C T G T C T C A C T G A G A A G T C C A A T T N C C A G T C T A T C C A C A T G T T A C C T A G G A T A C C T C A T 
3 6 1 C A A G A A T C A A A G A C T T C T T T A A A T T T C T C N T T T G A T A C A C C C A T G A A A A T T T N N C A T G A A 
4 2 1 T N T C T T C C T C T T C C T G T T C A A T A A A T G A T C A C C T T N N A C T T G A A A A A A A A A A A A C C C T A T 
4 8 1 A G T G A G T C G T A T N A C A A G G G C G A A T T C C A G C A C A C T G G C N G N C G T T A A T A G N G G G A T C C A 
5 4 1 A G C T C G G T A C C A A G C T T G A T G C N T A N C N T G A G T A T N T A T A G T G T N A C C T A A A T A G C T N G G 
6 0 1 C G T A A T T T G N N T N N N N G T N N C T G T G T G A A T G T A T C G T T N N A A N A C A C C A C N N N N N C N N C N 
6 6 1 N A A A C A C T A A C C N G G N N N C T 
C38.2: Sequence alignment of cDNA subclone TT4#8 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
T T 4 # 8 •119 a q c a t q q a a t c c t t a q a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 178 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I I M I I M I I I I _ 
M o u s e M U P 工工 ：531 a g c a t g g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 590 
TT4tt8 ：179 c c c q a g a a t g a a g a a t g g c c t g a g c c t c c a g t g t t g a g t g g a g a c t t c t c a c c a g g a c t c 238 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M l l M l l l l l l l l l l 
M o u s e M U P 工I :591 c c c g a g a a t g a a g a a t g g c c t g a g c c t c c a g t g t t g a g t g g a g a c t t c t c a c c a g g a c t c 650 
TT4tt8 :239 c a c c a t c a t c c c t t c c t a t c c a t a c a g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a t t c c 298 
l l l l i m i l l l l l l l l l l l l l l l l l l l l l l l l l l l 丄 I 丄 I I I 丄 M M M I 山 丄 丄 I 7 0 9 
M o u s e M U P 11 :651 c a c c a t c a t c c c t t c c t a t c c a t a c a g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a t t - c 709 
T T 4 # 8 .299 c a t c c t g t c t c a c t g a g a a g t c c a a t t n c c a g t c t a t c c a c a t g t t a c c t a g g a t a c c t c 358 
M M I I I M M M M I M I M M I M I 1 1 1 1 1 1 1 1 1 1 1 1 1 M l M l M M M I 11 I 
M o u s e M U P II :710 c a t c c t g t c t c a c t g a g a a g t c c a a t t - c c a g t c t a t c c a c a t g t t a c c t a g g a t a c c t c 768 
T T 4 # 8 :359 a t c a a g a a t c a a a g a c t t c t t t a a a t t t c t c n t t t g a t a c a c c c a t g a a a a t t t n n c a t g 418 
i i i i i T i i i i i m m m m i i m m I I I I I I I I I I I I I I M I I N 込 力 
M o u s e M U P 工工 -.169 a t c a a g a a t c a a a g a c t t c t t t a a a t t t c t c - t t t g a t a t a c c c a t g a c a a t t t t t c a t g 827 
T T 4 # 8 ：419 a a t n t c t t c c t c t t c c t g t t c a a t a a a t g a t 4 4 9 I I I I M M M M I M M M M M I M M M 
M o u s e M U P 工工 ：828 a a t t t c t t c c t c t t c c t g t t c a a t a a a t g a t 858 C38.3: Summary of sequence alignment of cDNA subclone TT4#8 with mouse MUP II 
FluoroDD gel TT (APS + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert ^ ^ 
Fr^ c^rm^^ Tit n Subclone released by p Sequence homology E-value 
: PPARa (+/+) PPARa (-/-) ^ o . £coRI cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  
^TTTf Mouse major urinary igi 
TT4 ++ + ++ ++ TT4#8 430 M l 3 forward protein II (MUP II) 323/331 (970/0) 
(385 bp) - � (872 bp)  
383 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C39.1: DNA sequence of cDNA subclone TT4#9 using M13 reverse primer and the sequence of3,-AP5 
1 T C C G C T A T T T A G G T G A C A C T A T A G A A T A C T C A A G C T A T G C A T C A A G C T T G G T A C C G A G C T 
6 1 C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T G T A A T A CGACTCACTA A P 5 
1 2 1 TAGGGCTTTT TTTTTTTTCA A G T G C A A G G G T G A T C A T T T A T T G A A C A G G A A G A G G A A G A A 
1 8 1 A T T C A T G A A A A A T T T T C A T G G G T G T A T C A A A G A G A A A T T T A A A G A A G T C T T T G A T T C T T G 
2 4 1 A T G A G G T A T C C T A G G T A A C A T G T G G A T A G A C T G G A A T T G G A C T T C T C A G T G A G A C A G G A T 
3 0 1 G G A A T G C A G A T C A C A G A A T T T A T A C T G G G G A T G C T G T A T G G A T A G G A A G G G A T G A T G G T G 
3 6 1 G A G T C C T G G T G A G A A G T C T N C C A C T C A A C A C T G G A G G C T C A G G C C A T T C T T C A T T C T C G G 
4 2 1 G C C T G G A G G C A G C G A T T G G C A T T G G A T A G G T C A A T G A T A T T T T C T C T A A G G A T T C C A T G C 
4 8 1 T A G C T C C T G T G T G A A A T G G T T A T C C G C T A A N N G C G A A T T C T G C A G A T A T C C A T C A C A C T G 
5 4 1 G C N G C C G C T C G A G C A T G C A T C T A G A G G G C C A N T T C G C C C T A T A G T G A G T C G T A T T A C A N T 
6 0 1 T C A C T G N N C G T C G T T T T A C A N G T N G T G A C T G N G A A N N C C T G G C G T T A C C C A N C T N A A T C G 
6 6 1 C C T G G C A G C A C A T N C C C T N C N C A G C N G G C G T A A T G C C C C 
C39.2: Sequence alignment of cDNA subclone TT4#9 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database . 
TT4tt9 •140 a a q t q c a a q q g t g a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t t t c a t 199 
‘ l l l l l l l l l l l l M I M M M M M M M I M M M l l l l l l l l l l l l l l  
M o u s e MUP II :871 aagtgcaagggtaatcatttattgaacaggaagaggaagaaattcatgaaaaattgtcat 812 
t t 4 # 9 :200 q q g t g t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c 2 5 9 
M M imiiiiiiiiiiiiiiimmiiiiimmmimm丨丨丨11丨丨丨I 
M o u s e M U P II :811 g g g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c 752 
T T 4 # 9 :260 a t q t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t 3 1 9 
l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l M I 
M o u s e M U P I I : 7 5 1 a t g t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t 6 9 2 
T T 4 # 9 :320 t t a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g a g a a g t c t 379 
i m i i i i i i m i m i i i i i i i i m m i m i i m m m m i i i m i i i i i 
M o u s e MUP 工工 ：691 ttatactggggatgctgtatggataggaagggatgatggtggagtcctggtgagaagtct 632 
T T 4 # 9 :38〇 n c c a c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c t g g a g g c a g c g a t t g g 4 3 9 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M I M I I I I 丨 丨 I I 口” 
M o u s e M U P 工工 ：631 - c c a c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c t g g a g g c a g c g a t t g g 5 7 3 
T T 4 # 9 : 4 4 0 c a t t g q a t a q g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 4 8 1 
M M M M M M M M M M I M I I I I M M M M I I I N I I .119 
M o u s e M U P II :572 c a t t g g a t a g g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 5 3 1 T T 4 # 8 .丄丄y C39.3： Summary of sequence alignment of cDNA subclone TT4#9 with mouse MUP II 
FluoroDD gel TT (APS + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert p 一 Fmpment Subclone released by mer Sequence homology E-value 
F r a ^ e n t p p A R a (+/+) PPARa (-/-) ^ o . 五coRI cut Pnmer (Transcript size) (% Identity) 
Fed Starved Fed Starved M  Mouse major urinary e-180 
TT4 + ++ ++ TT4#9 430 M13 reverse protein II (MUP II) 338/342 (98%) 
(385 bp) (872 bp) ^  
384 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C40.1: DNA sequence of cDNA subclone TT5#1 using M13 forward -20 primer and the sequence of 5'-ARP2 
1 G A A T G A T T A N N C T C A C T A T A G G G C G A A T T G G G C C C T C T A G G A T G C A T G C T C G G A G C G G C C 
6 1 GCCAGTGTGA TGGATATCTG CAGAATTCGC C C T T A G C G G A TAACAATTTC ACACAGGAGC ARP2 
1 2 1 T A G C A T G G A A T C C T T A G A G A A A A T A T C A T T G A C C T A T C C A A T G C C A A T C G C T G C C T C C A G 
1 8 1 G C C C G A G A A T G A A G A A T G G C C T G A G C C T C C A G T G T T G A G T G G A G A C T T C T C A C C A G G A C T 
2 4 1 C C A C C A T C A T C C C T T C C T A T C C A T A C A G C A T C C C C A G T A T A A A T T C T G T G A T C T G C A T T C 
3 0 1 C A T C C T G T C T C A C T G A G A A G T C C A A T T C C A G T C T A T C C A C A T G T T A C C T A G G A T A C C T C A 
3 6 1 T C A A G A A T C A A A G A C T T C T T T A A A T T T C T C T T T G A T A T A C C C A T G A C A A T T T T T C A T G A A 
4 2 1 T T T C T T C C T C T T C C T G T T C A A T A A A T G A T T A C C C T T G C A C T G A A A A A A A N A A A G C N C T A T 
4 8 1 A G T G A G T C G T A T T A C A A G G G C G A A T T C C A G C A C A C T G G C N G C C G T T A C T A G T G G A T C C G A 
5 4 1 G C T C N G T A C N A G C T G A T G C A T A G C T G A G T A T T C T A T A G T G T C A C C T A A A T A G C T N G G C G T 
6 0 1 A A T C A T G N N C A T A G C N G T N N T C N G T G T G A N N T N G T N A T N C G C T N N N N N T N C N A N A C A C A T 
6 6 1 A C G A G C C N G A A N C N T N A G G G T N A A G C N N N G G G T G C N T A A T G A N T G A N C N A N C T C A T T N A A 
7 2 1 T N C T T N G C C 
C40.2: Sequence alignment of cDNA subclone TT5#1 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
T T 5 # 1 :122 a g c a t g g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 1 8 1 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l I M M M i l l � q � 
M o u s e M U P 工工 ：531 a g c a t g g a a t c c t t a g a g a a a a t a t c a t t g a c c t a t c c a a t g c c a a t c g c t g c c t c c a g g 590 
T T 5 # 1 :182 cccgagaatgaagaatggcctgagcctccagtgttgagtggagac^t ^〒t^〒，〒〒agg〒〒〒干 2 4 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M M l l l l l l l l l 1 • 
M o u s e M U P I I : 5 9 1 c c c g a g a a t g a a g a a t g g c c t g a g c c t c c a g t g t t g a g t g g a g a c t t c t c a c c a g g a c t c 6 5 0 
T T 5 # 1 :242 c a c c a t c a t c c c t t c c t a t c c a t a c a g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a t t c c 3 0 1 
i i i i i m i i i i i i m m m i i m i i i i i i i i i m i i 丄 丄 I 1 M l I i l l 1丄 
M o u s e M U P 工工 ：651 c a c c a t c a t c c c t t c c t a t c c a t a c a g c a t c c c c a g t a t a a a t t c t g t g a t c t g c a t t c c 710 
T T 5 # 1 :302 a t c c t g t c t c a c t g a g a a g t c c a a t t c c a g t c t ^ 〒 种 〒 〒 〒 ？ 巧 3 6 1 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M l l l l l l l l l l l l M o u s e M U P II : 7 1 1 a t c c t g t c t c a c t g a g a a g t c c a a t t c c a g t c t a t c c a c a t g t t a c c t a g g a t a c c t c a t 770 
T T 5 # 1 :362 c a a g a a t c a a a g a c t t c t t t a a a t t t c t c t t t g a t a ^ c ; : ? ? ， 們 冗 〒 朽 ， t ^ 4 2 1 
iiiTiimiiiiiimmmmii丨丨丨III丨 I丨丨ii uui UUUi 83� 
M o u s e M U P 工工 ：771 c a a g a a t c a a a g a c t t c t t t a a a t t t c t c t t t g a t a t a c c c a t g a c a a t t t t t c a t g a a t 830 
TTBttl :422 t t c t t c c t c t t c c t g t t c a a t a a a t g a t t a c c c t t g c a c t 4 6 1 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I M I I I 
M o u s e M U P 工工 ：831 t t c t t c c t c t t c c t g t t c a a t a a a t g a t t a c c c t t g c a c t 8 7 0 C40.3: Summary of sequence alignment of cDNA subclone TT5#1 with mouse MUP II 
FluoroDD gel TT (APS + ARP2) Subcloning Sequencing  
Differential display pattern Size of insert ^ 
Fed Starved Fed Starved (bp)  
Mouse major urinary 0 
TT5 ++ + ++ ++ TT5#1 420 M l 3 forward p ^ m II (MUP II) 340/340 
(380 bp) -20 (872 bp) (100%) 
385 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C41.1: DNA sequence of cDNA subclone TT5#9 using M13 reverse primer and the sequence of 3 A P S 
1 A T T A C A C T C A C T A T A G G G C G A A T T G G G G C C T C T A G A T G C A T G C T C G A G C G G C C G C C A G T G 
6 1 T G A T G G A T A T C T G C A G A A T T CGCCCTTGTA ATACGACTCA CTATAGGGCT TTTTTTTTTT APS 
1 2 1 T C A G T G C A A G G G T A A T C A T T T A T T G A A C A G G A A G A G G A A G A A A T T C A T G A A A A A T T G T C A 
1 8 1 T G G G T A T A T C A A A G A G A A A T T T A A A G A A G T C T T T G A T T C T T G A T G A G G T A T C C T A G G T A A 
2 4 1 C A T G T G G A T A G A C T G G A A T T G G A C T T C T C A G T G A G A C A G G A T A G A A T G C A G A T C A C A G A A 
3 0 1 T T T A T A C T G G G G A T G C T G T A T G G A T A G G A A G G G A T G A T G G T G G A G T C C T G G T G A G A A G T C 
3 6 1 T C C A C T C A A C A C T G G A G G C T C A G G C C A T T C T T C A T T C T C G G G C C T G G A G G C A G C G A T T G G 
4 2 1 C A T T G G A T A G G T C A A T G A T A T T T T C T C T A A G G A T T C C A T G C T A C T C C T G T G T G A A A T T G T 
4 8 1 T A T C C G C T A A G G G C G A A T T C C A G C A C A C T G G C N G C C G T N A C T A G T G N A T C C G A G C T C N G T 
5 4 1 A C C C A G C T G A T G C A T A G C T G A G T A T N C T A T A G T G T C A C C T A A A T A G C T G G N C G T A A T C A T 
6 0 1 G G T C A T A G C N G N T N T C N G T G T G A N N T N G T N A T N C G C T C A C N A T N C A C A C N A C A T A C G A N C 
6 6 1 N G N A G C N T N A G T G T A N G C N N N N N T N C T A T N N A C N A C T C A T A A A 
C41.2: Sequence alignment of cDNA subclone TT5#9 with mouse MUP II by BLAST searching 
with the National Center for Biotechnology Information database 
TT5tt9 .123 a q t q c a a q q q t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g 182 
I I I I M I I I M M M M M M M M I M M I M I I I I 11111111丄丄 I丄 11 M 只” 
M o u s e M U P II :870 a g t g c a a g g g t a a t c a t t t a t t g a a c a g g a a g a g g a a g a a a t t c a t g a a a a a t t g t c a t g 3^1丄 
TT5tt9 :183 q g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a 242 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M M I M I I I 
M o u s e M U P 工工 ：810 g g t a t a t c a a a g a g a a a t t t a a a g a a g t c t t t g a t t c t t g a t g a g g t a t c c t a g g t a a c a 7 5 1 
TT5tt9 :243 t q t q q a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t a g a a t g c a g a t c a c a g a a t t 302 
M M l l l l l l l l l I I I I I I I I I I I I I I I I I I l l l l l l l l l l l l l l l l l l l i l l l l l 
M o u s e M U P 工I :750 t g t g g a t a g a c t g g a a t t g g a c t t c t c a g t g a g a c a g g a t g g a a t g c a g a t c a c a g a a t t 6 9 1 
T T 5 # 9 :303 tatactggggatgctgtatggataggaagggatgatggtgg，gt^〒〒’ggt^gaga，gY〒t^〒 362 l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l M l l l l l l l l l l l l l l l l l l I l l 
M o u s e M U P II :690 t a t a c t g g g g a t g c t g t a t g g a t a g g a a g g g a t g a t g g t g g a g t c c t g g t g a g a a g t c t c 6 3 1 
T T 5 # 9 :363 c a c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c t g g a g g c a g c g a t t g g c a 422 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I I I M i l l ；71 
M o u s e M U P 工工 ：630 c a c t c a a c a c t g g a g g c t c a g g c c a t t c t t c a t t c t c g g g c c t g g a g g c a g c g a t t g g c a 5 7 1 
T T 5 # 9 ：423 t t q q a t a g q t c a a t q a t a t t t t c t c t a a g g a t t c c a t g c t 4 6 2 
M I I M I I I M M M M M M M M M I I M I I I I I I I I I 。 ， 
M o u s e M U P 工工 ：57〇 t t g g a t a g g t c a a t g a t a t t t t c t c t a a g g a t t c c a t g c t 5 3 1 C41.3: Summary of sequence alignment of cDNA subclone TT5#9 with mouse MUP II 
FluoroDD gel TT (AP5 + ARP2) Subcloning Sequencing ；  Differential display pattern Size of insert 
F : - ppA一)。PARa(-7r “ t - : P_r ( « ) Fed Starved Fed Starved ^  
Mouse major urinary � 
TT5 + ++ ++ TT5#9 420 M13 reverse protein II (MUP II) 339/340 (99%) 
(380 bp) J (872 bp) � 
386 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C42.1: DNA sequence of cDNA subclone UU1#1 using M13 forward -20 primer and the sequence of3，-AP2 
1 T T T A C G A C C T N C T A T A G G G C G A A T T G G G C C C T C T A N A T G C A T G C T C G N A G C G G C C G C C A T 
6 1 GTGATGGATA TCTGCAGAAT TCGCCCTTGG TAATACGACT CACTATAGGG CTTTTTTTTT AP2 
1 2 1 T T G C T G T G C A T G A C A C T G G G A A C T T T A T T G C A G A A A G G A G G G A A G A T G G A G A A A C T C G T G 
1 8 1 T G A G G A T T A A T C A G G T A G A A A G A G A C T A T G C A G G G T A G A T T T A G A T G A A C A C A T T A G G T A 
2 4 1 A C T G T C A T G T G A A A A T G A T A C T A A G C T G A A T A A T G T C T T C A C A A T G A T G T T C A G G C C T T G 
3 0 1 G A T T T T G G A G A C C A T G G T A C A T A T T G A A T G A T T C C T C A T A A T T C A G A A G G A A C T T A G T A G 
3 6 1 G T T A G A T T G A A T A A G A T A C A T T T A G A T G G G A A A A C T A T C T T G G A G C T T T T A G G G A T C T T A 
4 2 1 A T G A T G T C A T A A G C A T C T G T A A A A G G T A A G G A C A T T A G A A G A G A G G G G A T G A G G A N G G T G 
4 8 1 C T G G C T T T G A A G C A G N N G A N T A T T N C A G T G C N A A N G A N T G A T G A T C T A T A C T G A A C A G A G 
5 4 1 G A T G A G A G G A C T C T C T G G A G T A T N C T T C T G A A A A N N G T A G G T C A C A C C N A A C N A C T T A G C 
6 0 1 N N N T C T C C A G T G A A A C N C T N C T C A G A C A T T G G A G C T C N C N A C A G N N N A G T G A N C T C T G A G 
6 6 1 A T G T A N N T A A T N C N T T T N G A C T C G C C N C A G T T T 
C42.2: Sequence alignment of cDNA subclone UU1#1 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
U U i # i ：128 q c a t q a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a t 1 8 7 
！M I I M I M I M I M I M M M I M M M I I l l l l l 1 1 1 1 1 1 1 111 I 11 丨 I 丨 I M 
M o u s e C Y P 4 A 1 0 : 2 0 7 7 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a 2 0 1 8 
U U 1 # 1 ： 1 8 8 t a a t c a g g t a g a a a g a g a c t a t g c a界 g t ^， ^ 3 ^，〒門 c；：巧， t ^ t |：，咒巧 C j：， 2 4 7 
l l l i m i l l l l l l l l l l l l l l l l i m i l l l l l l l l l l l l l l l l l 丄  I I I 丄 I I I M M I 
M o u s e C Y P 4 A 1 0 : 2 0 1 7 t a a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 1 9 5 8 
U U i # l ： 2 4 8 tgtgaaaatgatactaagctgaataatgtcttcacaatgatgt’〒agg〒〒t^Ygg予t^^t^t^g 3 0 7 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I 111 I 
M o u s e C Y P 4 A 1 0 : 1 9 5 7 t g t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t t t t g 1 8 9 8 
nui#l :308 q a g a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 367 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M l I M l l l l l I I 
M o u s e C Y P 4 A 1 0 : 1 8 9 7 g a g a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 1 8 3 8 
U U 1 # 1 : 3 6 8 t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t ^界，， t ^ 1 ^ t ^，， 3 ? t ^ t ^冗，^朽 4 2 7 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M M I I I I N N I I l l l l l M o u s e C Y P 4 A 1 0 : 1 8 3 7 t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c t t a a t g a t g t 
U U 1 # 1 :428 cataagcatctgtaaaaggtaaggacattagaag予罕予g罕罕罕，千罕予罕g予ngg〒罕〒〒早早？〒〒487 i imLimiiiimimimiiiimimimmiiii I I I I M I M M Mouse CYP4A10 :1777 c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a g g g t g c t g g c t t 1718 
丨〒丨丨〒丨丨广丨丨n丨丨丨丨n丨丨〒丨丨丨n丨丨n〒丨n丨〒丨丨〒丨丨Tmnmnmmm�r47 
M o u s e C Y P 4 A 1 0 ： 1 7 1 7 t g a a g c a g g g g a a t a t t c c a g t g c c a a g g a a t g a t g a t c t a t a c t g a a c a g a g g a t g a g a 1 6 5 8 
mnnm碰丨nmm丨rnmmmnrnnmm二mT 
M o u s e C Y P 4 A 1 0 ： 1 6 5 7 g g a c t c t c t g g a g t a t t c t t c t g a a a a a g g t a g g t c a c a c c - a a c a a c t t a g c - t t t c t c 1 6 0 0 
TTTjiiii : 608 c a g t q a a a c n c t n c t c a g a c a t t g g a g c t c 6 3 7 
I I I I I M M I I M M M I I I M M M M ， … 
M o u s e C Y P 4 A 1 0 ：1599 c a g t g a a a c t c t t c t c a g a c a t t g g a g c t c 1 5 7 0 C42.3: Summary of sequence alignment of cDNA subclone UU1#1 with mouse CYP4A10 
FluoroDD gel UU (AP2 + ARP 12) Subcloning Sequencing  
Differential display pattern Size of insert , , “ a i n p 
Fed Starved Fed Starved (bp)  
M l 3 forward Mouse CYP4A10 0 
UU1#1 + UU1#1 1000 20 (2077 bp) 491/510 (96%) 
(975 bp) — ^  
387 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C43.1: DNA sequence of cDNA subclone UU1#4 using M13 reverse primer and the sequence of5'-ARP12 
1 T G C C A A G C T A T T T A G G T G A C A C T A T A G A A T A C T C A A G C T A T G C A T C A A G C T T G G T A C C G A 
6 1 G C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G A T A A C A A T A R P 12 
1 2 1 T T C A C A C A G G A G G T A C T A A G G C T C T A C C C A C C T G T C C C A G G C A T T G T C A G A G A A C T C A G T 
1 8 1 A C A T C T G T C A C C T T C C C T G A T G G A C G C T C T C T A C C C A A A G G T G T C C A G G T C A C A C T C T C C 
2 4 1 A T T T A T G G T C T C C A C C A C A A C C C G A A G G T G T G G C C A A A T C C A G A G G T G T T T G A C C C T T C C 
3 0 1 A G G T T T G C A C C A G A C T C T C C C C G A C A C A G C C A C T C A T T C C T G C C C T T C T C A G G A G G A G C C 
3 6 1 A G G A A C T G C A T T G G G A A A C A A T T T G C T A T G A G T G A G C T G A A G G T G A T T G T G G C C C T G A C A 
4 2 1 C T G C T C C G C T T C G A A C T A C T G C C A G A N N C T A C C A G N G T N C C C A T G C C C T T A G C C C G A C T N 
4 8 1 G T G C T G A A G T C C A A N A A T G G G G A T C T A C C T A C A T C T C A A G A N G C T C C A C T G G T N C T G T T G 
5 4 1 T G G A G C T C C A T G T C T G N G A G A G N N C A C T G N A G A A G C T A G T G T G G T G T G A C T A C C T T T C A G 
6 0 1 A N A T C T C A G A G A G T C T C T C A T C N C N G N T C A G T A T N N A T C A T C A T N C N T G G G C N N T G N A N N 
6 6 1 A T T N C C N N G C T T C A A A N G C C 
C43.2: Sequence alignment of cDNA subclone UU1#4 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
U U 1 # 4 ：136 ctaaggctctacccacctgtcccaggcattgtc予g〒罕予予？t^?予罕千予？予〒？〒罕〒〒予〒？〒〒？ 195 
miffiimiiiiiiiiimiimmiimim丄III 1川丨丄丨I山丄 ^^^^  
M o u s e C Y P 4 A 1 0 ：1164 c t a a g g c t c t a c c c a c c t g t c c c a g g c a t t g t c a g a g a a c t c a g t a c a t c t g t c a c c t t c 12^3 
UU1#4 ： 196 cctgatggacgctctctacccaaaggtgtcc〒ggt^(^〒？〒？t^?t^?〒，t^〒t^，t^尹t^〒二〒，〒 255 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I M M I M N I N N I I I M o u s e C Y P 4 A 1 0 ：1224 c c t g a t g g a c g c t c t t t a c c c a a a g g t g t c c a g g t c a c a c t c t c c a t t t a t g g t c t c c a c i^BJ 
：256 mmnmm〒遍m丨mm前nmmnmmmnnmr" 
M o u s e C Y P 4 A 1 0 ： 1 2 8 4 c a c a a c c c g a a g g t g t g g c c a a a t c c a g a g g t g t t t g a c c c t t c c a g g t t t g c a c c a g a c 1 3 4 3 
U U i # 4 ：316 tctccccgacacagccactcattcctgcccttctcagga罕罕〒罕？？〒罕罕予予？〒罕〒予〒〒罕罕g 375 
i i i m i T i i i i i i i i i i i m m i i m i i m i l 11111111 m m I I I 丄丄丄 
M o u s e C Y P 4 A 1 0 ： 1 3 4 4 t c t c c c c g a c a c a g c c a c t c a t t c c t g c c c t t c t c a g g a g g a g c c a g g a a c t g c a t t g g g 1 4 0 3 
U U 1 # 4 :376 a a a c a a t t t g c t a t g a g t g a g c t g a a g g t g a H 轩 两 ？ ？ 巧
4 3 5 
iiiimiimmimmmm丨丨III丨11丨丨11丨丄丨I!丨I丨丨川III…� 
M o u s e C Y P 4 A 1 0 : 1 4 0 4 a a a c a a t t t g c t a t g a g t g a g c t g a a g g t g a t t g t g g c c c t g a c a c t g c t c c g c t t c g a a 1 4 6 3 
mnmmnnmmnr丨mmmmmmnmmmnr495 
M o u s e C Y P 4 A 1 0 : 1 4 6 4 c t a c t g c c a g a t c c t a c c a g g g t c c c c a t g c c c t t a g c c c g a c t t g t g c t g a a g t c c a a a 1 5 2 3 
U U i # 4 : 4 9 6 a a t g g g g a t c t a c c t a c a t c t c a a g a n g c t c c a ? 转 咒 ， g 〒 t ^ ? ( ^ ? 550 
M l I I I M M M M I M I M M M I l l l l l l l l l I 1 1 1 1 1 1 1 1 1 1 1 1丄 1 1 1 
M o u s e C Y P 4 A 1 0 ：1524 a a t - g g g a t c t a c c t a c a t c t c a a g a a g c t c c a c t g a t a c t g t t g t g g a g c t c c a l b " C43.3： Summary of sequence alignment of cDNA subclone UU1#4 with mouse CYP4A10 
FluoroDD gel UU (AP2 + ARP12) Subcloning Sequencing  
Differential display pattern Size of insert , , “ “ Fragment Subclone released by Sequence homology E'Value F r a ^ e m p p A R a (+/+) PPARa (-/-) N o . ECORI cut (Transcript size) (% Identity) Fed Starved Fed Starved ( b ^  
— Mouse CYP4A10 0 
UUl _ + _ _ UUl#4 1000 M l 3 reverse (2077 bp) 404/415 (97%) (975 bp) L ^  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C44.1: DNA sequence of cDNA subclone W 5 # 2 using M13 forward -20 primer and the sequence of 3,-AP2 
1 T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A N A T G C A T G C T C G N A G C G G C C G C C A G T 
6 1 GTGATGGATA TCTGCAGAAT T C G C C C T T G T AATACGACTC ACTATAGGGC TTTTTTTTTT AP2 
1 2 1 T G C A T G A C A C T G G G A A C T T T A T T G C A G A A A G G A G G G A A G A T G G A G A A A C T C G T G T G A G G A 
1 8 1 T T A A T C A G G T A G A A A G A G A C T A T G C G G G G T A G A T T T A G A T G A A C A C A T T A G G T A A C T G T C 
2 4 1 A T G T G A A A A T G A T A C T A A G C T G A A T A A T G T C T T C A C A A T G A T G T T C A G G C C T T G G A T T T T 
3 0 1 G G A G A C C A T G G T A C A T A T T G A A T G A T T C C T C A T A A T T C A G A A G G A A C T T A G T A G G T T A G A 
3 6 1 T T G A A T A A G A T A C A T T T A G A T G G G A A A A C T A T C T T G G A G C T T T T A G G G A T C T T A A T G A T G 
4 2 1 T C A T A A G C A T C T G T A A A A G G T A A G G A C A T T A G A A G A G A G G G G A T G A G G A G G G T G C T G G C T 
4 8 1 T T G A A G C A G G N G A A T A T N C C A G T G C C N A N N A A T G A T G A T C T A T A C T G A A C A G A G G A T G A G 
5 4 1 A G G A C T C T C T G G A G T A T C C T T C T G A A A A A G G T A G G T C A C A C C A C A A A C T A G C T T T C T C A G 
6 0 1 T G A A C C T T C T C A G A C A T N G N G C T C C A A N C G A N T N G T G A N C T C T G A A A T T A N N T N A T C C C T 
6 6 1 N N N G A C T N A G C A A G T N N G C T A G G C A T G G G G 
C44.2: Sequence alignment of cDNA subclone VV5#2 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
W 5 t t 2 ：122 q c a t g a c a c t g q g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a t 181 
I M I I M I M I I M M M I M M M M M M 111 丨1111111111 丨 11111 _ � 
M o u s e C Y P 4 A 1 0 ：2077 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a 2018 
V V 5 # 2 ：182 t a a t c a g g t a g a a a g a g a c t a t g c g g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 2 4 1 M M M I I M M M M M M M M I I I I I I I I I I I I I I M l  M o u s e C Y P 4 A 1 0 ：2017 t a a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 1958 
V V 5 # 2 :242 t q t q a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t t t t g 301 
M o u s e C Y P 4 A 1 0 ：1957 t g t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t c a g g c c t t g g a t t t t g 1898 
W 5 # 2 ：302 q a q a c c a t g g t a c a t a t t q a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 361 
l l l l l l l l l l l l l l l l l l l N l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I M M 
M o u s e C Y P 4 A 1 0 ：1897 g a g a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g a t 1838 
V V 5们 ：362 t q a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c t t a a t g a t g t 4 2 1 
I I I M M M M M M M M M M M I I I I I I I I I M I M M 1 
M o u s e C Y P 4 A 1 0 ：1837 t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c t t a a t g a t g t l / / y 
W 5 t t 2 :422 c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a g g g t g c t g g c t t 4 8 1 
I M I I I M M M M M M M M M M M M M I 11 111 11111丄 11 111 ^^^^ 
M o u s e C Y P 4 A 1 0 ：1777 c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a g g g t g c t g g c t t 1718 
W 5 # 2 :482 t q a a q c a g g n g a a t a t n c c a g t g c c n a n n a a t g a t g a t c t a t a c t g a a c a g a g g a t g a g a 541 
i i M i M i i I m i l I I I I I I I I I i i m m i i m i i i i i i i i i i i i i i i i i 
M o u s e C Y P 4 A 1 0 ：1717 t g a a g c a g g g g a a t a t t c c a g t g c c a a g g a a t g a t g a t c t a t a c t g a a c a g a g g a t g a g a 丄bbts 
W 5 # 2 ：542 q q a c t c t c t g g a q t a t c c t t c t g a a a a a g g t a g g t c a c a c c a 583 
iiiiiiiiiiiiiiii m m mil 11III m m m …； 
M o u s e C Y P 4 A 1 0 ： 1 6 5 7 g g a c t c t c t g g a g t a t t c t t c t g a a a a a g g t a g g t c a c a c c a 1 6 1 6 C44.3: Summary of sequence alignment of cDNA subclone W5#2 with mouse CYP4A10 
FluoroDD gel VV (AP2 + ARPl8) Subcloning — Sequencing  
Differential display pattern Size of insert 
Fi-agment Subclone released by p Sequence homology E-value 了 PPARa (+/+) PPARa (_/_) n o . Eco^ cut ？“™®: (Transcript size) (% Identity) 
Fed Starved Fed Starved M  
M l 3 forward Mouse CYP4A10 0 
(660bp) + ++ + + VV5#2 700 .20 (2077 bp) 454/462 (98%) 
389 
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C45.1: DNA sequence of cDNA subclone VV5#3 using M13 forward primer and the sequence of3,-AP2 
1 T T T A C G A C T C A C T A T A G G G C G A A T T G G G G C C T C T A G A A T G C A T G C T C G G A G C G G C C G C C A 
6 1 GTGTGATGGA TATCTGCAGA ATTCGCCCTT GTTAATACGA CTCACTATAG GGCTTTTTTT AP2 
1 2 1 T T T T T G C A T G A C A C T G G G A A C T T T A T T G C A G A A A G G A G G G A A G A T G G A G A A A C T C G T G T G 
1 8 1 A G G A T T A A T C A G G T A G A A A G A G A C T A T G C A G G G T A G A T T T A G A T G A A C A C A T T A G G T A A C 
2 4 1 T G T C A T G T G A A A A T G A T A C T A A G C T G A A T A A T G T C T T C A C A A T G A T G T N A C A G G C C T T G N 
3 0 1 G A T T T A G G A G A C C A T G G T A C A T A T T G A A T G A T T C C T C A T A A T T C A G A A G G A A C T T A G T A G 
3 6 1 G T T A G A T T G A A T A A G A T A C A T A T A N G T G G G A A A A C T A T C T A G G A G C T T T C A G G G A T C T T A 
4 2 1 A T G A T G T C A T A A G C A T C T G T A A A A G G T A A G G A C A T N A G A A G A G A N G G G A T G A A G A G G G T G 
4 8 1 C T G G C T T T G A A G C A G G G G A N T A T A C C A G T G C C A A N G A N T G A T G A T C T A T A C T G A A C A G A C 
5 4 1 G A T G A N A G G A C T C T C T G G A G T A N N C T N C T G N A A A A N G T A G G T C N C N N C C A C N A C C T A G C N 
6 0 1 T N N C T C N A G T G A A A C T C T T C T C A G A C N T T G N A G C N C N C N A C A N A N T C A N N G N A G C T T C T G 
6 6 1 A G A T G T A G G T N N A T C C A T N N T G G A C N T C A N N C C N A G T T T 
C45.2: Sequence alignment of cDNA subclone VV5#3 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
W 5 # 3 ：12 6 q c a t q a c a c t q g q a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a t 1 8 5 
I M I I M M M M M M M M M M I M M M I I I l l l l l 1 1 i 1 1 1 1 1 1 1 1 1 1 l l l l l 
M o u s e C Y P 4 A 1 0 : 2 0 7 7 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a 2 0 1 8 
W 5 t t 3 :186 t a a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 2 4 5 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M l l l l l I I 
M o u s e C Y P 4 A 1 0 : 2 0 1 7 t a a t c a g g t a g a a a g a g a c t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 1 9 5 8 
W 5 t t 3 :246 t g t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t n a c a g g c c t t g n g a t t t 3 0 5 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I M M M M I I I 
M o u s e C Y P 4 A 1 0 ： 1 9 5 7 t g t g a a a a t g a t a c t a a g c t g a a t a a t g t c t t c a c a a t g a t g t t - c a g g c c t t g - g a t t t 1 9 0 0 
W 5 # 3 ： 3 0 6 a q q a q a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g 3 6 5 
Mi〒iiiimii I I l l l l l l l l l l l l I I I l l l l l l l l lllllllll丄丄II I I I II 1 議 
M o u s e C Y P 4 A 1 0 ：1899 t g g a g a c c a t g g t a c a t a t t g a a t g a t t c c t c a t a a t t c a g a a g g a a c t t a g t a g g t t a g 1 8 4 0 
W 5 # 3 :366 a t t g a a t a a g a t a c a t a t a n g t g g g a a a a c t a t c t a g g a g c t t t c a g g g a t c t t a a t g a t 4 2 5 
M I I M M M M M M I I 11111 M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I M 111 11111 M 
M o u s e C Y P 4 A 1 0 ：1839 a t t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c t t a a t g a t 1 7 8 U 
W 5 # 3 : 4 2 6 g t c a t a a g c a t c t g t a a a a g g t a a g g a c a t n a g a a g a g a n g g g a t g a a g a g g g t g c t g g c 4 8 5 
I M M M M M M M M I M M M M l l l l l l l l l l l l I III丄 I I I I I I I I M M M 
M o u s e C Y P 4 A 1 0 : 1 7 7 9 g t c a t a a g c a t c t g t a a a a g g t a a g g a c a t t a g a a g a g a g g g g a t g a g g a g g g t g c t g g c 1 7 2 0 
衍〒丨丨〒丨丨〒〒丨〒丨n访a丨丨丨丨丨〒丨丨丨丨n〒丨n丨〒丨丨〒丨丨丨讯丨丨丨〒丨丨丨丨〒丨。〒丨丨竹545 
M o u s e C Y P 4 A 1 0 ：1719 t t t g a a g c a g g g g a a t a t t c c a g t g c c a a g g a a t g a t g a t c t a t a c t g a a c a g a g g a t g a 1 6 6 0 
：
5 4 6
 i T T - T m m m n n T r m n m n m m n n i n r m r r n M " 
M o u s e C Y P 4 A 1 0 ：1659 g a g g a c t c t c t g g a g t a t t c t t c t g a a a a a g g t a g g t c a c a c c a a c a a c t t a g c - t t t c t 1 6 0 1 
VV5tt3 ： 6 0 6 c n a g t g a a a c t c t t c t c a g a c n t t g n a g c 6 3 4 
I iiiiiiiimiimm 111 m ， ⑶ 
M o u s e C Y P 4 A 1 0 ： 1 6 0 0 c c a g t g a a a c t c t t c t c a g a c a t t g g a g c 1 5 7 2 C45.3: Summary of sequence alignment of cDNA subclone VV5#3 with mouse CYP4A10 
FluoroDD gel W (AP2 + ARP 18) Subcloning ~ Sequencing  
Differential display pattern Size of insert 
F : e n t p p A 一 ) 一 - 「 « ^ e ( 二 = f ( 。 二 ） 
Fed Starved Fed Starved W  ——7777^ M l 3 forward Mouse CYP4A10 0 VV5 + 付 + + W 5 # 3 700 .20 (2077 bp) 473/509 (92%) (660 bp) “ 
390 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C46.1: DNA sequence of cDNA subclone VV5#4 using M13 reverse primer and the sequence of5'-ARP18 
1 T C C N G C T A T T T A G G T G A C A C T A T A G A A T A C T C A A G C T A T G C A T C A A G C T T G G T A C C G A G C 
6 1 T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G A T A A C A A T T T A R P 18 
1 2 1 C A C A C A G G A T G A T G C T A C C A G G G T C C C C A T G C C C T T A G C C C G A C T T G T G C T G A A G T C C A A 
1 8 1 A A A T G G G A T C T A C C T A C A T C T C A A G A A G C T C C A C T G A T T C T G T T G T G G A G C T C C A A T G T C 
2 4 1 T G A G A A G A G T T T C A C T G G A G A A A G C T A A G T T G T T G G T G T G A C C T A C C T T T T T C A G A A G A A 
3 0 1 T A C T C C A G A G A G T C C T C T C A T C C T C T G T T C A G T A T A G A T C A T C A T T C C T T G G C A C T G G A A 
3 6 1 T A T T C C C C T G C T T C A A A G C C A G C A C C C T C C T C A T C C C C T C T C T T C T A A T G T C C T T A C C T T 
4 2 1 T T A C A G A T G C T T A T G A C A T C A T T A A G A T C C C T A A A A G C T C C A A G A T A G T T T T C C C A T C T A 
4 8 1 A A T G T A T C T T A T T C A A T C T A A C C T A C T A A G T T C C T T C T G A A T T A T G A G G A A T C N T N C A A T 
5 4 1 A T G T A C C A T G G T C T C C A A A A T C C C A G G C N T G A A C A T C A T N G T G A A G A C A T N A T T C A G C T N 
6 0 1 A G T A T C A T T T N C A C A T G A C A G T N A C C T A N T G T G T T C A T C T A N A T C A C C N T G C A T A G T C T C 
6 6 1 T T C T A N C N G A T N A N T C N C A C C G A G N T T C T C A T N T C C C 
C46.2: Sequence alignment of cDNA subclone VV5#4 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
W 5 # 4 ： 1 3 5 c t a c c a g g g t c c c c a t g c c c t t a g c c c g a c t t g t g ? ! ^ 罕予〒罕 t^ ??予予，予〒，罕〒〒〒〒予〒？ 1 9 4 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I I I I I N I I I 1 I I I 1 � 
M o u s e C Y P 4 A 1 0 ：1477 c t a c c a g g g t c c c c a t g c c c t t a g c c c g a c t t g t g c t g a a g t c c a a a a a t g g g a t c t a c c 1536 
W 5 # 4 ： 195 t:acat:ct:caagaagctccactgattctgtt:gtgg，？？1^?(;:，，gt^?Y朽朽，g，巧t^二，254 l l l l l i l l l l l l l l l l l l l l l l l l M M I I I I I I I M M M M M M M M M M M M 
M o u s e C Y P 4 A 1 0 :1537 t a c a t c t c a a g a a g c t c c a c t g a t a c t g t t g t g g a g c t c c a a t g t c t g a g a a g a g t t t c a 1596 
=25丨丨〒〒丨〒丨丨丨〒丨丨丨丨〒丨丨〒顶〒丨〒丨〒丨丨丨丨丨丨丨丨丨丨丨-〒丨丨丨丨丨-丨〒丨〒丨314 
M o u s e C Y P 4 A 1 0 ：1597 c t g g a g a a a g c t a a g t t g t t g g t g t g a c c t a c c t t t t t c a g a a g a a t a c t c c a g a g a g t c 1656 
W 5 # 4 ： 3 1 5 c t c t c a t c c t c t g t t c a g t a t a g a t c a t c a t t c c t t g g c a c t g g 〒 ， t ^ 〒 t ^ t ^ ? ? ? ? t ^ 罕 ？ t ^ 〒 ？ 3 7 4 I I I I 1 I I I I I I I I I I I I I I M I 1 I I I I I I I I 1 I I I I I I I I I M I I 1 I I I I I I I I 
M o u s e C Y P 4 A 1 0 ：1657 c t c t c a t c c t c t g t t c a g t a t a g a t c a t c a t t c c t t g g c a c t g g a a t a t t c c c c t g c t t c 1 7 1 6 
W 5 # 4 ： 3 7 5 a a a g c c a g c a c c c t c c t c a t c c c c t c t c t t c t a a t 轩 〒 ？ 朽 〒 - ? 〒 t ^ ， t ^ 4 3 4 1 I I I I I I 1 I 1 I 1 I 1 I I I I I I I I I I I I I I I 1 I I I I I I I I I I I M M M N I I I I N 1 1 N I M o u s e C Y P 4 A 1 0 ：1717 a a a g c c a g c a c c c t c c t c a t c c c c t c t c t t c t a a t g t c c t t a c c t t t t a c a g a t g c t t a t l//b 
W 5 # 4 ：435 gacatcattaagatccctaaaagctccaagatagl^Ht^???，巧t^，，，t^朽，(^〒 〒？ 494 f l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M M I I I N N I I I I I I 
M o u s e C Y P 4 A 1。 ：1777 g a c a t c a t t a a g a t c c c t a a a a g c t c c a a g a t a g t t t t c c c a t c t a a a t g t a t c t t a t t c 1836 
W 5 # 4 : 4 9 5 aatctaacctactaagttccttct朽，t^ 1^，t^ Wg矜，巧nt^ n(|:，，t^ ，t^ g1^，？？，〒？g〒？〒 5 5 4 
I I I I I I 1 I 1 I I 1 I I I I 1 I I丨丨丨丨丨I丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨I丨丄丨III 
M o u s e C Y P 4 A 1。 ：1837 i a t c t i i c c t a i k a g t t c c t t c t g a a t t a t g a g g a a t c a t t c a a t a t g t a c c a t g g t c t 1896 
nnnmimnm丨 rnnrm丨mnnmmn〒丨 m rnrm 二4 
M o u s e C Y P 4 A 1 0 ：1897 c i a U a t c c a a g g c c t g a a c a t c a t t g t g a a g a c a t t a t t c a g c t t a g t a t c a t t t t c a c 1956 
丨前nnmrmmmnn丨nnimmmm : 
M o u s e C Y P 4 A 1 0 :1957 a t g a c a g t t a c c t a a t g t g t t c a t c t a a a t c t a c c c t g c a t a g t c t c t t 2005 C46.3: Summary of sequence alignment of cDNA subclone W5#4 with mouse CYP4A10 
FluoroDD gel VV (AP2 + ARP18) Subcloning Sequencing  
Differential display pattern Size of insert . Fragment r ^ ^ Subclone released by p蘭^r Sequence homology E'Value Fra為 =ent (+/+) PPARa (-/-) ^ 0 . EcoKL cut (Transcript size) (% Identity) 
Fed Starved Fed Starved (bp)  Mouse CYP4A10 0 VV5 + ++ + + VV5#4 700 M13 reverse (2077 bo) 515/529 (97%) 
(660 bp) ^ ^  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C47.1: DNA sequence of cDNA subclone VV8#5 using M13 forward -20 primer and the sequence of5,-ARP18 
1 N G A A T G N T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G N A G C G G 
6 1 C C G C C A G T G T GATGGATATC T G C A G A A T T C GCCCTTAGCG GATAACAATT TCACACAGGA ARP 18 
1 2 1 T G A T G C T A C C C A A A C A G C A T C T G C T T A A A A T C C C A C C C A C A G C A G T A A A T A G G G A C T A G A 
1 8 1 C A C A G C A G C C T C A T A G G A T C T G C T C T G T G G T G A A C G G C C T C C C T C T G T G A A T C C T G G G T G 
2 4 1 T C T C T C C C T G A C A C A A T C A G C G C C A C A G G C T C A T G C T G C T G T G G A C C A G A G C T C C C C T G T 
3 0 1 G A A G A G G G A G A T G A A A G A A A G G G G A G C C G C T G A C C T G C A G G G A T G C A G T A T C T T T C C C C A 
3 6 1 C A G C C C C G G C A G A G C A G C C A T T T G T C A C A G C C T T A T T C C T C A G A C T C T G G G G C T A T T A T A 
4 2 1 G T T T A T G C T T G T T T C T T N N A G T T T C T A A A T T T T G T A T C T T G T T C T A A A A T A A T A T G T G G C 
4 8 1 A A T A A A A A A G A G A G A A G A N A T T A C T T G C N N A N N A N N A A A A G C C C T A T A G T G A G T C G T A T N 
5 4 1 A C A A G G N C G A A T T C C A G C A C C C T G G C G G N C N G T N A C T A N T N G A T C C G A G C T C G G T A C C A A 
6 0 1 G C T N G A T G C N T N N C T G A G N A T N N N A T N N T G T N N C T A A N T A G C T G G G N G T A N T A T G N T C A T 
6 6 1 A N N N G T T C C T G T G T G A N N T G N T A T N C G C N T C N A A T C C C C C A A T T N G N C C C G A A C T T A N N G 
7 2 1 T T A G C N G G G G N N N 
C47.2: Sequence alignment of cDNA subclone VV8#5 with mouse HMG-CoAS by BLAST searching 
with the National Center for Biotechnology Information database 
W 8 # 5 ：124 t g c t a c c c a a a c a g c a t c t g c t t a a a a t c c c a c c c a c a g c a g t a a a t a g g g a c t a g a c a c 183 l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M M I I m i l l 
M o u s e H M G - C o A S :1613 t g c t a c c c a a a c a g c a t c t g c t t a a a a t c c c a c c c a c a g c a g t a a a t a g g g a c t a g a c a c 1 6 " 
W 8 # 5 :184 a g c a g c c t c a t a g g a t c t g c t c t g t g g t g a a c g g c c t c c c t c t g t g a a t c c t g g g t g t c t 243 
l l l l l l l l l l l l l l l l l l I I I I I M M M I I I I M M M M M I l l 11 M I J 1 1 — … ^ ？ ” 
M o u s e H M G - C o A S ：1673 a g c a g c c t c a t a g g a t c t g c t c t g t g g t g a a c g g c c t c c c t c t g t g a a t c c t g g g t g t c t 1 7 3 2 
W 8 # 5 :244 ctccctgacacaatcagcgccacaggctcatgctg?!^罕辨〒？？〒罕予罕〒〒〒〒？〒〒早〒早，，303 
|||||1111111111111111111111111111111111111111111111111 1NII 
M o u s e H M G - C o A S ：1733 c t c c c t g a c a c a a t c a g c g c c a c a g g c t c a t g c t g c t g t g g a c c a g a g c t c c c c t g t g a a 1792 
M o u s e H M G - C o A S ：1793 g a g g g a g a t g a a a g a a a g g g g a g c c g c t g a c c t g c a g g g a t g c a g - a t c t t t c c c c a c a g 1 8 5 1 
--�mmmmmnnrmrnnn�mmmrmnnmm丨二7 
M o u s e H M G - C o A S :1852 - c c c g g c a g a g c a g c c a t t t g t t a c a g - c t t a t t - c t c a g a c t c t - g g g c t a t t a t a g t t 1907 
W 8 # 5 ： 424 tatgcttgtttcttnnagtttctaaattttgtatct:tgt^t^?Y〒〒，〒 1^〒33g〒？朽，，〒 483 l l l l l l l l l l l l l l M M M M M M M M M M I I M M M M M M I M M M I I M o u s e H M G - C O A S : 1 9 0 8 t a t g c t t g t t t c t t a a a g t t t c t a a a t t t t g t a t c t t g t t c t a a a a t a a t a t g t g g c a a t 1 9 6 7 
V V 8 # 5 ：484 a a a a a a g a g a g a a g a n a t t a c t t g 507 l l l l l l l l l l l l l l I I I I I I M _ 
M o u s e H M G - C o A S ： 1 9 6 8 t a a a a a g a g a g a a g a a a t t a c t t g 1 9 9 1 
C47.3； Summary of sequence alignment of cDNA subclone W8#5 with mouse HMG-CoAS 
FluoroDD gel VV (AP2 + ARP 18) Subcloning Sequencn^ • ~ 
Differential display pattern Size of insert “ F 
F : - 二 y P - e r « ) 
Fed Starved Fed Starved ^  
Mouse 3-hydroxy-3 -
methylglutaryl-
M l 3 forward Coenzyme A 0 
VV8 - + - - VV8#5 460 _20 synthase 2 374/384 (97%) 
(430 bp) (HMG-CoAS) 
(2011 bp)  
392 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C48.1: DNA sequence of cDNA subclone VV8#6 using M13 reverse primer and the sequence of3，-AP2 
1 T G C C A A G C T A T T T A G G T G A C A C T A T A G A A T A C T C A A G C T A T G C A T C A A G C T T G G T A C C G A 
6 1 GCTCGGATCC ACTAGTAACG GCCGCCAGTG TGCTGGAATT CGCCCTTGTA ATACGACTCA AP2 
1 2 1 CTATAGGGCT TTTTTTTTTT GCAAGTAATT TCTTCTCTCT TTTTAATTGC CCCATATTAT 
1 8 1 T T T A G A A C A A G A T A C A A A A T T T A G A A A C T T T A A G A A A C A A G C A T A A A C T A T A A T A G C C C A 
2 4 1 G A G T C T G A G A A T A A G C T G T A A C A A A T G G C T G C T C T G C C G G G C T G T G G G G A A A G A T C T G C A 
3 0 1 T C C C T G C A G G T C A G C G G C T C C C C T T T C T T T C A T C T C C C T C T T C A C A G G G G A G C T C T G G T C 
3 6 1 C A C A G C A G C A T G A G C C T G T G G C G C T G A T T G T G T C A G G G A G A G A C A C C C C A G G A T T C C A C A 
4 2 1 G A G G G N A G G C C C G T T C A C C C A C A G A A G C A G A T C C C T A T G N A G G G C T G C T G T G T C T A G T C C 
4 8 1 C T A T T T A C T G C T G T G G G T G G G A T T T A A A G C A G A T G C T G T N T G G G T A C C A T C A T C C G T G T G 
5 4 1 A A A T T G T T A T C C G C T A A G G G C G A N T T C T G C A G A T A T C C N T C C A A C T G G G C G G C C G C T C C N 
6 0 1 A N C A T G C A T C T A G A N N G G C N C A A T T C G C C C T A T A G T G A G T T G T A T A C C A T T N A C N T G G C G 
6 6 1 T T G T T N T A N A N G T G N N G A N N G N N A N N C C N T G G C G T A C C C A A T T A N T G C N N G C G C A C N T C C 
7 2 1 C C T T 
C48.2: Sequence alignment of cDNA subclone VV8#6 with mouse HMG-CoAS by BLAST searching 
with the National Center for Biotechnology Information database 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M I I I I I I I M M M M M M I M M M I 
M o u s e H M G - C o A S : 1 9 9 1 c a a g t a a t t t c t t c t c t c t t t t t a a t t g c c a c a t a t t a t t t t a g a a c a a g a t a c a a a a t t 
W 8 # 6 : 2 0 2 t a g a a a c t t t a a g a a a c a a g c a t a a a c t a t a a t a g c ： 〒 〒 a g a g t ^ � t g予 g � a � a a g � � g〒 予 〒 2 6 1 
||〒|||||||||||||||||||1111111丨丨丨丨1丨1丨丨丨丨丨丨丨丨丨丨1丨丨丨丄llll丄丨丄丨丨 
M o u s e H M G - C o A S ：1931 t a g a a a c t t t a a g a a a c a a g c a t a a a c t a t a a t a g c c c a g a g t c t g a g a a t a a g c t g t a a 1872 
M o u s e H M G - C o A S ： 1 8 7 1 c a a a t g g c t g c t c t g c c g g g c t g t g g g g a a a g a t c t g c a t c c c t g c a g g t c a g c g g c t c c 1 8 1 2 
W 8 # 6 ：322 c c t t t c t t t c a t c t c c c t c t t c a c a g g g g a g c t c t g g t c c a c a c c t g t g g 3 8 1 
丨丨1|丨1丨1丨丨丨丨丨丨丨1丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨丨1丨丨丨I丨丨丨I丨丨I丨丨L丨丨 “ 
M o u s e H M G - C O A S ： 1 8 1 1 c c t t t c t t t c a t c t c c c t c t t c a c a g g g g a g c t c t g g t c c a c a g c a g c a t g a g c c t g t g g 1 7 5 2 
:382 n丨丨丨〒mmnimmn�mm�r丨〒nmnnn 
M o u s e H M G - C O A S : 1 7 5 1 c g c t g a t t g t g t c a g g g a g a g a c a - c c c a g g a t t - c a c a g a g g g - a g g - c c g t t c a - c c a 1 6 9 7 
W 8 # 6 :442 c a g a a g c a g a t c c c t a t g n a g g g c t g c t g t g t c t a g t c c c t a t t t a c t g c t ^ 5 0 1 
111 I I I I I I I I L L L L L I I I I I I M 1 I I I I I I I I I I 11 11 M M 11 11 , — … 1 
Mouse HMG-COAS ： 1696 丨clalg-a丨glclalg丨at-c^丨tiatga--ggctgctgtgtctagtccctatttactgctgtgggtggg 1641 
W8i±6 ： 502 a t t t a a a g c a g a t g c t g t n t g g g t a 526 
M M i m i i m i m iiiiii …， 
M o u s e H M G - C o A S ： 1 6 4 0 a t t t t a a g c a g a t g c t g t t t g g g t a 1 6 1 6 C48.3: Summary of sequence alignment of cDNA subclone VV8#6 with mouse HMG-CoAS 
FluoroDD gel VV (AP2 + ARP 18) Subcloning S e q u e n c i ^  
Differential display pattern ^ l e a s e d b T Sequence homology E-value 
Fra^ ent ppARa (+/+) | PPARcc (-/-) " c u t ？丨耐： (Lnscnpt s.ze) (% Identity) 
Fed Starved Fed Starved M  
Mouse 3-hydroxy-3-
methylglutaryl-
Coenzyme A e-169 
VV8 _ + - - VV8#6 460 M13 reverse synthase 2 372/385 (96%) 
(430 b p ) ( H M G - C o A S ) 
(2011 bp)  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C49.1: DNA sequence of cDNA subclone WW1#3 using M13 forward -20 primer and the sequence of3,-AP2 
1 A T T A C G A C T C A C T A T A G G G C G A A T T G G G C C C T C T A G A A T G C A T G C T C G N A G C G G C C G C C A 
6 1 G T G T G A T G G A T A T C T G C A G A A T T C G C C C T T G T T A A T A C G A C T C A C T A T A G G G C T T T T T T T AP2 
1 2 1 T T T T G C T G T A G C A T C A G G C A C G A G C C A G G C C A G C C T G T G T T T A A T G G A A G G G A C C C A A T T 
1 8 1 C A G A A G G A A G G A T G A C A T C G T A G G G T G G T C A T T T A T N T G T G G G A T C T A C C A C T T T T C C C A 
2 4 1 C A A A G A T G G G G C T C T G A G T G T G T T C T T C A A A T A T T A T A A A A A G G A A A G G G T G G T C G A A G C 
3 0 1 G C A G G A T A G G G G G C A T A G A C A T A G G A A C G G C T T C A A A G A C T G T G G C T G C T G C A G C T T C T G 
3 6 1 T T C C T G T C T C A T C G A T G G T C A G C A C A G C C T T A T G C A C A G C C T T G C T G A G C T T C A G G G G A G 
4 2 1 C A T T C T C C T C T G T G A T T C C G G A G A G G T C A G C C C C A T T G T T G A A G A T C C G G G T G A T G C C C A 
4 8 1 G T G G A C T C A T G A G T G T C T T C A A G T T A T A G T C T C C A G A G A T G G A C A G T C T G G G G A T A T G G A 
5 4 1 T C T G G A C T A A C C T T C T G T G C N T G T N T A G C A G G A T C T N A G A G A T G A G C T C N T G N C T G A G A G 
6 0 1 T T T G C T C N N A T G C T G C A T N T C C C A T N T N C C G N C A N G A N G A A G A C A G C A C T G G C G T T G C C C 
6 6 1 A C G T T A T T N C A T C A G C A G C A C C N A G C N T G G G G 
C49.2: Sequence alignment of cDNA subclone WW1#3 with mouse Spil-3 by BLAST searching 
with the National Center for Biotechnology Information database 
wwi#3 - - � T m m T m � � m � m n � � m � n m � m T n m T � f n m n m � r8 4 
M o u s e S p i l - 3 ： 1 3 5 9 g c t g t a g c a t c a g g c a c g a g c c a g g c c a g c c t g t g t t t a a t g g a a g g a a c c c a a t t c a g a 1 3 0 0 
: i 8 5 而 n前m們而m m n n r m而m n m n m m m r 4 4 
M o u s e S p i l - 3 : 1 2 9 9 a g g a a g g a t g a c a t c t t a g g g t g g t c a t t t a t g t g t g g g a t c t a c c a c t t t t c c c a c a a a 1 2 4 0 
- - � r m � T m � f f i m竹m m  rnrmmmmTf顶n�mr = � 
M o u s e S p i l - 3 ： 1 2 3 9 g a g g g g g c t c t g a g t g t g t t c t t c a a a t a t t a t g a a a a g g a a a g g g t g a t c g a a g c g c a c 1 1 8 0 
M o u s e S p i l - 3 ： 1 1 7 9 g a t a g g g g g c a t a g a a t a a g g a a c g g c t a g t a a g a c t g t a g c t g c t g c a g c t t c t g t t c c 1120 
丽而丨mr丨丨mn丨nnmm丨〒nnmnmmm丨〒〒mm丨丨=。 
M o u s e S p i l - 3 ： 1 1 1 9 t g t c t c a t c c a t g g t c a g c a c a g c c t t a t g c a c a g c c t g g c t g a g c t t c a g g g g a g c a t t 1 0 6 0 面 H r n T m 〒 丨 r n n m 丨 〒 〒 n n m m 丨 m m m T m m m m n 丨 ? r : 。 。 
M o u s e S p i l - 3 : 1 0 5 9 i t c c t c t g t g a t t c c g g a g a g g t c a g c c c c a t t g t t g a a g a t c c g g g t g a t g c c c a g t g g 1 0 0 0 
M o u s e S p i l - 3 : 9 9 9 a i t c i t g a g t g t i t t c a a g t t a t a t t c t c c a g a g a t g g a c a g t c t g g g g a a g t g g a t c t g 9 4 0 
M o u s e s p i l - 3 : 9 3 9 g g i t i i i i t t i t g g g i c L t t t i g c a g g a a c t t g g a g a t g a g c t c c t t g c t g a g a g t t t g 8 8 0 
W W 1 # 3 : 6 0 5 c t c 6 0 7 I I I 
M o u s e S p i l - 3 ： 8 7 9 c t c 8 7 7 
C49.3： Summary of sequence alignment of cDNA subclone WW1#3 with mouse Spil-3 
FluoroDD gel WW (AP2 + ARP 19) Subcloning S e q u e n c i n g — — _ 
Differential di 一 y pattern ^ l e a l d b T . Sequence homology E-value 
F r a ^ e n t p p A R a (+/+) | PPARa (-/-) I ' m cut P ^ e r ( U s c n p t s.ze) (% Identity) 
Fed Starved Fed Starved (bp)   Mouse serine 
M l 3 forward protease inhibitor 0 
WWl ++ + ++ ++ WW1#3 1520 20 1-3 (Spil-3) 453/483 (93%) 
(1500 bp) (1366 bp)  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C50.1: DNA sequence of cDNA subclone WW1#4 using M13 forward -20 primer and the sequence of3，-AP2 
1 NTTACGACTC ACTATAGGGC GAATTGGGCC CTCTAGATGC ATGCTCGAGC GGCCGCCAGT 
6 1 GTGATGGATA TCTGCAGAAT TCGCCCTTGT AATACGACTC ACTATAGGGC TTTTTTTTTT AP2 
1 2 1 TGCTGTAGCA TCAGGCACGA GCCAGGCCAG CCTGTGTTTA ATGGAAGGGA CCCAATTCAG 
1 8 1 ^ G A A G G A T GACATCGTAG GGTGGTCATT TATGTGTGGG ATCTACCACT TTTCCCACAA 
2 4 1 AGATGGGGCT CTGAGTGTGT TCTTCAAATA TTATGAAAAG GAAAGGGTGG TCGAAGCGCA 
3 0 1 GGATAGGGGG CATAGACATA GAAACCATTT GTAAAGACTG TAACTGCTGC AGCTTCTGTT 
3 6 1 CCTGTCTCAT CGATGGTCAG CACAGCCTTA TGCACAGCCT GGCTGAGCTT CAGGGGAGCA 
4 2 1 TNCTCCTCTG TGATTCCGGA GAGGTCAGCC CCATTGTTGA AGATCCGGGT GATGCCCAGT 
4 8 1 GGACTCATGA GTGTCNNCAA AGTNATATTC TCCAGAGATG GACAGTCTGG GGAAGTGGAT 
5 4 1 CTGGGCTAAC CTTCTGCGCN TGTTTAGCAG GAACTNAGAG ATGAGCNCNT GNCTGAGAGT 
6 0 1 TNGCTCAGAT GCTGCATNTN NCATCATCGG NCAGANNGNN GACNGCGGTG GCATNGCCTG 
6 6 1 CATNNNCNNT CCGCNGCCNC CAGCNTGNAC NNGCCGCNGC NANTGGTGCC C 
C50.2: Sequence alignment of cDNA subclone WW1#4 with mouse Spil-3 by BLAST searching 
with the National Center for Biotechnology Information database 
丽:122�T前〒nm�mm�m而mTm�nmmTT�fmmmm : 
M o u s e S p i l - 3 ：1359 g c t g t a g c a t c a g g c a c g a g c c a g g c c a g c c t g t g t t t a a t g g a a g g a a c c c a a t t c a g a 1300 
M o u s e S p i l - 3 :1299 a g g a a g g a t g a c a t c t t a g g g t g g t c a t t t a t g t g t g g g a t c t a c c a c t t t t c c c a c a a a 1240 
� n m T m � m � m m m T m rnnmmmmTfnm�mr 
M o u s e S p i l - 3 : 1 2 3 9 g a g g g g g c t c t g a g t g t g t t c t t c a a a t a t t a t g a a a a g g a a a g g g t g a t c g a a g c g c a c 1 1 8 0 
:3�2 〒丨丨n〒〒？m丨m�airm�aTmrmmnnmn�mnmr6i 
M o u s e S p i l - 3 ：1179 g a t a g g g g g c a t a g a a t a a g g a a c g g c t a g t a a - g a c t g t a g c t g c t g c a g c t t c t g t t c 1 1 2 1 
M o u s e s p i l - 3 :1120 i t g t c t c a t c c a t g g t c a g c a c a g c c t t a t g c a c a g c c t g g c t g a g c t t c a g g g g a g c a t 1 0 6 1 
M o u s e s p i l - 3 :1060 t i i i i t ^ i t ^ g g i U c l ^ i ^ g a g g t c a g c c c c a t t g t t g a a g a t c c g g g t g a t g c c c a g t g 1001 
丽#4 前丨nmnnrnn丨rm丨mnmffimn�mT�mTf丨 p 二 
M o u s e s p i l - 3 ：1000 g i i t c a t g i g t g t c t t c - a a g t t a t a t t c t c c a g a g a t g g a c a g t c t g g g g a a g t g g a t c 942 
酣 : 5 4 2 溜mm衍TrrTm丽mTnmmrrrT！〒= 
M o u s e s p i l - 3 : 9 4 1 t g g g i t i a c i t t i i g g g c c i c t t t a g c a g g a a c t t g g a g a t g a g c t c c t t g c t g a g a g t t 8 8 2 
丽#4 : 6 �2 n � T n m m n n n，m m � r n r T T r � r m m n T M ；;: 
M o u s e s p i l - 3 :881 t g i t c i i g i t g i t g i i ^ t t c c c a t c a t c g g g c a g g a g g a a g a c a g c a g t g g c a t t g c c t 822 
丽 i # 4 ： 6 6 0 g c a t 6 6 3 
M M 
M o u s e S p i l - 3 ： 8 2 1 g c a t 8 1 8 C50.3: Summary of sequence alignment of cDNA subclone WW1#4 with mouse Spil-3 
FluoroDD gel WW (AP2 + ARP 19) Subcloning Sequencing  
i Differential display pattern t l e a t e d ^ Sequence homology E-value 
F r a ^ e n t p p A R a (+/+) | PPARa (-/-) " c u t ？匪。^  (Transcript size) (% Identity) ‘ Fed Starved Fed Starved ^  
Mouse serine 
M l 3 forward protease inhibitor 0 
W W l ++ + ++ ++ WWl#4 1520 .20 1-3 (Spil-3) 499/544 (91%) 
(1500 bp) (1366 bp)  
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Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C51.1: DNA sequence of cDNA subclone WW1#7 using M13 reverse primer and the sequence of 5,-ARP19 
1 TCCAAGCTAT TTAGGTGACA CTATAGAATA CTNAAGCTAT GCATCAAGCT TGGTACCGAG 
6 1 C T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G A T A A C A A T T A R P 1 9 
121 TCACACAGGA TTTTGGCTCC TACTGCTTAA ATACAGACTA GGACAGGGCT CTGTCTCCTC 
1 8 1 A G C C T C G G T C A C C A C C C A G C T C T G G G A C A G C A A G C T G A A A A T G A C T C C C T C C A T C T C A T G 
2 4 1 GGGTCTACTG CTTCTGGCAG GCCTGTGTTG CCTGGTCCCC AGCTTTCTGG CTGAGGATGT 
3 0 1 T C A G G A G A C A G A C A C C T C C C A G A A G G A T C A G T C C C C A G C C T C C C A T G A G A T C G C T A C A A A 
3 6 1 CCTGGGAGAC TTTGCAATCA GCCTATACCG GGAGCTGGTC CATCAGTCCA ACACTTCCAA 
4 2 1 CATCTTCTTC TCCCCAGTGA GCATTGCCAC AGCCTTTGCT ATGCTCTCCC TAGGGAGCAA 
4 8 1 NNGTGACACT CACACGCAGA TCCTAGANGG CCTGCAGTTC AACCTCACAC NAACATCGGA 
5 4 1 GGCTGACATC CACAAGTCCT CCNACACCTC CCTCCAAACC CTCAACAGAC AAGACAGTGA 
6 0 1 GCTGCAGTNG AGCANCNGCA ATGNCNNCTC GTCACCATGA CNGANCTGNT GAAANTTCTG 
6 6 1 NAGAGCCNGA CTTATCNCNG ANNNTCTGTT ATNA 
C51.2: Sequence alignment of cDNA subclone WW1#7 with mouse Spil-3 by BLAST searching 
with the National Center for Biotechnology Information database 
™ : •〒而 mm 〒而〒 mTmTmmmTmnnnnmTT前〒Tm : 
M o u s e S p i l - 3 ：1 g t c a c c a c c c a g c t c t g g g a c a g c a a g c t g a a a a t g a c t c c c t c c a t c t c a t g g g g t c t a 60 
丽#7 丨n丨丨m�mmmm丨〒丨mmn�mnmT丨〒丨丨愤〒雨馆丨〒= 
M o u s e S p i l - 3 ：61 c t g c t t c t g g c a g g c c t g t g t t g c c t g g t c c c c a g c t t t c t g g c t g a g g a t g t t c a g g a g 120 
m�mTmnmTm 前 TnnTmTnnm〒而mmrr•而= 
M o u s e s p i l - 3 ：121 i c a g i c a i i t i i c a g a a g g a t c a g t c c c c a g c c t c c c a t g a g a t c g c t a c a a a c c t g g g a 180 
^^^^ n n M f M M i i f M M M M f m f i n n i m ；：： 
M o u s e s p i l - 3 ：181 g i c t t t g i a a t c a g c c t a t a c c g g g a g c t g g t c c a t c a g t c c a a c a c t t c c a a c a t c t t c 240 丽 i#7 :428nnTTmn�mnnTmmnn�nn�nnmnmmTni�Tn:: 
M o u s e s p i l - 3 ：241 t t i t c c c c a g t g a g c a t t g c c a c a g c c t t t g c t a t g c t c t c c c t a g g g a g c a a g g g t g a c 300 
綱
7
 t n u n m n n N M r m M m n N m ；；： 
M o u s e s p i l - 3 :301 a i i c i c i i g i i g i t i i t a g a g g g c c t g c a g t t c a a c c t c a c a c a a a c a t c g g a g g c t g a c 360 
M o u s e s p i l - 3 :361 二t^cl:c!:ti^cU。acct-cctccaaaccctcaacagaccagacagtgagctgca 419 
W m # 7 :607 g 607 
M o u s e S p i l - 3 :420 g 4 2 0 C51.3： Summary of sequence alignment of cDNA subclone WW1#7 with mouse Spil-3 
FluoroDD gel WW (AP2 + ARP19) Subcloning Sequencing  
r D i f f e r e n - d i s p l a y pattern — Sequence homology E-value 
F r a ^ e n t p p ^ R a (+/+) | PPARa (-/-) t o R I cut ？口丽 (Transcnpt size) (% Identity) 
Fed Starved Fed Starved   Mouse serine 
protease inhibitor 0 
W W l ++ + ++ ++ WW1#7 1520 M l 3 reverse 1-3 (Spil-3) 413/421 (98%) 
(1500 bp) ^ (1366 bp)  
396 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C52.1: DNA sequence of cDNA subclone XX1#2 using M13 forward -20 primer and the sequence of3,-AP10 
1 N T T A C G A C T C A C T A T A G A N N C A G A A A T A A G G G C C C T C N T N A G N A A T G C A T G C N T C G A A N C 
61 GGCCGCCAGA TNNGAATGGC ATATCTGCAG AAATTCGCCC TTGATAATAC GACTCACTAT APIO 
1 2 1 A G G G C T T T T T T T T T T T T A G C A T G A C A C T G G G A A C T T T A T T G C A G A A A G G A G G G A A G A T G 
1 8 1 G A G N A A A N C T C G T G T G A G G A T T A A T C A G G T A G A A A G A G N A C T A T G C C A G G G T A G A T T T A G 
2 4 1 N A T G A A N C C C C N T T A G G T A C C T G T C A T G T G A A A N N A T G A T A C C T N G C T G A A T A N C G T N T T 
3 0 1 C C C C A A T G A T G T T C A G G C C C T T G G A T T T T G G A G A A C C N T G G T A C T T A T T G A A A T G A T T C C 
3 6 1 C T C A T A A T T T T N G A A A A G G A A C T T A G T N G G T T A G A T T G A T T N G A A T N C T T T T N G A T G G G A 
4 2 1 A N C T A T C T T G G A G C C T T T T A G G G A T C T T A T G A T G T T T N G C N N N N N G T N N G T N N G N C N T T G 
4 8 1 A A G N G C G G G G N T G C N G N G G T G C T G G N N T T G A A G C C N G G G A N N T N T N N C A G T T G C C C C G G G 
5 4 1 N N T T G G T T G G N T T C T T T T C T T G G C N C G C G N N G G G N N T G G G G N N G G N N N C T T T T C T T G G G N 
6 0 1 N G T T N T T T T T T T T C T T G G A A C N N A A N G G N N N N G N T N N A A A A C C A A A A A A A A A T A N N G N N T 
6 6 1 A T N N T A N N A G N T G N A C N T C T T T T T T T N G G G A N N T T N G G N N G G C T T C C C C C A C G G A N N T T T 
7 2 1 G G G T G G N G G C C T T T T T G G N G A N T T G T T N G G T T G N N T C C C T T T T T T T T N N N N N N N 
C52.2: Sequence alignment of cDNA subclone XX1#2 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
x x i # 2 ： I
4
。 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t ^ ? - a 严 a ， ， n ? t ^ ? 巧 ? I
9 9 
I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l M M I I I I I I I M M I I I I I 抓。 
M o u s e C Y P 4 A 1 0 : 2 0 7 7 g c a t g a c a c t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g - - a a a c t c g t g t g a g g 2 0 2 0 
I I M M I I M M M M M M M M M M M N M M M IIIII丨丨丄丄丨丨丨丄丨…； 
M o u s e C Y P 4 A 1 0 ： 2 0 1 9 a a t a a t c a g g t a g a a a g a g - a c t a t g - c a g g g t a g a t t t a g - a t g a a - - c a c a t t a g g t a 1 9 6 5 
x x i # 2 ：260 cctgtcat:gtgaaannatgatacctngctgaatanc¥tmtt^c(j:c?”t^〒5^t^?，〒c〒 319 
I I I I I I I I I I I I I I m m I I I I I I I I M M 丨 M M M 丨丨丨丨丨 I 
M o u s e C Y P 4 A 1 0 : 1 9 6 4 a c t g t c a t g t g a a a - - a t g a t a c t a a g c t g a a t a a t g t c t t - c a c a a t g a t g t t c a g g - c 1 9 0 9 
X X 1 # 2 :32。cttggattttggagaaccntggtactt:attgaaatgat^1^c??t^?，t|:，，t^t^ttng,a，，〒〒 379 I I I I I I I I I I I I I I 111 l l l l l l I M M 11 I I I 11 M M M M I I I I I I I …； 
M o u s e C Y P 4 A 1 0 : 1 9 0 8 c t U g a t t t ^ a g - a c c a t g g t a c a t a t t g - a a t g a t t - c c t c a t a a t t — c a g a a g g 1 8 5 5 
X X 1 # 2 :380 a a c t t a g t n g g t t a g a t t g a t t n g a ， ， t 二 〒 〒 ， 〒 ？ 〒 W 〒 ， 〒 c 了 Y U ^38 
丨I m丨11 11111111111 I 11 I 111 111丨11 11丨I丨丨丨丨丨丨111丨丨丨丨1… 
M o u s e C Y P 4 A 1 0 : 1 8 5 4 a a c t t a g t a g g t t a g a t t g a a t a a g a t a c a t t t a g a t g g g a a a a c t a t c t t g g a g - c t t t 1 7 9 6 
: 4 3 9 t a g g g a t c t t a 4 4 9 imimm 
M o u s e C Y P 4 A 1 0 ： 1 7 9 5 t a g g g a t c t t a 1 7 8 5 
C52.3: Summary of sequence alignment of cDNA subclone XX1#2 with mouse CYP4A10 
一 F l u o r o D D g e l X X (AP10 + ARP12) Subcloning Sequencing = 
I" Differential display pattern — ^^YeatedW Sequence homology E-value 
Fragment ppARa (+/+) PPAR« (-/-)__ ''no IcoTl cut ？醒红 （Transcript size) (% Identity) 
. Fed S t a r v e d F e d Starved ^ 广丨入 八^ = - 7 7 
M13 forward Mouse CYP4A10 7e-45 
XXI + _ - XX1#2 1030 20 (2077 bp) 267/311 (85%) 
(990 bp) ‘ 
397 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C53.1: DNA sequence of cDNA subclone XX1#3 using M13 forward -20 primer and the sequence of3’-AP10 
1 TTACGACTCA CTATAGGGCG AATTGGGCCC TCTAGATGCA TGCTCGAGCG GCCGCCAGTG 
61 TGATGGATAT CTGCAGAATT CGCCCTTGTA ATACGACTCA CTATAGGGCT TTTTTTTTTT APIO 
1 2 1 TAGCATGACA CTGGGAACTT TATTGCAGAA AGGAGGGAAG ATGGAGAAAC TCGTGTGAGG 
1 8 1 ATTAATCAGG TAGAAAGAGA CTATGCAGGG TAGATTTAGA TGAACACATT AGGTAACTGT 
2 4 1 CATGTGAAAA TGATACTAAG CTGAATAACG TCTTCACAAT GATGTTCAGG CCTTGGATTT 
301 TGGAGACCAT GGTACATATT GAATGATTCC TCATAATTCA GAAGGAACCT TAGTAGGTTA 
3 6 1 GATTGAATAA GATACATTTA GATGGGAAAA CTATCTTGGA GCTTTTAGGG ATCTTAATGA 
4 2 1 TGTCATAAGC ATCTGTAAAA GGTAAGGACA TTAGAAGAGA GGGGATGAGG AGGGTGCTGG 
4 8 1 CTTTGAAGCA NNNGANTANN CCAGTGCCAA NGAATGATGA TCTATACTGA ACNNANGATG 
5 4 1 AGAGGACTTC CTGGAGTATN CTTNTGAAAA NNGTANGTNC CACCCACCAA CTNAGCTTTN 
6 0 1 TCAGTGAAAC TNTTNTAGAC ATNGAGCTNC CAANNGAATT NTGNGCTTTG ANATGTNGTA 
6 6 1 ATCCTTTTGA CTGNNCNNTG 
C53.2: Sequence alignment of cDNA subclone XX1#3 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
: 1 2 3〒-馆丨丨丨〒惯丨n丨丨丨丨n n � m m m丨丨愤m m丨丨m n m m t ： 
M o u s e C Y P 4 A 1 0 : 2 0 7 7 g i a t g a i a i t g g g a a c t t t a t t g c a g a a a g g a g g g a a g a t g g a g a a a c t c g t g t g a g g a a 2 0 1 8 
:1
83 mmmm丨mm丨丨丨m�?mmmmmmn丨 f丨nmt丨n ；;^  
M o u s e C Y P 4 A 1 0 : 2 0 1 7 U i t i a g g t i g a i i g i g i i t a t g c a g g g t a g a t t t a g a t g a a c a c a t t a g g t a a c t g t c a 1 9 5 8 
Mouse C Y P 4 A 1 0 : 1 9 5 7 丨 g i g U i U i i i W i i g 乂 g ^ i U ^ t g 乂 t c a c a a t g a t g t t c a g g c c t t 羽 a t t t t g 1 8 9 8 
M o u s e C Y P 4 A 1 0 : 1 8 9 7 U g a i i i U g t i c i t a t U a i t g i t t c c t c a t a a t t c a g a a g g a a - c t t a g t a g g t t a ^ 1 8 3 9 
nmnmnnnnnnmmnnnmmnnnm丨Tm丨丨〒2:: 
M o u s e C Y P 4 A 1 0 : 1 8 3 8 丨 g i ^ ^ g ^ U U U ^ a t g g g a a a a c t a t c t t g g a g c t t t t a g g g a t c t t a a t g a t g 1 7 7 9 
则3 丨n丨丨mTn丨mm前丨mn丨nm�m而丨mm前mm丨： 
Mouse CYP4A10 :1778 UiiiUUi丄UUU^UU^二⑵；ag哪ggatgag例ggtgctggct 1719 
M o u s e C Y P 4 A 1 0 : 1 7 1 8 U U U - g g g U a t i t t i i a g i g i c a a g g a a t g a t g a t c t a t a c t g a a c a g a g g a t g a g 1 6 5 9 
xxi#3 -.543 R�TTp，T��TMfnirnTTn 
M o u s e C Y P 4 A 1 0 : 1 6 5 8 a g g a c t c t c t g g a g t a t t c t t c t g a a a a 1 6 3 1 C53.3: Summary of sequence alignment of cDNA subclone M M with mouse CYP4A10 
F l u o r o D D g e l XX (AP10 + ARP12) Subcloning Sequencmg  
Differential display pattern ^ r l l l c T h f Sequence homology E-value 
PPARa (+/+) | PPARa ( - / - ) �" c u t P ^ e r (Transcnpt s.ze) (% Identity) 
‘ Fed Starved Fed Starved ^ 门…�, ^  M l 3 forward Mouse CYP4A10 0 
XXI + _ - XX1#3 1030 20 (2077 bp) 431/448 (96%) 
(990 bp)  
398 
Appendix C: DNA sequence and sequence alignment of cDNA subclones 
C54.1: DNA sequence of cDNA subclone XX1#9 using M13 forward -20 primer and the sequence of5'-ARP12 
1 TCCAGCTATT TAGGTGACAC TATAGAATAC TCAAGCTATG CATCAAGCTT GGTACCGAGC 
6 1 T C G G A T C C A C T A G T A A C G G C C G C C A G T G T G C T G G A A T T C G C C C T T A G C G G ATAACAATTT A R P 1 2 
1 2 1 C A C A C A G G A G G T A C T A A G G C T C T A C C C A C C T G T C C C A G G C A T T G T C A G A G A A C T C A G T A C 
1 8 1 ATCTGTCACC TTCCCTGATG GACGCTCTTT ACCCAAAGGT GTCCAGGTCA CACTCTCCAT 
2 4 1 TTATGGTCTC CACCACAACC CGAAGGTGTG GCCAAATCCA GAGGTGTTTG ACCCTTCCAG 
3 0 1 GTTTGCACCA GACTCTCCCC GACACAGCCA CTCATTNCCT GCCCTTCTCA GGAGGAGCCA 
3 6 1 GGAACTGCAT TGGGAAACAA TTTGCTATGA GTGAGCTGAA GGTGATTGTG GCCCTGACAC 
4 2 1 TGCTCCGCTT CGAACTACTG CCAGATCCTA CCAGGGTCCC CATGCCCCTT AGCCCGACTT 
4 8 1 GTGCTGAAGT NCNAAAATNG GATCTACCTA CATCTCNAGA AGCTCCCTGA TTCTGTTGTG 
5 4 1 GAGCTCCAAT GTCTGAGAAG AGTTNCACTG GANAANGCTA AGTNGTGGNT GTGACCTACC 
6 0 1 TNTTCANAAA NANTACTCCN GAGAGTNCCC TCATCCCTGN TNAGTATNNA TNNTNTTTNN 
6 6 1 T G G C C C N G N A TATNNCCNGN T T T A A G C C G C N C T T T 
C54.2: Sequence alignment of cDNA subclone XX1#9 with mouse CYP4A10 by BLAST searching 
with the National Center for Biotechnology Information database 
X 浦 ：i
34
 n n m n n T m T n n T m m n n n m m n T n n m n r 丨 
Mouse CYP4A10 :1164 it^i^^t^it^iiic^^itgtcccaggcattgtcagagaactcagtacatctgtcaccttc 1223 
e n r n T m n n m r n T m n r n m n n n n T m m ^ m n n = 3 
M o u s e C Y P 4 A 1 0 : 1 2 2 4 c c t g a t g g a c g c t c t t t a c c c a a a g g t g t c c a g g t c a c a c t c t c c a t t t a t g g t c t c c a c 1 2 8 3 
Mouse CYP4A10 :1284 UUiiiigiiggUtggciaiatccagaggtgtttgacccttccaggtttgcaccagac 1343 
- - n M i M ! i M i i f M i n n M ^ M n M M ： ! 
M o u s e C Y P 4 A 1 0 -.1344 t c t c c i i g i i i i a g c c a c t c a t t - c c t g c c c t t c t c a g g a g g a g c c a g g a a c t g c a t t g g 1402 
Mouse CYP4A1。 ：1403 U^i^ili^c^iUgigUigctgaaggtgattgtggccctgacactgctccgcttcga 1462 
X飾 n 而 m m 丨丨 m n 丨前 m n 丨 n m n m m m 蒲丨厂 = 1 
M o u s e C Y P 4 A 1。 ：1463 U U ^ U 。 i g i A ^ A 二 g ^ g t c c c c a t g - c c c t t a g c c c g a c t t g t g c t g a a g t c c a 1521 
n n r m n n m m n r m T m T n m r n n n m n r 丨 
M o u s e C Y P 4 A 1 0 : 1 5 2 2 i a i i U g i t i t a i i t i c i t c t c a a g a a g c t c c a c t g a t a c t g t t g t g g a g c t c c a a t g t 1 5 8 1 
Mouse CYP4M。：1582 iigiUaUgtitiiiUgagiaagitaagttgttggtgtgacctacctttttcagaaga 1641 
X X 1 # 9 ： 613 n t a c t c c n g a g a g t n c c c t c a t c c 636 
immmm i丨丨丨丨丄丨丨 
M o u s e C Y P 4 A 1 0 : 1 6 4 2 a t a c t c c a g a g a g t c c t c t c a t c c 1 6 6 5 C54.3: Summary of sequence alignment of cDNA subclone M m with mouse CYP4A10 
FluoroDD gel XX (AP 10 + ARP 12) Subcloning Sequencing  
Differential display pattern ^ e T e a l d b T Sequence homology E-value 
F r a ^ e n t p p A 一 ) �P P A R a (-/-) ' ^ o " c u t 醋 (Transcnpt size) (% Identity) 
_ _ ^ _ F e ^ a r v e d Fed Starved ； ^ K l ^ ^ ^ ^ C Y ^ 0 
XXI + _ _ XXI#9 1030 M13 reverse (2077 bp) 480/504 (95%) 
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